MOH/F/FAR/195.26(AR)-e



KEMENTERIAN KESIHATAN MALAYSIA
PROGRAM PERKHIDMATAN FARMASI

# Laporan Tahunan
# Annual Report

# 2025

PROGRAM PERKHIDMATAN FARMASI
*PHARMACEUTICAL SERVICES PROGRAMME*

# Laporan Tahunan
# Annual Report
# 2025

**PROGRAM PERKHIDMATAN FARMASI**
*PHARMACEUTICAL SERVICES PROGRAMME*

**LAPORAN TAHUNAN PROGRAM PERKHIDMATAN FARMASI 2025**
*PHARMACEUTICAL SERVICES PROGRAMME ANNUAL REPORT 2025*

MOH/F/FAR/195.26(AR)-e
eISSN 2735-1254

Diterbitkan oleh:
**Program Perkhidmatan Farmasi**
**Kementerian Kesihatan Malaysia**
Lot 36, Jalan Profesor Diraja Ungku Aziz,
46200 Petaling Jaya, Selangor.
T 603 7841 3200

**©Kementerian Kesihatan Malaysia**

**HAK CIPTA TERPELIHARA**
Pertanyaan hendaklah ditujukan kepada alamat di atas. Tiada bahagian dalam penerbitan ini boleh diterbitkan semula, disalin, disimpan dalam sistem yang boleh dicapai semula, atau disebarkan dalam apa-apa bentuk atau cara, sama ada secara elektronik, mekanikal, rakaman atau cara lain, tanpa memperoleh kebenaran bertulis terlebih dahulu daripada penerbit.

***ALL RIGHTS RESERVED***
*All enquiries should be delivered to the above address. No part of this publication may be reproduced, copied, stored in a retrieval system, or distributed in any form or by any means, whether electronic, mechanical, by recording, or otherwise, without prior written permission of the publisher.*



# ISI KANDUNGAN
## *INSIDE THIS REPORT*


MENGENAI LAPORAN INI
*ABOUT THIS REPORT* ..... 02

PROGRAM PERKHIDMATAN FARMASI SEKILAS PANDANG
PHARMACEUTICAL SERVICES PROGRAMME AT A GLANCE ..... 03

PIAGAM PELANGGAN
*CLIENT CHARTER* ..... 04

VISI & MISI
*VISION & MISSION* ..... 06

OBJEKTIF BAHAGIAN
*DIVISION OBJECTIVE* ..... 07

CARTA ORGANISASI
*ORGANISATIONAL CHART* ..... 08

KEPIMPINAN KAMI
*OUR LEADERS* ..... 09

JAWATANKUASA EDITORIAL
*EDITORIAL COMMITTEE* ..... 12

BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI
*PHARMACY POLICY AND STRATEGIC PLANNING DIVISION* ..... 13

1.0 Pengenalan
*Introduction* ..... 15

2.0 Aktiviti dan Sorotan
*Activities and Highlights* ..... 17

3.0 Pencapaian dan Pengiktirafan
*Achievement and Recognition* ..... 44

4.0 Penerbitan dan Kajian
*Publication and Research* ..... 47

5.0 Kolaborasi dan Penglibatan Antarabangsa
*International Collaboration and Participation* ..... 54

BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI
*PHARMACY PRACTICE AND DEVELOPMENT DIVISION* ..... 63

1.0 Pengenalan
*Introduction* ..... 65

2.0 Aktiviti dan Sorotan
*Activities and Highlights* ..... 67

3.0 Pencapaian dan Pengiktirafan
*Achievement and Recognition* ..... 92

4.0 Penerbitan dan Kajian
*Publication and Research* ..... 93

BAHAGIAN PENGUATKUASAAN FARMASI
*PHARMACY ENFORCEMENT DIVISION* ..... 97

1.0 Pengenalan
*Introduction* ..... 99

2.0 Aktiviti dan Sorotan
*Activities and Highlights* ..... 102

3.0 Pencapaian dan Pengiktirafan
*Achievement and Recognition* ..... 122

4.0 Penerbitan dan Kajian
*Publication and Research* ..... 123

5.0 Kolaborasi dan Penglibatan Antarabangsa
*International Collaboration and Participation* ..... 125

BAHAGIAN REGULATORI FARMASI NEGARA
*NATIONAL PHARMACEUTICAL REGULATORY AGENCY* ..... 128

1.0 Pengenalan
*Introduction* ..... 131

2.0 Aktiviti dan Sorotan
*Activities and Highlights* ..... 133

3.0 Pencapaian dan Pengiktirafan
*Achievement and Recognition* ..... 139

4.0 Penerbitan dan Kajian
*Publication and Research* ..... 141

5.0 Kolaborasi dan Penglibatan Antarabangsa
*International Collaboration and Participation* ..... 142

BAHAGIAN LEMBAGA FARMASI MALAYSIA
*PHARMACY BOARD MALAYSIA DIVISION* ..... 147

1.0 Pengenalan
*Introduction* ..... 148

2.0 Aktiviti dan Sorotan
*Activities and Highlights* ..... 155

3.0 Pencapaian dan Pengiktirafan
*Achievement and Recognition* ..... 161

4.0 Penerbitan dan Kajian
*Publication and Research* ..... 165

GLOSARI TERMA, SINGKATAN DAN AKRONIM
*GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS* ..... 166




# MENGENAI LAPORAN INI

Laporan Tahunan Program Perkhidmatan Farmasi 2025 merekodkan tadbir urus dan pencapaian Program Farmasi serta aktiviti bagi perkhidmatan farmasi di bawah Kementerian Kesihatan Malaysia (KKM) sepanjang tahun 2025. Laporan ini menyediakan gambaran menyeluruh berkaitan strategi dan inisiatif yang dilaksanakan oleh Program ini dalam menyampaikan perkhidmatan farmasi terbaik kepada rakyat.

# *ABOUT THIS REPORT*

*Pharmaceutical Services Programme Annual Report 2025 reported on the governance and achievements of the Pharmacy Programme, and activities for pharmaceutical services under the Ministry of Health (MOH) throughout the year 2025. This report provides a holistic view of the strategies and initiatives implemented by the Programme in delivering the best pharmaceutical services to the nation.*



# PROGRAM PERKHIDMATAN FARMASI

Program Perkhidmatan Farmasi (PPF) merupakan program di bawah KKM yang bertanggungjawab untuk memastikan orang awam mendapat keluaran farmaseutikal yang berkualiti, selamat dan berkesan, melindungi kepentingan mereka melalui penguatkuasaan undang-undang yang berkaitan, serta memastikan ubat-ubatan digunakan oleh penyedia perkhidmatan kesihatan dan juga pesakit secara wajar.

Sejak ditubuhkan pada tahun 1951, PPF telah melalui beberapa siri transformasi untuk memastikan perkhidmatan yang diberikan sejajar dengan hasrat kerajaan, setanding dengan perkembangan perkhidmatan farmasi sejagat serta kemajuan industri farmaseutikal.

PPF terdiri daripada lima (5) Bahagian utama yang diketuai oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi). Kelima-lima Bahagian ini mempunyai peranan yang penting dalam aspek yang berbeza dengan satu matlamat yang sama iaitu untuk menyediakan perkhidmatan farmasi yang terbaik kepada rakyat.

# *PHARMACEUTICAL SERVICES PROGRAMME*

*The Pharmaceutical Services Programme (PSP) is a programme under the MOH which is responsible for ensuring that the public gets access to safe, efficacious and quality pharmaceutical products, protecting their interest via enforcement of relevant legislations, and ensuring rational use of medicines by both healthcare providers and patients.*

*Since its establishment in 1951, PSP has gone through a series of transformations in order to ensure the services provided are in line with national transformation plans, on par with international standards and advancement of the pharmaceutical industry.*

*PSP consists of five (5) main divisions headed by the Deputy Director-General of Health (Pharmaceutical Services). These five (5) main divisions play important roles in different aspects and approaches towards the same objectives that are providing the best pharmacy services to the nation.*

## 5 BAHAGIAN UTAMA PROGRAM PERKHIDMATAN FARMASI

| BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI | BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI | BAHAGIAN PENGUATKUASAAN FARMASI | BAHAGIAN REGULATORI FARMASI NEGARA | BAHAGIAN LEMBAGA FARMASI MALAYSIA |
|---|---|---|---|---|
| *PHARMACY POLICY AND STRATEGIC PLANNING DIVISION* | *PHARMACY PRACTICE AND DEVELOPMENT DIVISION* | *PHARMACY ENFORCEMENT DIVISION* | *NATIONAL PHARMACEUTICAL REGULATORY AGENCY* | *PHARMACY BOARD MALAYSIA DIVISION* |

## PIAGAM PELANGGAN PROGRAM PERKHIDMATAN FARMASI 2025

## *CLIENTS' CHARTER OF THE PHARMACEUTICAL SERVICES PROGRAMME 2025*

| BIL | PIAGAM PELANGGAN \| *CLIENT CHARTER* | SASARAN *TARGET* | PENCAPAIAN *ACHIEVEMENT* |
|---|---|---|---|
| 1 | Keputusan penyenaraian ubat ke dalam Formulari Ubat KKM (FUKKM) dimaklumkan kepada pemohon dalam masa tiga (3) hari bekerja dari tarikh Mesyuarat Panel FUKKM dijalankan<br>*Notification to applicant on the result of the listing of medicine(s) into the Ministry of Health Medicine Formulary (MOHMF) done within three (3) working days from the MOHMF panel meeting date* | 100% | 100%<br>(43/43) |
| 2 | Pengeluaran Kebenaran Import/ Eksport Dadah Berbahaya dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima<br>*Issuance of Authorization for the Import/ Export of Psychotropic Substances within seven (7) working days upon receipt of complete application* | 100% | 100%<br>(295/295) |
| 3 | Pengeluaran Kebenaran Import/ Eksport Bahan Psikotropik dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima<br>*Issuance of Authorization for the Import/ Export of Psychotropic Substances within seven (7) working days upon receipt of complete application* | 100% | 100%<br>(382/382) |
| 4 | Kelulusan e-Permit (Eksport) Bahan Kimia Prekursor dalam tempoh tujuh (7) hari bekerja dari tarikh permohonan lengkap diterima<br>*Issuance of e-Permit (Export) Precursor Chemical within seven (7) working days upon receipt of complete application* | 100% | 100%<br>(1,206/1,206) |
| 5 | Kelulusan e-Permit (Import) Bahan Terkawal dalam tempoh tiga (3) hari bekerja dari tarikh permohonan lengkap diterima<br>*Issuance of e-Permit (Import) Controlled Substance within three (3) working days upon receipt of complete application* | 100% | 100%<br>(998/998) |
| 6 | Keputusan bagi permohonan sijil iklan ubat dan iklan perkhidmatan kesihatan (selain iklan laman web) dibuat dalam tempoh lima (5) hari bekerja dari tarikh permohonan lengkap diterima<br>*Decision for application of medicines advertisement certificate and healthcare services advertisement certificate (other than website advertisement) made within five (5) working days upon receipt of complete application* | 90% | 97.75%<br>(4,352/4,452) |
| 7 | Keputusan bagi permohonan sijil iklan ubat dan iklan perkhidmatan kesihatan dalam laman web dibuat dalam tempoh 30 hari dari tarikh permohonan lengkap diterima<br>*Decision for application of medicines advertisement certificate and healthcare services advertisement certificate for website advertisements made within 30 days upon receipt of complete application* | 90% | 95.11%<br>(253/266) |
| 8 | Aduan berkaitan kesalahan di bawah undang-undang farmasi yang diterima diberi maklum balas tindakan dalam tempoh 14 hari bekerja dari tarikh aduan lengkap diterima<br>*Complaint related to infringement of Pharmacy Laws responded within 14 working days upon receipt of complete complaint* | 100% | 100%<br>(1,605/1,605) |
| 9 | Sampel aduan selesai dianalisis oleh Makmal Forensik Kimia Bahagian Penguatkuasaan Farmasi dalam tempoh 30 hari bekerja dari tarikh penerimaan sampel lengkap<br>*Complaint sample completed analysis by Pharmacy Enforcement Division Chemical Forensic Laboratory within 30 working days from the sample receipt date* | 90% | 78.01%<br>(110/141) |
| 10 | Laporan analisa peranti digital disiapkan dalam tempoh 120 hari dari tarikh penerimaan peranti<br>*Digital device analysis report completed within 120 days upon receipt of the device* | 75% | 96.05%<br>(170/177) |
| 11 | Pengeluaran Sijil Pendaftaran Ahli Farmasi dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan<br>*Issuance of Full Registration of Pharmacist's Certificate within seven (7) working days upon receipt of complete application and in accordance with legislation* | 100% | 100%<br>(1,151/1,151) |
| 12 | Pengeluaran Sijil Pendaftaran Pertubuhan Perbadanan dalam tempoh enam (6) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan<br>*Issuance of Registration of Body Corporate's Certificate within six (6) working days upon receipt of complete application and in accordance with legislation* | 100% | 100%<br>(83/83) |
| 13 | Pengeluaran Sijil Tahunan Ahli Farmasi dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan<br>*Issuance of Annual Certificate of Pharmacist within seven (7) working days upon receipt of complete application and in accordance with legislation* | 100% | 100%<br>(23,694/ 23, 694) |
| 14 | Pengeluaran Sijil Pendaftaran Ahli Farmasi Provisional dalam tempoh tujuh (7) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan<br>*Issuance of Registration of Provisional Pharmacist's Certificate within seven (7) working days upon receipt of complete application and in accordance with legislation* | 100% | 100%<br>(1,115/1,115) |
| 15 | Pengeluaran Sijil Tahunan Pertubuhan Perbadanan dalam tempoh enam (6) hari bekerja dari tarikh terima permohonan lengkap dan menurut perundangan<br>*Issuance of the Annual Certificate of Body Corporate within six (6) working days upon receipt of a complete application and in accordance with legislation* | 100% | 100%<br>(1,541/1,541) |

## PIAGAM PELANGGAN TERAS KEMENTERIAN KESIHATAN MALAYSIA 2025

## *CLIENTS' CHARTER OF THE MINISTRY OF HEALTH 2025*

| BIL | PIAGAM PELANGGAN \| *CLIENT CHARTER* | SASARAN *TARGET* | PENCAPAIAN *ACHIEVEMENT* |
|---|---|---|---|
| 1 | Preskripsi didispen dalam tempoh 30 minit<br>*Prescription dispensed in 30 minutes* | 95% | 93.51%<br>(43,280,999/<br>46,285,006) |
| 2 | Sijil Pendaftaran Ahli Farmasi diproses dalam tempoh tujuh (7) hari bekerja<br>*Pharmacist Registration Certificate processed within seven (7) working days* | 100% | 100%<br>(1,151/1,151) |



## VISI | *VISION*

Meningkatkan kesihatan rakyat menerusi kecemerlangan dalam amalan farmasi

*Enchancing our nation's health through excellence in the practice of pharmacy*

## MISI | *MISSION*

Menguatkuasakan undang-undang dan memperbaharui polisi untuk memastikan produk dan perkhidmatan farmaseutikal adalah berkualiti

*Uphold legislation and improve policies to ensure the quality of pharmaceutical products and services*

Memastikan sistem organisasi yang efektif dan responsif ke arah kelestarian perkhidmatan berkualiti

*Ensure effective and responsive organisational system towards sustainable quality services*

Membina keupayaan dan profesionalisme menerusi pembangunan bakat dan pemerkasaan tenaga kerja

*Build capabilities and professionalism through talent development and workforce empowerment*

Memperhebat kerjasama ke arah mencapai piawaian dan amalan terbaik

*Intensify collaboration towards best practices and standards*

Menjamin kesihatan rakyat melalui kawalan regulatori ubat-ubatan dan kosmetik berlandaskan kecemerlangan saintifik

*To safeguard the nation's health through scientific excellence in the regulatory control of medicinal products and cosmetics*

# OBJEKTIF BAHAGIAN | *DIVISION'S OBJECTIVES*

## BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI
## *PHARMACY POLICY AND STRATEGIC PLANNING DIVISION*

- Membangunkan dasar untuk sektor farmaseutikal selaras dengan keperluan penjagaan kesihatan negara
- Memastikan pengurusan sumber yang efisien dan cemerlang

- *Develop policies for the pharmaceutical sector in line with the needs of national health care*
- *Ensure excellent and efficient resources management*

## BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI
## *PHARMACY PRACTICE AND DEVELOPMENT DIVISION*

- Memastikan kebolehcapaian berterusan terhadap ubat-ubatan yang berkualiti, selamat dan kos efektif
- Memperkukuh penggunaan ubat-ubatan secara berkualiti dan rasional ke arah kesihatan yang lebih baik
- Meningkatkan perkhidmatan penjagaan farmaseutikal selaras dengan piawaian dan amalan terbaik

- *Ensure continuous access to the quality, safe and cost-effective medicines*
- *Strengthen the quality and rational use of medicines towards the better health*
- *Enhance pharmaceutical care services in line with the good standards and best practices*

## BAHAGIAN PENGUATKUASAAN FARMASI
## *PHARMACY ENFORCEMENT DIVISION*

- Memastikan penjualan, pembekalan, pemilikan dan pengiklanan substans, produk dan kosmetik mematuhi peruntukan undang-undang

- *Ensure all sales, supply, possession and advertising of substances, products and cosmetics are in compliance with the legal provisions*

## BAHAGIAN REGULATORI FARMASI NEGARA
## *NATIONAL PHARMACEUTICAL REGULATORY AGENCY*

- Memastikan bahawa bahan-bahan terapeutik yang dibenarkan di pasaran tempatan adalah selamat, berkesan dan berkualiti serta kosmetik yang telah dinotifikasikan adalah selamat dan berkualiti


- *To ensure that therapeutic substances approved for the local market are safe, effective and of quality and to ensure that notified cosmetic products are safe and of quality*

## BAHAGIAN LEMBAGA FARMASI MALAYSIA
## *PHARMACY BOARD MALAYSIA DIVISION*

- Memastikan pendaftaran ahli farmasi dan pertubuhan perbadanan mematuhi Akta Pendaftaran Ahli Farmasi 1951 dan peraturan-peraturannya
- Menetapkan piawai untuk etika, tingkah laku, kemahiran, pendidikan dan latihan serta Pembangunan Profesional Berterusan (CPD)

- *Ensure the registration of pharmacists and bodies corporate complies with Registration of Pharmacists Act 1951 and its regulations*
- *Set the standard for conduct, ethics, proficiency, education and training and Continuous Professional Development (CPD)*

# CARTA ORGANISASI
## *ORGANISATIONAL CHART*



# KEPIMPINAN KAMI | *OUR LEADERS*

## PIMPINAN PENGURUSAN ATASAN | *TOP MANAGEMENT*



**TIMBALAN KETUA PENGARAH KESIHATAN**

**Dr. Azuana binti Ramli**

Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi)

*Deputy Director-General of Health (Pharmaceutical Services)*



**PENGARAH BAHAGIAN**

**Puan Wan Noraimi binti Wan Ibrahim**

Pengarah Bahagian Regulatori Farmasi Negara

*Director of National Pharmaceutical Regulatory Agency*



**PENGARAH BAHAGIAN**

**Encik Mohd Zawawi bin Abdullah**

Pengarah Bahagian Penguatkuasaan Farmasi

*Director of Pharmacy Enforcement Division*



**PENGARAH BAHAGIAN**

**Puan Zuhaini binti Mukrim**

Pengarah Bahagian Amalan & Perkembangan Farmasi

*Director of Pharmacy Practice & Development Division*



**PENGARAH BAHAGIAN**

**Puan Siti Aisah binti Bahari**

Pengarah Bahagian Dasar & Perancangan Strategik Farmasi

*Director of Pharmacy Policy & Strategic Planning Division*



**PENGARAH BAHAGIAN**

**Puan Akmalyatun Kamal binti Kamaruddin**

Pengarah Bahagian Lembaga Farmasi Malaysia

*Director of Pharmacy Board Malaysia Division*

## BAHAGIAN DASAR & PERANCANGAN STRATEGIK FARMASI
## *PHARMACY POLICY & STRATEGIC PLANNING DIVISION*



**Puan Nur'Ain Shuhaila binti Shohaimi**
Timbalan Pengarah Cawangan Dasar Farmasi
*Deputy Director of Pharmacy Policy Branch*



**Puan Hazlinda Nazli binti Naem**
Timbalan Pengarah Cawangan Pembangunan Profesion Farmasi
*Deputy Director of Pharmacy Professional Development Branch*



**Dr. Abdul Haniff bin Mohamad Yahaya**
Timbalan Pengarah Cawangan Penyelidikan dan Pembangunan Farmasi
*Deputy Director of Pharmacy Research & Development Branch*



**Puan Nadzifah @ Rashidah binti Mohd Ariffin**
Timbalan Pengarah Cawangan Teknologi Maklumat dan Informatik Farmasi
*Deputy Director of Pharmacy Information Technology and Informatics Branch*



**Puan Nurhairani binti Abdul Latif**
Timbalan Pengarah Cawangan Perkembangan Infrastruktur dan Kualiti Farmasi
*Deputy Director of Pharmacy Infrastructure Development and Quality Branch*



**Encik Sabuting @ Sobiting bin Matanggal**
Ketua Profesion Cawangan Pembangunan Profesion Penolong Pegawai Farmasi
*Head of Profession for the Pharmacist Assistants Professional Development Branch*

## BAHAGIAN AMALAN & PERKEMBANGAN FARMASI
## *PHARMACY PRACTICE & DEVELOPMENT DIVISION*



**Puan Syahida binti Che Embi**
Timbalan Pengarah Cawangan Penjagaan Farmaseutikal
*Deputy Director of Pharmaceutical Care Branch*



**Puan Nur Azibahwati binti Aziz**
Timbalan Pengarah Cawangan Pengurusan Farmasi Logistik
*Deputy Director of Logistic Pharmacy Management Branch*



**Puan Fatkhiah binti Hj Khalil**
Timbalan Pengarah Cawangan Pengurusan Harga Ubat
*Deputy Director of Medicines Pricing Branch*



**Dr. Rosliana binti Rosli**
Timbalan Pengarah Cawangan Pengurusan Formulari
*Deputy Director of Formulary Management Branch*



**Puan Munira binti Muhammad**
Timbalan Pengarah Cawangan Penggunaan Ubat Berkualiti
*Deputy Director of Quality Use of Medicines Branch*

## BAHAGIAN PENGUATKUASAAN FARMASI
## *PHARMACY ENFORCEMENT DIVISION*



**Puan Nor Aza binti Hassan**
Timbalan Pengarah Cawangan Perundangan
*Deputy Director of Legislation Branch*



**Puan Saleha binti Abdul Rahman @ Ngah**
Timbalan Pengarah Cawangan Forensik Farmasi
*Deputy Director of Pharmacy Forensic Branch*



**Puan Asniza binti Alias**
Timbalan Pengarah Cawangan Kawalan Iklan
*Deputy Director of Advertisement Control Branch*



**Puan Siti Mariaton binti Abd Moksin**
Timbalan Pengarah Cawangan Pelesenan
*Deputy Director of Licensing Branch*



**Encik Mohd Azaruddin bin Azis**
Timbalan Pengarah Cawangan Perisikan dan Operasi
*Deputy Director of Intelligence and Operation Branch*

## BAHAGIAN REGULATORI FARMASI NEGARA
## *NATIONAL PHARMACEUTICAL REGULATORY AGENCY*



**Dr. Noraida binti Mohamad Zainoor**
Timbalan Pengarah
Pusat Koordinasi dan Perancangan Strategik Regulatori
*Deputy Director for the Centre of Regulatory Coordination and Strategic Planning*



**Dr. Rosliza binti Lajis**
Timbalan Pengarah
Pusat Penilaian Produk dan Kosmetik
*Deputy Director for the Centre of Product and Cosmetic Evaluation*

**Kosong**
Timbalan Pengarah
Pusat Komplians dan Kawalan Kualiti
*Deputy Director for the Centre of Compliance and Quality Control*

## BAHAGIAN LEMBAGA FARMASI MALAYSIA
## *PHARMACY BOARD MALAYSIA DIVISION*



**Puan Nurulfajar binti Mohd Jamid**
Timbalan Pengarah
Cawangan Pengiktirafan dan Etika
*Deputy Director of Accreditation and Ethics Branch*



**Puan Nurul Adha binti Othman**
Timbalan Pengarah
Cawangan Pendaftaran
*Deputy Director of Registration Branch*

## PENTADBIRAN SOKONGAN
## *MANAGEMENT SUPPORT*



**Puan Azlin binti Ahmad**
Ketua Unit
Pusat Pentadbiran Bahagian Regulatori Farmasi Negara
*Head of Administrative Unit, National Pharmaceutical Regulatory Agency*



**Puan Nur 'Amirah binti Mohd Maaszali**
Ketua Unit Pentadbiran
Bahagian Dasar dan Perancangan Strategik Farmasi
*Head of Administrative Unit, Pharmacy Policy and Strategic Planning Division*



**Puan Halipah binti Hamdan**
Ketua Unit Kewangan
Bahagian Dasar dan Perancangan Strategik Farmasi
*Head of Finance Unit, Pharmacy Policy and Strategic Planning Division*

# JAWATANKUASA EDITORIAL
# *EDITORIAL COMMITTEE*

## PENAUNG | *PATRON*

**YBRS. DR. AZUANA BINTI RAMLI**
Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi)
*Deputy Director-General of Health (Pharmaceutical Services)*

## PENASIHAT | *ADVISOR*

**YBRS. PUAN WAN NORAIMI BINTI WAN IBRAHIM**
Pengarah Bahagian Regulatori Farmasi Negara
*Director of the National Pharmaceutical Regulatory Agency*

**YBRS. PUAN SITI AISAH BINTI BAHARI**
Pengarah Bahagian Dasar dan Perancangan Strategik Farmasi
*Director of the Pharmacy Policy and Strategic Planning Division*

**YBRS. ENCIK MOHD ZAWAWI BIN ABDULLAH**
Pengarah Bahagian Penguatkuasaan Farmasi
*Director of the Pharmacy Enforcement Division*

**YBRS. PUAN ZUHAINI BINTI MUKRIM**
Pengarah Bahagian Amalan dan Perkembangan Farmasi
*Director of the Pharmacy Practice and Development Division*

**YBRS. PUAN AKMALYATUN KAMAL BINTI KAMARUDDIN**
Pengarah Bahagian Lembaga Farmasi Malaysia
*Director of the Pharmacy Board Malaysia Division*




## JAWATANKUASA EDITORIAL
## *EDITORIAL COMMITTEE*

**BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI**
***PHARMACY POLICY AND STRATEGIC PLANNING DIVISION***

**PUAN NUR'AIN SHUHAILA BINTI SHOHAIMI**
Timbalan Pengarah
*Deputy Director*

**ENCIK MOHD AZUWAN BIN MOHD ZUBIR**
*Ketua Penolong Pengarah Kanan*
*Senior Principal Assistant Director*

**CIK SITI NURUL FATHIHAH BINTI BAHARUDIN**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**PUAN LAU LING WEI**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**PUAN NURUZ ZAKIAH BINTI MD ZIN**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**CIK ERFI ERRISSA BINTI MD TARMIZI**
Personel MySTEP
*MySTEP Personnel*

**BAHAGIAN PENGUATKUASAAN FARMASI**
***PHARMACY ENFORCEMENT DIVISION***

**PUAN TAM JIA JIA**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**ENCIK ASHRAF BIN ABDUL MUTALIB**
Ketua Penolong Pengarah
*Principal Assistant Director*

**BAHAGIAN REGULATORI FARMASI NEGARA**
***NATIONAL PHARMACEUTICAL REGULATORY AGENCY***

**PUAN NURHIDAYATI BINTI MOHAMAD**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**PUAN YOGAMALAR A/P DORAIRAJOO**
Ketua Penolong Pengarah
*Principal Assistant Director*

**BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI**
***PHARMACY PRACTICE AND DEVELOPMENT DIVISION***

**CIK NUR ADILAH BINTI A. RAHMAN**
Penolong Pengarah Kanan
*Senior Assistant Director*

**CIK WAN NUR FARISHA BINTI WAN AHMAD FAKARUDDIN**
Pegawai Farmasi Kontrak
*Contract Pharmacist*

**CIK SHARYL CHENG JIA XI**
Pegawai Farmasi Kontrak
*Contract Pharmacist*

**BAHAGIAN LEMBAGA FARMASI MALAYSIA**
***PHARMACY BOARD MALAYSIA DIVISION***

**PUAN CHAN LIN YEE**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

**PUAN NURULBALKIS @ ZUBAIDAH ANUM BINTI HAMDAN**
Ketua Penolong Pengarah Kanan
*Senior Principal Assistant Director*

# BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI

## *PHARMACY POLICY AND STRATEGIC PLANNING DIVISION*



Jumlah Perjawatan Pegawai Farmasi di Kementerian Kesihatan Malaysia sehingga tahun 2025


*Total Number of Pharmacist Post in the Ministry of Health Malaysia up to the year 2025*

**10,342**

**100%**

Peratus **Pegawai Farmasi** yang Mencapai 40 Mata CPD Minimum, 2025

*Percentage of **Pharmacist** Attaining Minimum 40 CPD Points, 2025*




**100%**

Peratus **Penolong Pegawai Farmasi** yang Mencapai 40 Mata CPD Minimum, 2025

*Percentage of **Pharmacist Assistant** Attaining Minimum 40 CPD Points, 2025*

**837**

**PEGAWAI FARMASI KONTRAK**

*CONTRACT PHARMACIST*

Jumlah Graduan Farmasi Dilantik Sebagai Pegawai Farmasi secara Kontrak 2025

*Total of Pharmacy Graduates Appointed as Contract Pharmacist 2025*





# BAHAGIAN DASAR DAN PERANCANGAN STRATEGIK FARMASI
## *PHARMACY POLICY AND STRATEGIC PLANNING DIVISION*

## 1.0 PENGENALAN | *INTRODUCTION*

01
**Dasar Farmasi**
*Pharmacy Policy*

02
**Pembangunan Profesion Farmasi**
*Pharmacy Professional Development*

03
**Perkembangan Infrastruktur dan Kualiti Farmasi**
*Pharmacy Infrastructure Development and Quality*

04
**Penyelidikan dan Pembangunan Farmasi**
*Pharmacy Research and Development*

05
**Teknologi Maklumat dan Informatik Farmasi**
*Pharmacy Information Technology and Informatics*

06
**Pembangunan Profesion Penolong Pegawai Farmasi**
*Pharmacist Assistant Professional Development*

Bahagian Dasar dan Perancangan Strategik Farmasi (BDPSF) terdiri daripada enam (6) cawangan seperti di atas. Fungsi keseluruhan Bahagian ini adalah:

1. Merancang dan menyelaras aktiviti farmasi supaya selari dengan Dasar Ubat Nasional (DUNas) dan hala tuju KKM serta penyelarasan isu-isu berkaitan dasar, aduan dan perhubungan intra agensi dan inter agensi
2. Merancang pengurusan keperluan sumber manusia dan kompetensi Pegawai Farmasi dan Penolong Pegawai Farmasi di seluruh negara supaya lebih efisen dan cemerlang
3. Menyelaras dan memantau pembangunan infrastruktur farmasi dan sistem kualiti perkhidmatan farmasi di fasiliti kesihatan KKM
4. Merancang dan menyelaras halatuju serta aktiviti-aktiviti penyelidikan dan pembangunan bagi PPF
5. Merancang, menyelaras dan melaksanakan keperluan prasarana ICT, keselamatan ICT, penyelenggaraan peralatan/ rangkaian/ bilik server dan perisian ICT jabatan
6. Menyelaras dan melaksanakan pengurusan perkhidmatan, pengurusan aset dan stor, pengurusan perolehan, pengurusan kenderaan serta pengurusan fail dan dokumen bagi anggota di PPF
7. Menyelaras dan memantau kedudukan perbelanjaan dan kewangan PPF supaya lebih efisien

*Pharmacy Policy and Strategic Planning Division (BDPSF) consists of six (6) branches as above. The overall functions of the Division are:*

1. *Planning and coordinating pharmacy activities to be in line with the National Medicines Policy (DUNas) and the way forward of the MOH as well as coordinating policy-related issues, complaints and intra-agency and inter-agency relations*
2. *Planning for the management of human resource needs and competency of Pharmacy Officers and Pharmacist Assistant throughout the country to be more efficient and excellent*
3. *Coordinating and monitoring the development of pharmacy infrastructures and quality system of the pharmacy services at MOH health facilities*
4. *Planning and coordinating research and development priorities and activities for the Pharmaceutical Services Programme (PSP)*
5. *Planning, coordinating and implementing ICT infrastructure requirements, ICT security, maintenance of equipment/ network/ server room and departmental ICT software*
6. *Coordinating, performing and attending administrative matters, assets and store management, procurement management, transport/ fleet management as well as filing and document organization for PSP workforce*
7. *Coordinating and monitoring expenditure and financial status of the PSP to be more efficient*



## 2.0 AKTIVITI DAN SOROTAN | *ACTIVITIES AND HIGHLIGHTS*

### MESYUARAT KONSULTATIF ASEAN MENGENAI ASEAN DRUG SECURITY AND SELF–RELIANCE (ADSSR): PEMBANGUNAN PELAN STRATEGIK DAN PELAKSANAAN

Malaysia telah menganjurkan Mesyuarat Konsultatif ASEAN Keterjaminan dan Kemandirian Ubat-Ubatan ASEAN (ADSSR): Pembangunan Pelan Tindakan Strategik dan Pelaksanaan, pada 23 – 25 September 2025 di Putrajaya, Malaysia. Mesyuarat perundingan ini telah diadakan susulan Deklarasi Komitmen Pemimpin ASEAN mengenai Keterjaminan dan Kemandirian Ubat-Ubatan ASEAN (ADC ADSSR) pada Sidang Kemuncak ASEAN ke-46 pada 26 Mei 2026 di Kuala Lumpur. Mesyuarat ini telah dirasmikan oleh Ketua Pengarah Kesihatan Malaysia, manakala ucapan alu-aluan telah disampaikan oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi); ianya mencerminkan sokongan dan komitmen penuh terhadap inisiatif ADSSR.

Hari pertama mesyuarat merangkumi lapan sesi pembentangan oleh penceramah jemputan serta pembentangan negara oleh ASEAN Member States (AMS) dan Timor-Leste. Mesyuarat ini telah dihadiri oleh wakil dari Brunei, Kemboja, Indonesia, Malaysia, Filipina, Singapura, Thailand dan Timor-Leste serta Sekretariat ASEAN. Penceramah jemputan telah berkongsi situasi terkini mengenai keterjaminan ubat-ubatan mengikut kitaran hayat farmaseutikal, manakala AMS dan Timor-Leste telah membentangkan isu cabaran keterjaminan ubat-ubatan di negara masing-masing serta langkah-langkah mengatasinya.

Hari kedua dan ketiga mesyuarat merupakan sesi tertutup yang dipengerusikan oleh Malaysia dengan objektif utama untuk membangunkan pelan tindakan strategik dan Rangka Kerja Pelaksanaan bagi inisiatif ADSSR. Mesyuarat ini juga bertujuan untuk mengenal pasti bidang keutamaan bagi pelaksanaan ADSSR serta menentukan tindakan khusus bagi menangani cabaran sedia ada.

### *ASEAN CONSULTATIVE MEETING ON THE ASEAN DRUG SECURITY AND SELF-RELIANCE (ADSSR): DEVELOPMENT OF THE STRATEGIC PLAN OF ACTION AND IMPLEMENTATION*

*Malaysia hosted the ASEAN Consultative Meeting on ASEAN Drug Security and Self-Reliance (ADSSR): Development of the Strategic Plan of Action and Implementation, from 23 – 25 September 2025 in Putrajaya, Malaysia. This consultative meeting was convened following the adoption of the ASEAN Leaders Declaration of Commitment on ASEAN Drug Security and Self-Reliance (ADC ADSSR) at the 46th ASEAN Summit on 26 May 2026 in Kuala Lumpur. The meeting was officiated by the Director General of Health Malaysia, while welcoming remarks were delivered by the Deputy Director General of Health (Pharmaceutical Services), showing their utmost support and commitment towards the ADSSR initiatives.*

*The first day of the meeting featured eight sessions of presentations by invited speakers and country presentations by representatives from ASEAN Member States (AMS) and Timor-Leste. This meeting was attended by representatives from Brunei, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand and Timor-Leste and the ASEAN Secretariat. Invited speakers provided updates on medicines security according to the pharmaceutical life-cycle while the AMS and Timor-Leste highlighted challenges of medicines security in their country and how they overcame it.*

*The second and third day of the meeting was a closed session, chaired by Malaysia with the primary objective to develop a strategic plan of action and implementation Framework for the ADSSR initiative. The consultative meeting also aimed to define priority areas for ADSSR implementation and identify specific actions to address existing challenges.*




Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi) Malaysia bersama wakil dari ASEAN dan Sekretariat ASEAN
*The Deputy Director General of Health (Pharmaceutical Services) Malaysia and representatives from ASEAN Member States and the ASEAN Secretariat*




Mesyuarat tertutup antara wakil dari ASEAN dan Sekretariat ASEAN
*Closed meeting between representatives of ASEAN Member States and the ASEAN Secretariat*

## SESI LIBAT URUS EKOSISTEM FARMASEUTIKAL NEGARA

Satu Deklarasi Komitmen ASEAN mengenai Keterjaminan dan Kemandirian Ubat-ubatan di ASEAN, *ASEAN Drug Security & Self Reliance* (ADSSR) telah dimeterai oleh para pemimpin tertinggi negara anggota ASEAN pada Sidang Kemuncak ASEAN ke-46 di Kuala Lumpur pada 26 Mei 2025 dan KKM telah diberikan mandat untuk menerajui pelaksanaan projek kolaborasi ADSSR bersama kementerian dan agensi berkaitan. Justeru, satu pelan hala tuju peringkat kebangsaan perlu dibangunkan untuk memastikan keterjaminan ubat-ubatan di Malaysia.

Cawangan Penyelidikan dan Pembangunan Farmasi, Bahagian Dasar dan Perancangan Strategik Farmasi telah mengadakan Sesi Libat Urus Ekosistem Farmaseutikal Negara pada 17 – 19 September 2025, di *Putrajaya International Convention Centre, PICC*. Seramai 75 orang peserta dari sektor awam dan swasta termasuk wakil pemain industri farmaseutikal telah mengambil bahagian di dalam sesi libat urus ini yang bertujuan untuk membangunkan Pelan Hala Tuju Keterjaminan Ubat-ubatan di Malaysia *(Malaysia Medicine Security, MyMedSecure)*. Selain itu, sesi libat urus ini juga bertujuan untuk mendapatkan pandangan/ input daripada para pemegang taruh berkaitan perkara-perkara berikut:

Isu utama berkaitan keterjaminan ubat-ubatan di Malaysia

1. Ketersediaan polisi/ garis panduan sekitar inisiatif keterjaminan ubat-ubatan di Malaysia;
2. Peluang sedia ada yang dapat dimanfaatkan untuk memacu keterjaminan ubat-ubatan di Malaysia;
3. Kekuatan ekosistem farmaseutikal Malaysia yang wajar diketengahkan di rantau ASEAN melalui platform ADSSR; dan
4. Cadangan penambahbaikan bagi memastikan keterjaminan ubat-ubatan di Malaysia tercapai.

## *NATIONAL PHARMACEUTICAL ECOSYSTEM ENGAGEMENT SESSION*

*A Declaration of Commitment by ASEAN on Drug Security and Self-Reliance in ASEAN, known as the ASEAN Drug Security & Self-Reliance (ADSSR), was endorsed by the Heads of Government of ASEAN Member States at the 46th ASEAN Summit in Kuala Lumpur on 26 May 2025. The MOH has been mandated to lead the implementation of collaborative ADSSR projects together with relevant ministries and agencies. In this regard, a national-level roadmap needs to be developed to ensure medicine security in Malaysia.*

*The Pharmacy Research and Development Branch, Pharmaceutical Policy and Strategic Planning Division, organised the National Pharmaceutical Ecosystem Stakeholder Engagement Session from 17 - 19 September 2025 at the Putrajaya International Convention Centre (PICC). A total of 75 participants from both the public and private sectors, including representatives from the pharmaceutical industry, took part in this engagement session. The session aimed to develop the Malaysia Medicine Security Roadmap (Malaysia Medicine Security, MyMedSecure). In addition, the engagement session sought to gather views/ inputs from stakeholders on the following matters:*

*Key issues related to medicine security in Malaysia*

1. *The availability of policies/ guidelines related to medicine security initiatives in Malaysia;*
2. *Existing opportunities that can be leveraged to advance medicine security in Malaysia;*
3. *Strengths of Malaysia's pharmaceutical ecosystem that should be highlighted at the ASEAN level through the ADSSR platform; and*
4. *Recommendations for improvement to ensure the achievement of medicine security in Malaysia.*



Para peserta sedang berbincang dan memberikan idea bernas bagi membangunkan Pelan Hala Tuju Keterjaminan Ubat-ubatan di Malaysia *(MyMedSecure)*
*Participants engaging in discussions and contributing constructive ideas towards the development of the Malaysia Medicine Security Roadmap (MyMedSecure)*

## BENGKEL PENYEDIAAN LAPORAN PANEL PAKAR *MALAYSIAN STATISTICS ON MEDICINES (MSOM)* 2023-2024

Bengkel Penyediaan Laporan *Malaysian Statistics on Medicines (MSOM)* 2023–2024 telah diadakan pada 16 dan 17 Julai 2025 bertempat di *Putrajaya International Convention Centre (PICC)*, Putrajaya. Bengkel ini telah dirasmikan oleh Puan Siti Aisah binti Bahari, Pengarah Bahagian Dasar dan Perancangan Strategik Farmasi. Bengkel ini menghimpunkan pakar perubatan dan pegawai farmasi daripada pelbagai disiplin kepakaran untuk meneliti serta membincangkan dapatan awal Laporan MSOM 2023–2024. Perbincangan disusun mengikut bab-bab dalam laporan MSOM bagi memastikan input yang bersasar dan sistematik.

Objektif utama bengkel ini adalah untuk mendapatkan maklum balas daripada kumpulan pakar dalam bidang masing-masing berkaitan corak penggunaan ubat-ubatan di Malaysia. Tumpuan diberikan kepada analisa terhadap perubahan corak penggunaan ubat antara tahun 2023 dan 2024, serta faktor-faktor yang mempengaruhi perubahan tersebut, termasuk amalan klinikal, kemaskini garis panduan rawatan dan perubahan dasar kesihatan semasa.

Panel pakar menilai data penggunaan ubat-ubatan mengikut kepakaran masing-masing dan memberikan tafsiran terhadap pola penggunaan ubat-ubatan. Perbincangan turut menyasarkan kepada pengenalpastian faktor-faktor yang menyumbang kepada perubahan corak penggunaan, seperti pengenalan garis panduan baharu, perkembangan pilihan rawatan, perubahan beban penyakit, serta pelaksanaan dasar dan program kesihatan. Maklum balas yang diterima adalah penting untuk memperkukuhkan ketepatan dan kefahaman dapatan laporan MSOM.

Bengkel ini telah berjaya mengumpulkan pandangan dan maklum balas daripada pakar pelbagai bidang kepakaran. Input yang diperoleh telah menyumbang secara signifikan kepada peningkatan kualiti dan ketepatan. Laporan MSOM 2023–2024, sekali gus memastikan MSOM terus berfungsi sebagai rujukan yang berimpak dalam pemantauan penggunaan ubat-ubatan di Malaysia.

## *MALAYSIAN STATISTICS ON MEDICINES (MSOM) REPORT PREPARATION WORKSHOP 2023-2024*

*The MSOM report preparation workshop 2023-2024 was conducted on 16–17 July 2025 at the Putrajaya International Convention Centre (PICC), Putrajaya. The workshop was officiated by Puan Siti Aisah binti Bahari, Director of Pharmacy Policy and Strategic Planning Division. The workshop brought together multidisciplinary experts and stakeholders to review and deliberate on the preliminary findings of the MSOM 2023–2024 report. Discussions were structured according to the respective chapters of the report to ensure focused and systematic input.*

*The primary objective of the workshop was to obtain expert feedback from specialists across various clinical disciplines on medicine utilisation trends in Malaysia. Emphasis was placed on identifying and interpreting changes in utilisation patterns between 2023 and 2024, as well as providing contextual explanations based on clinical practice, guideline updates, and policy developments.*

*Expert panels reviewed medicine utilisation data relevant to their respective specialties and provided narrative interpretations of observed trends. Discussions focused on identifying potential drivers of changes in utilisation patterns, including the introduction of new clinical guidelines, emerging therapeutic options, shifts in disease burden, and policy or programme-related interventions. Feedback was provided to enhance the clarity, clinical relevance, and interpretability of the MSOM findings.*

*The workshop successfully facilitated meaningful engagement with clinical experts across multiple disciplines. The feedback and insights obtained were instrumental in strengthening the analytical depth, accuracy, and relevance of the MSOM 2023–2024 report. Overall, the workshop contributed to ensuring that the MSOM remains a robust and policy-relevant reference for monitoring medicine utilisation in Malaysia.*




Ahli-ahli Bengkel Penyediaan Laporan *Malaysian Statistics on Medicines (MSOM)* 2023–2024 yang hadir
*MSOM 2023-2024 Report Preparation Workshop Members attended*

## MESYUARAT JAWATANKUASA TEKNIKAL PENYELIDIKAN FARMASI (KLUSTER PENYELIDIKAN) 2025

Mesyuarat Jawatankuasa Teknikal Penyelidikan Farmasi (Kluster Penyelidikan) telah diadakan pada 26 Februari 2025 bertempat di Kompleks Jabatan Perdana Menteri, Putrajaya. Mesyuarat ini dirasmikan oleh Dr. Abdul Haniff bin Mohamad Yahaya, Timbalan Pengarah Bahagian Dasar dan Perancangan Strategik Farmasi (Cawangan Penyelidikan dan Pembangunan Farmasi). Mesyuarat ini melibatkan penyertaan pegawai farmasi serta ahli akademik yang telah dilantik dan dibahagikan mengikut kluster masing-masing. Sebanyak lapan (8) Kluster Penyelidikan telah dikenalpasti, iaitu:

5. *Medicine Development, Industry & Regulatory*
6. *Access to Medicines*
7. *Pharmacotherapy Optimisation*
8. *Pharmacy Policy & Practice*
9. *Medicine Consumerism*
10. *Digital-in-health & Data Analytics*
11. *Governance & Pharmacy Enforcement*
12. *Pharmacy Workforce & Capacity Building*

Objektif utama mesyuarat ini adalah untuk mengenal pasti tajuk-tajuk penyelidikan farmasi yang berpotensi dilaksanakan berdasarkan jurang penyelidikan (research gaps) dalam domain berkaitan dan keperluan khusus setiap kluster. Selain itu, mesyuarat ini turut bertujuan untuk mencadangkan keperluan latihan bagi pembangunan kapasiti serta menetapkan hala tuju dan perancangan strategik bagi setiap kluster penyelidikan.

Hasil perbincangan di peringkat kluster telah membolehkan Cawangan Penyelidikan dan Pembangunan (R&D) Farmasi mengenal pasti serta menyenarai pendek Bidang Kajian Keutamaan Tinggi Penyelidikan Farmasi. Senarai tersebut kemudiannya telah dibentangkan kepada Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi) dalam Mesyuarat Polisi Bil. 4/2025 pada 17 November 2025.

## *PHARMACEUTICAL RESEARCH TECHNICAL COMMITTEE (RESEARCH CLUSTER) MEETING 2025*

*The Pharmaceutical Research Technical Committee (Research Cluster) Meeting was held on 26 February 2025 at the Prime Minister's Complex, Putrajaya. The meeting was officiated by Dr. Abdul Haniff bin Mohamad Yahaya, Deputy Director of the Pharmacy Policy and Strategic Planning Division (Pharmacy Research and Development (R&D) Branch).*

*The meeting involved the participation of appointed pharmacy officers and academicians, who were grouped according to their respective clusters. A total of eight (8) Research Clusters were identified, namely:*

1. *Medicine Development, Industry & Regulatory*
2. *Access to Medicines*
3. *Pharmacotherapy Optimisation*
4. *Pharmacy Policy & Practice*
5. *Medicine Consumerism*
6. *Digital-in-Health & Data Analytics*
7. *Governance & Pharmacy Enforcement*
8. *Pharmacy Workforce & Capacity Building*

*The main objective of the meeting was to identify potential pharmacy research topics that could be undertaken based on research gaps within the relevant domains and the specific needs of each cluster. In addition, the meeting aimed to propose capacity-building training requirements and to establish the direction and strategic planning for each research cluster.*

*The outcomes of the cluster-level discussions enabled the Pharmacy Research and Development Branch to identify and shortlist High Priority Pharmacy Research Areas. This list was subsequently presented to the Deputy Director-General of Health (Pharmaceutical Services) during Policy Meeting No. 4/2025 held on 17 November 2025.*



Ahli-ahli dan sekretariat Mesyuarat Jawatankuasa Teknikal Penyelidikan Farmasi (Kluster Penyelidikan) 2025
*Members and Secretariat of The Pharmaceutical Research Technical Committee (Research Cluster) Meeting 2025*

## PERSIDANGAN *1ST EAST COAST PHARMACY RESEARCH & QUALITY ASSURANCE* 2025

Persidangan *1st East Coast Pharmacy Research & Quality Assurance Conference* 2025 telah berjaya dianjurkan pada 29 hingga 30 Ogos 2025 di AC Hotel by Marriott, Kuantan, Pahang. Bertemakan *"Pharmacy Revolution with Technology: Transforming Research & Quality Initiatives into Smarter Patient Care"*, persidangan ini menekankan peranan teknologi sebagai pemangkin utama dalam memajukan penyelidikan farmasi serta memperkukuh inisiatif kualiti bagi meningkatkan kecekapan dan keberkesanan penjagaan pesakit.

Seramai 200 peserta telah menyertai persidangan ini, terdiri daripada ahli farmasi dan pegawai penyelidik sektor awam, institusi akademik serta pemerhati dari negeri-negeri seluruh Malaysia. Persidangan ini bertujuan memperkukuh aktiviti penyelidikan dan amalan berasaskan bukti, meningkatkan pelaksanaan inisiatif kualiti farmasi serta penambahbaikan berterusan, menyediakan platform formal bagi penyebaran hasil kajian, dan menggalakkan kolaborasi serta perkongsian ilmu dalam kalangan profesional.

Pelaksanaan persidangan merangkumi dua sesi plenari, pembentangan lisan dan poster bagi dua kategori - penyelidikan dan pembangunan (R&D) serta *Quality Assurance* (QA). Sesi *Quick Pitch* telah diadakan bagi pembentangan poster R&D serta Forum Inisiatif Kualiti yang menampilkan panel ahli farmasi berpengalaman untuk berkongsi pandangan mengenai inovasi berasaskan teknologi dan pemerkasaan kualiti dalam perkhidmatan farmaseutikal. Keseluruhan sesi ini menyediakan platform komprehensif kepada peserta untuk membentangkan hasil kajian, audit dan projek penambahbaikan kualiti, di samping menggalakkan perbincangan ilmiah serta penilaian kritikal secara berstruktur.

Persidangan ini telah berjaya meningkatkan penglibatan dalam penyelidikan dan inisiatif kualiti farmasi dengan menyediakan platform rasmi untuk perkongsian serta perbincangan ilmiah, menggalakkan penerapan amalan berasaskan bukti dan kualiti, serta menjadi asas kukuh kepada penganjuran persidangan seumpamanya pada masa akan datang.

## *1ST EAST COAST PHARMACY RESEARCH & QUALITY ASSURANCE CONFERENCE 2025*

*The 1st East Coast Pharmacy Research & Quality Assurance Conference 2025 was successfully held from 29 to 30 August 2025 at AC Hotel by Marriott, Kuantan, Pahang, serving as a strategic regional platform to strengthen research capacity and quality initiatives within pharmaceutical services, while fostering a culture of research- and quality-driven practices among pharmacy professionals. The conference, themed "Pharmacy Revolution with Technology: Transforming Research & Quality Initiatives into Smarter Patient Care," emphasised the role of technology as a key catalyst in advancing pharmaceutical research and strengthening quality initiatives to enhance the efficiency and effectiveness of patient care.*

*A total of 200 participants attended the conference, comprising pharmacists and research officers from the public sector, academic institutions, as well as observers from various states across Malaysia. The conference aimed to strengthen research activities and evidence-based practices, enhance the implementation of pharmacy quality initiatives and continuous improvement, provide a formal platform for the dissemination of research findings, and promote collaboration and knowledge sharing among professionals.*

*The conference programme comprised two plenary sessions, oral and poster presentations for two categories - Research and Development (R&D) as well as Quality Assurance (QA). There was a Quick Pitch Session for R&D poster presentations, as well as a Quality Initiative Forum featuring a panel of experienced pharmacists who shared insights on technology-driven innovation and quality empowerment in pharmaceutical services. Collectively, these sessions provided a comprehensive platform for participants to present research findings, audits, and quality improvement projects, while fostering structured scholarly discussion and critical appraisal.*

*Overall, the conference successfully enhanced engagement in pharmacy research and quality initiatives by providing an official platform for scholarly exchange and discussion, promoting the adoption of evidence-based and quality-focused practices, and establishing a strong foundation for the organisation of similar conferences in the future.*

### Senarai Pemenang untuk Kategori Poster R&D
### *List of Winners for R&D Poster Category*

| Kedudukan<br>*Ranking* | Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|---|
| Johan<br>*Champion* | *Investigating Decline in Estimated Glomerular Filtration Rate in Atrial Fibrillation Patients Treated with Warfarin vs Novel Oral Anticoagulants (IDEAL-AF)* | Norhidayah binti Khamar Ludin (Hospital Pekan, JKN Pahang) |
| Naib Johan<br>*Runner-up* | *Low Molecular Weight Heparin Versus Unfractionated Heparin as Venous Thromboembolism Prophylaxis in Neurosurgery* | Yeoh Mei Ting (Hospital Tengku Ampuan Afzan, JKN Pahang) |
| Tempat Ketiga<br>*Second Runner-up* | *Analysis of Pharmacist's Intervention on Prescribing Errors in Outpatient Pharmacy Setting in West Pahang Region* | Kwong Kien Seang (Hospital Raub, JKN Pahang) |
| Saguhati<br>*Consolation Prize* | *From Struggle to Strategies: A Qualitative Study on Smoking Cessation Barrier Among Patients with Chronic Obstructive Pulmonary Disease* | Lukman Nul Hakim bin Md Khairi (Hospital Sultanah Nur Zahirah, JKN Terengganu) |

### Senarai Pemenang untuk Kategori Lisan R&D
### *List of Winners for R&D Oral Category*

| Kedudukan<br>*Ranking* | Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|---|
| Johan<br>*Champion* | *Clinical and Economic Impact of Pharmacist-led Interventions on Drug-related Problems in Haematology Unit, Hospital Tengku Ampuan Afzan* | Chua Peck Wei (Hospital Sultan Haji Ahmad Shah, Temerloh, JKN Pahang) |
| Naib Johan<br>*Runner-up* | *Evaluating the Impact of Pharmacy Integrated Community Care (PICC) on Quality of Life (QOL) among Diabetic Patients in Terengganu* | Masturah binti Rosli (Bahagian Perkhidmatan Farmasi, JKN Terengganu) |
| Tempat Ketiga<br>*Second Runner-up* | *Clinical and Cost Evaluation on Oral Treatment of Iron Deficiency Anemia among Children in Pahang* | Nuratikah binti M. Nordin (Hospital Tengku Ampuan Afzan, Kuantan, JKN Pahang) |
| Saguhati<br>*Consolation Prize* | *Validation and Item Reduction Potential of the Malaysia Medication Adherence Assessment Tool (MyMAAT) in Non-Dialysis Chronic Kidney Disease Patients* | Lim Ming Chiang (Hospital Sultan Haji Ahmad Shah, Temerloh, JKN Pahang) |

### Senarai Pemenang untuk Kategori Poster QA
### *List of Winners for QA Poster Category*

| Kedudukan<br>*Ranking* | Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|---|
| Johan<br>*Champion* | *Improving the Percentage of Quality Submissions by Other Enforcement Agencies to the Pharmacy Enforcement Branch (CPF) Kelantan* | Mohammad Izani bin Ab Rashid (Bahagian Perkhidmatan Farmasi, JKN Kelantan) |
| Naib Johan<br>*Runner-up* | *Improving the Compliance Rate in Completing Special Controlled Medicines Application Forms at Dungun Hospital* | Nor Fadzilah binti Mat Daud (Hospital Dungun, JKN Terengganu) |
| Tempat Ketiga<br>*Second Runner-up* | *Reducing the Percentage of Unclaimed Medicines Supplied to Patients Through the Integrated Medication Dispensing System (SPUB) in the Besut District* | Muhamad Azlan bin Ahmad Suhairun (Klinik Kesihatan Jerteh, PKD Besut, JKN Terengganu) |
| Saguhati<br>*Consolation Prize* | *To Improve Understanding of Medications Among Chinese & Indian Patients in Mentakab Health Clinic* | Ahmad Irfan bin Ruslan (Klinik Kesihatan Bandar Mentakab, PKD Temerloh, JKN Pahang) |

**Senarai Pemenang untuk Kategori Lisan QA**
***List of Winners for QA Oral Category***

| **Kedudukan** *Ranking* | **Tajuk Penyelidikan** *Research Title* | **Pembentang** *Presenter* |
|---|---|---|
| Johan *Champion* | *Towards Reducing Near-Miss Medication Errors in Outpatient Pharmacy Department at Pejabat Kesihatan Daerah Bentong* | Mohamad Fariz Haiqal bin Mohd Ruslan (Klinik Kesihatan Chemomoi, PKD Bentong, JKN Pahang) |
| Naib Johan *Runner-up* | *To Increase Percentage of CAPD Patients Achieving Desired Target Hemoglobin in MTAC Dialysis HRPZ II* | S. Leevanea a/p Subramaniam (Hospital Raja Perempuan Zainab II, JKN Kelantan) |
| Tempat Ketiga *Second Runner-up* | *Towards Reducing Incidence of Interventions of Prescriptions During Chronic Kidney Disease (CKD) Clinic* | Noorul Atiqah binti Ramli (Hospital Jengka, JKN Pahang) |
| Saguhati *Consolation Prize* | *Towards Increasing the Percentage of Bedside Dispensing in Medical Wards of Hospital Sultanah Nur Zahirah* | Nurul Syafiqah binti Mustafar (Hospital Sultanah Nur Zahirah, JKN Terengganu) |



Sesi bergambar peserta dan sekretariat persidangan bersama Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi)
*Photo session of the conference participants and secretariat with The Deputy Director General of Health (Pharmaceutical Services)*

## PERSIDANGAN *3RD NORTHERN MALAYSIA PHARMACY RESEARCH* 2025

Bahagian Perkhidmatan Farmasi, Jabatan Kesihatan Negeri Pulau Pinang dengan kerjasama Bahagian Perkhidmatan Farmasi, Jabatan Kesihatan Negeri Kedah dan Perlis serta Persatuan Farmasi Malaysia Cawangan Pulau Pinang telah menganjurkan *3rd Northern Malaysia Pharmacy Research Conference* 2025 pada 22 hingga 24 September 2025 bertempat di Hotel Seri Malaysia, Kepala Batas, Pulau Pinang.

## *3RD NORTHERN MALAYSIA PHARMACY RESEARCH CONFERENCE 2025*

*The 3rd Northern Malaysia Pharmacy Research Conference 2025 was successfully organized by the Pharmaceutical Services Division of the Penang State Health Department, in collaboration with the Pharmaceutical Services Divisions of Kedah and Perlis State Health Department, and the Malaysian Pharmaceutical Society Penang Branch. The event took place from September 22 to 24, 2025, at Hotel Seri Malaysia, Kepala Batas, Penang.*

Dengan tema *Revolutionizing Pharmacy: Research for a Healthier Future*, objektif penganjuran persidangan ini adalah sebagai satu platform perkongsian hasil penyelidikan yang dijalankan oleh pegawai farmasi di fasiliti serta membolehkan penyebaran maklumat dan pengetahuan baru kepada anggota kesihatan. Selain itu, peluang membentangkan hasil penyelidikan dilihat sebagai satu bentuk pengiktirafan kepada pegawai yang terlibat di dalam penyelidikan, di samping memupuk budaya penyelidikan di kalangan anggota.

Sebanyak 49 kajian daripada negeri Pulau Pinang, Kedah dan Perlis telah terpilih untuk menyertai persidangan ini, merangkumi 20 pembentangan secara lisan dan 29 pembentangan dalam bentuk poster. Di samping itu, enam (6) sesi plenari dan *educational symposium* turut diadakan sebagai pengisian program dan perkongsian ilmu.

Ulasan daripada pihak juri antaranya memuji peningkatan kualiti dan tahap penyelidikan yang lebih kompetitif berbanding tahun-tahun sebelumnya, dengan kepelbagaian topik selain farmasi klinikal seperti pengurusan farmasi logistik, perkhidmatan *Medication Therapy Adherence Clinic (MTAC)* dan farmakoterapi berhenti merokok. Terdapat tren positif dari segi metodologi, di mana terdapat kajian yang melangkaui reka bentuk kuantitatif mudah dengan memasukkan kajian kualitatif yang penting dalam memahami punca dan konteks sesuatu perkara, di samping kebanyakan kajian menunjukkan tahap penguasaan statistik yang tinggi.

*Held under the theme "Revolutionizing Pharmacy: Research for a Healthier Future," the conference aimed to serve as a premier platform for sharing research findings conducted by pharmacists across various facilities, disseminating new information and knowledge to health personnel, and providing recognition to research personnel while fostering a stronger research culture among staff.*

*A total of 49 studies from the states of Penang, Kedah, and Perlis were selected to participate, comprising 20 oral presentations and 29 poster presentations. In addition, the programme featured seven (7) impactful plenary sessions and educational symposia focused on knowledge sharing.*

*The jury provided favourable evaluations, noting a substantial improvement in both the quality and competitiveness of the research compared to previous years. The studies demonstrated a broad range of topics extending beyond clinical pharmacy, reflected enhanced methodological rigor through the inclusion of qualitative research designs, and exhibited a generally high level of statistical competence in data analysis.*

**Senarai Sesi Plenari dan *Educational Symposium***
***List of Plenary Sessions and Educational Symposia***

| **Bil.** *No.* | **Tajuk** *Title* | **Pembentang** *Presenter* |
|---|---|---|
| 1. | *Beyond Trial and Error: The Pharmacist's Role in Precision Prescribing* | Dr. Nur Aizati Athirah Daud (Pensyarah Farmasi, Universiti Sains Malaysia) |
| 2. | *Synthesising Evidence: Advancing Clinical Practice Through Systematic Review and Meta-Analysis* | Dr. Sutha a/p Rajakumar (Pegawai Farmasi, Hospital Seberang Jaya) |
| 3. | *Smart Research for Pharmacists: Using AI Tools* | Dr. Rabia Hussain (Pensyarah Farmasi, Universiti Sains Malaysia) |
| 4. | *Neuro and Liver Protective Effects of Palm Vitamin E Tocotrienols* | Emeritus Professor Dr. Yuen Kah Hay (Avantsar Sdn. Bhd.) |
| 5. | *Cognitive Decline: What Every Pharmacist Needs to Know About Dementia Before It's Too Late* | Dr. Christina Malini a/p Christopher (Pensyarah Farmasi, Universiti Sains Malaysia) |
| 6. | *Research for Pharmacists: Strategies for Success* | Dr. Navin Kumar a/l Loganadan (Pegawai Farmasi, Hospital Putrajaya) |
| 7. | *From Clinical Trial to Practice-Changing Evidence: Malaysia's Journey Towards Hepatitis C Elimination* | Dr. Chan Huan Keat (Pegawai Farmasi, National Institutes of Health) |

### Senarai Pemenang untuk Kategori Poster
### *List of Winners for Poster Category*

| Kedudukan<br>*Ranking* | Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|---|
| Johan<br>*Champion* | *Knowledge and Attitudes on Pain Management Among Healthcare Providers at Hospital Balik Pulau, Penang* | Choo Mun Yee<br>(Hospital Balik Pulau, Pulau Pinang) |
| Naib Johan<br>*Runner-up* | *Evaluation of Reported Adverse Drug Reactions: A Retrospective Analysis of Patients in Hospital Kulim* | Nor Syahirah binti Shukri<br>(Hospital Kulim, Kedah) |
| Tempat Ketiga<br>*Second Runner-up* | *Development and Validation of a Questionnaire to Evaluate the Knowledge on Registered Medicinal Products Among Healthcare Personnel in Perlis* | Gwee Zi Yan<br>(Bahagian Perkhidmatan Farmasi, JKN Perlis) |
| Saguhati<br>*Consolation Prize* | *Evaluation of Intranasal Corticosteroid Spray Technique and Adherence Among Allergic Rhinitis Patients in Hospital Seberang Jaya* | See Say Li<br>(Hospital Seberang Jaya, Pulau Pinang) |
| Saguhati<br>*Consolation Prize* | *The Effectiveness of Vildagliptin in Patients with Type 2 Diabetes Mellitus in Public Health Clinics in Penang* | Hor Sweet Fong<br>(Klinik Kesihatan Bandar Tasek Mutiara, Pulau Pinang) |
| Saguhati<br>*Consolation Prize* | *Cost Analysis of Intra- Interfacility Aseptic Pharmaceutical Preparations in A Tertiary Malaysia Public Hospital* | Ooi Zi Theng<br>(Hospital Sultanah Bahiyah, Kedah) |

### Senarai Pemenang untuk Kategori Lisan
### *List of Winners for Oral Category*

| Kedudukan<br>*Ranking* | Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|---|
| Johan<br>*Champion* | *Patients' Pain Belief and Adherence to Morphine Use in Chronic Cancer Pain in Hospital Sultanah Bahiyah* | Lim Hoi Leng<br>(Hospital Sultanah Bahiyah, Kedah) |
| Naib Johan<br>*Runner-up* | *Optimising Anticoagulant Therapy Among Patients with Atrial Fibrillation Using HoSM-AC Tool: A Pilot Study* | Lingeesh a/l Balakirushnan<br>(Hospital Sultanah Maliha, Kedah) |
| Tempat Ketiga<br>*Second Runner-up* | *Determinants of Successful Smoking Cessation Outcomes at Public Health Clinics In Perlis* | Nurfaizah binti Azmi<br>(Klinik Kesihatan Kangar, Perlis) |
| Saguhati<br>*Consolation Prize* | *Access to Essential Medicines for Children in Community Pharmacies in Perlis* | Ang Wei Chern<br>(Hospital Tuanku Fauziah, Perlis) |
| Saguhati<br>*Consolation Prize* | *The Role of Antimicrobial Stewardship in Carbapenem Optimization: A Retrospective Study on Utilization, Costs, And Outcomes* | Khor Wei Ping<br>(Hospital Seberang Jaya, Pulau Pinang) |
| Saguhati<br>*Consolation Prize* | *Challenges in the Implementation of Standardized Parenteral Nutrition (SPN) For Neonates: A Qualitative Study from A Clean- Room Equipped Tertiary Hospital, Hospital Sultanah Bahiyah* | Khor Lian Fen<br>(Hospital Sultanah Bahiyah, Kedah) |

### Pemenang untuk Anugerah Khas Juri: Pembentang Terbaik
### *Winner for Special Jury Award: Best Presenter*

| Tajuk Penyelidikan<br>*Research Title* | Pembentang<br>*Presenter* |
|---|---|
| *Assessment of Diabetes Knowledge and Its Associated Factors Among Type 2 Diabetes Mellitus (T2DM) Patients at Kangar Health Clinic* | Tan Zhen Sheng<br>(Klinik Kesihatan Kangar, Perlis) |



Peserta dan juri Persidangan *3rd Northern Malaysia Pharmacy Research* 2025
*Participants and judges for 3rd Northern Malaysia Pharmacy Research Conference 2025*

## SESI SEMAKAN (AUDIT) PETUNJUK PRESTASI UTAMA (KPI) PERINGKAT PROGRAM PERKHIDMATAN FARMASI, KKM TAHUN 2025

Cawangan Perkembangan Infrastruktur & Kualiti Farmasi, Bahagian Dasar & Perancangan Strategik Farmasi, Program Perkhidmatan Farmasi KKM selaku Penyelaras KPI Program Perkhidmatan Farmasi, KKM telah mengadakan Sesi Semakan (Audit) Petunjuk Prestasi Utama (KPI) peringkat program bagi tahun 2025 pada 4 Ogos 2025 sehingga 21 Ogos 2025.

Sesi Semakan (Audit) KPI ini melibatkan 19 orang juruaudit daripada semua bahagian di bawah Program Perkhidmatan Farmasi, bertujuan untuk menyemak pencapaian KPI yang dipantau dan bagi menjamin ketepatan & integriti pencapaian yang dilaporkan. Aktiviti audit adalah satu proses verifikasi yang sistematik bagi:

- Melaksanakan semakan terhadap pencapaian KPI yang dipantau di setiap peringkat fasiliti KKM termasuk pengenalpastian punca data (traceability) yang dilaporkan.
- Menilai kepatuhan fasiliti KKM terhadap pelaksanaan KPI mengikut standard yang telah ditetapkan.
- Memastikan setiap risiko dikenal pasti serta tindakan penambahbaikan yang sesuai dilaksanakan bagi setiap KPI yang tidak mencapai sasaran.

Audit ini dilaksanakan berpandukan Garis Panduan Audit KPI Sektor Teknikal KKM.

## *AUDIT REVIEW SESSION OF KEY PERFORMANCE INDICATORS (KPI) PHARMACEUTICAL SERVICES PROGRAMME LEVEL, MOH, YEAR 2025*

*The Infrastructure Development & Pharmacy Quality Branch, Division of Policy & Strategic Planning, PSP, MOH in its capacity as the KPI Coordinator for the PSP, conducted the Key Performance Indicator (KPI) Audit Review Session for the year 2025 from 4 August 2025 to 21 August 2025.*

*The KPI Audit Review Session involved 19 auditors from all divisions under the PSP, MOH and was conducted to review the monitored KPI achievements and to ensure the accuracy and integrity of the reported results. The audit activity is a systematic verification process aimed at:*

- *Reviewing the KPI achievements monitored at every MOH facility level, including identification of the reported data sources (traceability).*
- *Assessing facility compliance with KPI implementation in accordance with established standards.*
- *Ensuring that all risks are identified and that appropriate corrective actions are implemented for each KPI that does not achieve its target.*

*The audit was conducted in accordance with the 2025 Technical Sector KPI Audit Guidelines of the Ministry of Health, and the achievements audited covered the period from January to June 2025.*



Juruaudit Sesi Semakan Petunjuk Prestasi Utama (KPI) Peringkat Program Perkhidmatan Farmasi
*Auditors for the Review Session of Key Performance Indicators (KPI) Pharmaceutical Services Programme level*

## TAKLIMAT PEMANTAPAN INTEGRITI PENJAWAT AWAM, PROGRAM PERKHIDMATAN FARMASI, KKM TAHUN 2025

Cawangan Perkembangan Infrastruktur & Kualiti Farmasi, Bahagian Dasar & Perancangan Strategik Farmasi, Program Perkhidmatan Farmasi KKM telah mengadakan satu Sesi Taklimat Pemantapan Integriti Penjawat Awam, Program Perkhidmatan Farmasi, KKM Tahun 2025 di Pusat Konvensyen Antarabangsa Putrajaya (PICC) pada 17 September 2025.

Taklimat ini dihadiri seramai 50 orang pegawai dengan kerjasama Institut Integriti Malaysia (IIM). Taklimat ini bertujuan untuk meningkatkan refleksi kesedaran kendiri mengenai etika & integriti, memberi pendedahan mengenai proses membuat keputusan secara beretika & berintegriti dan membudayakan amalan terbaik berdasarkan nilai-nilai murni, etika & integriti dalam kalangan warga Program Perkhidmatan Farmasi.

## *PUBLIC SERVICE INTEGRITY STRENGTHENING BRIEFING, PHARMACEUTICAL SERVICES PROGRAMME (PSP), MOH, YEAR 2025*

*The Infrastructure Development & Pharmacy Quality Branch, Division of Policy & Strategic Planning, PSP, MOH conducted the 2025 Public Servants' Integrity Enhancement Briefing Session for the PSP at the Putrajaya International Convention Centre (PICC) on 17 September 2025.*

*The briefing was attended by 50 officers in collaboration with the Institut Integriti Malaysia (IIM). It aimed to enhance self-reflection on ethics and integrity, provide exposure to ethical and integrity-based decision-making processes, and cultivate best practices grounded in core ethical and integrity values among staff of the PSP, MOH.*




Barisan peserta Sesi Taklimat Pemantapan Integriti Penjawat Awam Program Perkhidmatan Farmasi
*Participants of the Public Service Integrity Strenghtening Briefing, Pharmaceutical Services Programme*

## PELAKSANAAN DAN PENAMBAHBAIKAN MYPHIS KE ARAH PENDIGITALAN PERKHIDMATAN FARMASI

Sepanjang tahun 2025, Pharmacy Information System (MyPhIS) terus menjadi tulang belakang utama sistem yang menguruskan perkhidmatan logistik farmasi dan pembekalan ubat-ubatan di fasiliti KKM. Sistem ini bukan sahaja memperkukuh kecekapan operasi farmasi, malah meningkatkan ketepatan pengurusan stok serta kesinambungan bekalan ubat kepada pesakit.

Sehingga 31 Disember 2025, pelaksanaan MyPhIS telah mencapai liputan yang meluas di fasiliti KKM, dengan jumlah keseluruhan 1,341 terdiri daripada Hospital, Klinik Kesihatan, Pejabat Kesihatan Daerah dan Cawangan Farmasi Logistik Negeri. Pelaksanaan naik taraf sistem kepada MyPhIS 3.0, yang memberi fokus kepada penyelarasan keperluan pengguna, pembangunan sistem serta persediaan pelaksanaan migrasi data, dijangka akan selesai pada suku kedua 2026. Sehingga Disember 2025, pembangunan aplikasi berada pada tahap 48%. Seterusnya, pengujian dan migrasi data akan dilaksanakan pada tahun 2026.

## *IMPLEMENTATION AND ENHANCEMENT OF MYPHIS TOWARDS DIGITAL TRANSFORMATION OF PHARMACY SERVICES*

*Throughout 2025, the Pharmacy Information System (MyPhIS) continued to serve as the primary backbone system managing pharmaceutical logistics services and medicine supply across facilities under the MOH. The system not only strengthened the operational efficiency of pharmacy services but also enhanced the accuracy of stock management and ensured continuity of medicine supply to patients.*

*As of 31 December 2025, the implementation of MyPhIS had achieved extensive coverage across MOH facilities, with a total of 1,341 facilities comprising hospitals, health clinics, district health offices, and state pharmacy logistics branches. The system upgrade to MyPhIS version 3.0, which focuses on aligning user requirements, system development, and preparations for data migration implementation, is expected to be completed in the second quarter of 2026. As of December 2025, application development stood at 48%. Subsequently, system testing and data migration will be carried out in 2026.*

Bagi memastikan kesinambungan perkhidmatan MyPhIS selaras dengan perkembangan teknologi terkini, pembekalan perkakasan pengguna baharu telah dilaksanakan melibatkan 280 fasiliti sepanjang tahun 2025. Bagi pelaksanaan baharu pula, sebanyak 20 fasiliti telah melaksanakan MyPhIS yang melibatkan pembekalan perkakasan dan aplikasi, termasuk sokongan teknikal daripada pihak pembekal.

Sepanjang tahun 2025, penyelenggaraan dan sokongan teknikal MyPhIS telah menguruskan sejumlah 36,121 tiket bagi memastikan kestabilan sistem serta kesinambungan operasi di fasiliti KKM. Pecahan kategori tiket adalah seperti berikut:

1. Service Requests (melibatkan pertanyaan, data dan First Call Resolution): 14,799
2. Isu Aplikasi: 8,784
3. Perkakasan (Hardware): 7,904
4. Perisian (Software): 3,911
5. Rangkaian (Network): 315
6. Integrasi: 408

Dalam usaha meningkatkan interoperabiliti dan pertukaran data antara sistem kesihatan, MyPhIS telah mengekalkan serta memperluaskan integrasi dengan beberapa sistem sumber. Liputan fasiliti yang mempunyai integrasi adalah seperti berikut:

1. CCMS: 255 fasiliti
2. TPC-OHCIS: 93 fasiliti
3. HIS@KKM: 5 fasiliti
4. EM-HIS: 1 fasiliti

Bagi memperkukuh penyelarasan pelaksanaan MyPhIS di peringkat negeri serta meningkatkan pematuhan SOP pelaksanaan, satu Bengkel Penyelarasan bersama Pegawai Perhubungan MyPhIS Negeri telah diadakan pada 5 hingga 7 Ogos 2025 bertempat di Kuala Terengganu. Bengkel ini melibatkan seramai 30 pegawai (Farmasi dan ICT) dan memfokuskan kepada pengukuhan kerjasama pelaksanaan antara negeri dan pusat, perbincangan isu pelaksanaan di fasiliti dan cadangan penambahbaikan SOP dan mekanisme penyelarasan.

## MYUBAT SEBAGAI PENERIMA ANUGERAH KHAS INOVASI (AKI) DALAM ANUGERAH INOVASI KEMENTERIAN KESIHATAN MALAYSIA (AIKKM) 2022-2025

Aplikasi MyUBAT telah dinobatkan sebagai penerima Anugerah Khas Inovasi (AKI) bagi Tahun 2023 sempena Majlis Penyampaian Anugerah Inovasi Kementerian Kesihatan Malaysia (AIKKM) yang telah diadakan pada 4 November 2025 bertempat di Auditorium Perdana NIH, Shah Alam.

Aplikasi MyUBAT yang dibangunkan sepenuhnya secara dalaman dengan memanfaatkan kepakaran sedia ada telah dilancarkan secara rasmi oleh Program Perkhidmatan Farmasi pada April 2020. Pembangunan MyUBAT merupakan satu inisiatif strategik Program Perkhidmatan Farmasi dalam usaha mendigitalkan penyampaian perkhidmatan farmasi, sejajar dengan aspirasi dan agenda Kerajaan Digital.

*To ensure the continuity of MyPhIS services in line with the latest technological developments, the provision of new hardware was implemented across 280 facilities throughout 2025. For new implementations, a total of 20 facilities adopted MyPhIS, involving the supply of hardware and applications, including technical support from the vendor.*

*Throughout 2025, MyPhIS maintenance and technical support managed a total of 36,121 tickets to ensure system stability and continuity of operations across MOH facilities. The breakdown of ticket categories is as follows:*

1. *Service Requests (including enquiries, data matters, and First Call Resolution): 14,799*
2. *Application Issues: 8,784*
3. *Hardware: 7,904*
4. *Software: 3,911*
5. *Network: 315*
6. *Integration: 408*

*In efforts to enhance interoperability and data exchange between healthcare systems, MyPhIS continued to maintain and expand integrations with several source systems. The facility coverage with system integrations is as follows:*

1. *CCMS: 255 facilities*
2. *TPC-OHCIS: 93 facilities*
3. *HIS@MOH: 5 facilities*
4. *EM-HIS: 1 facility*

*To strengthen coordination of MyPhIS implementation at the state level and improve compliance with implementation SOPs, a Coordination Workshop with State MyPhIS Liaison Officers was held from 5 to 7 August 2025 in Kuala Terengganu. The workshop involved 30 officers (from Pharmacy and ICT disciplines) and focused on strengthening implementation collaboration between state and central levels, discussing implementation issues at facility level, and proposing improvements to SOPs and coordination mechanisms.*

## *MYUBAT AS THE RECIPIENT OF THE ANUGERAH KHAS INOVASI (AKI) AT THE ANUGERAH INOVASI KEMENTERIAN KESIHATAN MALAYSIA (AIKKM) 2022-2025*

*The MyUBAT application was crowned the recipient of the Anugerah Khas Inovasi (AKI) for 2023 in conjunction with the Anugerah Inovasi Kementerian Kesihatan Malaysia (AIKKM) ceremony. The event was held on 4 November 2025, at the Perdana Auditorium NIH, Shah Alam.*


*The MyUBAT application, developed entirely in-house by leveraging existing expertise, was officially launched by the Pharmacy Services Programme in April 2020. The development of MyUBAT is a strategic initiative by the Pharmaceutical Services Programme to digitize the delivery of pharmacy services, in line with the aspirations and agenda of the Digital Government.*

Pelaksanaan MyUBAT bermula dengan pendigitalan perkhidmatan nilai tambah bagi memudahkan urusan pesakit mendapatkan bekalan ubat susulan daripada fasiliti kesihatan tanpa perlu beratur atau menunggu lama. Melalui aplikasi ini, pesakit diberikan pilihan untuk mendapatkan perkhidmatan farmasi mengikut keperluan masing-masing, termasuk perkhidmatan janji temu di kaunter farmasi, penghantaran ubat melalui perkhidmatan kurier, pengambilan ubat secara pandu lalu serta pengambilan bekalan ubat melalui lokar simpanan yang ditetapkan.


Secara keseluruhannya, inovasi MyUBAT telah berjaya menyumbang kepada pengurangan kadar kehadiran pesakit ke fasiliti kesihatan sebanyak 2%, di samping peningkatan pendaftaran pengguna baharu sebanyak 10% setiap tahun. Selain itu, melalui kerjasama Awam-Swasta bersama Pos Malaysia Sdn. Bhd., sejumlah RM1.03 juta dana sumbangan telah berjaya dikumpulkan dan disalurkan bagi menyokong rawatan pesakit kanser dengan sokongan inisiatif MyUBAT.

*The implementation of MyUBAT began with the digitalization of value-added services to make it easier for patients to obtain follow-up medication supplies from health facilities without having to queue or wait for long periods. Through this application, patients are given the option to choose pharmacy services based on their specific needs, including appointment services at the pharmacy counter, medication delivery via courier services, drive-thru collection, and medication pickup via designated storage lockers.*

*Overall, the MyUBAT innovation has successfully contributed to a 2% reduction in patient attendance rates at health facilities, alongside a 10% annual increase in new user registrations. Furthermore, through a Public-Private partnership with Pos Malaysia Sdn. Bhd., a total of RM1.03 million in donated funds was successfully collected and channeled to support cancer treatment initiatives through the MyUBAT platform.*




Evolusi MyUBAT
*Evolution of MyUBAT*




Evolusi MyUBAT: Mendefinisikan Semula Perkhidmatan Farmasi (2020-2025)
*The Evolution of MyUBAT: Redefining Pharmacy Services (2020-2025)*




Aplikasi Myubat Menerima Anugerah Khas Inovasi (AKI)
*Myubat Application Conferred the Special Innovation Award (AKI)*

## HARI FARMASI SEDUNIA PERINGKAT KEBANGSAAN 2025

Sambutan Hari Farmasi Sedunia Peringkat Kebangsaan 2025 telah diadakan pada 25 September 2025 di Dewan Serbaguna KKM bertempat di Putrajaya. Majlis perasmian sambutan tersebut telah disempurnakan oleh Menteri Kesihatan. Tema tahun semasa iaitu 'Think Health, Think Pharmacist' menekankan kepentingan farmasi sebagai tunjang sokongan sistem kesihatan. Majlis sambutan telah menunjukkan penghargaan terhadap dedikasi dan profesionalisme ahli farmasi dalam penyampaian perkhidmatan farmaseutikal negara yang inklusif, inovatif dan berintegriti dalam memacu pembangunan sistem kesihatan negara. Turut dilancarkan bersama sambutan ini adalah Program Santuni Orang Kurang Upaya (OKU): Kenali Ubat Anda.

Majlis tersebut telah dimeriahkan dengan persembahan koir yang terdiri daripada sembilan (9) orang kanak-kanak OKU (pendengaran) yang berpakaian tradisional rakyat Malaysia menyanyikan lagu Negaraku dalam terjemahan bahasa isyarat.

Sambutan Hari Farmasi Sedunia ini telah dihadiri oleh wakil-wakil dari KKM, Jabatan Kesihatan Negeri, *Pharmaceutical Association of Malaysia* (PhAMA), *Malaysian Organisation of Pharmaceutical Industries* (MOPI), *Malaysian Pharmacists Society* (MPS), *Malaysian Community Pharmacy Guild* (MCPG), *Malaysian Academy of Pharmacy* (MAP) dan Rakan Strategik OKU dari KKM, persatuan dan syarikat farmaseutikal.

## *NATIONAL LEVEL WORLD PHARMACIST DAY 2025*

*The National Level World Pharmacists Day Celebration 2025 was held on 25 September 2025 at the MOH's Dewan Serbaguna in Putrajaya. The opening ceremony was officiated by the Minister of Health. The theme for this year, 'Think Health, Think Pharmacist' emphasised the importance of pharmacy as a core pillar supporting the healthcare system. The celebration recognised and appreciated the dedication and professionalism of pharmacists in delivering pharmaceutical services that are inclusive, innovative and driven by integrity, in support of the nation's healthcare system development. Also launched in conjunction with this celebration was the Know Your Medicine for Persons with Disability Programme.*

*The event was enlivened by a choir performance consisting of nine (9) PWDs (hearing) children dressed in traditional Malaysian attire, who then performed the national anthem Negaraku translated into sign language.*

*The World Pharmacists Day celebration was attended by representatives from MOH, State Health Departments, the Pharmaceutical Association of Malaysia (PhAMA), Malaysian Organisation of Pharmaceutical Industries (MOPI), Malaysian Pharmacists Society (MPS), Malaysian Community Pharmacy Guild (MCPG), Malaysian Academy of Pharmacy (MAP) and OKU Strategic Partners from MOH, associations, and pharmaceutical companies.*




Persembahan Pasukan Koir Dari Taska Istika Jaya
*Choir Presentation from Taska Istika Jaya*



Majlis Sambutan Hari Farmasi Sedunia Peringkat Kebangsaan 2025
*Celebration for The National Level World Pharmacists Day 2025*

## BENGKEL PENYELARASAN PERJAWATAN SKIM SOKONGAN DI BAWAH AKTIVITI PERKHIDMATAN FARMASI KKM

Bengkel penyelarasan ini telah diadakan pada 25 hingga 26 Jun 2025 bertempat di Putrajaya International Convention Centre (PICC), Putrajaya. Bengkel ini dianjurkan oleh Cawangan Pembangunan Profesion Farmasi yang melibatkan seramai 33 orang peserta terdiri daripada Ketua Cawangan Pengurusan Bahagian Perkhidmatan Farmasi (BPF) Negeri, wakil Pegawai Farmasi dari fasiliti kesihatan, wakil Pegawai Farmasi dari Bahagian Amalan dan Perkembangan Farmasi, IPKKM serta dari Bahagian Penguatkuasaan Farmasi, IPKKM.

Bengkel ini bertujuan untuk menentukan keperluan skim sokongan di bawah aktiviti perkhidmatan farmasi berdasarkan norma perjawatan terkini, seterusnya menyelaras semula perjawatan skim sokongan yang terlibat agar dapat mengoptimumkan perkhidmatan yang diberikan.

Selain itu, bengkel ini turut menjemput penceramah daripada Bahagian Sumber Manusia KKM untuk memberikan penerangan berkaitan pengurusan perjawatan dan dasar semasa yang berkuatkuasa.

## *WORKSHOP ON COORDINATION OF SUPPORT SCHEME STAFFING UNDER THE MOH PHARMACY SERVICE ACTIVITIES*

*The workshop was held from 25 to 26 June 2025 at the Putrajaya International Convention Centre (PICC), Putrajaya. Organised by the Pharmacy Professional Development Branch, the course was attended by 33 participants consisting of the Head of the State Pharmaceutical Services Division (BPF) Management Branch, representatives of Pharmacists from health facilities, representatives of Pharmacists from the Pharmacy Practice and Development Division, IPKKM, as well as representatives of Pharmacists from the Pharmacy Enforcement Division, IPKKM.*

*The objective of the workshop was to determine the requirements of support schemes under pharmacy service activities based on the latest staffing norms, and subsequently realign the staffing of the support schemes involved in order to optimize the services provided.*

*In addition, speaker from the Human Resource Division, MOH were invited to provide information regarding staffing management and current policies in force.*




Barisan peserta Bengkel Penyelarasan Perjawatan Skim Sokongan di Bawah Aktiviti Perkhidmatan Farmasi, KKM
*Participants of the Workshop on Coordination of Support Scheme Staffing Under the MOH Pharmacy Service Activities*

## KURSUS KEMAHIRAN KOMUNIKASI BERKESAN DALAM ERA GLOBALISASI DIGITAL UNTUK PENOLONG PEGAWAI FARMASI KEMENTERIAN KESIHATAN MALAYSIA TAHUN 2025

Kursus ini telah diadakan pada 12-13 Jun 2025 bertempat di Akademi Imigresen Malaysia, Port Dickson, Negeri Sembilan dengan jumlah peserta seramai 50 orang terdiri daripada Penolong Pegawai Farmasi U5 daripada seluruh Malaysia yang kebanyakkannya 8 tahun dah kebawah dalam lantikan. Sebanyak 8 orang penceramah berpengalaman terlibat dalam menjayakan kursus ini, termasuklah seorang Pegawai Psikologi Negeri Sembilan.

Berikut adalah objektif penganjuran kursus:

- Menerangkan konsep komunikasi yang berkesan dalam hubungan interpersonal dan organisasi;
- Meningkatkan kefahaman tentang kepentingan komunikasi verbal dan non-verbal yang berkesan seiring dengan dunia teknologi terkini;
- Mengaplikasikan teknik komunikasi secara berkesan di peringkat individu dan kumpulan dalam era globalisasi digital

## *EFFECTIVE COMMUNICATION SKILLS COURSE IN THE ERA OF DIGITAL GLOBALISATION FOR ASSISTANT PHARMACISTS OF THE MINISTRY OF HEALTH MALAYSIA 2025*

*This course was held from 12-13 June 2025 at the Malaysian Immigration Academy, Port Dickson, Negeri Sembilan, with a total of 50 participants comprising U5 Assistant Pharmacists from across Malaysia, the majority of whom had eight years or less of service experience. A total of eight experienced speakers were involved in making this course a success, including a Psychologist Officer from Negeri Sembilan.*

*The objectives of the course were as follows:*

- *To explain the concept of effective communication in interpersonal and organisational relationships;*
- *To enhance understanding of the importance of effective verbal and non-verbal communication in line with the latest technological advancements; and*
- *To apply effective communication techniques at both individual and group levels in the era of digital globalisation.*



Barisan peserta kursus mengabdikan gambar di lobi Dewan Bagunan Akademik, Akademi Imigresen Malaysia, Port Dickson, Negeri Sembilan

*Course participants posing for a group photograph at the lobby of the Academic Building Hall, Malaysian Immigration Academy, Port Dickson, Negeri Sembilan*

## BENGKEL PEMURNIAN PENGHURAIAN KERJA SKIM PERKHIDMATAN PENOLONG PEGAWAI FARMASI KEMENTERIAN KESIHATAN MALAYSIA

Bengkel ini telah diadakan pada 25-27 Ogos 2025 yang bertempat di Dewan Anggerik, Bahagian Regulatori Farmasi Negara, Kementerian Kesihatan Malaysia.

Berikut adalah objektif bengkel ini:

- Memurnikan dan mengemas kini penghuraian tugas Penolong Pegawai Farmasi (PPF) gred U5 hingga U8 selaras dengan keperluan semasa sistem kesihatan negara dan perkembangan dalam bidang farmasi KKM mengikut skim Sistem Saraan Perkhidmatan Awam (SSPA);
- Menyeragamkan skop fungsi dan bidang tugas bagi semua gred Penolong Pegawai Farmasi supaya selari dengan struktur organisasi dan arahan perkhidmatan semasa;
- Mengukuhkan peranan dan tanggungjawab teknikal dan penyeliaan yang dimainkan oleh Penolong Pegawai Farmasi terutamanya dalam aspek pembekalan ubat, penyediaan sediaan farmaseutikal, penyeliaan pelatih, dan urusan pengurusan logistik;
- Menghasilkan dokumen penghuraian kerja yang komprehensif dan terkini untuk Penolong Pegawai Farmasi untuk digunapakai dalam pelaksanaan tugas seharian serta rujukan dalam penilaian prestasi dan kenaikan pangkat.

Seramai 50 orang peserta yang terdiri daripada Penolong Pegawai Farmasi berpengalaman luas pelbagai gred dari kepelbagaian fasiliti di seluruh Malaysia telah menghadiri bengkel ini bagi bersama-sama menyumbangkan idea dan kefahaman. Fasilitator bagi bengkel ini merupakan seorang Penolong Pegawai Farmasi yang pernah bertugas di Cawangan Pembangunan Profesion Penolong Pegawai Farmasi, Program Perkhidmatan Farmasi Kementerian Kesihatan Malaysia. Hasil daripada bengkel ini akan dibentangkan dalam Mesyuarat Polisi bagi persetujuan bersama dimuat turun semula di laman web Jabatan Perkhidmatan Awam.

## WORKSHOP ON THE REFINEMENT OF JOB DESCRIPTIONS FOR THE ASSISTANT PHARMACIST SERVICE SCHEME, MINISTRY OF HEALTH MALAYSIA

*This workshop was held from 25-27 August 2025 at Dewan Anggerik, National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia.*

*The objectives of the workshop were as follows:*

- *To refine and update the job descriptions for Assistant Pharmacists from grades U5 to U8 in line with the current needs of the national healthcare system and developments in the pharmacy field within the Ministry of Health Malaysia, based on the Public Service Remuneration System (SSPA) scheme*
- *To standardise the scope of functions and responsibilities for all Assistant Pharmacist grades so that they are aligned with the organisational structure and current service directives;*

- *To strengthen the technical and supervisory roles and responsibilities carried out by Assistant Pharmacists, particularly in aspects of medicine supply, pharmaceutical preparation, trainee supervision, and logistics management; and*
- *To produce a comprehensive and updated job description document for Assistant Pharmacists to be used in the implementation of daily tasks as well as for reference in performance evaluations and promotions.*

*A total of 50 participants comprising highly experienced Assistant Pharmacists of various grades from diverse healthcare facilities throughout Malaysia attended the workshop to contribute ideas and share their expertise. The facilitator for this workshop was an Assistant Pharmacist who previously served at the Assistant Pharmacist Professional Development Branch, Pharmaceutical Services Programme, Ministry of Health Malaysia. The outcomes of this workshop will be presented at the Policy Meeting for collective agreement before being uploaded to the Public Service Department website.*



Kesemua para peserta bengkel bergambar bersama di hadapan Dewan Anggerik, Bahagian Regulatori Farmasi Negara
*All workshop participants posing for a group photograph in front of Dewan Anggerik, National Pharmaceutical Regulatory Agency*

## LAIN-LAIN AKTIVITI
## *OTHER ACTIVITIES*


| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel *Critical Appraisal* bagi Penyelidik Farmasi 2025<br>*Critical Appraisal Workshop for Pharmacy Researchers 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 29 hingga 30 April 2025, *Putrajaya International Convention Centre (PICC)*<br>*29 to 30 April 2025, Putrajaya International Convention Centre (PICC)* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 35 pegawai farmasi<br>*35 pharmacists* |
| Objektif<br>*Objective* | Meningkatkan keupayaan dan kemahiran pegawai daripada PPF dalam menilai serta menganalisis kualiti penyelidikan secara kritikal dan berstruktur. Selain itu, para peserta turut diberikan pendedahan dan peluang untuk menjalankan penilaian kritikal terhadap manuskrip penyelidikan melalui penggunaan kecerdasan buatan *(A.I.)* seperti *Chat GPT*, dengan penekanan kepada penggunaan teknik prompt dan soalan yang bersesuaian bagi membantu menghasilkan penilaian manuskrip yang lebih berkualiti dan sistematik.<br>*Enhancing the capacity and competencies of officers from the PSP in critically and systematically evaluating and analysing research quality. In addition, participants were exposed to and provided with opportunities to conduct critical appraisals of research manuscripts through the use of artificial intelligence (A.I.) tools such as ChatGPT, with emphasis on the application of appropriate prompting techniques and questions to support the production of higher-quality and more systematic manuscript reviews.* |
| Hasil<br>*Outcome* | Para peserta memperoleh keyakinan yang lebih tinggi dalam penilaian dan pembuatan keputusan berasaskan bukti, membangunkan kemahiran praktikal dalam semakan manuskrip yang berstandard. Secara keseluruhan, bengkel ini telah menyumbang kepada pemerkasaan budaya penyelidikan, peningkatan tahap kesiapsiagaan untuk semakan rakan sebaya dan penerbitan, serta penyelarasan amalan penilaian penyelidikan yang lebih konsisten merentasi institusi farmasi.<br>*Participants gained increased confidence in evidence-based evaluation and decision-making, developed practical skills in standardised manuscript review. Overall, the workshop contributed to fostering a stronger research culture, improved readiness for peer review and publication, and greater consistency in research evaluation practices across pharmacy institutions.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Jawatankuasa Teknikal Mentor Penyelidikan Farmasi 2025<br>*Pharmacy Research Mentor Technical Advisory Committee Meeting 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 28 Mei 2025 dan 30 Jun 2025, Google Meet (Secara maya)<br>*28 May 2025 and 30 June 2025, Google Meet (Virtually)* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | Pegawai farmasi dari fasiliti kesihatan<br>*Pharmacy officers from healthcare facilities* |
| Objektif<br>*Objective* | Memperkasa budaya penyelidikan farmasi melalui bimbingan dan sokongan teknikal kepada penyelidik muda dalam pelaksanaan penyelidikan. Secara umumnya, Jawatankuasa ini berperanan dalam merancang, menyelaras, memantau dan melaksanakan inisiatif berkaitan program mentor penyelidikan di bidang farmasi bagi memastikan kajian yang dijalankan lebih sistematik, relevan, dan mempunyai impak tinggi.<br>*To strengthen the culture of pharmacy research through mentorship and technical support for early-career researchers in the conduct of research activities. In general, the Committee is responsible for planning, coordinating, monitoring, and implementing initiatives related to pharmacy research mentorship programmes, with the aim of ensuring that studies conducted are more systematic, relevant, and of high impact.* |
| Hasil<br>*Outcome* | Ahli Jawatankuasa Teknikal Mentor Penyelidikan Farmasi telah membangunkan modul program mentor penyelidikan farmasi. Ini termasuk menyediakan modul dan garis panduan yang komprehensif mengenai konsep, peranan serta tanggung jawab mentor mentee dalam program ini.<br>*Members of the Pharmacy Research Mentor Technical Advisory Committee developed a pharmacy research mentorship programme module. This included the preparation of comprehensive modules and guidelines outlining the concepts, roles, and responsibilities of mentors and mentees within the programme.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Penulisan Manuskrip Kajian Farmasi 2025<br>*Pharmacy Research Manuscript Writing Workshop 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 28 hingga 30 Oktober 2025, Hotel Grand Puteri Terengganu<br>*28 to 30 October 2025, The Grand Puteri Hotel Terengganu* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 19 peserta dari PPF<br>*19 participants from PSP* |
| Objektif<br>*Objective* | Menyokong pegawai PPF menghasilkan manuskrip yang sesuai untuk diterbitkan dalam jurnal tempatan atau antarabangsa. Bengkel ini juga memberi peluang kepada pegawai untuk memperuntukkan masa khusus bagi penulisan manuskrip tanpa gangguan daripada tugasan rutin di pejabat.<br>*To support officers in the PSP in producing manuscripts suitable for publication in local or international journals. The workshop also provided officers with dedicated time to focus on manuscript writing without disruptions from routine office duties.* |
| Hasil<br>*Outcome* | Sebanyak 18 kajian menarik telah dibincangkan pada hari terakhir bengkel ini. Para peserta juga diberi peluang untuk mendapatkan khidmat nasihat dan pandangan daripada penceramah, fasilitator, serta peserta lain bagi menghasilkan manuskrip yang berkualiti.<br>*A total of 18 engaging studies were discussed on the final day of the workshop. Participants were also given the opportunity to receive guidance and feedback from the speakers, facilitators, and fellow participants to help produce high-quality manuscripts.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Kelab Jurnal Anjuran Program Perkhidmatan Farmasi 2025<br>*Journal Club by Pharmaceutical Services Programme 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 29 Oktober 2025, Hotel Grand Puteri, Terengganu dan Google Meet<br>*29 October 2025, Hotel Grand Puteri, Terengganu and Google Meet* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 60 orang peserta<br>*60 participants* |
| Objektif<br>*Objective* | Mewujudkan satu platform bagi perkongsian dan perbincangan ilmu dalam kalangan pegawai farmasi di PPF. Inisiatif ini juga berperanan menggalakkan budaya penyelidikan serta pembelajaran berterusan, seterusnya meningkatkan kemahiran profesional dan amalan berasaskan bukti di tempat kerja.<br>*To create a platform for knowledge sharing and discussion among pharmacy officers at PSP. This initiative also seeks to promote a culture of research and continuous learning, thereby enhancing professional skills and evidence-based practice in the workplace.* |

| | |
|---|---|
| Hasil<br>*Outcome* | Peserta memperoleh pemahaman yang lebih mendalam mengenai kaedah menilai kualiti penyelidikan, menginterpretasi data secara kritikal, serta mengenal pasti faktor-faktor yang mempengaruhi keberkesanan rawatan antara statin generik dan jenama. Perbincangan ini turut menggalakkan pertukaran idea dan pengalaman antara peserta, seterusnya menyokong peningkatan amalan berasaskan bukti di kalangan pegawai farmasi.<br>*Participants gained a deeper understanding of how to critically evaluate research quality, interpret data, and identify factors influencing the effectiveness of generic versus brand-name statins. The discussion also encouraged the exchange of ideas and experiences among participants, further supporting the enhancement of evidence-based practice among pharmacy officers.* |

| | |
|---|---|
| Aktiviti<br>*Activity* | Kolokium Penyelidikan dan Pembangunan Farmasi 2025<br>*Pharmacy Research and Development Virtual Colloquium 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 4 hingga 5 November 2025, Google Meet (Secara maya)<br>*4 to 5 November 2025, Google Meet (Virtually)* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | Lebih 300 orang peserta telah menghadiri kolokium ini secara dalam talian<br>*More than 300 participants attended the colloquium virtually* |
| Objektif<br>*Objective* | Menyediakan platform rasmi kepada Pegawai Farmasi yang telah menamatkan pengajian di peringkat Sarjana atau *PhD* untuk mengetengahkan, berkongsi dan membincangkan hasil kajian penyelidikan mereka. Inisiatif ini bukan sahaja menggalakkan perkongsian ilmu dan pengalaman penyelidikan, malah turut membantu pegawai berkenaan memenuhi keperluan pembentangan hasil penyelidikan selepas tamat pengajian.<br>*To provide an official platform for pharmacists who have completed their Master's or PhD studies to present, share, and discuss their research findings. This initiative not only promotes the dissemination of knowledge and research experiences but also supports participants in fulfilling the requirement to present their research outcomes upon completion of their postgraduate studies.* |
| Hasil<br>*Outcome* | Sesi soal jawab yang diadakan telah mewujudkan suasana perbincangan yang interaktif, sekali gus menggalakkan penglibatan aktif para hadirin serta membolehkan pemahaman yang lebih mendalam terhadap topik-topik kajian yang dibentangkan.<br>*The inclusion of interactive question-and-answer sessions fostered active engagement among participants and enabled the audience to gain a deeper understanding of the research topics discussed.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel *Advanced Biostatistics Using R* 2025<br>*Advanced Biostatistics Using R Workshop 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 14 hingga 16 April 2025, Bilik Latihan ICT, National Pharmaceutical Regulatory Agency (NPRA)<br>*14 to 16 April 2025, ICT Training Room, National Pharmaceutical Regulatory Agency (NPRA)* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | Pegawai farmasi dan pegawai penyelidik dari ibu pejabat serta seluruh negeri di Malaysia<br>*Pharmacy officers and research officers from the headquarters as well as all states in Malaysia* |
| Objektif<br>*Objective* | Meningkatkan kemahiran pegawai farmasi dalam mengaplikasikan kaedah statistik lanjutan menggunakan perisian *R* dan *Posit Cloud* bagi menyokong penyelidikan, farmakoepidemiologi serta analisis dasar berasaskan bukti.<br>*To enhance the skills of pharmacy officers in applying advanced statistical methods using R and Posit Cloud software to support research, pharmacoepidemiology, and evidence-based policy analysis.* |
| Hasil<br>*Outcome* | Para peserta memperoleh pengetahuan serta kemahiran praktikal yang dipertingkatkan dalam mengaplikasi kaedah biostatistik lanjutan menggunakan perisian *R*. Bengkel ini dijangka dapat menyumbang kepada pengukuhan amalan berasaskan bukti, peningkatan kualiti penyelidikan farmaseutikal serta penentuan keputusan yang lebih berkesan dalam Program Perkhidmatan Farmasi.<br>*Participants gained enhanced knowledge and practical skills in applying advanced biostatistical methods using R. The workshop is expected to contribute to improved evidence-based practices, higher quality pharmaceutical research, and more informed decision-making within the Pharmaceutical Services Programme.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Jawatankuasa Panel Penilai Inovasi Farmasi (JPPIF) Program Perkhidmatan Farmasi Bil.1/2025 dan Bil. 2/2025<br>*Mesyuarat Jawatankuasa Panel Penilai Inovasi Farmasi (JPPIF) Program Perkhidmatan Farmasi Bil.1/2025 dan Bil. 2/2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | Bil.1/2025: 23 Jun 2025<br>*No.1/2025: 23 June 2025*<br><br>Bil.2/2025: 4 Disember 2025<br>*No.2/2025: 4 December 2025*<br><br>Bilik Mesyuarat Mutiara, PPF dan Google Meet<br>*Bilik Mesyuarat Mutiara, PSP and Google Meet* |

| | |
|---|---|
| Objektif<br>*Objective* | • Menilai projek-projek *Quality Improvement Initiatives* (QIIs) farmasi yang telah menerima pengiktirafan di peringkat kebangsaan tahun 2024.<br>• Mencadangkan pengesyoran hala tuju projek QIIs farmasi untuk diangkat kelulusan bagi menambah baik dasar/polisi perkhidmatan farmasi.<br>• Memaklumkan hasil penilaian berkaitan hala tuju projek QIIs Farmasi kepada pengurusan tertinggi di peringkat program dan negeri.<br>• *Evaluating Pharmacy Quality Improvement Initiatives (QIIs) projects that have received national-level recognition.*<br>• *Recommending the direction of pharmacy QIIs projects for approval to enhance pharmacy service policies.*<br>• *Informing top management at the program and state levels about the evaluation results and future direction of pharmacy QIIs projects* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Pembentukan Jawatankuasa & Mesyuarat Jawatankuasa Kerja Pembangunan Garis Panduan Peluasan Inisiatif Penambahbaikan Kualiti Farmasi Bil. 1/2025 dan Bil. 2/2025<br>*Establishment of the Committee & Working Committee Meetings for the Development of Guidelines on the Expansion of Pharmacy Quality Improvement Initiatives No. 1/2025 and No. 2/2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | Lantikan: 8 Julai 2025<br>*Appointment of the Committee: 8 July 2025*<br><br>Bil.1/2025: 18 & 19 September 2025; Bilik Mesyuarat Kristal, PPF<br>*No.1/2025: 18 & 19 September 2025; Bilik Mesyuarat Kristal, PSP*<br><br>Bil.2/2025: 27 Oktober 2025; Google Meet<br>*No.2/2025: 27 October 2025; Google Meet* |
| Objektif<br>*Objective* | Membangunkan satu garis panduan yang komprehensif dan praktikal bagi menyokong peluasan pelaksanaan inisiatif penambahbaikan kualiti farmasi (PHARMQIIS) secara sistematik dan mampan di fasiliti KKM<br>*To develop comprehensive and practical guidelines to support the systematic and sustainable expansion of pharmacy quality improvement initiatives (PHARMQIIS) implementation across MOH facilities* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Penganjuran Anugerah Inovasi Kementerian Kesihatan Malaysia 2025 – Penyelaras bagi Kategori Inovasi Perkhidmatan<br>*Organization of the Ministry of Health Malaysia Innovation Awards 2025 – Coordinator for the Service Innovation Category* |
| Tarikh/ Tempat<br>*Date/ Venue* | Saringan pertama: 17 September 2025; Bilik Mesyuarat Pintar 1, Institut Kesihatan Negara<br>*Initial Screening: 17 September 2025; Bilik Mesyuarat Pintar 1, Institut Kesihatan Negara*<br><br>Saringan kedua: 8-10 Oktober 2025; Bilik Mesyuarat Pintar 1, Institut Kesihatan Negara, Setia Alam & *Google Meet*<br>*Second Screening: 8-10 October 2025; Bilik Mesyuarat Pintar 1, National Institute of Health & Google Meet*<br><br>Saringan akhir: 4 November 2025; Institut Kesihatan Negara, KKM<br>*Final Screening: 4 November 2025; National Institute of Health, MOH* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | Bahagian Khidmat Pengurusan, IPKKM<br>Institut Kesihatan Negara, KKM<br>*Management Services Division, Ministry of Health Headquarters*<br>*National Institute of Health, MOH* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Seminar Perkongsian Inisiatif Penambahbaikan Kualiti Farmasi Kementerian Kesihatan Malaysia Bil.1/2025<br>*Sharing Seminar on Pharmacy Quality Improvement Initiatives, Ministry of Health Malaysia No. 1/2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 9 September 2025; Dewan Nusantara, Institut Penilaian Negara (INSPEN), Kajang, Selangor<br>*9 September 2025; Dewan Nusantara, Institut Penilaian Negara (INSPEN), Kajang, Selangor* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 96 peserta<br>*96 participants* |
| Objektif<br>*Objective* | • Berkongsi amalan terbaik (*best practices*) dan pengalaman anggota farmasi dalam membangunkan QIIs merangkumi *Quality Assurance* (QA), Kumpulan Inovatif & Kreatif (KIK), Inovasi, dan Lean<br>• Menggalakkan pembudayaan kualiti dalam perkhidmatan melalui pendedahan kepada kajian-kajian QIIs yang telah berjaya mendapat pengiktirafan di peringkat kebangsaan dan antarabangsa<br>• Menyediakan platform perkongsian di peringkat Program Perkhidmatan Farmasi.<br>• *To share best practices and the experiences of pharmacy personnel in developing QIIs, encompassing Quality Assurance (QA), Innovative and Creative Circles (ICC), Innovation, and Lean.*<br>• *To foster a culture of quality in service delivery through exposure to QIIs studies that have successfully achieved national and international recognition.*<br>• *To provide a sharing platform at the Pharmaceutical Services Programme level.* |

| | |
|---|---|
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Penulisan Jurnal Pharmacy Quality Improvement Initiatives (PharmQIIs) Bil. 1/2025<br>*Pharmacy Quality Improvement Initiatives (PharmQIIs) Journal Writing Workshop No. 1/2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 14-16 April 2025; Park Inn by Radisson Hotel Putrajaya<br>*14-16 April 2025; Park Inn by Radisson Hotel Putrajaya* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 33 pegawai Farmasi yang terlibat dalam penulisan manuskrip penambahbaikan kualiti untuk penerbitan<br>*33 pharmacists involved in the preparation of quality improvement manuscripts for publication* |
| Objektif<br>*Objective* | • Menyemak dan membetulkan draf-draf manuskrip untuk penerbitan Jilid 4 Tahun 2025<br>• Memperkasa kemahiran penulis untuk menyediakan manuskrip mengikut format dan standard penerbitan jurnal secara *peer-review.*<br>• Memperkenalkan sistem MySitasi kepada penulis<br>• *To review and revise manuscript drafts for the publication of Volume 4, 2025.*<br>• *To enhance authors' skills in preparing manuscripts according to the format and standards of peer-reviewed journal publications.*<br>• *To introduce the MySitasi system to the authors* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Peningkatan Kualiti Perkhidmatan Farmasi, Program Perkhidmatan Farmasi Kementerian Kesihatan Malaysia<br>*Pharmaceutical Services Quality Improvement Workshop, Pharmaceutical Services Programme, Ministry of Health Malaysia* |
| Tarikh/ Tempat<br>*Date/ Venue* | 18-20 Februari 2025; KSL Esplanade Hotel Klang, Selangor<br>*18-20 February 2025; KSL Esplanade Hotel Klang, Selangor* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 40 pegawai Farmasi yang terlibat secara langsung dalam pengumpulan data, pemantauan indikator kualiti, dan pelaporan *Key Performance Indicator* (KPI) sistem penjagaan kesihatan<br>*40 pharmacists directly involved in data collection, quality indicator monitoring, and healthcare system Key Performance Indicator (KPI) reporting* |

| | |
|---|---|
| Objektif<br>*Objective* | • Memberi pendedahan terperinci mengenai indikator KPI baharu yang diperkenalkan bermula tahun ini, serta kaedah pelaporan yang tepat dan selaras di peringkat KKM.<br>• Memperkukuh kefahaman berhubung *National Policy for Quality in Healthcare* (NPQH), pelan tindakan yang digariskan, serta indikator yang dipantau<br>• *To provide detailed exposure to the newly introduced KPI indicators starting this year, as well as accurate and standardized reporting methods at the MOH level.*<br>• *To strengthen understanding of the National Policy for Quality in Healthcare (NPQH), its outlined action plans, and the monitored indicators.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Penceramah & Fasilitator bagi Bengkel Lean Healthcare, Jabatan Farmasi Hospital Kuala Lumpur<br>*Speakers & Facilitators for the Pharmacy Department, Hospital Kuala Lumpur Lean Healthcare Workshop* |
| Tarikh/ Tempat<br>*Date/ Venue* | 18-19 Jun 2025; Bilik Seminar Aras 5, Kompleks Pakar dan Rawatan Harian, Hospital Kuala Lumpur<br>*18-19 June 2025; Bilik Seminar Aras 5, Kompleks Pakar dan Rawatan Harian, Hospital Kuala Lumpur* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 30 pegawai farmasi Hospital Kuala Lumpur yang terlibat dalam pelaksanaan projek Lean<br>*30 Hospital Kuala Lumpur pharmacist involved in the implementation of the Lean project* |
| Objektif<br>*Objective* | • Meningkatkan kefahaman anggota terhadap konsep Lean dan mengaplikasinya dalam tugas harian supaya perkhidmatan farmasi lebih efisien<br>• Meningkatkan kemahiran anggota farmasi dalam pengendalian projek Lean 2025 di Jabatan Farmasi.<br>• *To enhance staff understanding of Lean concepts and their application in daily tasks for more efficient pharmacy services.*<br>• *To improve the skills of pharmacy personnel in managing 2025 Lean projects within the Pharmacy Department* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Penceramah & Fasilitator bagi Bengkel Manuscript Writing Quality Assurance (QA) Farmasi Negeri Selangor Tahun 2025<br>*Speakers & Facilitators for Selangor State Pharmacy Quality Assurance (QA) Manuscript Writing Workshop 2025* |
| Tarikh/ Tempat<br>*Date/ Venue* | 27 & 28 Mei 2025; Bilik Kuliah 1, Blok D2, Aras 5, Institut Kesihatan Negara<br>*27 & 28 May 2025; Bilik Kuliah 1, Blok D2, Aras 5, Institut Kesihatan Negara* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 40 Pegawai Farmasi JKN Selangor yang terlibat dalam penulisan manuskrip penambahbaikan kualiti untuk penerbitan<br>*40 pharmacists directly involved in data collection, quality indicator monitoring, and healthcare system Key Performance Indicator (KPI) reporting* |
| Objektif<br>*Objective* | • Memberi pendedahan kepada anggota farmasi berkaitan kriteria penulisan manuskrip *Quality Assurance* (QA) yang berkualiti.<br>• Meningkatkan kefahaman anggota farmasi tentang teknik penulisan manuskrip untuk penerbitan jurnal dan cara-cara memenuhi piawaian yang ditetapkan.<br>• *To provide exposure to pharmacy personnel regarding the criteria for writing high-quality Quality Assurance (QA) manuscripts.*<br>• *To enhance the understanding of pharmacy personnel regarding manuscript writing techniques for journal publication and how to meet the established standards.* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Penceramah & Fasilitator bagi Bengkel Jaminan Kualiti (QA) Penguatkuasaan Farmasi 2025<br>*Speakers & Facilitators for the Pharmacy Enforcement Quality Assurance (QA) Workshop* |
| Tarikh/ Tempat<br>*Date/ Venue* | 6-8 Mei 2025; Hotel Sentral Riverview, Melaka<br>*6-8 May 2025; Hotel Sentral Riverview, Malacca* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Organization* | 36 Pegawai Penguatkuasaan Farmasi yang melaksanakan projek *Quality Assurance* (QA) di negeri<br>*36 Pharmacy Enforcement Officers conducting Quality Assurance (QA) projects at states* |
| Objektif<br>*Objective* | Meningkatkan pengetahuan dan kemahiran pegawai penguatkuasaan farmasi khususnya dalam pelaksanaan projek jaminan kualiti<br>*To enhance the knowledge and skills of pharmacy enforcement officers, particularly in the implementation of quality assurance projects* |
| Gambar<br>*Photo* |  |

## 3.0 PENCAPAIAN DAN PENGIKTIRAFAN | *ACHIEVEMENT AND RECOGNITION*

### PENGURUSAN ISO
### *ISO MANAGEMENT*

Pelaksanaan Sistem Pengurusan Kualiti MS ISO 9001:2015

*Implementation of MS ISO 9001: 2015 Quality Management System*

QUALITY SYSTEM
SIRIM
IQNET
RECOGNIZED CERTIFCATION

CERTIFIED TO ISO 9001:2015
CERT. NO. : QMS 01408

Program Perkhidmatan Farmasi di IPKKM telah mendapat pensijilan Sistem Pengurusan Kualiti MS ISO 9001:2015 sejak tahun 2018. Pelbagai aktiviti telah dilaksanakan dan diselaraskan oleh Jawatankuasa Kerja ISO Program Perkhidmatan Farmasi KKM sepanjang tahun 2025.

Pada 10-12 Mac 2025, Audit Pemantauan Kedua MS ISO 9001:2015 Program Perkhidmatan Farmasi KKM telah dilaksanakan oleh pihak SIRIM QAS Sdn. Bhd secara fizikal. Barisan juruaudit terdiri daripada Encik Mohd Hafiz bin Mohd Zaki dan Matron Ham Fin Lan. Secara keseluruhan, Program Perkhidmatan Farmasi KKM telah melaksanakan Sistem Pengurusan Kualiti (SPK) mengikut keperluan standard MS ISO 9001:2015, serta mampu mencapai sasaran yang dirancang. Hasil audit pemantauan juga mendapati tiada ketidakakuran.

*The Pharmaceutical Services Programme at the IPKKM has been certified with MS ISO 9001: 2015 Quality Management System since 2018. Various activities have been implemented and coordinated by the ISO Working Committee of the Pharmaceutical Services Programme throughout year 2025.*

*The Pharmaceutical Services Programme underwent the Second Surveillance Audit of MS ISO 9001:2015 with SIRIM QAS Sdn Bhd on 10-12 March 2025. The auditors involved were Mr. Mohd Hafiz bin Mohd Zaki and Matron Ham Fin Lan. The Pharmaceutical Services Programme KKM has carried out the Quality Management System based on the MS ISO 9001:2015 standard and has been able to achieve planned objectives. The surveillance audit reported no non-conformities.*










Audit Pemantauan Kedua MS ISO 9001:2015
*The Second Surveillance Audit of MS ISO 9001:2015*

## SENARAI PEMENANG *2ND INTERNATIONAL LEAN HEALTHCARE CONFERENCE 2025* (ILHC 2025)
## *LIST OF WINNERS OF 2ND INTERNATIONAL LEAN HEALTHCARE CONFERENCE 2025 (ILHC 2025)*

### *Lean Champion*

Cik Saidatul Sheeda binti Ahmad Shukri, Bahagian Dasar dan Perancangan Strategik Farmasi Program Perkhidmatan Farmasi

*Cik Saidatul Sheeda binti Ahmad Shukri, Pharmacy Policy & Strategic Planning Division, Pharmaceutical Services Programme*

| **PEMENANG / *WINNER (GOLD MEDALIST)*** | | |
|---|---|---|
| **KATEGORI** *CATEGORY* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| *Oral Presentation* | *Vanishing Ink: Improving Efficiency of JKUT Medication Management Through Paperless Transition, Hospital Kuala Lumpur* | Hospital Kuala Lumpur |
| | *Streamlining Therapeutic Drug Monitoring Services: A Lean Approach with Electronic Transformation (SLIM-IT)* | Hospital Seberang Jaya, JKN Pulau Pinang |
| | *Improving Indent and Supply Process of Floor Stock Medication by Ward Supply Pharmacy* | Hospital Bukit Mertajam, JKN Pulau Pinang |
| | *Lean Healthcare Initiative Towards Improving Processing Time for Pharmacy Value Added Services (VAS) at Hospital Putrajaya* | Hospital Putrajaya, JKWPKL&P |
| *Poster Presentation* | *Optimizing Procurement Workflow: Elevating Efficiency Process For Drug & Non-Drug Contracts Items in Pharmacy Department* | Hospital Kuala Lumpur |
| | *Lean Transformation via Satellite Pharmacy Implementation at Hospital Sultanah Aminah* | Hospital Sultanah Aminah, JKN Johor |
| | *Reducing Patient Waiting Time During The Screening Process At Outpatient Pharmacy, Hospital Tengku Ampuan Afzan* | Hospital Tengku Ampuan Afzan, JKN Pahang |
| | *Simplifying Complexities: Streamlining the Workflow to Enhance Efficiency in Application of Special Approval Medicine* | Hospital Kuala Lumpur |
| | *Lean Approaches in Improving Long Patient Waiting Time at the Outpatient Pharmacy Department of Hospital Tuanku Ampuan Najihah* | Hospital Tuanku Ampuan Najihah, JKN Negeri Sembilan |

| **ANUGERAH KHAS / *SPECIAL AWARDS*** | | |
|---|---|---|
| **KATEGORI** *CATEGORY* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| *Oral Presentation (Most Innovative Lean Healthcare Project)* | *Vanishing Ink: Improving Efficiency of JKUT Medication Management Through Paperless Transition, HKL* | Hospital Kuala Lumpur |
| *Oral Presentation (Most Outstanding Lean Healthcare Project)* | *Streamlining Therapeutic Drug Monitoring Services: A Lean Approach with Electronic Transformation (SLIM-IT)* | Hospital Seberang Jaya, JKN Pulau Pinang |
| *Poster Presentation (Best Poster)* | *Simplifying Complexities: Streamlining the Workflow to Enhance Efficiency in Application of Special Approval Medicine, HKL* | Hospital Kuala Lumpur |

## SENARAI PEMENANG ANUGERAH INOVASI KKM TAHUN 2025
## *LIST OF WINNERS OF MOH INNOVATION AWARD 2025*

| KATEGORI PERKHIDMATAN / *SERVICE CATEGORY* | | |
|---|---|---|
| **PEMENANG** *WINNER* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| Pertama *First Place* | *SignHealth* | Bahagian Perkhidmatan Farmasi Negeri Sembilan |

| KATEGORI PROSES / *PROCESS CATEGORY* | | |
|---|---|---|
| **PEMENANG** *WINNER* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| Kedua *Second Place* | RetroID | Hospital Tuanku Ampuan Najihah, JKN Negeri Sembilan |
| Kelima *Fifth Place* | Aplikasi Project File Monitoring (PFM) | JKN Johor |

| KATEGORI TEKNOLOGI / *TECHNOLOGY CATEGORY* | | |
|---|---|---|
| **PEMENANG** *WINNER* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| Ketiga *Third Place* | KASPER | Hospital Kulim, Jabatan Kesihatan Negeri Kedah |

| KATEGORI PRODUK / *PRODUCT CATEGORY* | | |
|---|---|---|
| **PEMENANG** *WINNER* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| Ketiga *Third Place* | GLAUCO-AID | Hospital Sultanah Bahiyah, Jabatan Kesihatan Negeri Kedah |

## Senarai pemenang Konvensyen Inovasi dan Kreativiti Kementerian Kesihatan Malaysia (KIK KKM) Tahun 2025
## *List of winners of MOH Innovation and Creativity Convention (ICC) 2025*

| KATEGORI PRIMER PENAMBAHBAIKAN / *PRIMARY IMPROVEMENT CATEGORY* | | |
|---|---|---|
| **PEMENANG** *WINNER* | **TAJUK PROJEK** *PROJECT'S TITLE* | **FASILITI / NEGERI** *FACILITY / STATE* |
| Ketiga *Third Place* | FTV 2.0 | Cawangan Penguatkuasaan Farmasi, Bahagian Perkhidmatan Farmasi, Jabatan Kesihatan Negeri Johor |

## 4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*

### PENERBITAN PENYELIDIKAN OLEH PEGAWAI FARMASI PADA TAHUN 2025

Pada tahun 2025, Pegawai Farmasi dari seluruh negara di bawah Program Perkhidmatan Farmasi berjaya menerbitkan sebanyak 136 artikel penyelidikan di jurnal tempatan dan antarabangsa. Selain itu, sasaran penerbitan dan pembentangan penyelidikan oleh Ibu Pejabat Program Perkhidmatan Farmasi turut berjaya dicapai, dengan empat (4) artikel penyelidikan dan laporan teknikal berjaya diterbitkan serta lapan (8) pembentangan telah dibentangkan sepanjang tahun tersebut.

### *RESEARCH PUBLICATIONS BY PHARMACISTS IN YEAR 2025*

*In 2025, pharmacists from across the country under the Pharmaceutical Services Programme successfully published a total of 136 research articles in local and international journals. Additionally, the publication and presentation targets set by the Pharmaceutical Services Programme Headquarters were achieved, with four (4) research articles and technical reports published, as well as eight (8) presentations delivered throughout the year.*

Penerbitan artikel penyelidikan dan laporan teknikal yang dihasilkan oleh pegawai Ibu Pejabat Program Perkhidmatan Farmasi
*The publication of research articles and technical reports published by officers from the Pharmaceutical Services Programme Headquarters*

| Bil. *No.* | Institusi *Institution* | Laporan artikel *Report Title* | Maklumat penerbitan *Publication Information* | Pengarang *Authors* |
|---|---|---|---|---|
| 1. | DPSF | *System Usability Scale (SUS): Measuring the Quality of the Web Application by PSP* | Yasim, M. H. M., Shukri, S. S. A., Nordin, N., & Zulkifli, N. W. (2025). The Usability Assessment of PRiSMA and MyPharma-C Web Application System. Indonesian Journal of Pharmacy, 36(1), 178-186. https://doi.org/10.22146/ijp.7938 | Mohd Hadafi Mohd Yasim, Saidatul Sheeda Ahmad Shukri, Noraini Nordin, Nur Wahida Zulkifli |
| 2. | DPSF, UKM & UniSZA | *Development of nurse effective adaptation transition (NEAT) model of newly employed nurses in Ministry of Health Hospitals* | Baharum, H., Ismail, A., Awang, Z., McKenna, L., Ibrahim, R., Mohamed, Z., Hassan, N. H., & Mohamad Yahaya, A. H. (2024). The influencing factors of newly employed nurses' adaptation in Malaysia: a structural equation modelling assessment. BMC nursing, 23(1), 879. https://doi.org/10.1186/s12912-024-02543-2 | Hafidza Baharum, Aniza Ismail, Zainudin Awang, Lisa McKenna, Roszita Ibrahim, Zainah Mohamed, Nor Haty Hassan, Abdul Haniff Mohamad Yahaya |
| 3. | BPF, DPSF & BPF Pahang | *The prevalence of unregistered and falsified medicinal products in Malaysia* | Abdul Karim, K. A., Ahmad, A. E., Abdullah, M. Z., Alias, A., Setan, S., Sulaiman, M. A. A., & Muhsin, N. I. 'Ainaa. (2025). Estimated prevalence of unregistered and falsified medicinal products in Malaysia: a nationwide cross-sectional study conducted from March to November 2023. *Journal of Pharmaceutical Policy and Practice*, *18*(1). https://doi.org/10.1080/20523211.2025.2557879 | Khairul Anuar Abdul Karim, Asyraf Elmiza Ahmad, Mohd Zawawi Abdullah, Asniza Alias, Salina Setan, Manzatul Azrul Azrie Sulaiman, and Nor Ilham 'Ainaa Muhsin |
| 4. | Pahang, Johor, A&P, Negeri Sembilan, Kedah, Sabah, Perlis, Melaka, HKL, Kelantan, Pulau Pinang | *Pharmacist Involvement in Managing Direct-acting Antiviral Agent (DAA) for Hepatitis C Virus (HCV) Infected Patients In An Ambulatory Setting: A Prospective Analysis (P-DAA Study)* | Ahtheemathurra a/p Ballasingam, Kwan Ee Wei, Poh Wei Yoon, Chuah Sim Mei, Cynthia Ang Bee Li, Cheng Yew ChongNeo Wen Ting, Amalina binti Ahmad Nordin, Fong Suh Chen, Nur Izzati binti Kamal Roslan, Nur Hidayah binti Ismail, Mazura binti Ishak, Pharmacist Involvement in Managing Drug-Drug Interactions for Hepatitis C Virus (HCV)-infected Patients on Direct-acting Antiviral Agent (DAA) : A Multicentre Cohort Study (P-DAA Study), July 2025, The International Journal of Gastroenterology and Hepatology Diseases 04 | Ahtheemathurra a/p Ballasingam, Kwan Ee Wei, Poh Wei Yoon, Chuah Sim Mei, Cynthia Ang Bee Li, Cheng Yew Chong,Neo Wen Ting, Amalina binti Ahmad Nordin, Fong Suh Chen, Nur Izzati binti Kamal Roslan, Nur Hidayah binti Ismail, Mazura binti Ishak |

Senarai pembentangan yang telah dibentangkan oleh Pegawai di Ibu Pejabat Program Perkhidmatan Farmasi
*The list of presentations presented by officers from the Pharmaceutical Services Programme Headquarters*

| Bil. *No.* | Tajuk Pembentangan *Title of Presentation* | Nama Persidangan, Lokasi & Tarikh *Conference Name, Location & Date* | Nama Pembentang *Presenter's Name* |
|---|---|---|---|
| 1 | *Management of Breakthrough Seizure and Status Epilepticus in the Emergency Department: A Prospective, Observational, Multicenter Study* | Emergency Medicine Annual Scientific Meeting (EMAS) 2025<br>Shangri-La Hotel,<br>Kuala Lumpur, Malaysia<br>August 23, 2025 | Koh Hock Peng<br>Hospital Kuala Lumpur |
| 2 | *Status Epilepticus in the Emergency Department: Incidence, Mortality Association, and Predictive Factors* | 8th HKL Research Day 2025<br>Hotel Grand Continental Kuala Lumpur, Malaysia<br>October 2, 2025 | Koh Hock Peng<br>Hospital Kuala Lumpur |
| 3 | *Bridging the Gaps: A Qualitative Study on Medication Knowledge and Practices among the Visually Impaired Population in Malaysia* | 1st Kedah International Health Conference 2025<br>Raia Hotel & Convention Center, Alor Setar, Kedah, Malaysia<br>July 31, 2025 | Norazila Abdul Ghani<br>Hospital Jitra |
| 4 | *Voice in the Dark: Medication Management Challenges & Strategies Among Malaysia's Visually Impaired* | 14th Allied Health Scientific Conference<br>Bangi Resort Hotel, Bangi, Selangor, Malaysia<br>September 9 -10, 2025 | Sheikh Shafizal Sheikh Ilman<br>Institut Penyelidikan Tingkahlaku Kesihatan<br>*Institute of Health Behavioural Research* |
| 5 | *Knowledge of Rational Use of Medicines Among Know Your Medicine (KYM) Ambassadors in Malaysia: A national Cross- Sectional Study* | 12th National Public Health Conference<br>Everly Hotel, Putrajaya, Malaysia<br>July 8 - 9, 2025 | Nurashma Juatan<br>Institut Penyelidikan Tingkahlaku Kesihatan<br>*Institute of Health Behavioural Research* |
| 6 | *Optimizing Anticoagulation Reversal Care : Exploring Knowledge and Practice among Healthcare Professionals in Malaysian Government Hospitals* | ASEAN Federation of Cardiology Congress 2025<br>Setia Spice Convention Centre, Penang, Malaysia<br>July 18 - 20, 2025 | Mohemmad Redzuan bin Mohemmad Rizal<br>Bahagian Amalan dan Perkembangan Farmasi |
| 7 | *Incidence, Mortality and Predictors of Status Epilepticus in Malaysian Emergency Departments* | Non-communicable Diseases Malaysia 2025<br>Taylor's University, Malaysia<br>September 12 - 14, 2025 | Sharini binti Sha'ari<br>Hospital Tuanku Ampuan Najihah |
| 8 | *Determinants of Cost Savings Through Pooled Procurement: Evidence from Malaysia's Public Sector Medicines Pricing Initiative* | APRU Global Health Conference 2025<br>Universiti Malaya, Malaysia<br>October 28 - 31, 2025 | Gopi a/l Muniandy<br>Bahagian Amalan dan Perkembangan Farmasi |

## JURNAL *PHARMACY QUALITY IMPROVEMENT INITIATIVES* JILID 4, ISU 1 DAN ISU 2 TAHUN 2025

*Journal of Pharmacy Quality Improvement Initiatives* (PharmQIIs) adalah jurnal *peer-reviewed* yang diterbitkan oleh Program Perkhidmatan Farmasi, KKM. Jurnal ini merupakan salah satu daripada inisiatif kami untuk berkongsi amalan praktis terbaik (best practice) dan pengalaman anggota farmasi semasa mengendalikan projek Inisiatif Penambahbaikan Kualiti (QIIs). Jurnal ini diharap dapat menggalakkan lebih ramai profesional farmasi untuk menerajui inisiatif penambahbaikan kualiti, seterusnya menyumbang kepada penyampaian perkhidmatan penjagaan kesihatan yang lebih cemerlang.

## *JOURNAL OF PHARMACY QUALITY IMPROVEMENT INITIATIVES VOLUME 4, ISSUE 1 AND ISSUE 2 2025*

*The Journal of Pharmacy Quality Improvement Initiatives (PharmQIIs) is a peer-reviewed journal published by the Pharmaceutical Services Programme (PSP), MOH. This journal is one of our initiatives to share best practices and practical knowledge when conducting Quality Improvement Initiatives (QIIs). This journal aims to inspire more pharmacy professionals to spearhead quality improvement initiatives, ultimately contributing to a more outstanding healthcare service delivery.*

Berikut merupakan senarai artikel dalam *Journal of Pharmacy Quality Improvement Initiatives*:
*Articles in Journal of Pharmacy Quality Improvement Initiatives are as follows:*

**Jilid 4, Isu 1 2025**
***Volume 4, Issue 1 2025***

1. Pembangunan Perkhidmatan Pembekalan Ubat Susulan yang Efisien ke Kawasan Pedalaman Melalui MED-LINK 2.0
2. Mengurangkan Peratus Kesilapan Pengubatan Semasa Perpindahan Penjagaan Pesakit Dalam Hospital Kluster Hospital Tuanku Ampuan Najihah Melalui *Kit TORCH (Transfer of Care Re-Engineering For Cluster Hospital)*
3. *To Improve the Appropriate Use of Proton Pump Inhibitors at Outpatient Pharmacy, Hospital Raja Perempuan Zainab II*
4. *Improving Percentage of Psoriasis Prescription Dispensed Within 30 Minutes Among Psoriasis Outpatients in Tuanku Ja'afar Seremban Hospital*
5. *Trimming Time: Unveiling the Impact of Lean Management on Waiting Time Efficiency at Specialist Clinic Outpatient Pharmacy Hospital Kuala Lumpur (HKL)*

**Jilid 4, Isu 2 2025**
***Volume 4, Issue 2 2025***

1. Meningkatkan Penglibatan Kanak-Kanak Dalam Aktiviti Penggunaan Ubat Berkualiti-Pengguna (PUB-P) dengan Menggunakan *Pharmazee Eduboard* (PE)
2. Meningkatkan Kecekapan Operasi AC-MTAC Dengan Menggunakan *SMART MTAC Trolley*: Inisiatif Penambahbaikan Kualiti di Hospital Labuan
3. Formulari Ubat Pejabat Kesihatan Daerah Dungun (FUPKDD): Rujukan Maklumat Ubat Pantas Secara Dalam Talian
4. Meningkatkan Kefahaman Pengambilan Ubat Dalam Kalangan Pesakit Diabetes Mellitus Melalui Pelaksanaan DFIT 2B FIT semasa Proses Pendispensan di Klinik Kesihatan Bestari Jaya
5. Fail Tahan Virtual (FTV): Inovasi Proses untuk Meningkatkan Kecekapan Penyediaan Fail Tahan di Pintu Masuk Negeri Johor
6. *The Impact of Lean Management Implementation on Patient Waiting Time at Outpatient Pharmacy in Tawau Health Clinic*
7. *Optimisation of the Waiting Time in the Outpatient Pharmacy Department (OPD) at Hospital Tuanku Ampuan Najihah*
8. *Improving Work Efficiency to Reduce Patient Waiting Time Through Lean Management at Outpatient Pharmacy Unit, Kamunting Health Clinic, Perak*

Isu terkini tersedia dan boleh diakses dengan melayari portal rasmi Program Perkhidmatan Farmasi di pautan https://pharmacy.moh.gov.my/ms/dokumen/journal-pharmacy-quality-improvement-initiatives-pharmqiis.html

*The latest issue is available and can be accessed through official Pharmaceutical Services Programme portal via link https://pharmacy.moh.gov.my/en/documents/journal-pharmacy-quality-improvement-initiatives-pharmqiis.html*




Penerbitan Jurnal PharmQIIs, Jilid 4, Isu 1 2025
*Publication of PharmQIIS, Volume 4, Issue 1 2025*

## PELANCARAN PELAN ANTIRASUAH ORGANISASI PROGRAM PERKHIDMATAN FARMASI (PPF) TAHUN 2025-2029

Program Perkhidmatan Farmasi, IPKKM telah melancarkan Pelan Antirasuah Organisasi Program Perkhidmatan Farmasi Tahun 2025-2029 pada 27 Mac 2025 oleh mantan Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi), YBrs. Puan Norhaliza binti A Halim.

Pelan Antirasuah Organisasi (OACP) Program Perkhidmatan Farmasi, Ibu Pejabat Kementerian Kesihatan Malaysia merupakan dokumen penting yang menyatakan komitmen PPF IPKKM dalam membendung sebarang amalan atau tindakan yang berkaitan dengan rasuah, masalah integriti dan governans. Pelan ini mengandungi 53 inisiatif yang merangkumi 5 bidang keutamaan serta melibatkan semua bahagian di Program Perkhidmatan Farmasi.

Kerangka dasar dan strategi OACP ini telah dibangunkan melalui sesi perbincangan dan libat urus dengan pegawai-pegawai kanan yang dilantik berdasarkan fungsi utama daripada semua bahagian di bawah PPF IPKKM. Kesemua pegawai-pegawai yang dilantik ini telah menunjukkan komitmen yang tinggi bagi memastikan pembangunan OACP ini dapat direalisasikan.

Bagi memastikan kejayaan pelaksanaan OACP ini, warga kerja PPF IPKKM akan memberikan sepenuh komitmen bagi setiap strategi yang dirancang dalam memastikan visi PPF iaitu "menjadi peneraju dalam perkhidmatan farmasi yang berintegriti dengan elemen akauntabiliti serta kompeten, demi kesejahteraan rakyat yang berterusan" dapat dicapai menjelang 2029.

## *LAUNCH OF THE ORGANIZATIONAL ANTI-CORRUPTION PLAN PHARMACEUTICAL SERVICES PROGRAMME (PSP), 2025–2029*

*Pharmaceutical Services Programme, MOH, launched the Organisational Anti-Corruption Plan (OACP) of the Pharmaceutical Services Programme for 2025–2029 on 27 March 2025. The launch was officiated by the former Deputy Director-General of Health (Pharmaceutical Services), YBrs. Puan Norhaliza binti A Halim.*

*The Organizational Anti-Corruption Plan (OACP), Pharmaceutical Services Programme, Ministry of Health Malaysia, is an important document that reflects PPF IPKKM's commitment to curbing any practices or actions related to corruption, integrity issues, and governance. The plan comprises 53 initiatives covering five priority areas and involves all divisions within the Pharmaceutical Services Programme.*

*The policy and strategic framework of the OACP was developed through a series of discussions and engagement sessions with appointed senior officers, selected based on their core functions from all divisions under the PSP, MOH HQ. All appointed officers demonstrated a high level of commitment to ensure that the development of the OACP was successfully realized.*

*To ensure the successful implementation of the OACP, all staff of the Pharmaceutical Services Programme, Ministry of Health Malaysia, will give their full commitment to every strategy outlined, in order to achieve the PPF vision: "to be a leader in pharmacy services with integrity, accountability, and competence, for the continuous well-being of the people" by 2029.*





Pelancaran Pelan Antirasuah Organisasi Program Perkhidmatan Farmasi Tahun 2025-2029
*Launch of the Organisational Anti-Corruption Plan (OACP) of the Pharmaceutical Services Programme for 2025-2029*

Senarai penerbitan di peringkat negeri dilaporkan pada tahun 2025
*List of publication at state level reported in 2025*

| **Bil.** *No.* | **Institusi** *Institution* | **Tajuk Projek Kualiti** *Quality Project Title* | **Tajuk Artikel** *Article Title* | **Maklumat Penerbitan** *Publication Information* | **Pengarang** *Authors* |
|---|---|---|---|---|---|
| 1. | Hospital Sultanah Bahiyah, JKN Kedah | *A clinical audit on the venous thromboembolism prophylaxis in the medical-surgical intensive care unit of a tertiary referral hospital* | *A Clinical Audit On The Venous Thromboembolism Prophylaxis In The Medical-Surgical Intensive Care Unit Of A Tertiary Referral Hospital* | *Malaysian Journal of Pharmaceutical Sciences Volume 23, No. 1, 2025* | Tan Guo Hong, Eng Wei Lerk, Violet, Ooi Kiat Lay, Faridah Yusof And Asmah Zainudin |
| 2. | Hospital Tengku Ampuan Afzan, JKN Pahang | *To Increase Time In Therapeutic Range (TTR) Among Warfarin MTAC Patients* | *Increasing The Percentage Of Valve Replacement (VR) Patients Achieving Optimum Time In Therapeutic Range (TTR) On Lifelong Warfarin Therapy* | Laporan Teknikal JKN Pahang 2025 | Kwan Ee Wei, Alyaa Madihah binti Ahmad Tamezi, Fahmi Adli bin Abd Razak, Nasreen binti Nazmi, Norzahidah binti Zamani, Nurzuraini binti Yusof, Thilaga Manogaran, Najwa binti Che Abdullah, Marhani binti Ismail |
| 3. | Bahagian Perkhidmatan Farmasi, JKN Pahang | Aplikasi stoRx | Aplikasi Storx | Laporan Teknikal JKN Pahang 2025 | Adi Asraf bin Yusof, Aziarani binti Sabirim, Zaidah binti Ab Karim |

| **Bil.** *No.* | **Institusi** *Institution* | **Tajuk Projek Kualiti** *Quality Project Title* | **Tajuk Artikel** *Article Title* | **Maklumat Penerbitan** *Publication Information* | **Pengarang** *Authors* |
|---|---|---|---|---|---|
| 4. | Hospital Parit Buntar, JKN Perak | *To Increase the Rate of Patient's Follow Up for Diabetic Medication Therapy Adherence Clinic* | *To Increase The Rate Of Patients', Follow Up In Diabetes Medication Therapy Adherence Clinic (DMTAC), Hospital Parit Buntar* | *2025 Perak Technical Report* | Ong XZ, Nor Hamiza AH |
| 5. | Hospital Kampar, JKN Perak | *FastFind* | *Fastfind: A Method Using Barcode Scanner To Improve Kad Temujanji Service In Outpatient Pharmacy, Hospital Kampar* | *2025 Perak Technical Report* | Nurul Aida Ashyqin ZI, Siti Noradila S, Khoo THI, Kartheyany Naidu SMN |
| 6. | Pejabat Kesihatan Daerah Kampar, JKN Perak | *Reducing The Percentage of Improper Insulin Pen Care Handling Among Patients in Kampar District Health Office* | *Reducing The Percentage Of Improper Insulin Pen Care Handling Among Patients In Kampar District Health Office* | *2025 Perak Technical Report* | Nor Zuraida AW, Tang XH, Saidatul Umairah S, Elleasha MK, Nurul Diyana MS, Hazrina Aliya HA, Farah Mardiah AK, Nuraini O, Ahmad Faris MN, Muhammad Amirul Helmi R |
| 7. | Pejabat Farmasi Bahagian Sarikei, JKN Sarawak | *Pharmacy Indent Tracking System* | *Development Of Pharmacy Indent Tracking System To Facilitate The Recording And Monitoring Of Stock Supply Performance Among Sarawak Pharmacy Logistic Division And Sarawak Pharmacy Divisional Offices* | *Sarawak Pharmacy e-Bulletin 2025* | Harry Chua Kheng Sin, Winnie Tiew Ging Ting, Ee Ho Law, Wong Gan Kian |
| 8. | Hospital Tengku Ampuan Rahimah, JKN Selangor | *Reducing the Percentage of Prescribing Error for Iron Dextran in Obstetrics and Gynaecology (O&G) Department, Hospital Tengku Ampuan Rahimah (HTAR), Klang* | *Reducing The Percentage Of Prescribing Error For Iron Dextran Prescription In Obstetrics And Gynaecology (O&G) Department, Hospital Tengku Ampuan Rahimah (HTAR), Klang* | *Q Bulletin, Volume 1, No.34, Jan-Dec 2025* | Parimala Vijai Indrian, Low Shin Yee, P'ng Xiu Wen, Tan Huay Synn, Muna Atirah Ramli, Navamani Nedincheliyin |
| 9. | Pejabat Kesihatan Daerah Klang, JKN Selangor | *Improving The Percentage of Patients On Clopidogrel Who Received Appropriate Prescriptions in Primary Care Settings* | *Improving The Percentage Of Patients On Clopidogrel Who Received Appropriate Prescriptions In Primary Care Settings* | *Q Bulletin, Volume 1, No.34, Jan-Dec 2025* | Simran Kaur Labir Singh, Norharlina Sulaiman, Noor Harzana Harun, Cheang Ching Ye, Lean Ean Pheng, Khoo Chong Chiang |

| **Bil.** *No.* | **Institusi** *Institution* | **Tajuk Projek Kualiti** *Quality Project Title* | **Tajuk Artikel** *Article Title* | **Maklumat Penerbitan** *Publication Information* | **Pengarang** *Authors* |
|---|---|---|---|---|---|
| 10. | Hospital Sultanah Nur Zahirah, JKN Terengganu | *Audit on Individual follow up medication counseling at Outpatient Pharmacy* | *Clinical Audit on Individual Follow-Up Medication Counselling at the Outpatient Pharmacy* | *Compendium of Clinical Audits 2025, HSNZ Kuala Terengganu* | Nurul Nadiah binti Othman, Mazlina binti Mukhtar, Che Ku Nor Halisa binti Che Ku Hamzah, Farah Najiha binti Zamalolaily |
| 11. | Pejabat Kesihatan Putrajaya, JKWPKL&P | *Kapten KAP: Developing And Evaluating A Hand Puppet Intervention To Enhance Medication Literacy In Children* | *Projek Penambahbaikan Perkhidmatan Kenali Ubat Anda Bagi Literasi Kesihatan Kanak-Kanak Melalui Kaedah Boneka Tangan Kapten KAP* | *Pharmacy Research Quality Report 2025 (JKWPKLP)* | Syareena Izani Binti Razak, Norhafiza Binti Hashim, Syafi'ah Binti Bakaruddin, Nur Hanisah Binti Mohamed, Radhiatul Mardhiyah Binti Ngajidin |
| 12. | Hospital Putrajaya, JKWPKL&P | *MedRec* | *Menggunakan MedRec Bagi Rekonsiliasi Ubatan Semasa Transfer of Care Dari Kemasukan Wad Sehingga Temujanji Di Klinik Pakar, Hospital Putrajaya* | *Pharmacy Research Quality Report 2025 (JKWPKLP)* | Sreeveetha Sreedharan, Mogan Ram Sethiaram, Nurul Jannah Sofwan, Siti Salwani Razali, Fazlina Yasmin Jahabar Sathik, Goh Jing Xin, Norizzati Abd Aziz, Nurul Farhana Zolkifli, Lim Jia Hui, Tan Hui Q, Shangari Devaraj, Dr. Navin Kumar Loganadan, Maizan Saad, Shulizal Aida M Salleh |

## PENERBITAN GARIS PANDUAN AKREDITASI *CONTINUOUS PHARMACY EDUCATION* (CPE) DI FASILITI FARMASI KKM EDISI KE-2

Garis Panduan Akreditasi *Continuous Pharmacy Education (CPE) di* Fasiliti Farmasi KKM Edisi ke-2 telah diterbitkan oleh Bahagian Dasar dan Perancangan Strategik Farmasi pada November 2025. Ia merupakan penambahbaikan kepada garis panduan yang diterbitkan pada tahun 2018 selaras dengan keperluan semasa dalam aspek regulatori *Continuing Professional Development* (CPD) dan pembangunan profesion.

Dokumen ini bertujuan sebagai rujukan kepada anggota farmasi dalam melaksanakan akreditasi CPE di fasiliti farmasi di bawah KKM yang melibatkan penganjur selain pihak KKM. Pemantauan kredibiliti penganjur aktiviti CPE (*CPE Provider*) melalui proses akreditasi penganjur adalah penting dan kritikal bagi memastikan ilmu pengetahuan yang disampaikan adalah berkualiti, serta mencapai objektif pembelajaran dan mempertingkat kompetensi profesional anggota farmasi.

## *PUBLICATION OF 'GUIDELINES FOR ACCREDITATION OF CONTINUOUS PHARMACY EDUCATION (CPE) IN MOH PHARMACY FACILITIES - 2ND EDITION'*

*The 2nd Edition of the Guidelines for Accreditation of Continuous Pharmacy Education (CPE) in MOH Pharmacy Facilities was published by the Pharmacy Policy and Strategic Planning Division in November 2025. This edition is an enhancement of the guidelines originally issued in 2018, developed in line with current Continuing Professional Development (CPD) regulatory and professional requirements.*

*The document serves as a reference for pharmacy personnel in implementing CPE accreditation at MOH pharmacy facilities, involving programs organized by external parties. It emphasizes accreditation and monitoring of CPE providers, to ensure that the activities deliver high-quality knowledge, achieve learning objectives, and strengthen the professional competencies of pharmacy personnel.*




Garis Panduan Akreditasi *Continuous Pharmacy Education* (CPE) di Fasiliti Farmasi KKM Edisi ke-2
*Guidelines for Accreditation of Continuous Pharmacy Education (CPE) in MOH Pharmacy Facilities 2nd Edition*

## 5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA
## *INTERNATIONAL COLLABORATION AND PARTICIPATION*

### MESYUARAT PEGAWAI-PEGAWAI KANAN MENGENAI PEMBANGUNAN KESIHATAN (SOMHD) KE-19 SEMPENA SIDANG KEMUNCAK ASEAN KE-46

Sempena Sidang Kemuncak ASEAN ke-46 di bawah Kepengerusian Malaysia, KKM telah diberi penghormatan untuk menjadi tuan rumah serta Pengerusi Mesyuarat Pegawai-Pegawai Kanan mengenai Pembangunan Kesihatan (SOMHD) ke-19 dan mesyuarat-mesyuarat berkaitan yang telah berlangsung pada 30 Jun hingga 4 Julai 2025 di Hotel Sheraton, Petaling Jaya. Mesyuarat ini telah dihadiri oleh Pegawai-Pegawai Kanan Kesihatan dari Negara-Negara Anggota ASEAN (AMS). Ucapan perasmian telah disampaikan oleh Timbalan Ketua Pengarah Kesihatan (Penyelidikan dan Sokongan Teknikal), Datuk Dr. Nor Fariza, serta Timbalan Ketua Setiausaha Komuniti Sosio-Budaya ASEAN (ASCC), Yang Terutama En. San Lwin.

Mesyuarat ini memberi tumpuan kepada pelaksanaan program di bawah empat Kluster Kesihatan ASEAN, iaitu:

1. Gaya hidup sihat
2. Kesiapsiagaan dan respon bencana
3. Pengukuhan sistem kesihatan dan akses penjagaan
4. Keselamatan makanan

### *THE 19TH ASEAN SENIOR OFFICIALS MEETING ON HEALTH DEVELOPMENT (SOMHD) IN CONJUNCTION WITH THE 46TH ASEAN SUMMIT*

*In conjunction with the 46th ASEAN Summit under Malaysia's Chairmanship, MOH was honoured to host and chair the 19th Senior Officials' Meeting on Health Development (SOMHD) and its related meetings, held from 30 June to 4 July 2025 at the Sheraton Hotel, Petaling Jaya. The meetings were attended by Senior Health Officials from ASEAN Member States (AMS). The opening remarks were delivered by the Deputy Director-General of Health (Research and Technical Support), Datuk Dr. Nor Fariza, and the Deputy Secretary-General of the ASEAN Socio-Cultural Community (ASCC), His Excellency Mr. San Lwin.*

*The Meeting focused on the implementation of programmes under the four ASEAN Health Clusters, namely:*

1. *Promoting healthy lifestyles*
2. *Responding to all hazards and emerging threats*
3. *Strengthening health systems and access to care*
4. *Ensuring food safety*

Mesyuarat telah mengambil maklum pembentangan oleh Dr. Abdul Haniff bin Mohamad Yahaya, wakil SOMHD Malaysia selaku Negara Peneraju bagi inisiatif Keterjaminan dan Kemandirian Ubat-Ubatan ASEAN (ASEAN Drug Security and Self-Reliance, ADSSR), berhubung kemajuan pelaksanaan inisiatif tersebut. Pembentangan tersebut merangkumi kemas kini aktiviti projek yang sedang berjalan dalam empat domain utama, iaitu: (i) ubat-ubatan penting, (ii) ubat-ubatan yang tidak berdaya maju secara komersial, (iii) ubat-ubatan kos tinggi, dan (iv) produk biologi. Mesyuarat seterusnya turut mengambil maklum keperluan penyelarasan dengan inisiatif berkaitan di bawah kumpulan kerja badan sektoral ASEAN, termasuk Polisi Kawal Selia Farmaseutikal ASEAN (APRP) di bawah Kumpulan Kerja Produk Farmaseutikal (PPWG), Pertukaran Maklumat Harga untuk Produk Perubatan (PIEMEDS) (AHC 3, Filipina), serta Inisiatif Penyelarasan Antidot di Rantau Asia Tenggara (ICAPS) (AHC 3, Thailand).


Mesyuarat ini juga mengambil maklum potensi kerjasama dengan pihak berkepentingan yang berkaitan dalam pembangunan Pelan Tindakan Strategik ADSSR, termasuk badan-badan sektoral ASEAN di bawah Komuniti Ekonomi ASEAN (AEC), PPWG, dan Jawatankuasa ASEAN mengenai Sains, Teknologi dan Inovasi (COSTI). Mesyuarat menyokong penyertaan titik tumpu *(focal points)* ADSSR dalam mesyuarat akan datang bagi merangka serta melaksanakan Pelan Tindakan Strategik tersebut.

*The Meeting noted a presentation by Dr. Abdul Haniff bin Mohamad Yahaya, SOMHD Malaysia Representative and Lead Country for the ASEAN Drug Security and Self-Reliance (ADSSR) initiative, on the progress of the initiative. The presentation included updates on ongoing project activities across four key domains: (i) essential medicines, (ii) non-commercially viable medicines, (iii) high-cost medicines, and (iv) biological products. The Meeting further noted the need for coordination with related initiatives under ASEAN sectoral body working groups, including the ASEAN Pharmaceutical Regulatory Policy (APRP) under the Pharmaceutical Product Working Group (PPWG), the Price Information Exchange for Medical Products (PIEMEDS) (AHC 3, Philippines), and the Initiative for Coordinated Antidotes in the South-East Asia Region (ICAPS) (AHC 3, Thailand).*

*The Meeting also acknowledged the potential for collaboration with relevant stakeholders in the development of the Strategic Plan of Action for ADSSR, including ASEAN sectoral bodies under the ASEAN Economic Community (AEC), PPWG, and the ASEAN Committee on Science, Technology and Innovation (COSTI). The Meeting expressed its support for the participation of ADSSR focal points in upcoming meetings to formulate and implement the Strategic Plan of Action.*



Pegawai-Pegawai Kanan Kesihatan dari AMS yang menghadiri mesyuarat tersebut
*Senior Health Officials from AMS who attended the meeting*




Dr. Abdul Haniff bin Mohamad Yahaya sedang memberikan input sebagai wakil SOMHD Malaysia
*Dr. Abdul Haniff bin Mohamad Yahaya is giving the input as the representative of SOMHD Malaysia*

## MESYUARAT ASEAN MENGENAI *ASEAN VACCINE SECURITY AND SELF–RELIANCE (AVSSR)*: PENILAIAN PENCAPAIAN DAN PEMACUAN PELAN STRATEGIK PASCA 2025

Mesyuarat ini dianjurkan oleh *National Vaccine Institute, Ministry of Public Health*, Thailand pada 19 Ogos 2025 di Mandarin Hotel Bangkok, Bangkok, Thailand. Tujuan mesyuarat ini diadakan adalah untuk menilai pencapaian Pelan Strategik dan Tindakan AVSSR 2021-2025 dan menetapkan keutamaan dan hala tuju AVSSR bagi pasca 2025.

Delegasi Malaysia terdiri daripada wakil dari PPF, Kementerian Ekonomi dan Pejabat Projek Vaksin Malaysia (MVPO), Kementerian Sains, Teknologi dan Inovasi (MOSTI). Wakil daripada setiap negara anggota ASEAN (AMS) telah membentangkan kemajuan, cabaran utama, dan pengajaran negara dalam pelaksanaan Pelan Strategik AVSSR (2021-2025). Laporan kemajuan Malaysia telah dibentangkan oleh wakil PPF.

Antara faedah yang diperolehi daripada mesyuarat ini adalah kita dapat berkongsi perkembangan terkini berkaitan keterjaminan vaksin di kalangan AMS. Di samping itu, ianya juga menjadi platform jalinan jaringan dengan AMS, organisasi antarabangsa dan rakan pembangunan bagi memberi peluang belajar dan berkongsi pengalaman untuk menyokong inisiatif keterjaminan vaksin dan ubat-ubatan kebangsaan dan ASEAN.

## *ASEAN MEETING ON THE ASEAN VACCINE SECURITY AND SELF-RELIANCE (AVSSR): REVIEWING PROGRESS AND ADVANCING THE STRATEGIC ACTION BEYOND 2025*

*This meeting was organized by the National Vaccine Institute, Ministry of Public Health, Thailand on 19 August 2025 at the Mandarin Hotel Bangkok, Thailand. The purpose of the meeting was to review the progress of the AVSSR Strategic and Action Plan 2021-2025 and to discuss the priorities for the next phase beyond 2025.*

*The Malaysian delegates comprised representatives from the PSP, Ministry of Economy and Malaysia Vaccine Project Office (MVPO), Ministry of Science, Technology and Innovation (MOSTI). The Representatives from each ASEAN Member State (AMS) presented their country's progress, key challenges, and lessons learned in implementing the AVSSR Strategic Plan 2021–2025. Malaysia's progress report was presented by the PSP representative.*

*Among the benefits gained from this meeting was the opportunity to share the latest developments regarding vaccine security among AMS. Furthermore, it served as a networking platform with AMS, international organisations and development partners, providing opportunities to learn and share experiences in supporting national and ASEAN vaccine and medicine security initiatives.*




Delegasi Malaysia
*The Malaysian delegates*

## *ASEAN VACCINE SECURITY AND SELF-RELIANCE* (AVSSR): PROGRAM PEMBANGUNAN SUMBER MANUSIA VAKSIN

Latihan yang dianjurkan oleh *National Vaccine Institute, Ministry of Public Health*, Thailand pada 20 Ogos 2025 di Hotel Mandarin Bangkok ini bertemakan "Membina Dasar Vaksin yang Daya Tahan bagi Kesiapsiagaan Epidemik / Pandemik: Perspektif ASEAN dalam Konteks Global dan Serantau". Delegasi Malaysia telah diwakili oleh pegawai daripada PPF, Kementerian Ekonomi dan Pejabat Projek Vaksin Malaysia (MVPO) di bawah MOSTI.

Susulan kejayaan latihan tahun 2024, program tahun 2025 ini mengalih fokus ke arah memperkukuhkan dasar vaksin dan meningkatkan kesiapsiagaan serantau, dengan mengambil iktibar daripada pandemik COVID-19 bagi menangani cabaran kritikal seperti akses vaksin yang saksama dan ketersediaan regulatori. Kurikulum komprehensif yang disediakan merangkumi kuliah, kajian kes praktikal, dan sesi interaktif yang dikendalikan oleh pakar antarabangsa daripada *International Vaccine Institute (IVI)*, *Department of Disease Control, Thailand*, *Coalition for Epidemic Preparedness Innovations (CEPI)*, *International Health Policy Program (IHPP) Foundation*, *Thailand*, *Pan American Health Organization (PAHO),* dan *Regional Vaccine Management Committee (RVMC)*.

Antara topik utama yang diterokai termasuk "Misi 100 Hari CEPI" untuk ketersediaan vaksin, kewajipan negara di bawah Perjanjian Pandemik WHO, serta model serantau yang berjaya seperti Dana Pusingan PAHO, yang berfungsi sebagai rujukan bagi perolehan pukal dan ekosistem pembuatan yang mampan.

Para peserta berjaya memperolehi pemahaman mendalam mengenai strategi vaksin global di samping memperkukuhkan rangkaian kerjasama dalam kalangan pemegang taruh dasar vaksin serantau. Dengan memupuk kolaborasi dan perkongsian pengalaman bersama rakan pembangunan, program ini memastikan Malaysia dan rakan sejawat di ASEAN berada pada kedudukan yang lebih baik untuk menyokong keterjaminan vaksin kebangsaan dan serantau, sekali gus menyumbang kepada ekosistem pembangunan vaksin yang lebih berdaya tahan dan mampan.

## *ASEAN VACCINE SECURITY AND SELF-RELIANCE (AVSSR): VACCINE HUMAN RESOURCE DEVELOPMENT PROGRAM*

*The training was organized by the National Vaccine Institute, Ministry of Public Health, Thailand, on 20 August 2025 at the Mandarin Hotel Bangkok under the theme "Building Resilient Vaccine Policies for Epidemic / Pandemic Readiness: ASEAN Perspectives in Global and Regional Contexts". The Malaysian delegation was represented by officials from the PSP, Ministry of Economy; and the Malaysia Vaccine Project Office (MVPO) under the MOSTI.*

*Building on the achievements of the 2024 training, the 2025 program shifted its focus toward strengthening vaccine policy and regional preparedness, drawing on critical lessons from the COVID-19 pandemic to address challenges in equitable access and regulatory readiness. The comprehensive curriculum featured lectures, practical case studies, and interactive sessions led by international experts from the International Vaccine Institute (IVI), Department of Disease Control, Thailand, Coalition for Epidemic Preparedness Innovations (CEPI), International Health Policy Program (IHPP) Foundation, Thailand, Pan American Health Organization (PAHO), and the Regional Vaccine Management Committee (RVMC).*

*Key topics explored included the "CEPI 100 Days Mission" for vaccine readiness, country obligations under the WHO Pandemic Agreement, and successful regional models such as the PAHO Revolving Fund, which serves as a leverage for pooled procurement and sustainable manufacturing ecosystems.*

*Participants gained a deeper understanding of global vaccine strategies while successfully strengthening networks among regional vaccine policy stakeholders. By fostering collaboration and sharing experiences with development partners, the program ensured that Malaysia and its ASEAN counterparts are better positioned to support national and regional vaccine security, ultimately contributing to a more resilient and sustainable vaccine development ecosystem.*




Peserta Program Pembangunan Sumber Manusia Vaksin AVSSR 2025
*The participants of AVSSR Vaccine Human Resource Development Program 2025*

## MESYUARAT PERUNDINGAN SERANTAU PERTAMA MENGENAI KETERJAMINAN DAN KEMANDIRIAN DIAGNOSTIK ASEAN (ADxSSR)

Mesyuarat Perundingan Serantau Pertama mengenai Keterjaminan dan Kemandirian Diagnostik ASEAN (ADxSSR) telah dianjurkan oleh Indonesia pada 17 hingga 18 Jun 2025 di Bali, Indonesia. Mesyuarat ini bertujuan menyediakan platform bagi Negara-Negara Anggota ASEAN (AMS) untuk membincangkan kajian yang dijalankan oleh pasukan Institut Penyelidikan Ekonomi untuk ASEAN dan Asia Timur (ERIA) bertajuk *"ASEAN Diagnostic Security and Self-Reliance (ADxSSR) Roadmap".*

Dalam sesi tersebut, dapatan utama serta laporan penuh kajian telah dibentangkan kepada para perwakilan. Mesyuarat ini turut berfungsi sebagai wadah untuk menyelaraskan maklum balas akhir daripada AMS, di samping mengumpulkan pandangan di peringkat global dan serantau. Perbincangan yang diadakan bertujuan merangka cadangan ke arah pembentukan satu kerangka kerja serantau bagi memperkukuh Liputan Kesihatan Sejagat (UHC) serta kesiapsiagaan kecemasan melalui pelaksanaan inisiatif ADxSSR.

Selaku Negara Peneraju bagi Keterjaminan dan Kemandirian Ubatan ASEAN (ADSSR), Malaysia yang diwakili oleh Dr. Abdul Haniff bin Mohamad Yahaya telah dijemput untuk berkongsi pengalaman serta kemajuan negara dalam pelaksanaan dan pengurusan inisiatif ADSSR.

## *THE FIRST REGIONAL CONSULTATIVE MEETING ON ASEAN DIAGNOSTIC SECURITY AND SELF-RELIANCE (ADxSSR)*

*The First Regional Consultative Meeting on ASEAN Diagnostic Security and Self-Reliance (ADxSSR) was organised by Indonesia on 17–18 June 2025 in Bali, Indonesia. The meeting served as a platform for ASEAN Member States (AMS) to deliberate on a study conducted by the Economic Research Institute for ASEAN and East Asia (ERIA) entitled "ASEAN Diagnostic Security and Self-Reliance (ADxSSR) Roadmap."*

*During the session, the key findings and the complete study report were presented to the delegates. The meeting also provided an avenue to consolidate final feedback from AMS, while gathering global and regional perspectives. The discussions aimed to formulate recommendations towards the establishment of a regional framework to strengthen Universal Health Coverage (UHC) and emergency preparedness through the implementation of the ADxSSR initiative.*

*As the Lead Country for ASEAN Drug Security and Self-Reliance (ADSSR), Malaysia, represented by Dr. Abdul Haniff bin Mohamad Yahaya, was invited to share the country's experience and progress in the implementation and management of the ADSSR initiative.*




Delegasi AMS di Mesyuarat Perundingan Serantau Pertama mengenai Keterjaminan dan Kemandirian Diagnostik ASEAN (ADxSSR)
*AMS delegates at the First Regional Consultative Meeting on ASEAN Diagnostic Security and Self-Reliance (ADxSSR)*



Sesi perkongsian pengalaman dan kemajuan Malaysia dalam menguruskan inisiatif ADSSR oleh Dr. Abdul Haniff bin Mohamad Yahaya
*Sharing session of the experience and development of Malaysia in ADSSR initiatives by Dr. Abdul Haniff bin Mohamad Yahaya*

## MESYUARAT PERUNDINGAN SERANTAU MENGENAI MISI 100 HARI

Mesyuarat ini dianjurkan oleh *Ministry of Health, Indonesia* dan *Coalition for Epidemic Preparedness Innovations (CEPI)* pada 27 Oktober 2025 di *The Westin Hotel* Jakarta, Indonesia. Mesyuarat ini menghimpunkan setiap anggota ASEAN, Sekretariat ASEAN, penyelidik, pengeluar, rakan industri serta organisasi masyarakat sivil bagi membincangkan tahap kesiapsiagaan Asia Tenggara dalam menghadapi pandemik pada masa hadapan.

## *REGIONAL CONSULTATIVE MEETING ON THE 100 DAYS MISSION*

*This meeting was organised by the Ministry of Health, Indonesia and the Coalition for Epidemic Preparedness Innovations (CEPI) on 27th October 2025 at The Westin Hotel Jakarta, Indonesia. This meeting brought together ASEAN Member States (AMS), the ASEAN Secretariat, researchers, manufacturers, industry partners and civil society organisations to discuss Southeast Asia's preparedness for future pandemic.*

Delegasi Malaysia terdiri daripada wakil PPF, Kementerian Kesihatan Malaysia dan Pejabat Projek Vaksin Malaysia (MVPO), MOSTI. Wakil daripada setiap Negara Anggota ASEAN (AMS) telah membentangkan pengalaman serta keperluan negara masing-masing dalam usaha membina daya tahan vaksin dalam kalangan AMS. Bagi Malaysia, pembentangan mengenai pengalaman dan keperluan negara dalam membina daya tahan vaksin telah disampaikan oleh wakil PPF.

Mesyuarat ini menyediakan platform yang penting bagi AMS untuk berkongsi pengalaman masing-masing dan mengenal pasti keperluan utama dalam membina ketahanan vaksin, sekaligus menggalakkan pendekatan kolaboratif bagi memperkukuh keselamatan kesihatan serantau. Dalam dialog, para peserta membincangkan cara-cara untuk memperkukuh pengeluaran dan rantaian bekalan vaksin tempatan, menyumbang kepada Misi 100 Hari bagi pembangunan vaksin secara pantas, memastikan akses vaksin yang adil semasa pandemik akan datang, serta membina kerjasama yang kukuh antara kerajaan, penyelidik, sektor swasta, dan organisasi masyarakat sivil. Perbincangan ini dijangka dapat menghasilkan pandangan yang boleh dilaksanakan, menggalakkan kerjasama serantau, dan menyokong perancangan strategik untuk mewujudkan ekosistem vaksin ASEAN yang lebih tahan dan berdikari.

*The Malaysian delegation representatives are from the PSP, Ministry of Health Malaysia, and the Malaysia Vaccine Project Office (MVPO), MOSTI. Representatives from each AMS presented their respective country experiences and needs in efforts to build vaccine resilience among AMS. For Malaysia, the presentation on national experiences and needs in strengthening vaccine resilience was delivered by a representative of the PSP.*

*This meeting provides a valuable platform for AMS to share country experiences and identify key needs in building vaccine resiliency, fostering a collaborative approach to strengthen regional health security. In the round table dialogue, participants discuss ways to strengthen local vaccine production and supply chains, contribute to the 100 Days Mission for rapid vaccine development, ensure fair access to vaccines during future pandemics, and build strong partnerships among governments, researchers, the private sector, and civil society. These discussions are expected to generate actionable insights, promote regional cooperation, and support strategic planning for a more resilient and self-sufficient Southeast Asian vaccine ecosystem.*




Wakil daripada setiap Negara Anggota ASEAN yang menghadiri Mesyuarat Perundingan Serantau Mengenai Misi 100 hari
*Representatives from each AMS who joined the Regional Consultative Meeting on the 100 days Mission*

## PROGRAM PEMBANGUNAN EKOSISTEM BAGI INDUSTRI FARMASEUTIKAL DAN BIOFARMASEUTIKAL DI REPUBLIK RAKYAT CHINA DAN REPUBLIK KOREA

Program Perkhidmatan Farmasi telah menyertai Program Pembangunan Ekosistem bagi Industri Farmaseutikal dan Biofarmaseutikal yang dilaksanakan di Republik Rakyat China pada 11 hingga 18 Oktober 2025 serta di Republik Korea pada 8 hingga 13 November 2025.

Program ini merupakan salah satu pelan tindakan strategik yang dikenal pasti di bawah Pelan Induk Perindustrian Baharu 2030 (NIMP 2030) dan dibiayai melalui Dana Pembangunan Perindustrian Baharu (NIDF). Objektif utama program ini adalah untuk menggalakkan pembangunan ekosistem perindustrian berimpak tinggi dengan memacu industri domestik ke arah pengeluaran produk farmaseutikal dan biofarmaseutikal bernilai tambah tinggi. Sasaran ini dicapai melalui penerokaan potensi usaha sama strategik atau aktiviti penyumberan luar *(outsourcing)* di Malaysia.

Selain itu, program ini bertujuan mengenal pasti sumber pembekal ubat-ubatan baharu bagi memastikan akses berterusan kepada ubat-ubatan penting, seterusnya mengurangkan risiko gangguan rantaian bekalan global dan menyokong usaha negara ke arah mencapai tahap keterjaminan ubatan yang mampan. Program ini melibatkan penyertaan pelbagai pihak berkepentingan daripada kementerian dan agensi berkaitan bagi memastikan pencapaian hasil yang berimpak tinggi kepada negara.

Delegasi Malaysia yang diketuai oleh Lembaga Pembangunan Pelaburan Malaysia (MIDA) turut disertai oleh wakil daripada MOSTI serta KKM. Wakil KKM terdiri daripada:

- Bahagian Dasar & Perancangan Strategik Farmasi
- Bahagian Perolehan dan Penswastaan
- Bahagian Regulatori Farmaseutikal Negara (NPRA)

Sepanjang pelaksanaan program, sebanyak tujuh (7) syarikat farmaseutikal telah dikunjungi di Shanghai dan Beijing, Republik Rakyat China, manakala empat (4) syarikat farmaseutikal telah dikunjungi di Republik Korea. Selain itu, seminar pelaburan yang dianjurkan oleh pejabat antarabangsa MIDA di kedua-dua negara telah menyediakan platform strategik untuk perbincangan lanjut antara syarikat-syarikat berpotensi dan delegasi Malaysia.

Secara keseluruhannya, program ini bukan sahaja berjaya mencapai objektif yang ditetapkan, malah turut memberikan pendedahan, pengetahuan dan pengalaman baharu, khususnya kepada delegasi KKM, berkaitan strategi rundingan di peringkat antarabangsa dalam mempromosikan Malaysia sebagai destinasi pelaburan farmaseutikal yang berdaya saing.

## *THE ECOSYSTEM DEVELOPMENT PROGRAMME FOR THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES IN THE PEOPLE'S REPUBLIC OF CHINA AND THE REPUBLIC OF KOREA*

*The Pharmaceutical Services Programme participated in the Ecosystem Development Programme for the Pharmaceutical and Biopharmaceutical Industries in the People's Republic of China from 11 to 18 October 2025, and in the Republic of Korea from 8 to 13 November 2025.*

*This programme was identified as a strategic action plan under the New Industrial Master Plan 2030 (NIMP 2030) and was funded through the New Industrial Development Fund (NIDF). The primary objective of the programme was to promote the development of a high-impact industrial ecosystem by driving the domestic industry towards the production of high value-added pharmaceutical and biopharmaceutical products. This was pursued through the exploration of potential strategic joint ventures or outsourcing opportunities in Malaysia.*

*In addition, the programme aimed to identify new sources of pharmaceutical suppliers to ensure sustained access to essential medicines, thereby mitigating the risks associated with global supply chain disruptions and supporting national efforts towards achieving sustainable drug security. The programme involved the participation of multiple stakeholders from relevant ministries and agencies to ensure high-impact outcomes for the country.*

*The Malaysian delegation, led by the Malaysian Investment Development Authority (MIDA), included representatives from the MOSTI and the MOH. The MOH delegation comprised representatives from:*

- *Pharmacy Policy & Strategic Planning Division*
- *Procurement and Privatisation Division*
- *National Pharmaceutical Regulatory Agency (NPRA)*

*During the programme, a total of seven (7) pharmaceutical companies were visited in Shanghai and Beijing, People's Republic of China, while four (4) pharmaceutical companies were visited in the Republic of Korea. In addition, investment seminars organised by MIDA's international offices in both countries provided a strategic platform for further engagement and discussions between potential companies and the Malaysian delegation.*

*Overall, the programme not only achieved its intended objectives but also provided valuable exposure, knowledge, and experience, particularly for the MOH delegation, in relation to international negotiation strategies and efforts to promote Malaysia as a competitive destination for pharmaceutical investment.*




Wakil Malaysia serta pihak berkepentingan yang berkaitan bagi Republik Rakyat China
*Representatives from Malaysia and relevant stakeholders of the People's Republic of China*




Sesi libat urus bagi Ecosystem Development Programme for the Pharmaceutical and Biopharmaceutical Industries di Republik Korea
*Engagement session of the Ecosystem Development Programme for the Pharmaceutical and Biopharmaceutical Industries in the Republic of Korea*

## PROGRAM SEKOLAH *SUMMER* AARHUS *PHARMACOEPIDEMIOLOGY* 2025

Program Sekolah *Summer Aarhus Pharmacoepidemiology* 2025 telah berlangsung selama lima hari dan menghimpunkan peserta daripada pelbagai latar belakang profesional dalam bidang kesihatan awam, epidemiologi dan farmasi. Program ini memberi pendedahan komprehensif terhadap konsep, kaedah dan aplikasi farmakoepidemiologi dalam penggunaan dan keselamatan ubat menggunakan data dunia sebenar.

Antara topik utama yang dibincangkan termasuk reka bentuk kajian pemerhatian (*cohort*, *case-control*), kaedah kawalan kendiri seperti *Self-Controlled Case Series (SCCS)* dan *case-crossover*, penilaian keselamatan vaksin dan ubat, serta pengendalian isu metodologi seperti *confounding*, *bias* dan *random error*. Penekanan turut diberikan kepada kaedah tafsiran dapatan kajian seperti *confidence interval*, *sensitivity analysis*, *negative control* dan *triangulation* bagi menyokong dapatan yang lebih kukuh.

Selain itu, kursus ini turut merangkumi aplikasi farmakoepidemiologi dalam populasi khas seperti wanita hamil, di samping pengenalan kepada pendekatan baharu termasuk penggunaan data besar *(big data)*, kecerdasan buatan *(A.I)* dan *causal machine learning* dalam penyelidikan kesihatan.

Penyertaan dalam program ini amat relevan dengan tugas penyediaan *Malaysian Statistics on Medicines (MSOM)*, khususnya dalam meningkatkan kefahaman terhadap kekuatan dan keterbatasan data perolehan sebagai proksi penggunaan ubat, serta memperkukuh keupayaan mentafsir pola penggunaan ubat secara lebih kritikal dan berasaskan bukti. Pengetahuan yang diperoleh juga menyokong usaha penambahbaikan metodologi MSOM dan pembangunan dasar farmasi yang lebih berinformasi, selari dengan keperluan perancangan strategik di Kementerian Kesihatan Malaysia.

## *AARHUS PHARMACOEPIDEMIOLOGY SUMMER SCHOOL 2025*

*Aarhus Pharmacoepidemiology Summer School 2025 is a five-day advanced training programme designed to strengthen competencies in pharmacoepidemiology, with a strong emphasis on the analysis and interpretation of real-world data for medicines utilisation and safety assessment.*

*The programme covered core and advanced methodological topics, including observational study designs (cohort and case–control studies), self-controlled designs such as Self-Controlled Case Series (SCCS) and case-crossover methods, vaccine and medicine safety evaluation, and critical methodological issues including confounding, bias, and random error. Particular emphasis was placed on the interpretation of uncertainty through confidence intervals and on advanced interpretative approaches such as sensitivity analysis, negative control strategies, and triangulation to support robust causal inference.*

*In addition, the programme addressed pharmacoepidemiology applications in special populations, including pregnancy, and introduced emerging approaches such as the use of big data, artificial intelligence, and causal machine learning in health research and policy-relevant evidence generation.*

*Participation in this programme is relevant to the development and continuous improvement of the Malaysian Statistics on Medicines (MSOM). The knowledge and skills acquired enhance the ability to critically interpret national medicines procurement data as a proxy for utilisation, to better understand the strengths and limitations of such data, and to strengthen the analytical and interpretative framework underpinning MSOM outputs. This contributes directly to improving the robustness, credibility, and policy relevance of MSOM in supporting evidence-informed pharmaceutical policy and strategic planning.*

Secara keseluruhan, Program Sekolah *Summer Aarhus Pharmacoepidemiology* 2025 telah memberi nilai tambah yang signifikan dari segi peningkatan kompetensi teknikal, pemikiran analitikal dan perspektif strategik dalam analisis penggunaan dan keselamatan ubat di peringkat nasional.

*Overall, the Aarhus Pharmacoepidemiology Summer School 2025 provided significant strategic value by strengthening technical expertise, analytical judgement, and methodological awareness necessary for advancing national-level medicines utilisation analysis and supporting evidence-based decision-making within the Ministry of Health Malaysia.*



Peserta Program Sekolah Summer *Aarhus Pharmacoepidemiology* 2025
*The participants of Aarhus Pharmacoepidemiology Summer School 2025*

# BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI

## *PHARMACY PRACTICE AND DEVELOPMENT DIVISION*



**BILANGAN PERKHIDMATAN FARMASI PENILAIAN UBAT-UBATAN DI RUMAH**
NUMBER OF HOME MEDICATION REVIEW (HMR)

**15,170**

**2,250,092**

**BILANGAN PRESKRIPSI SUSULAN YANG DIDISPENS MELALUI PERKHIDMATAN NILAI TAMBAH FARMASI**
NUMBERS OF FOLLOW-UP PRESCRIPTIONS DISPENSED THROUGH VALUE-ADDED SERVICES




**2,156,775**
**BILANGAN KAUNSELING UBAT-UBATAN YANG DIJALANKAN**
*NUMBER OF MEDICATION COUNSELLING SESSIONS CONDUCTED*

**307,011**
**BILANGAN PHARMACOTHERAPY REVIEW YANG DIJALANKAN BAGI PERKHIDMATAN KLINIK KEPATUHAN TERHADAP UBAT-UBATAN**
NUMBER OF PHARMACOTHERAPY REVIEW CONDUCTED IN MEDICATION THERAPY ADHERENCE CLINIC (MTAC) SERVICES

**195** **BILANGAN SESI WAWANCARA TV DAN RADIO**
*NUMBER OF TV AND RADIO INTERVIEW SESSIONS*

**57** **BILANGAN ARTIKEL KESIHATAN**
*NUMBER OF HEALTH ARTICLES*

**57** **BILANGAN INFOGRAFIK KESIHATAN**
*NUMBER OF HEALTH INFOGRAPHICS*





**1,381,134**
**BILANGAN INTERVENSI PRESKRIPSI PESAKIT LUAR**
NUMBERS OF INTERVENTIONS OF OUT-PATIENT PRESCRIPTIONS

**745,355**
**BILANGAN INTERVENSI PRESKRIPSI PESAKIT DALAM**
NUMBERS OF INTERVENTIONS OF IN-PATIENT PRESCRIPTIONS

**634,677,619**
**BILANGAN PRESKRIPSI PESAKIT LUAR DITERIMA**
*NUMBER OF OUTPATIENT PRESCRIPTIONS RECEIVED*

**14,302,101**
**BILANGAN PRESKRIPSI PESAKIT DALAM DITERIMA**
*NUMBER OF INPATIENT PRESCRIPTIONS RECEIVED*




**RM3,860.23 Juta**
**PEROLEHAN UBAT-UBATAN KKM (RM)**
*MOH MEDICINES PROCURED (RM)*



**RM1,453.51 Juta**
**PEROLEHAN BUKAN UBAT KKM (RM)**
*MOH NON-MEDICINES PROCURED (RM)*

**13** entiti kimia baru *new chemical entities*
**PENYENARAIAN UBAT BARU KE DALAM FORMULARI UBAT KKM**
*NEW MEDICINES LISTED IN THE MOH MEDICINE FORMULARY*

**RM342.93 Juta**
Fasiliti KKM *MOH Facilities*

**RM267.43 Juta**
Fasiliti Bukan KKM / Institusi Swasta
*Non-MOH Facilities / Private Institution*

**KOS PERMOHONAN UBAT KELULUSAN KHAS (UKK) YANG DILULUSKAN (RM)**
COST OF APPROVED SPECIAL APPROVAL MEDICINES (SAM) APPLICATIONS (MYR)

**30,794**
**PROGRAM KENALI UBAT ANDA**
*KNOW YOUR MEDICINES PROGRAMME*



**2,576**
**BILANGAN DUTA KENALI UBAT ANDA**
*NUMBER OF 'KNOW YOUR MEDICINES' AMBASSADOR*




**231,169**
**BILANGAN PERTANYAAN UBAT**
*NUMBERS OF DRUG INFORMATION ENQUIRIES*



# BAHAGIAN AMALAN DAN PERKEMBANGAN FARMASI
# *PHARMACY PRACTICE AND DEVELOPMENT DIVISION*

## 1.0 PENGENALAN | *INTRODUCTION*

Bahagian Amalan dan Perkembangan Farmasi (BAPF) bertanggungjawab memastikan keperolehan dan kepenggunaan ubat-ubatan yang berkualiti melalui amalan farmasi yang berkesan bagi mempertingkatkan perkhidmatan farmasi di Malaysia supaya setanding dengan kemajuan perkembangan perkhidmatan farmasi di negara-negara maju. Terdapat lima (5) cawangan yang beroperasi di bawah pengawasan BAPF, iaitu Cawangan Pengurusan Farmasi Logistik, Cawangan Penjagaan Farmaseutikal, Cawangan Pengurusan Formulari, Cawangan Penggunaan Ubat Berkualiti dan Cawangan Pengurusan Harga Ubat.

*The Pharmacy Practice and Development Division (BAPF) is responsible for ensuring the quality of drug procurement and usage through effective pharmacy practice in order to improve pharmacy services in Malaysia to be on par with other developed countries. There are five (5) branches operated under the management of BAPF i.e. Logistic Pharmacy Management Branch, Pharmaceutical Care Branch, Formulary Management Branch, Quality Use of Medicines Branch and Medicines Price Management Branch.*

Berikut merupakan fungsi utama bagi cawangan dan seksyen di bawah Bahagian Amalan dan Perkembangan Farmasi:
*Below are the main functions of branches and sections under the Pharmacy Practice and Development Division:*

**CAWANGAN PENGURUSAN FARMASI LOGISTIK**
*LOGISTIC PHARMACY MANAGEMENT BRANCH*

Menyelaras dan memantau keperluan dan perbelanjaan peruntukan, kontrak, pembekalan ubat-ubatan, aktiviti kesiapsiagaan dan pengurusan stor di fasiliti KKM dengan memastikan pekeliling, tatacara serta peraturan berkuat kuasa dipatuhi.

*Coordinate and monitor allocation requirements and expenses, contracts, medicine supply, preparedness activities and store management at MOH facilities by ensuring that circulars, procedures and regulations in force are complied with.*

**CAWANGAN PENJAGAAN FARMASEUTIKAL**
*PHARMACEUTICAL CARE BRANCH*

Merancang, menyelaras, memantau dan memperkasakan aktiviti amalan penjagaan farmaseutikal yang menyeluruh di fasiliti KKM bagi memastikan penggunaan ubat-ubat secara optimum agar dapat meningkatkan kualiti penyampaian perkhidmatan kepada pesakit.

*Plan, coordinate, monitor and empower comprehensive pharmaceutical care practice activities at MOH facilities to ensure the optimal use of medicines in order to improve the quality of service delivery to patients.*

**CAWANGAN PENGURUSAN FORMULARI**
*FORMULARY MANAGEMENT BRANCH*

Merancang polisi dan pelan tindakan berkaitan Formulari Ubat Kementerian Kesihatan Malaysia (FUKKM) dan Ubat Kelulusan Khas (UKK) dalam usaha untuk meningkatkan akses terhadap ubat-ubatan bagi rakyat Malaysia.

*Plan policies and action plans related to the Ministry of Health Medicines Formulary (MOHMF) and Special Approval Medicines (SAM) in an effort to increase access to medicines for Malaysians.*

**CAWANGAN PENGGUNAAN UBAT BERKUALITI**
*QUALITY USE OF MEDICINES BRANCH*

Memberikan pendidikan kepada orang awam berkaitan penggunaan ubat secara berkualiti serta memastikan kesinambungan penjagaan kesihatan dan kepatuhan pesakit kepada rawatan di dalam komuniti.

*Provision of education to the public on quality use of medicines as well as ensuring continuity of care and patient compliance to treatment in the community.*

**CAWANGAN PENGURUSAN HARGA UBAT**
*MEDICINES PRICE MANAGEMENT BRANCH*

Mengurus aktiviti pemantauan, analisis dan penetapan harga ubat-ubatan untuk mendapatkan harga patut bagi meningkatkan ketelusan harga ubat di sektor swasta serta perolehan ubat yang menguntungkan kerajaan.

*Manage the activities of monitoring, analyzing and setting the price of medicines to get the reasonable price to increase the transparency of medicine prices in the private sector as well as the procurement of medicines that benefit the government.*

**SEKSYEN KOORDINASI**
*COORDINATION SECTION*

Mengurus, memantau dan menyelaras perihal keperluan peruntukan dan perbelanjaan, latihan, pelaksanaan aktiviti kualiti, pengurusan mesyuarat dan pelan tindakan serta aduan, pertanyaan atau pelaporan yang berkaitan dengan Bahagian Amalan dan Perkembangan Farmasi. Selain menyelaras dan memantau aktiviti Audit Dalam Amalan Farmasi (ADAF).

*Manage, monitor, and coordinate matters related to the allocation and expenditure requirements, training, implementation of quality activities, meeting management, action plans, as well as complaints, inquiries, or reports related to the Pharmaceutical Practice and Development Division. In addition to coordinating and monitoring the activities of the Audit Dalam Amalan Farmasi (ADAF).*

## 2.0 AKTIVITI DAN SOROTAN | *ACTIVITIES AND HIGHLIGHTS*

### LATIHAN SIMULASI BEKALAN PERUBATAN SEMASA BENCANA (*PharmDEX*) 2025

Latihan simulasi bekalan perubatan semasa bencana (*PharmDEX)* 2025 telah berlangsung pada 18-20 Ogos 2025 di Hotel KSL Esplanade, Klang. Latihan simulasi ini adalah langkah strategik hasil kolaborasi antara BAPF, KKM dan Fakulti Farmasi, Universiti Kebangsaan Malaysia (UKM). Latihan simulasi ini bertujuan mengukuhkan kapasiti kesiapsiagaan dan keupayaan respons ahli farmasi melalui pengalaman secara imersif dengan menyediakan simulasi praktikal dan interaktif yang menyerupai situasi sebenar. Ini membolehkan peserta membuat keputusan di bawah tekanan serta menguji keberkesanan komunikasi dan koordinasi di setiap fasa bencana. *PharmDEX* menggunakan pendekatan pelbagai senario bencana, termasuk pandemik, banjir, dan *insiden Chemical, Biological, Radiological, Nuclear, and Explosive* (CBRNE). Ianya turut dijalankan menggunakan kad peranan di mana peserta mewakili pelbagai fungsi dan tanggungjawab operasi farmasi di peringkat ibu pejabat, negeri, hospital, pejabat kesihatan daerah, dan klinik kesihatan. Berdasarkan penilaian yang dijalankan, peserta berpendapat bahawa *PharmDEX* membantu meningkatkan keupayaan membuat keputusan, memperkukuh komunikasi dan koordinasi antara pelbagai peringkat operasi, serta menjadikan perkongsian maklumat lebih cekap. Ini menyumbang kepada pembangunan kapasiti modal insan dalam bidang farmasi logistik, sekaligus memberi impak positif terhadap daya tahan perkhidmatan farmasi dalam menghadapi bencana.

### *SIMULATION EXERCISE ON MEDICAL SUPPLY MANAGEMENT DURING DISASTERS (PharmDEX) 2025*

*The simulation exercise on medical supply management during disasters (PharmDEX) 2025 was conducted from 18-20 August 2025 at Hotel KSL Esplanade, Klang. This simulation exercise was a strategic collaborative initiative between the BAPF, MOH and the Faculty of Pharmacy, Universiti Kebangsaan Malaysia (UKM). The simulation exercise aimed to strengthen the preparedness capacity and response capability of pharmacists through an immersive experience, providing practical and interactive simulations that closely resemble real-life situations. It enabled participants to make decisions under pressure and to test the effectiveness of communication and coordination across all disaster phases. PharmDEX employed a multi-scenario disaster approach, including pandemics, floods, and Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) incidents. The exercise also incorporated role cards, where participants represented various pharmacy operational functions and responsibilities at the headquarters, state, hospital, district health office, and health clinic levels. Based on evaluations conducted, participants reported that PharmDEX helped enhance decision-making skills, strengthen communication and coordination across different operational levels, and improve the efficiency of information sharing. This contributed to building human resource capacity in pharmacy logistics, while also positively impacting the resilience of pharmacy services during disasters.*



Peserta Pharmdex 2025 Bersama Puan Wan Noraimi binti Wan Ibrahim, Pengarah Amalan dan Perkembangan Farmasi dan Prof. Madya Dr. Ernieda binti Md Hatah dari Fakulti Farmasi, UKM

*Pharmdex 2025 Participants with Puan Wan Noraimi binti Wan Ibrahim, Director Of Pharmaceutical Practice and Development, and Associate Professor Dr. Ernieda binti Md Hatah from the Faculty of Pharmacy, UKM.*

### PROGRAM ERAT (*EMPOWERING PATIENTS LIVING WITH DIABETES)*

Majlis peluncuran Program ERAT telah disempurnakan oleh YB Datuk Seri Dr. Dzulkefly Ahmad, Menteri Kesihatan, pada 4 November 2025 bertempat di Hotel Marriott, Putrajaya. Program ERAT memberi tumpuan kepada dua (2) komponen utama, iaitu pemerkasaan pesakit dan keluarga melalui pelaksanaan ujian kendiri paras gula darah atau *Self-Monitoring of Blood Glucose (SMBG)* di rumah, serta peningkatan kompetensi pegawai farmasi DMTAC melalui pelaksanaan latihan dan bengkel yang komprehensif.

ERAT adalah satu inisiatif reformasi kesihatan secara berkolaborasi di antara Program Perkhidmatan Farmasi (PPF), Persatuan Farmasi Malaysia (MPS) dan syarikat farmaseutikal Novo Nordisk Malaysia. Sebanyak 3,000 set glucometer akan diagihkan kepada pesakit DMTAC di seluruh negara bagi membantu mereka memantau paras gula secara kendiri dengan lebih mudah, kerap dan berkesan.

Melalui Program ERAT, KKM komited untuk memperkukuh pengurusan serta kawalan diabetes melalui pemerkasaan penjagaan kesihatan kendiri. Inisiatif ini diharap dapat melahirkan pesakit yang lebih berpengetahuan dan bertanggungjawab terhadap kesihatan diri.

### *ERAT (EMPOWERING PATIENTS LIVING WITH DIABETES) PROGRAMME*

*The launch of ERAT Programme (Empowering Patients Living with Diabetes) was officiated by YB Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health on 4 November 2025 at the Marriott Hotel Putrajaya. The ERAT programme focuses on two (2) components which are empowering patients and families through the implementation of self-monitoring of blood glucose (SMBG) at home and enhancing the competency of DMTAC pharmacist through comprehensive training and workshops.*

*ERAT is a health reform initiative collaboratively undertaken between the Pharmaceutical Services Programme (PSP), the Malaysian Pharmacists Society (MPS) and the pharmaceutical company Novo Nordisk Malaysia. A total of 3,000 glucometer sets will be distributed to DMTAC patients nationwide to support more convenient, frequent, and effective self-monitoring of blood glucose.*

*Through the ERAT Programme, the MOH is committed to strengthening diabetes management by empowering self-care in practices. This initiative is expected to nurture patients who are more knowledgeable and responsible for their own health.*






Majlis Peluncuran Program ERAT
*Launching Ceremony of the ERAT Programme*

## SESI LIBAT URUS PROGRAM PERKHIDMATAN FARMASI BERSAMA *PHARMACEUTICAL ASSOCIATION OF MALAYSIA* (PhAMA)

Pada 16 Disember 2025, Program Perkhidmatan Farmasi telah mengadakan sesi libat urus bersama Pharmaceutical Association of Malaysia (PhAMA) bagi memperkukuh kerjasama awam–swasta dalam meningkatkan akses pesakit kepada ubat-ubatan inovatif. Perbincangan tertumpu kepada penambahbaikan proses penyenaraian dalam Formulari Ubat KKM (FUKKM) dan pelaksanaan Analisis Impak Bajet (BIA), pembangunan kapasiti *Health Technology Assessment* (HTA), serta penggunaan data *real-world evidence* (RWE) tempatan bagi menyokong penilaian formulari yang telus serta berasaskan bukti dan nilai.

## *ENGAGEMENT WITH PHARMACEUTICAL ASSOCIATION OF MALAYSIA (PhAMA)*

*On 16 December 2025, the Pharmaceutical Services Programme held an engagement session with the Pharmaceutical Association of Malaysia (PhAMA) to strengthen public–private collaboration in improving patient access to innovative medicines. Discussions focused on enhancing the MOH Medicines Formulary (MOHMF) listing process, implementation of Budget Impact Analysis (BIA), strengthening Health Technology Assessment (HTA) capacity, and leveraging local real-world evidence (RWE) to support transparent, evidence-based and value-driven formulary evaluations.*

## PELAKSANAAN INISIATIF PEMAPARAN HARGA UBAT DI KEMUDAHAN JAGAAN KESIHATAN SWASTA DAN FARMASI KOMUNITI DI BAWAH AKTA KAWALAN HARGA DAN ANTIPENCATUTAN 2011 [*AKTA 723*]

Selaras dengan komitmen Kerajaan untuk memperkukuh ketelusan harga ubat, Perintah Penandaan Harga Ubat 2025 [P.U. (A) 141] telah diwartakan pada 1 Mei 2025 di bawah Akta Kawalan Harga dan Antipencatutan 2011 [*Akta 723*] melalui pelaksanaan Inisiatif Pemaparan Harga Ubat. Pewartaan ini turut melibatkan pemberian kuasa kepada Pegawai Farmasi daripada Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup (KPDN) sebagaimana yang diperuntukkan melalui Warta Kerajaan No. 14186 dan 14187.

Sebagai persediaan pelaksanaan, sesi advokasi telah diadakan bagi meningkatkan kesedaran dan kefahaman pihak berkepentingan terhadap keperluan pematuhan inisiatif ini. Dua sesi utama telah dijalankan iaitu pada 27 Februari 2025 yang dihadiri oleh seramai 1,091 orang peserta serta pada 21 Julai 2025 dengan kehadiran seramai 400 orang peserta.

## *IMPLEMENTATION OF THE MEDICINE PRICE DISPLAY INITIATIVE AT PRIVATE HEALTHCARE FACILITIES AND COMMUNITY PHARMACIES UNDER THE PRICE CONTROL AND ANTI-PROFITEERING ACT 2011 [ACT 723]*

*In line with the Government's commitment to strengthening medicine price transparency, the Price Marking Order for Medicines 2025 [P.U. (A) 141] was gazetted on 1 May 2025 under the Price Control and Anti-Profiteering Act 2011 [Act 723] through the implementation of the Medicine Price Display Initiative. The gazettement also involved the delegation of enforcement powers from the Ministry of Domestic Trade and Cost of Living (KPDN), as provided under Government Gazette Nos. 14186 and 14187.*

*As part of the implementation preparations, advocacy sessions were conducted to enhance stakeholders' awareness and understanding of the initiative's compliance requirements. Two main sessions were held, namely on 27 February 2025 with 1,091 participants, and on 21 July 2025 with 400 participants in attendance.*

Tempoh peralihan *(grace period*) telah ditetapkan bermula 1 Mei 2025 sehingga 1 Ogos 2025 bagi memberi ruang kepada premis terlibat membuat penyesuaian terhadap keperluan pemaparan harga ubat. Bagi tempoh 1 Ogos 2025 hingga 31 Disember 2025, pendekatan penguatkuasaan secara pendidikan telah dilaksanakan melalui pemeriksaan pendidikan di mana semua premis yang diperiksa telah diberikan penerangan serta tatacara melalui soalan lazim (FAQ) bagi penyediaan senarai harga ubat. Pendekatan ini telah diumumkan di media massa pada 2 Mei 2025 dan penguatkuasaan penuh akan dimulakan pada 1 Januari 2026.

*A transition (grace) period was set from 1 May 2025 to 1 August 2025 to allow affected premises to make the necessary adjustments to comply with the medicine price display requirements. For the period from 1 August 2025 to 31 December 2025, an educational enforcement approach was implemented through educational inspections, whereby all inspected premises were provided with information and guidance, including frequently asked questions (FAQs), to assist them in preparing and displaying their price lists. This approach was announced in the mass media on 2 May 2025, and full enforcement will commence on 1 January 2026.*





Sesi Libat Urus Bersama Pihak Berkepentingan
*Engagement Session with Stakeholders*

## *PHARMACY INTEGRATED COMMUNITY CARE (PICC)*

*Pharmacy Integrated Community Care* (PICC) merupakan satu inisiatif yang diperkenalkan bagi mengoptimumkan rawatan diabetes pesakit di komuniti. PICC melibatkan aktiviti dalam kumpulan yang dijalankan di dalam komuniti mengikut modul yang berstruktur, komprehensif dan standard. PICC merupakan program berkonsepkan "tuisyen diabetes" dalam komuniti bagi mengoptimumkan rawatan pesakit diabetes. PICC dilaksanakan melalui kolaborasi pakar perubatan keluarga, pegawai perubatan, pegawai farmasi, pegawai dietetik, pegawai sains pemakanan, jururawat, penolong pegawai perubatan, ahli fisioterapi serta wakil komuniti (contoh: *MyCHAMPION* [Duta Kenali Ubat Anda / Pasukan Sukarelawan KOSPEN]).

Elemen penting dalam PICC adalah pengurusan ubat-ubatan, amalan gaya hidup sihat, dan pemakanan seimbang. Pada tahun 2023, PICC telah diangkat sebagai *Key Performance Indicator* (KPI) Dimensi Daya Saing Agensi (DDSA). Bagi tahun 2023, lima (5) negeri intervensi telah dipilih iaitu Kelantan, Terengganu, Kedah, Perak dan Sarawak. Indikator KPI ini adalah: Peratus pesakit diabetes yang mencapai penurunan HbA1c selepas melengkapkan sesi PICC ≥65%. KPI ini telah berjaya dicapai dengan pencapaian nasional bagi 2023 adalah: 67.98%. Pada tahun 2025, PICC masih kekal diangkat sebagai KPI Dimensi Daya Saing Agensi dan diperluaskan ke seluruh negara. KPI ini telah berjaya mencapai sasaran yang ditetapkan dengan pencapaian nasional bagi 2025 adalah: 75.86%.

## *PHARMACY INTEGRATED COMMUNITY CARE (PICC)*

*Pharmacy Integrated Community Care (PICC) is an initiative introduced to optimize diabetes treatment among patients in the community. PICC involves group-based activities conducted within the community using structured, comprehensive, and standardized modules. It is a community-based program that adopts a "diabetes tuition" concept to optimize the management and treatment of diabetes patients. PICC is implemented through collaboration among family medicine specialists, medical officers, pharmacists, dietitians, nutrition science officers, nurses, assistant medical officers, physiotherapists, and community representatives (e.g. MyCHAMPION [Know Your Medicine Ambassador / KOSPEN Volunteer Team]).*

*The key elements of PICC include medication management, healthy lifestyle practices, and balanced nutrition. In 2023, PICC was designated as a Key Performance Indicator (KPI) under the Agency Competitiveness Dimension (DDSA). For that year, five (5) states were selected as intervention states, namely Kelantan, Terengganu, Kedah, Perak, and Sarawak. The KPI indicator was the percentage of diabetes patients who achieved a reduction in HbA1c after completing the Pharmacy Integrated Community Care (PICC) sessions of at least 65%. This KPI was successfully achieved, with a national achievement of 67.98% in 2023. In 2025, PICC continued to be maintained as a KPI under the Agency Competitiveness Dimension and was expanded nationwide. The KPI once again achieved the set target, with a national achievement of 75.86% in 2025.*






Aktiviti Pharmacy Integrated Community Care (PICC)
*Pharmacy Integrated Community Care (PICC) Activity*

## PROMOSI PROGRAM KENALI UBAT ANDA MELALUI MEDIA SOSIAL

Bahagian Amalan dan Perkembangan Farmasi sentiasa komited untuk terus meningkatkan kefahaman dan kesedaran masyarakat melalui penganjuran pelbagai inisiatif dan program. Dalam usaha tersebut, pelbagai platform digunakan untuk hebahan promosi dalam menyampaikan maklumat yang tepat terutamanya berkaitan isu penggunaan ubat-ubatan yang berkualiti kepada pengguna. Maklumat pendidikan ubat-ubatan turut dibuat hebahan dalam bentuk infografik dan video pendidikan yang dimuat naik ke laman media sosial Program Perkhidmatan Farmasi KKM. Bahagian Amalan dan Perkembangan Farmasi juga secara aktif terlibat dalam sesi wawancara di radio, televisyen dan bual bicara di media sosial. Usaha menyebarluaskan capaian informasi berkenaan isu penggunaan ubat-ubatan kepada masyarakat dipertingkatkan menerusi kolaborasi bersama-sama pihak media. Pelbagai topik telah diutarakan untuk memberi kesedaran dan pendidikan kepada pengguna berkaitan ubat-ubatan. Sebanyak 57 infografik berkaitan maklumat ubat-ubatan telah dihasilkan dan 195 sesi wawancara tv dan radio berjaya disiarkan sebagai medium penyampaian informasi kepada masyarakat.

## *PROMOTION OF KNOW YOUR MEDICINES PROGRAMME THROUGH SOCIAL MEDIA*

*The Pharmacy Practice and Development Division remains committed to continually enhancing public understanding and awareness through the organization of various initiatives and programs. In this effort, diverse platforms are utilized for promotional outreach to deliver precise information, particularly regarding the use of quality medications, to consumers. Educational information on medications is also disseminated in the form of infographics and educational videos uploaded to the social media pages of the Pharmaceutical Services Program under the MOH. The Pharmacy Practice and Development Division are also actively involved in interview sessions on radio, television, and talk shows on social media. The endeavor to disseminate information regarding the use of medications to the public is intensified through collaborative efforts with the media. Various topics have been addressed to raise awareness and provide education to consumers regarding medications. A total of 57 infographics related to medication information have been produced, and 195 TV and radio interview sessions have been successfully broadcasted as a means of conveying information to the public.*





































Infografik maklumat berkaitan ubat-ubatan dan pendidikan pengguna
*Infographics on information related to medicines and consumer education*




Penyampaian maklumat ubat-ubatan melalui sesi wawancara di stesen TV dan radio
*Medicines information being conveyed through interview sessions in TV and radio stations*




Bahan Pendidikan dalam bentuk Video
*Educational Materials in Video form*

## PENULISAN ARTIKEL KESIHATAN BERKAITAN PENGGUNAAN UBAT SECARA BERKUALITI

Penulisan artikel melalui pelbagai platform sama ada media massa atau media sosial adalah merupakan salah satu jenis sebaran maklumat berkaitan penggunaan ubat secara berkualiti kepada masyarakat. Cawangan Penggunaan Ubat Berkualiti berjaya berkolaborasi dengan beberapa platform penerbitan seperti Dewan Kosmik, Sinar Daily, The Malaysian Medical Gazette, Helo Medik dan The Star. Sejumlah 57 artikel telah berjaya ditulis dan diterbitkan pada tahun 2025. Penulis artikel merupakan pegawai farmasi yang bertugas di fasiliti KKM seluruh negara.

## *HEALTH ARTICLES RELATED TO QUALITY USE OF MEDICINES*

*Writing articles through various platforms either mass media or social media, is one of the types of information dissemination related to the use of quality medicine to the community. Quality Use Medicines Branch has successfully collaborated with several publisher platforms such as Dewan Kosmik, Sinar Daily, The Malaysian Medical Gazette, Helo Medik dan The Star. A total of 57 articles have been successfully written and published in 2025. The authors of these articles are pharmacists working at the MOH facilities nationwide.*




Artikel Kesihatan yang diterbitkan pada tahun 2025
*Health Articles published in 2025*

## KURSUS PEMANTAPAN AUDITOR AUDIT DALAM AMALAN FARMASI (ADAF)

Kursus Pemantapan Auditor ADAF telah dihadiri oleh 30 peserta yang terdiri daripada Penyelaras ADAF Negeri/ Institusi serta barisan auditor yang bertanggungjawab melaksanakan urusan ADAF di lapangan. Penganjuran kursus ini merupakan satu inisiatif strategik yang dirangka khusus untuk meningkatkan kompetensi teknikal para auditor, di samping memastikan penyelarasan prosedur pelaksanaan audit yang jitu di seluruh negara.

Fokus utama diberikan kepada usaha memperkasa kualiti pelaporan penemuan agar lebih berimpak tinggi dan berintegriti, yang seterusnya berfungsi sebagai instrumen sokongan kritikal kepada pihak pengurusan untuk membuat keputusan. Selain itu, penekanan turut diberikan untuk mengoptimumkan platfom e-ADAF bagi memacu transformasi digital, sekali gus menjamin proses pengauditan yang lebih efektif, telus, dan berkualiti.

## *PHARMACY PRACTICE INTERNAL AUDIT AUDITOR EMPOWERMENT COURSE*

*ADAF Auditor Empowerment Course was attended by 30 participants, comprising of state/institutional ADAF coordinators and auditors who are responsible for conducting ADAF operations on-site. The course serves as a strategic initiative to enhance technical competencies of auditors while ensuring the precise standardization of audit procedures nationwide.*

*Primary focus was placed on strengthening the quality of reporting on findings to ensure greater impact and integrity, thereby serving as a critical support instrument for management in the decision-making process. In addition, emphasis was given to optimising the e-ADAF platform to drive digital transformation, ensuring a more effective, transparent, and high-quality audit process.*




Kursus Pemantapan Auditor di Hotel Grand Continental, Kuala Terengganu | 28-30 April 2025
*ADAF Auditor Empowerment Course held at Grand Continental Hotel, Kuala Terengganu | 28-30 April 2025*

## AKTIVITI TAMBAHAN
## *ADDITIONAL ACTIVITIES*

| | |
|---|---|
| Aktiviti<br>*Activity* | Perbincangan Perolehan Ubat Oral Antiviral Oleh Fasiliti Kesihatan KKM Bersama Syarikat Pfizer (Malaysia) Sdn. Bhd.<br>*Discussion on the Procurement of Oral Antiviral Drugs by MOH Health Facilities with Pfizer (Malaysia) Sdn. Bhd.* |
| Tarikh / Tempat<br>*Date / Venue* | 2 Februari 2024 di Bilik Mesyuarat Delima, Program Perkhidmatan Farmasi<br>*2 February 2024 at Delima Meeting Room, Pharmaceutical Services Programme* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Perbincangan ini dijalankan secara fizikal di Bilik Mesyuarat Delima, Program Perkhidmatan Farmasi, dan juga secara maya dengan penyertaan seramai 15 orang pegawai daripada kedua-dua pihak.<br>*The discussion was conducted physically at the Delima Meeting Room, Pharmaceutical Services Programme, and also virtually with the participation of 15 officers from both parties.* |
| Objektif<br>*Objectives* | Menyelaras perancangan perolehan ubat antiviral Paxlovid® dengan pemegang pendaftaran produk tersebut bagi memastikan kesinambungan bekalan antiviral untuk rawatan COVID-19 di fasiliti kesihatan KKM.<br>*Coordinating the procurement planning of the antiviral drug Paxlovid® with the product registration holder to ensure the continuity of the antiviral supply for COVID-19 treatment at MOH healthcare facilities.* |
| *Hasil<br>**Outcome* | Memastikan bekalan Paxlovid® sentiasa tersedia di fasiliti kesihatan KKM melalui penyelarasan dengan pemegang pendaftaran, untuk memastikan rawatan COVID-19 yang berterusan dan efisien.<br>*To ensure a continuous supply of Paxlovid® in MOH healthcare facilities through coordination with the product registrant, to ensure ongoing and efficient COVID-19 treatment.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Spesifikasi Konsesi Perkhidmatan Logistik Perubatan KKM Sesi 2027-2030<br>*Meeting on the Specifications of Approved Products Purchase List (APPL) MOH Session 2027-2030* |
| Tarikh / Tempat<br>*Date / Venue* | 21-23 Oktober 2025 di Crystal Crown Hotel Harbour View, Port Klang<br>*21-23 October 2025 at Crystal Crown Hotel Harbour View, Port Klang* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Mesyuarat ini telah dihadiri oleh seramai 30 orang pegawai yang terdiri daripada wakil-wakil Program Perkhidmatan Farmasi, Bahagian Regulatori Farmasi Negara, Jabatan Kesihatan Negeri serta fasiliti-fasiliti kesihatan KKM<br>*The meeting was attended by a total of 30 officers, comprising representatives from the Pharmaceutical Services Programme, the National Pharmaceutical Regulatory Agency, State Health Departments, and MOH healthcare facilities.* |

| | |
|---|---|
| Objektif<br>*Objectives* | • Menentukan spesifikasi teknikal yang sesuai bagi produk farmaseutikal di bawah Konsesi Logistik bagi memastikan kesesuaian dengan keperluan klinikal serta penggunaan di fasiliti kesihatan KKM.<br>• Memastikan spesifikasi yang dirangka memenuhi standard kualiti dan keselamatan yang ditetapkan oleh KKM dan badan regulatori berkaitan.<br>• Memastikan spesifikasi yang dirangka selaras dengan garis panduan, dasar dan keperluan semasa yang ditetapkan.<br>• Menyemak isu dan cabaran dalam proses perolehan serta logistik, dan mengenal pasti langkah-langkah penambahbaikan bagi meningkatkan keberkesanan sistem perolehan.<br>• *To determine appropriate technical specifications for pharmaceutical products under the Logistics Concession, ensuring suitability for clinical needs and utilization within MOH healthcare facilities.*<br>• *To ensure that the drafted specifications comply with the quality and safety standards stipulated by the Ministry of Health (MOH) and relevant regulatory bodies.*<br>• *To ensure alignment of the drafted specifications with established guidelines, policies and current requirements.*<br>• *To review issues and challenges encountered in the procurement and logistics processes, and to identify improvement measures to enhance the effectiveness of the procurement system.* |
| *Hasil<br>**Outcome* | Sebanyak 498 spesifikasi ubat-ubatan di bawah Konsesi Logistik telah berjaya disediakan bagi tujuan pelantikan Sesi 2027-2030.<br>*A total of 498 medicine specifications under the Logistics Concession were successfully prepared for appointment for the 2027–2030 session.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Semakan Garis Panduan Pengurusan Produk Rangkaian Sejuk di Fasiliti Kementerian Kesihatan Malaysia<br>*Meeting for the Review of Cold Chain Management in Ministry of Health Facilities Guideline* |
| Tarikh / Tempat<br>*Date / Venue* | 7-9 Oktober 2025 di Hotel Premiere, Klang<br>*7-9 October 2025 at Premiere Hotel, Klang* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Mesyuarat ini telah dihadiri oleh seramai 40 orang pegawai yang terdiri daripada wakil-wakil Program Perkhidmatan Farmasi, Bahagian Pembangunan Kesihatan Keluarga, Bahagian Perkembangan Kesihatan Awam, Bahagian Regulatori Farmasi Negara, Bahagian Dasar dan Perancangan Strategik Farmasi, Jabatan Kesihatan Negeri serta fasiliti-fasiliti kesihatan KKM.<br>*The meeting was attended by a total of 40 officers, comprising representatives from the Pharmaceutical Services Programme, Family Health Development Division, Public Health Development Division, National Pharmaceutical Regulatory Agency, Pharmacy Policy and Strategic Planning Division, State Health Departments, and MOH healthcare facilities.* |

| | |
|---|---|
| Objektif<br>*Objectives* | Mendapatkan input bagi menyemak dan mengemaskini Garis Panduan Pengurusan Produk Rangkaian Sejuk di Fasiliti KKM agar garis panduan tersebut kekal relevan dengan keperluan serta piawaian semasa.<br>*To gather feedback for reviewing and updating the Cold Chain Product Management in the MOH Facilities Guideline to align with contemporary standards and needs.* |
| *Hasil<br>**Outcome* | Satu draf Garis Panduan Pengurusan Produk Rangkaian Sejuk di Fasiliti KKM telah disediakan. Draf tersebut akan melalui proses semakan semula dan penyuntingan lanjut bagi memastikan segala input yang diterima diambil kira sebelum dimuktamadkan.<br>*The draft of the Cold Chain Product Management in the MOH Facilities Guideline has been developed. These will be subjected to further review and revision to ensure all inputs are addressed before final approval.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Sesi Penyuntingan Video dan Pemurnian Modul Latihan Farmasi Logistik (Beginner) 2025<br>*Video Editing and Technical Refinement of the Pharmacy Logistics Training Module (Beginner) 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 24 Jun 2025 di Bilik Mesyuarat Mutiara, Program Perkhidmatan Farmasi<br>*24 June 2025 at Mutiara Meeting Room, Pharmaceutical Services Programme* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Sesi ini telah dihadiri oleh seramai 18 orang pegawai yang terdiri daripada wakil-wakil Program Perkhidmatan Farmasi, Jabatan Kesihatan Negeri serta fasiliti-fasiliti kesihatan KKM.<br>*The meeting was attended by a total of 18 officers, comprising representatives from the Pharmaceutical Services Programme, State Health Departments, and MOH healthcare facilities.* |
| Objektif<br>*Objectives* | Memastikan ketepatan teknikal, konsistensi dan kesesuaian maklumat di dalam modul latihan agar selaras dengan Garis Panduan Pengurusan Farmasi Logistik KKM.<br>*To ensure the technical accuracy, consistency and suitability of the information within the training module, in alignment with the MOH Malaysia Pharmacy Logistics Management Guidelines.* |
| *Hasil<br>**Outcome* | Modul Latihan Farmasi Logistik (Beginner) 2025 telah berjaya dihasilkan dan dimuat naik ke laman sesawang Program Perkhidmatan Farmasi bagi tujuan rujukan dan pelaksanaan.<br>*The Pharmacy Logistics Training Module (Beginner) 2025 has been successfully developed and uploaded to the Pharmaceutical Services Programme website for reference and implementation purposes.* |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Pembangunan Bank Soalan Malaysia Advanced Clinical Pharmacy Programme (MyACCP) 2025<br>*Development of Question for The Malaysia Advanced Clinical Pharmacy Programme (MyACCP) Workshop 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 24-26 Jun 2025 di Premiere Hotel, Klang<br>*24-26 June 2025 at the Premiere Hotel, Klang* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 45 orang terdiri daripada Pakar Perubatan dan Pegawai Farmasi dari KKM termasuk tenaga pengajar dari Fakulti Farmasi Kementerian Pengajian Tinggi (KPT)<br>*45 individuals consisting of Consultants and Pharmacists from MOH, including lecturers from the Faculty of Pharmacy under the Ministry of Higher Education (MOHE)* |

| | |
|---|---|
| Objektif<br>*Objectives* | • Membangunkan bank soalan bagi kegunaan penilaian akhir pelatih MyACPP<br>• Menghasilkan standard modul penilaian yang standard dan komprehensif<br>• *Developing a question bank for use in the final assessment of MyACPP trainees*<br>• *Producing standardized and comprehensive assessment module standards* |
| Hasil<br>*Outcome* | 10 set soalan yang standard dan komprehensif telah berjaya dibangunkan untuk sembilan (9) bidang pengkhususan termasuk Farmasi Kardiologi, Diabetes, Nuklear, Pediatrik, Respiratori, Onkologi, Farmakokinetik Klinikal dan Antimicrobial stewardship (AMS)<br>*A total of 10 standardized and comprehensive question sets have been successfully developed across nine (9) areas of specialisation in pharmacy namely Cardiology, Diabetes, Nuclear, Pediatrics, Respiratory, Oncology, Clinical Pharmacokinetics and Antimicrobial stewardships (AMS)* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Pemantapan Formulari Ubat Kementerian Kesihatan Malaysia<br>*Ministry of Health Medicines Formulary Enhancement Workshop* |
| Tarikh / Tempat<br>*Date / Venue* | 23–25 Jun 2025; Institut Kesihatan Negara, Selangor<br>*23–25 June 2025; National Institutes of Health, Selangor* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 30 orang Pegawai Farmasi dari sekitar Lembah Klang di bawah KKM<br>*30 pharmacists from Klang Valley under the MOH* |
| Objektif<br>*Objectives* | • Mengkaji semula ubat dalam FUKKM yang memerlukan permohonan Ubat Kelulusan Khas (UKK) serta yang digunakan secara off-label dengan mengambil kira input praktis semasa daripada fasiliti KKM bagi menambah baik tadbir urus ubat dalam FUKKM selaras dengan praktis dan keperluan.<br>• *To review medications in the MOHMF that require Special Approval Medicine (SAM) applications or are utilised off-label, incorporating current clinical practice input from MOH facilities to enhance pharmaceutical governance in alignment with prevailing standards and requirements.* |
| Hasil<br>*Outcome* | Susulan bengkel ini, beberapa cadangan pengemaskinian dalam FUKKM termasuk pengemaskinian indikasi dan pemansuhan ubat daripada FUKKM telah dikemukakan dan dibentangkan dalam Mesyuarat Panel FUKKM. Selain itu, beberapa indikasi off-label bagi ubat yang telah disenaraikan dalam FUKKM juga telah dikenal pasti dan dibentangkan dalam Mesyuarat Panel FUKKM untuk pengecualian permohonan UKK dan penggunaan borang keizinan pesakit.<br>*Following this workshop, several proposed updates to the MOHMF—including revised indications and the delisting of specific medications—were formulated and presented to the MOHMF Panel Meeting. Additionally, various off-label indications for existing medications listed in MOHMF were identified and presented to the Panel to facilitate exemptions from Special Approval Medicine (SAM) application and the mandatory use of patient consent forms.* |

| | |
|---|---|
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Teknikal Formulari Ubat Kementerian Kesihatan Malaysia<br>*Ministry Of Health Medicines Formulary Technical Meeting* |
| Tarikh / Tempat<br>*Date / Venue* | 10-13 November 2025; Pusat Konvensyen Antarabangsa Putrajaya (PICC), Putrajaya<br>*10-13 November 2025; Putrajaya International Convention Centre (PICC), Putrajaya* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 54 Pegawai Farmasi dari sekitar Lembah Klang di bawah KKM<br>*54 pharmacists from Klang Valley under the MOH* |
| Objektif<br>*Objectives* | • Mengkaji semula ubat dalam FUKKM yang merupakan produk *multisource* dan mengemas kini maklumat ubat-ubatan berkaitan selaras dengan maklumat terkini yang berdaftar dengan Pihak Berkuasa Kawalan Dadah (PBKD).<br>• Mengenal pasti ubat-ubatan generik *single source* yang dimohon melalui permohonan Ubat Kelulusan Khas (UKK) untuk penyediaan *dossier* bagi penyenaraian ke dalam FUKKM.<br>• *To review multisource medicines in the MOHMF and update relevant medicinal information in accordance with the latest information registered with the Drug Control Authority (DCA).*<br>• *To identify single-source generic medications requested via Special Approval Medicine (SAM) applications for dossier submission* |
| Hasil<br>*Outcome* | Beberapa cadangan pengemaskinian FUKKM telah dibangkitkan semasa mesyuarat ini untuk diusulkan ke Mesyuarat Panel FUKKM, merangkumi pengemaskinian indikasi, dos, dan *prescribing restriction*, serta pemansuhan ubat-ubatan tertentu. Di samping itu, ahli mesyuarat turut menyediakan *dossier* bagi permohonan penyenaraian ubat dan indikasi baharu ke dalam FUKKM.<br>*Several proposed updates to the MOHMF were formulated during this meeting to be tabled to the MOHMF Panel; these encompass amendments to indications, dosages, and prescribing restrictions, as well as the delisting of specific medications. Additionally, members of the meeting prepared dossiers for the listing of new drugs and indications in the MOHMF.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Pengukuhan Penyelidikan & Pembangunan Kapasiti Bidang Farmakoekonomi<br>*Workshop on Research Enhancement and Capacity Building in Pharmacoeconomics* |
| Tarikh / Tempat<br>*Date / Venue* | 4-6 Februari 2025<br>Institut Kesihatan Negara (NIH), Selangor<br>*4-6 February 2025*<br>*National Institutes of Health (NIH), Selangor* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 53 orang Pegawai Farmasi di bawah KKM<br>*53 Pharmacists under the MOH* |
| Objektif<br>*Objectives* | • Memperkukuh kompetensi penyelidikan dan meningkatkan aplikasi Analisis Impak Bajet (BIA) dalam perkhidmatan farmasi.<br>• Membangunkan projek Analisis Impak Bajet (BIA) yang selaras dengan Petunjuk Prestasi Utama (KPI) Pengurusan Tertinggi, KKM.<br>• *To strengthen research competencies and enhance the application of Budget Impact Analysis (BIA) within pharmacy services.*<br>• *To develop a Budget Impact Analysis (BIA) project aligned with the Key Performance Indicators (KPI) of the Top Management MOH.* |
| Hasil<br>*Outcome* | Analisis Impak Bajet (BIA) yang komprehensif telah disediakan sebagai aplikasi farmakoekonomi dalam perkhidmatan farmasi. Susulan daripada bengkel tersebut, 17 model BIA telah dibentangkan kepada Jawatankuasa Ubat dan Terapeutik (JKUT) di peringkat negeri atau institusi bagi menyokong pembuatan keputusan berasaskan bukti.<br>*Comprehensive Budget Impact Analyses (BIA) were prepared as a pharmacoeconomic application within pharmacy service. Following the workshop, 17 BIA models were presented to the Drug and Therapeutics Committee (JKUT) at the state or institutional level to support evidence-based decision-making.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Pembangunan Kerangka Kerja Farmakoekonomi<br>*Pharmacoeconomic Framework Development Workshop* |
| Tarikh / Tempat<br>*Date / Venue* | 29 Mei 2025; Pusat Konvensyen Antarabangsa Putrajaya (PICC), Putrajaya<br>*29 May 2025; Putrajaya International Convention Centre (PICC), Putrajaya* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Sesi 1: 22 peserta terdiri daripada Pakar Perunding Perubatan dan Pegawai Farmasi di bawah Jawatankuasa Ubat-ubatan KKM (13 disiplin)<br>*Session 1: 22 participants comprising of Medical Consultants and Pharmacists under the MOH Drug Working Committee (representing 13 disciplines)*<br><br>Sesi 2: 17 peserta daripada KKM dan agensi bukan KKM. Peserta termasuk Ahli Jawatankuasa Penilaian Dossier, Pegawai Farmasi dari Hospital KKM, Pegawai Perubatan dan Pegawai Farmasi dari Institut Kesihatan Negara (NIH), Cawangan Penilaian Teknologi Kesihatan (MahTas), Bahagian Perkembangan Perubatan dan Pensyarah dari Kementerian Pendidikan Tinggi.<br>*Session 2: 17 participants from MOH and non-MOH agencies. This includes members of the Dossier Evaluation Committee, Pharmacists from MOH Hospitals, Medical Officers and Pharmacists from the National Institutes of Health (NIH), Health Technology Assessment Section (MaHTAS), Medical Development Division, and Lecturers from the Ministry of Higher Education.* |

| | |
|---|---|
| Objektif<br>*Objectives* | • Memperincikan hala tuju untuk membangunkan satu rangka kerja yang komprehensif bagi pelaksanaan penilaian farmakoekonomi di Malaysia.<br>• Menilai kepentingan keperluan pelaksanaan pelbagai bentuk penilaian farmakoekonomi seperti cost-effectiveness analysis (CEA), cost-utility analysis (CUA) dan lain-lain, khususnya dalam konteks permohonan penyenaraian ubat ke dalam FUKKM.<br>• *To outline the direction for developing a comprehensive framework for the implementation of pharmacoeconomic evaluations in Malaysia.*<br>• *To assess the importance of conducting various types of pharmacoeconomic evaluations, including cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and other methods, particularly in the context of applications for medicine listing in the Ministry of Health Malaysia Medicines Formulary (MOHMF).* |
| Hasil<br>*Outcome* | Cadangan mengintegrasikan analisis keberkesanan kos ke dalam rangka kerja penilaian ubat-ubatan FUKKM, dengan sokongan pakar-pakar klinikal, mencerminkan hala tuju baharu dalam memperkasakan penilaian farmakoekonomi di Malaysia. Perbincangan memfokuskan kepada usaha mengutamakan terapi berimpak dan berkos tinggi, mempertingkatkan penglibatan awal Jawatankuasa Kerja Ubat-ubatan (JKKU), serta mengenal pasti jurang kapasiti teknikal. Ini termasuklah keperluan terhadap kepakaran ekonomi kesihatan, latihan bersasar, dan struktur pelaporan yang lebih mantap.<br>*The proposed integration of Cost-Effectiveness Analysis (CEA) into the FUKKM medicine evaluation framework, supported by clinical experts, reflects an emerging direction towards strengthening pharmacoeconomic assessment in Malaysia. Current deliberations focus on prioritising high-impact and high-cost therapies, enhancing early engagement of the Drug Working Committee (DWC), and identifying technical capacity gaps, including the need for health economics expertise, targeted training, and improved reporting structures.* |
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Teknikal Farmakoekonomik 2025<br>*Pharmacoeconomic Technical Meeting 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 2 – 4 September 2025; Travelodge Ipoh, Perak<br>*2 – 4 September 2025; Travelodge Ipoh, Perak* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 20 orang Pegawai Farmasi di bawah Jawatankuasa Induk Teknikal Farmakoekonomi, Bahagian Amalan dan Perkembangan Farmasi, KKM<br>*20 Pharmacists under the Pharmacoeconomics Technical Steering Committee, Pharmacy Practice and Development Division, MOH* |
| Objektif<br>*Objectives* | • Menetapkan hala tuju strategik pembangunan kerangka farmakoekonomi bagi menyokong Formulari Ubat Kementerian Kesihatan Malaysia (MOHMF), selaras dengan Pelan Induk Dasar Ubat Nasional (DUNas) 2022-2026<br>• Membincangkan hala tuju strategik aktiviti farmakoekonomik tahun 2026 yang melibatkan pegawai farmasi berkelayakan dalam farmakoekonomi peringkat kementerian dan negeri<br>• *To deliberate on the strategic direction for the development of a Pharmacoeconomic Framework to support the Ministry of Health Malaysia's Medicines Formulary (MOHMF), in alignment with the National Medicines Policy Master Plan (DUNas) 2022-2026*<br>• *To discuss the strategic direction for pharmacoeconomic activities in 2026 involving qualified pharmacoeconomics pharmacists in ministry and state levels* |

| | |
|---|---|
| Hasil<br>*Outcome* | Jawatankuasa membincangkan pelaksanaan rangka kerja farmakoekonomi bagi penyenaraian ubat di Malaysia, dengan keutamaan kepada ubat berimpak dan berkos tinggi. Perbincangan meliputi pengukuhan kapasiti, kerjasama strategik, penggunaan nilai ambang keberkesanan kos, serta keperluan penubuhan bank data kos penjagaan kesihatan nasional bagi menyokong keputusan yang lebih telus dan mampan.<br>*The Committee deliberated on the implementation of a pharmacoeconomic framework for medicine listing in Malaysia, prioritising high-impact and high-cost medicines. Discussions covered capacity strengthening, strategic collaboration, the use of cost-effectiveness thresholds, and the establishment of a standardised national healthcare cost database to support transparent and sustainable decision-making.* |
| Gambar<br>*Photo* |  <br>  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Sesi Penerangan Inisiatif Pemaparan Harga Ubat Kepada Anggota Kesihatan Di Jabatan Kesihatan Negeri (JKN) Sesi 1 hingga 7 Bagi Tahun 2025<br>*Briefing Sessions on the Medicine Price Display Initiative for Healthcare Personnel at the State Health Departments (JKN), Sessions 1-7, 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 18 Julai 2025, Secara Google Meet<br>29 Julai 2025, Dewan Auditorium, Hospital Pasir Gudang Johor Bahru<br>4 Ogos 2025, Dewan Auditorium, Hospital Pulau Pinang<br>6 Ogos 2025, Dewan Besar Lembaga Zakat, Menara Zakat, Jalan Teluk Wanjah, 05200 Alor Setar, Kedah<br>13 Ogos 2025, Dewan Syarahan, Masjid Negara Kuala Lumpur<br>2 September 2025, Dewan Auditorium, Hospital Sultanah Nur Zahirah<br>11 September 2025, Bilik Mesyuarat Utama Jabatan Kesihatan Sabah<br>*18 July 2025, via Google Meet*<br>*29 July 2025, Auditorium Hall, Hospital Pasir Gudang Johor Bahru*<br>*4 August 2025, Auditorium Hall, Hospital Pulau Pinang*<br>*6 August 2025, Grand Hall, Lembaga Zakat, Menara Zakat, Jalan Teluk Wanjah, 05200 Alor Setar, Kedah*<br>*13 August 2025, Lecture Hall, Masjid Negara Kuala Lumpur*<br>*2 September 2025, Auditorium Hall, Hospital Sultanah Nur Zahirah*<br>*11 September 2025, Main Meeting Room, Sabah State Health Department* |

| | |
|---|---|
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Seramai 638 Pegawai Farmasi, 66 Penolong Pegawai Farmasi, 59 Pegawai Perubatan, 16 Pegawai Pergigian, 33 Pembantu Tadbir, 32 Jururawat, 42 Penolong Pegawai Perubatan serta 22 pegawai lain telah hadir ke program ini.<br>*A total of 638 Pharmacists, 66 Pharmacist Assistants, 59 Medical Officers, 16 Dental Officers, 33 Administrative Assistants, 32 Nurses, 42 Assistant Medical Officers, and 22 other officers attended the programme.* |
| Objektif<br>*Objectives* | Objektif sesi ini adalah untuk menyampaikan maklumat berkaitan Inisiatif Pemaparan Harga Ubat kepada kakitangan kesihatan di peringkat negeri bagi memastikan pemahaman yang menyeluruh dan seragam.<br>*The objective of these sessions was to disseminate information on the Medicine Price Display Initiative to healthcare personnel at the state level to ensure comprehensive and consistent understanding.* |
| Hasil<br>*Outcome* | Sesi ini meningkatkan pemahaman kakitangan kesihatan berkaitan Inisiatif Pemaparan Harga Ubat serta memperkukuh peranan mereka sebagai agen penyampai maklumat kepada masyarakat. Sesi ini juga memantapkan kefahaman pegawai penguatkuasa farmasi bagi memastikan pelaksanaan inisiatif ini dilaksanakan secara berkesan dan terselaras.<br>*The sessions enhanced healthcare personnel's understanding of the initiative and strengthened their role as key communicators to the public. They also reinforced the capacity of pharmacy enforcement officers to ensure the effective and coordinated implementation of the initiative.* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Mesyuarat Kajian Pemantauan Harga Ubat (KPHU) 2025 Bil 1,2,3,4,5 & 6<br>*Medicine Price Monitoring Review Meeting (KPHU) 2025 No. 1, 2, 3, 4, 5 & 6* |
| Tarikh / Tempat<br>*Date / Venue* | 29-30 Julai 2025: Bilik Seminar, Hospital Pasir Gudang, Johor<br>4-5 Ogos 2025: Bilik Seminar, Hospital Pulau Pinang, Pulau Pinang<br>12-13 Ogos 2025: Bilik Seminar Masjid Negara, Kuala Lumpur<br>2-3 September 2025: Bilik Seminar ACC, Hospital Sultanah Zahirah, Kuala Terengganu, Terengganu<br>11-12 September 2025: Lintas Platinum Hotel, Kota Kinabalu, Sabah<br>10 Oktober 2025: Bilik Mesyuarat Nilam, Program Perkhidmatan Farmasi, Petaling Jaya, Selangor<br>*29-30 July 2025: Seminar Room, Hospital Pasir Gudang, Johor*<br>*4-5 August 2025: Seminar Room, Hospital Pulau Pinang, Penang*<br>*12-13 August 2025: Seminar Room, Masjid Negara, Kuala Lumpur*<br>*2-3 September 2025: ACC Seminar Room, Hospital Sultanah Zahirah, Kuala Terengganu, Terengganu*<br>*11-12 September 2025: Lintas Platinum Hotel, Kota Kinabalu, Sabah*<br>*10 October 2025: Nilam Meeting Room, Pharmaceutical Services Programme, Petaling Jaya, Selangor* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 142 orang pegawai farmasi fasiliti kerajaan daripada KKM, MINDEF dan MOHE (hospital pengajar universiti).<br>*A total of 142 government facility pharmacists from the Ministry of Health (MOH), the Ministry of Defence (MINDEF), and the Ministry of Higher Education (MOHE) (university teaching hospitals) participated in the meeting.* |

| | |
|---|---|
| Objektif<br>*Objectives* | Membincangkan mengenai metodologi KPHU 2025 termasuklah berkenaan kaedah kutipan data di premis terlibat, prosedur kemasukan data ke dalam borang kutipan data serta perbincangan berkenaan hala tuju dan isu-isu kutipan data sebelum ini.<br>*The discussion focused on the methodology for the 2025 Medicine Price Monitoring Review (KPHU), including data collection methods at selected premises, procedures for data entry into the data collection forms, as well as deliberations on the direction and issues arising from previous data collection exercises.* |
| Hasil<br>*Outcome* | Semua pegawai farmasi di fasiliti-fasiliti terpilih dan pegawai farmasi penguatkuasa negeri yang dilantik sebagai pemungut data memahami prosedur kutipan data dan metodologi kajian agar pelaksanaan kajian berjalan seperti yang dirancang dan teratur. Kutipan data di fasiliti kesihatan awam dan swasta bermula 1 Oktober hingga 30 November 2025.<br>*All pharmacists from selected facilities and appointed state pharmacy enforcement officers serving as data collectors were briefed to ensure a clear understanding of the study methodology and data collection procedures, thereby enabling the study to be implemented in an orderly and planned manner. Data collection at public and private healthcare facilities commenced from 1 October to 30 November 2025.* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Sesi Pendidikan dan Kesedaran Kepada Pengguna Berkaitan Inisiatif Pemaparan Harga Ubat<br>*Education and Awareness Session for Consumers on the Medicine Price Display Initiative* |
| Tarikh / Tempat<br>*Date / Venue* | 17 Jun 2025: Management and Science University - Shah Alam<br>12 Julai 2025: Dewan Teknokrat, Kolej Matrikulasi Pontian<br>25 September 2025: Hospital Sultan Ismail, Johor<br>7 Oktober 2025: Kementerian Sains, Teknologi, dan Inovasi Malaysia<br>8 November 2025: Muzium Chimney Labuan<br>5-7 Disember 2025: Dataran Putrajaya, Presint 3<br>*17 June 2025: Management and Science University – Shah Alam*<br>*12 July 2025: Teknokrat Hall, Pontian Matriculation College*<br>*25 September 2025: Hospital Sultan Ismail, Johor*<br>*7 October 2025: Ministry of Science, Technology and Innovation Malaysia*<br>*8 November 2025: Chimney Museum, Labuan*<br>*5-7 December 2025: Putrajaya Square, Precinct 3* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | Seramai 1,135 kakitangan awam, 990 orang awam, 557 pekerja swasta serta 275 pelajar telah hadir ke sesi pendidikan ini.<br>*A total of 1,135 civil servants, 990 members of the public, 557 private sector employees, and 275 students attended the education session.* |
| Objektif<br>*Objectives* | Sesi pendidikan ini berperanan sebagai platform interaksi dengan pengguna bagi meningkatkan pengetahuan dan kesedaran pengguna supaya mampu membuat keputusan yang rasional dalam mendapatkan rawatan dan ubat-ubatan berkualiti pada harga berpatutan. Inisiatif ini selaras dengan matlamat KKM untuk memperkukuh budaya pengguna yang cakna hak serta menyokong ketelusan dan integriti pasaran ubat.<br>*This education session served as an engagement platform with consumers to enhance their knowledge and awareness, enabling them to make informed and rational decisions in obtaining quality healthcare services and medicines at reasonable prices. This initiative is aligned with the objectives of the MOH to strengthen a culture of consumer awareness of rights, while promoting transparency and integrity within the medicines market.* |

| | |
|---|---|
| Hasil<br>*Outcome* | Sesi ini telah meningkatkan kesedaran pengguna mengenai hak mereka serta memperkukuh keupayaan untuk membuat keputusan bermaklumat dalam mendapatkan perkhidmatan kesihatan dan ubat-ubatan. Dalam jangka panjang, inisiatif ini menyumbang kepada peningkatan ketelusan, akauntabiliti dan integriti dalam pasaran ubat selaras dengan matlamat KKM.<br>*The session enhanced consumers' awareness of their rights and improved their ability to make informed decisions when obtaining healthcare services and medicines. In the long term, it contributes to greater transparency, accountability, and integrity within the medicines market in line with the objectives of the MOH.* |
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Sesi Lawatan Pemeriksaan dan Advokasi Ke Fasiliti Kesihatan Swasta<br>*Inspection and Advocacy Visit Session to Private Healthcare Facilities* |
| Tarikh / Tempat<br>*Date / Venue* | 18 Julai 2025; 29 Julai 2025; 4 Ogos 2025; 6 Ogos 2025; 13 Ogos 2025; 2 September 2025 dan 11&12 September 2025. Fasiliti kesihatan swasta di negeri Selangor, Johor, Pulau Pinang, Kedah, Kuala Lumpur, Terengganu dan Sabah<br>*18 July 2025; 29 July 2025; 4 August 2025; 6 August 2025; 13 August 2025; 2 September 2025; and 11 & 12 September 2025. Private healthcare facilities in the states of Selangor, Johor, Pulau Pinang, Kedah, Kuala Lumpur, Terengganu, and Sabah.* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 45 fasiliti dilawati<br>*A total of 45 facilities were visited* |
| Objektif<br>*Objectives* | Sesi lawatan pemeriksaan dilaksanakan bagi memberi advokasi kepada pengusaha dan anggota fasiliti kesihatan swasta serta menilai tahap pematuhan terhadap pelaksanaan pemaparan harga ubat.<br>*The inspection visit sessions were conducted to provide advocacy to operators and personnel of private healthcare facilities, as well as to assess the level of compliance with the implementation of medicine price display requirements.* |
| Hasil<br>*Outcome* | Sesi lawatan pemeriksaan yang dijalankan bersama Cawangan Penguatkuasaan Farmasi telah mengukuhkan pemahaman fasiliti kesihatan swasta berkaitan keperluan pemaparan harga ubat serta membolehkan penilaian awal tahap pematuhan dilaksanakan. Daripada 45 fasiliti yang diperiksa, 25 fasiliti didapati memuaskan, 11 fasiliti memerlukan penambahbaikan manakala 9 fasiliti tiada paparan, dengan kadar pematuhan pemaparan sebanyak 80% (36 fasiliti)<br>*The inspection visits, carried out in collaboration with the Pharmacy Enforcement Branch, strengthened private healthcare facilities' understanding of the requirements for medicine price display and enabled a preliminary assessment of compliance to be undertaken. Out of 45 facilities inspected, 25 facilities were found to be satisfactory, 11 facilities required improvement, and 9 facilities had no price display. Overall, the compliance rate for medicine price display was 80% (36 facilities).* |

| | |
|---|---|
| Gambar<br>*Photo* |   |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Advokasi dan Kemahiran Asas Bahasa Isyarat Penggunaan Ubat Berkualiti 2025<br>*Advocacy and Basic Sign Language Skills Workshop for Quality Use of Medicines 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 18 - 20 Februari 2025; Avillion Admiral Cove, Port Dickson<br>*18 - 20 February 2025; Avillion Admiral Cove, Port Dickson* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 65 pegawai farmasi KKM<br>*65 pharmacists from MOH facilities* |
| Objektif<br>*Objectives* | • Memberi pendedahan kepada pegawai farmasi tentang etika menyantuni OKU Penglihatan dan Pendengaran.<br>• Membantu pegawai farmasi dalam memahami keperluan pesakit OKU Penglihatan dan Pendengaran.<br>• Memberikan pendedahan asas bahasa isyarat kepada pegawai farmasi.<br>• Membantu pegawai farmasi untuk berkomunikasi dengan pesakit OKU Pendengaran dan Pertuturan.<br>• *Exposing pharmacists on the ethics of engaging with visually and hearing-impaired individuals.*<br>• *To equip pharmacists with a deeper understanding of the specific needs of visually and hearing-impaired patients.*<br>• *Providing pharmacists with foundational exposure to sign language.*<br>• *Empowering pharmacists to communicate effectively with hearing and speech-impaired patients.* |
| Hasil<br>*Outcome* | Peningkatan kesedaran dan kefahaman dalam kalangan pegawai farmasi mengenai etika dan pendekatan yang sesuai dalam menyantuni pesakit Orang Kurang Upaya (OKU) Penglihatan dan Pendengaran semasa penyampaian perkhidmatan melalui sesi Disablity Equality Training (DET) yang diadakan semasa bengkel ini. Pendedahan asas kemahiran bahasa isyarat telah diberikan kepada pegawai farmasi bagi membantu interaksi awal dan komunikasi asas dengan pesakit OKU Pendengaran. Bengkel ini turut menyokong usaha pemerkasaan perkhidmatan farmasi yang inklusif, selaras dengan aspirasi untuk memastikan akses maklumat dan perkhidmatan ubat yang adil, selamat dan berkualiti kepada semua lapisan masyarakat.<br>*The workshop successfully heightened the awareness and understanding of pharmacists regarding the ethics and appropriate approaches for engaging with visually and hearing-impaired patients through Disability Equality Training sessions. By providing foundational sign language skills, the program equipped pharmacists to better manage initial interactions and essential communication with hearing-impaired individuals. Furthermore, this initiative supported the empowerment of inclusive pharmaceutical services, reinforcing the commitment to ensuring equitable, safe, and quality access to medication information and healthcare services for all members of the community.* |

| | |
|---|---|
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Program Medication Review bersama-sama Persekutuan Orang Pekak Malaysia (MFD)<br>*Medication Review Programme in collaboration with the Malaysian Federation of The Deaf (MFD)* |
| Tarikh / Tempat<br>*Date / Venue* | 16 Ogos 2025; MFD, Menara KLH, Puchong<br>*16 August 2025; MFD, KLH Tower, Puchong* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 14 peserta daripada Persekutuan Orang Pekak Malaysia<br>5 pegawai farmasi Bahagian Amalan dan Perkembangan Farmasi<br>1 pegawai farmasi Hospital Kuala Lumpur<br>1 pegawai farmasi Hospital Putrajaya<br>3 pegawai farmasi Pusat Perubatan Universiti Malaya<br>1 pegawai farmasi Hospital Tuaran<br>*14 participants from Malaysian Federation of The Deaf (MFD)*<br>*5 pharmacists from the Pharmacy Practice and Development Division*<br>*1 pharmacist from Kuala Lumpur Hospital*<br>*1 pharmacist from Putrajaya Hospital*<br>*3 pharmacists from University Malaya Medical Centre*<br>*1 pharmacist from Tuaran Hospital* |
| Objektif<br>*Objectives* | • Menyemak dan melaksanakan rekonsiliasi ubat.<br>• Membantu pengurusan ubat-ubatan dalam kalangan peserta.<br>• Meningkatkan pengetahuan serta memperkasa peserta mengenai ubat-ubatan, kepatuhan, dan pengurusan penyakit secara menyeluruh.<br>• *To review and perform medication reconciliation.*<br>• *Assisting participants in medication management.*<br>• *To enhance the knowledge and empower participants regarding medication, compliance, and disease management.* |
| Hasil<br>*Outcome* | Program ini telah meningkatkan penggunaan ubat berkualiti dalam kalangan peserta melalui semakan dan rekonsiliasi ubat. Melalui kaunseling ubat secara individu, peserta diberikan penerangan terhadap cara pengambilan ubat yang betul dan kepentingan kepatuhan kepada rawatan serta panduan berkaitan pengurusan ubat-ubatan yang betul. Program ini membantu meningkatkan kefahaman peserta tentang penggunaan ubat berkualiti, khususnya dalam kalangan pesakit Pekak dengan penyakit kronik dan juga warga emas. Secara keseluruhannya, program ini memupuk sikap berdikari dalam kalangan peserta bagi menguruskan ubat-ubatan mereka secara teratur, selaras dengan aspirasi Kementerian Kesihatan Malaysia untuk memperkukuh keterlibatan pesakit dalam penjagaan kesihatan kendiri yang lebih inklusif.<br>*This program has improved the quality use of medicines among participants through medication review and reconciliation. Through individualized medication counselling, participants were provided with explanations on correct medication intake, the importance of treatment adherence, and guidance on proper medication management. The program helped enhance participants' understanding of the quality use of medicines, particularly among Deaf patients with chronic diseases and senior citizens. Overall, this initiative fosters independence among participants in managing their medication regimens systematically, in line with the Ministry of Health Malaysia's aspiration to strengthen patient engagement in more inclusive healthcare self-care.* |

| | |
|---|---|
| Gambar<br>*Photo* |  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Bengkel Training of Trainers (TOT) Duta Kenali Ubat Anda melibatkan Orang Kurang Upaya (OKU) Penglihatan dan Pendengaran 2025<br>*Training of Trainers (TOT) Workshop for Know Your Medicine Ambassadors involving Visually and Hearing-Impaired Individuals 2025* |
| Tarikh / Tempat<br>*Date / Venue* | 19-21 Ogos 2025, Hotel Seri Malaysia, Kepala Batas, Pulau Pinang (Zon Utara)<br>8-9 Oktober 2025, Sarawak Islamic Information Centre, Kuching, Sarawak<br>15-16 Oktober 2025, KSL Hotel & Resort, Johor Bahru<br>*19-21 August 2025, Hotel Seri Malaysia, Kepala Batas, Pulau Pinang (Northern Zone)*<br>*8-9 October 2025, Sarawak Islamic Information Centre, Kuching, Sarawak*<br>*15-16 October 2025, KSL Hotel & Resort, Johor Bahru* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 41 peserta termasuk 5 OKU Pendengaran (Zon Utara)<br>25 peserta termasuk 3 OKU Penglihatan (Sarawak)<br>22 peserta termasuk 4 OKU Pendengaran (Johor)<br>*41 participants, including 5 hearing-impaired individuals (Northern Zone)*<br>*25 participants, including 3 visually-imparied individuals (Sarawak)*<br>*22 participants, including 4 hearing-impaired individuals (Johor)* |
| Objektif<br>*Objectives* | Memperkasa wakil masyarakat dalam menyampaikan maklumat asas berkaitan ubat-ubatan.<br>*Empowering community representatives to disseminate basic information regarding medicines.* |
| Hasil<br>*Outcome* | Menerusi bengkel ini, wakil masyarakat termasuk golongan OKU Penglihatan dan OKU Pendengaran dilatih untuk bertindak sebagai ejen kesihatan komuniti agar turut membantu KKM dalam memberi maklumat asas tentang ubat-ubatan kepada komuniti OKU masing-masing.<br>*Through this workshop, community representatives, including visually and hearing-impaired individuals, were trained to serve as community health agents to assist the Ministry of Health in disseminating basic information about medicines to their respective disabled communities.* |

| | |
|---|---|
| Gambar<br>*Photo* |  <br>  <br>  |

| | |
|---|---|
| Aktiviti<br>*Activity* | Kursus Pemantapan Auditor ADAF<br>*ADAF Auditor Empowerment Course* |
| Tarikh / Tempat<br>*Date / Venue* | Hotel Grand Continental, Kuala Terengganu<br>*Grand Continental Hotel, Kuala Terengganu* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 30 peserta yang terdiri daripada Penyelaras ADAF Negeri/Institusi serta barisan auditor ADAF.<br>*30 participants, comprising of state/institutional ADAF coordinators and ADAF auditors.* |
| Objektif<br>*Objectives* | Kursus ini bertujuan untuk meningkatkan kompetensi auditor, menyelaraskan pelaksanaan audit, memperkasa pelaporan penemuan, serta menyokong penggunaan e-ADAF untuk memastikan audit yang lebih efektif dan berkualiti.<br>*The course aims to enhance auditor competencies, standardize audit implementation, and empower the quality of findings reported, while supporting the utilization of the e-ADAF system to ensure a more effective and high-quality auditing process.* |

| | |
|---|---|
| Hasil<br>*Outcome* | Kursus ini meningkatkan kompetensi auditor, menyelaraskan pelaksanaan audit, dan memperkasa kualiti pelaporan penemuan, di samping menyokong penggunaan platform e-ADAF bagi memastikan proses audit yang lebih efektif dan berkualiti.<br>*The course enhanced auditor competency, standardized audit implementation, and empower the quality of findings reported, while supporting the utilization of the e-ADAF platform to ensure a more effective and high-quality auditing process.* |
| Gambar<br>*Photo* |  |

## SENARAI AKTIVITI-AKTIVITI LAIN:
## *OTHER ACTIVITIES:*

1. Bengkel Pemurnian Garis Panduan Kaunseling Ubat-ubatan
   *Development of Medication Counseling Guidelines Workshop*
2. Bengkel Pemurnian Garis Panduan Petugas Kesihatan (Farmasi) di Tanah Suci
   *Development of Pharmacy Healthcare Personnel for Hajj Operations Guidelines Workshop*
3. Bengkel Pemurnian Modul Latihan *Malaysia Advanced Clinical Pharmacy Programme* (MyACPP) Fasa 2
   *Development of Malaysia Advanced Clinical Pharmacy Programme (MyACPP) Phase Training Module Workshop*
4. Hepatitis 2025: Kursus Pemantapan Farmasi Dalam Pengurusan Penyakit
   *Hepatitis 2025: Pharmacy Enhancement Course in Disease Management*
5. Persidangan Farmasi Kardiologi Kebangsaan (NCPU) 2025
   *National Cardiology Pharmacy Update (NCPU) 2025*
6. Bengkel Farmakoepidemiologi Farmasi Pediatrik
   *Pharmacoepidemiology in Pediatric Pharmacy Workshop*
7. Bengkel Farmasi Psikiatri Kebangsaan (NPPW) 2025
   *National Psychiatric Pharmacy Workshop (NPPW) 2025*
8. Bengkel Pemantapan Pegawai Farmasi DMTAC Di Bawah Program ERAT Zon Tengah
   *ERAT Workshop for DMTAC Pharmacists (Central Zone)*
9. Kursus Farmasi Kardiologi Kebangsaan 2025
   *National Cardiology Pharmacy Updates 2025*
10. Perbincangan Meja Bulat bersama *Pharmaceutical Association of Malaysia* (PhAMA) mengenai Penilaian Teknologi Kesihatan berkenaan Penggabungan Elemen Nilai yang Lebih Luas dalam Penilaian Ubat Inovatif di Malaysia (30 April 2025)
    *Round table discussion with the Pharmaceutical Association of Malaysia (PhAMA) on Health Technology Assessment (HTA) focusing on the Inclusion of Broader Value Elements for the Evaluation of Innovative Medicines in Malaysia (30 April 2025)*
11. Penceramah Kursus Pengenalan kepada Aktiviti Khas Cawangan Perundangan, Bahagian Penguatkuasaan Farmasi anjuran Bahagian Penguatkuasaan Farmasi (15 Mei 2025)
    *Speaker, Introduction Course on Special Activities of the Legislation Branch, Pharmacy Enforcement Division organised by the Pharmacy Enforcement Division (15 May 2025)*
12. Penceramah Pengurusan Formulari Ubat KKM (FUKKM) bagi Modul Latihan Tadbir Urus bagi Bakal Pemimpin Fasiliti Kesihatan KKM (7 Oktober 2025)
    *Speaker on the Management of the Ministry of Health Medicines Formulary (MOHMF) for the Governance Training Module for Aspiring Leaders of MOH Healthcare Facilities (7 October 2025)*
13. Perbincangan Santai: Analisis Keberkesanan Kos (16 Disember 2025)
    *Coffee Talk: Cost-Effective Analysis (16 December 2025)*
14. Mesyuarat Pelaksanaan Pemaparan Harga Ubat di Hospital Universiti Dengan Perkhidmatan Rawatan Swasta *(Private Wing)* (7 Julai 2025)
    *Meeting on the Implementation of Medicine Price Display at University Hospitals with Private Healthcare Services (Private Wing) (7 July 2025)*
15. Kaunter Libat Urus Pemaparan Harga Ubat Bersama Ahli Farmasi di *National Pharmacist Convention* (25-27 Julai 2025)
    *Engagement Counter on Medicine Price Display with Pharmacist at National Pharmacist Convention (25-27 July 2025)*
16. Sesi Penerangan Pemaparan Harga Ubat Bersama Pemegang Lesen A Negeri Pahang (27 September 2025)
    *Briefing Session on Medicine Price Display with Type A Licence Holders in Pahang (27 September 2025)*

## PENGLIBATAN SEBAGAI PENCERAMAH:

Senarai penglibatan sebagai penceramah jemputan bagi beberapa bengkel/ persidangan yang diadakan seperti berikut:

## *INVOLVEMENT AS SPEAKER:*

*List of involvement as a guest speaker for several workshops/ conferences held as below:*

1. Sesi Taklimat Berkenaan Pemaparan Harga Ubat Di MPS *Independent Community Pharmacists Town Hall* (28 April 2025)
   *Briefing Session on the Implementation of Medicine Price Display at the MPS Independent Community Pharmacists Town Hall (28 April 2025)*
2. Taklimat Khas Isu-Isu Semasa Mengenai Inisiatif Pemaparan Harga Ubat: Memperkasa Hak Pengguna Kepada '*Key Communicators*' Kerajaan (12 Mei 2025)
   *Special Briefing on Current Issues Related to the Medicine Price Display Initiative: Empowering Consumer Rights among Government Key Communicators (12 May 2025)*
3. Ahli Panel Forum Pemaparan Harga Ubat Sempena Mesyuarat Agung *Malaysian Community Pharmacy Guild (MCPG)* (18 Mei 2025)
   *Panelist for the Medicine Price Display Forum in Conjunction with the Annual General Meeting of the Malaysian Community Pharmacy Guild (MCPG) (18 May 2025)*
4. Kursus Pemakaian Akta Kawalan Harga dan Antipencatutan 2011 [*Akta 723*] Dalam Penguatkuasaan Penandaan Harga Bagi Ubat di Kemudahan Jagaan Kesihatan Swasta dan Farmasi Komuniti (3 September 2025)
   *Training Course on the Application of the Price Control and Anti-Profiteering Act 2011 [Act 723] in the Enforcement of Medicine Price Labelling at Private Healthcare Facilities and Community Pharmacies (3 September 2025)*

## 3.0 PENCAPAIAN DAN PENGIKTIRAFAN | *ACHIEVEMENT AND RECOGNITION*

### PENYERTAAN PERSIDANGAN PERSATUAN UNIVERSITI LINGKUNGAN PASIFIK (APRU) GLOBAL HEALTH CONFERENCE 2025

Persidangan APRU Global Health Conference 2025 telah diadakan dari 29 hingga 31 Oktober 2025 di Kuala Lumpur, Malaysia. Persidangan ini menghimpunkan pakar kesihatan global, penyelidik dan pembuat dasar bagi membincangkan isu strategik berkaitan sistem kesihatan. Cawangan Pengurusan Harga Ubat telah menyertai pembentangan oral bertajuk *"Determinants of Cost Savings through Pooled Procurement: Evidence from Malaysia's Public Sector Medicines Pricing Initiative."*

### *PARTICIPATION IN THE ASSOCIATION OF PACIFIC RIM UNIVERSITIES (APRU) GLOBAL HEALTH CONFERENCE 2025*


*The APRU Global Health Conference 2025 was held from 29 to 31 October 2025 in Kuala Lumpur, Malaysia. The conference brought together global health experts, researchers, and policymakers to discuss strategic issues related to health systems. The Medicines Price Management Branch participated in an oral presentation titled "Determinants of Cost Savings through Pooled Procurement: Evidence from Malaysia's Public Sector Medicines Pricing Initiative."*







Pembentangan di Persidangan APRU Global Health Conference 2025
*Presentation in the APRU Global Health Conference 2025*


## 4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*




Protokol Klinik Pematuhan Terapi Ubatan Pakej Penjagaan Kardiovaskular (CCB-MTAC) (Edisi Kedua)
*Cardiovascular Care Bundle Medication Therapy Adherence Clinic (CCB-MTAC) Protocol (Second Edition)*




Protokol Farmasi Psikiatri Edisi Kedua
*Psychiatric Pharmacy Protocol Second Edition*





Protokol Klinik Pematuhan Terapi Ubat Hepatitis (HepMTAC), Edisi Ketiga
*Hepatitis Medication Therapy Adherence Clinic (HepMTAC) Protocol, Third Edition*




Garis Panduan Kaunseling Ubat-ubatan Edisi Keempat (2025)
*Medication Counseling Guidelines Fourth Edition (2025)*




Garis Panduan Petugas Haji Malaysia Rombongan Perubatan (Perkhidmatan Farmasi) Edisi Pertama
*Guidelines for Malaysian Hajj Medical Team (Pharmaceutical Services) First Edition*




Senarai Ubat-Ubatan Penting Kebangsaan, Edisi Ketujuh
*National Essential Medicines List, 7th Edition*




Garis Panduan Latihan Sangkutan Pegawai Farmasi, Lantikan Preseptor dan Pusat Latihan dalam Bidang Pengkhususan Farmasi Klinikal atau Farmasi Klinikal dan Teknikal (Edisi 2025)
*Guidelines for Training of Pharmacist Attachments, Appointment of Preceptors and Training Centres in the Field of Clinical Pharmacy Specialization or Clinical and Technical Pharmacy (2025 Edition)*





Garis Panduan Permohonan Ubat Kelulusan Khas (UKK) Fasiliti-Fasiliti Kementerian Kesihatan Malaysia (KKM), Edisi Kedua
*Special Approval Medicines (SAM) Application Guideline for Ministry of Health Malaysia Facilities, Second Edition*




Garis Panduan Formulari Ubat Kementerian Kesihatan Malaysia, Edisi Keempat
*Ministry of Health Medicines Formulary Guideline, 4th Edition*




Kajian Impak Perolehan Bersama Terhadap Harga Ubat antara Kesihatan Malaysia
*Impact of Pooled Procurement on Medicines Pricing in the Public Sector*

| **Tajuk Penerbitan/ Kajian**<br>*Publication/ Research Title* | |
|---|---|
| Penerbitan artikel "Evaluating the effectiveness of a multi-hazard operational framework for managing pharmaceutical supply during disasters: insights from a tabletop exercise"<br>*Publication of the article "Evaluating the effectiveness of a multi-hazard operational framework for managing pharmaceutical supply during disasters: insights from a tabletop exercise"* |  <br>**Evaluating the effectiveness of a multi-hazard operational framework for managing pharmaceutical supply during disasters: insights from a tabletop exercise**<br>*Abdul Hafeez Ahmad Hamdi, Ermieda Hatah and Mohd Makmor Bakry*<br>Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia<br>*A. Halim Basri*<br>Health Services Division, Ministry of Defence, Malaysian Armed Forces Headquarters, Kuala Lumpur, Malaysia, and<br>*Wan Noraimi Wan Ibrahim, Nur Azibahwati Aziz, Nafiza Ahmad Hamdi, Khairun Nada Zulhifli, Mohd 'Izzat Idris, Tuan Chm Ong and Sahrlevenao Nair*<br>Pharmacy Practice and Development Division, Pharmaceutical Services Programme, Ministry of Health Malaysia, Selangor, Malaysia<br>**Abstract**<br>**Purpose** – Disasters pose a significant threat to healthcare systems, underscoring the need for evidence based operational frameworks to enhance the efficiency and effectiveness of pharmaceutical supply operations. Therefore, an operational framework for managing pharmaceutical supply was developed and validated through a multi-stage process, including scoping reviews, in-depth interviews and world cafe discussion methods. This study aims to further evaluate the effectiveness of the operational framework through a tabletop exercise.<br>**Design/methedology/approach** – A multi-hazard tabletop exercise was developed by the research team from March to July 2024 and conducted during a three-day workshop in August 2024. The exercise involved 25 participants from various operational levels, who were exposed to the scenarios first without the aid of the operational framework and then with the operational framework. Participants' perceptions of disaster management activities, the framework's effectiveness and the conduct and design of the exercise were gathered through a pre- and post-survey and hot wash assessment.<br>**Findings** – Participants' understanding and capability in disaster management activities were significantly improved after being introduced to the operational framework ($p < 0.001$). Most participants strongly agreed and agreed that the operational framework was comprehensive (96%, 24/25), easy to understand (100%, 25/25), enhanced efficiency (96%, 24/25) and facilitated effective coordination (96%, 24/25) and communication (96%, 24/25). All participants also strongly agreed and agreed that the tabletop exercise was well-structured, realistic and met its objectives.<br>**Practical implications** – This study demonstrated that the operational framework enhances policymakers and practitioners understanding and capabilities in managing pharmaceutical supply operations in multi-hazard disaster scenarios. The operational framework provides valuable guidance for efficient decision-making among practitioners and policymakers, enhancing effectiveness, efficiency and resilience in pharmaceutical supply operations.<br>**Originality/value** – There is a notable gap in the literature concerning the practical application and evaluation of frameworks in managing pharmaceutical supply operations in disaster settings. While conceptual models exist, few studies have rigorously tested their effectiveness in real-world or simulated disaster contexts. This paper aims to address this gap by presenting a practical and comprehensive operational framework that has been rigorously tested across multiple hazard scenarios throughout all phases of the disaster management cycle and at multiple operational levels.<br>**Keywords** Operations management, Simulation exercise, Decision-making, Disaster management<br>**Paper type** Research paper |
| Penerbitan artikel "Antimicrobial stewardship practice and metrics use to assess antibiotic consumption in paediatric ward: A national survey"<br>*Publication of the article "Antimicrobial stewardship practice and metrics use to assess antibiotic consumption in paediatric ward: A national survey"* |  <br>Original Article<br>Journal of Infection Prevention<br>**Antimicrobial stewardship practice and metrics use to assess antibiotic consumption in paediatric ward: A national survey**<br>Sage<br>**Nazedah Ain Ibrahim[1,2], Nurul Husna Syuhaidah Yusof[2,3], Sharini Sha'ari[1,4] and Lau Hui Shan[2,3]**<br>Abstract<br>**Background:** Antibiotics are widely prescribed therapeutic agents in the paediatric population.<br>**Aim/objective:** This survey aims to describe an overview of antimicrobial stewardship (AMS) and the type of metrics used to monitor antibiotic consumption in paediatric wards in Malaysian public hospitals.<br>**Methods:** This research was conducted as a multicentre, quantitative research online survey in all Ministry of Health Malaysia hospitals with paediatric ward services. The survey respondents were the pharmacists in charge of either a paediatric ward or antibiotic consumption in each facility.<br>**Results:** Out of the 145 hospitals, only 99 with eligible facilities were shortlisted for the survey. Of the 99 hospitals identified in this survey, only 91 of the facilities responded. The result from the survey revealed that only six hospitals had a paediatric infectious disease (ID) specialist. Only 26 out of the 91 facilities that responded performed paediatric antibiotic monitoring. The survey showed that the type of metrics used to monitor antibiotic consumption varied. 46.2% (12/26) of paediatric monitored facilities were using defined daily dose (DDD), 23.1% (6/26) using days of therapy, 19.2% (5/26) using the number of vials, 15.4% (4/26) using the number of patients and 11.5% (3/26) using the length of therapy as their consumption metrics. Half (50%, 13/26) of the paediatric monitored facilities did not use any denominator for reporting while some facilities (38.5%, 10/26) used patient days.<br>**Conclusion:** Although 90% of the facilities practice AMS, in paediatrics, there appears to be no standardisation especially in antimicrobial consumption monitoring. |
| Penerbitan artikel "Emergency medicine pharmacists' interventions in the tertiary hospitals' emergency departments in Malaysia"<br>*Publication of the article "Emergency medicine pharmacists' interventions in the tertiary hospitals' emergency departments in Malaysia"* |  <br>JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE<br>2025, VOL. 18, NO. 1, 2457410<br>https://doi.org/10.1080/20523211.2025.2457410<br>Taylor & Francis<br>RESEARCH ARTICLE<br>OPEN ACCESS<br>**Emergency medicine pharmacists' interventions in the tertiary hospitals' emergency departments in Malaysia**<br>Hock Peng Koh[a], Haliza Ab Jalal[b], Yee Ping Koo[c], Mary Siew Yng Chen[d], Manimegahlai Selvaratanam[e], Anaanthan Bhuvanendran Pillai[f], Wai Kit Wong[g], Xin Nee Guee[b], Sherene Su Ann Tan[h], Shirlyn Tan[i], Lih Jiuan Teh[i] and Rosalind Guen Lin Sia[j]<br>[a]Pharmacy Department, Ministry of Health Malaysia, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; [b]Pharmacy Department, Ministry of Health Malaysia, Hospital Sultanah Aminah, Johor Bahru, Malaysia; [c]Pharmacy Department, Ministry of Health Malaysia, Hospital Sultanah Bahiyah, Alor Setar, Malaysia; [d]Pharmacy Department, Ministry of Health Malaysia, Hospital Umum Sarawak, Kuching, Malaysia; [e]Pharmacy Department, Ministry of Health Malaysia, Hospital Raja Permaisuri Bainun, Ipoh, Malaysia; [f]Pharmacy Department, Ministry of Health Malaysia, Hospital Tuanku Ja'afar, Seremban, Malaysia; [g]Pharmacy Department, Ministry of Health Malaysia, Hospital Melaka, Melakas, Malaysia; [h]Pharmacy Department, Ministry of Health Malaysia, Hospital Pulau Pinang, George Town, Malaysia; [i]Pharmacy Department, Ministry of Health Malaysia, Hospital Tengku Ampuan Rahimah, Klang, Malaysia; [j]Pharmacy Department, Ministry of Health Malaysia, Hospital Putrajaya, Putrajaya, Malaysia |

Penerbitan artikel “Pharmacist Involvement in Managing Drug-drug Interactions (DDIs) for Hepatitis C Virus (HCV)-infected Patients on Direct-acting Antiviral Agent (DAA): A Multicentre Cohort Study (P-DAA Study)”

*Publication of the article “Pharmacist Involvement in Managing Drug-drug Interactions (DDIs) for Hepatitis C Virus (HCV)-infected Patients on Direct-acting Antiviral Agent (DAA): A Multicentre Cohort Study (P-DAA Study)“*



*Send Orders for Reprints to reprints@benthamscience.net*

*The International Journal of Gastroenterology and Hepatology Diseases,* **2025**, *4*, e266629063484 76

RESEARCH ARTICLE

**Pharmacist Involvement in Managing Drug-drug Interactions (DDIs) for Hepatitis C Virus (HCV)-infected Patients on Direct-acting Antiviral Agent (DAA): A Multicentre Cohort Study (P-DAA Study)**

Ahtheemathurra Ballasingam[1,2*], Kwan Ee Wei[2,3], Poh Wei Yoon[4], Chuah Sim Mei[2,5], Cynthia Ang Bee Li[2,6], Cheng Yew Chong[1,7], Neo Wen Ting[1,8], Amalinabinti Ahmad Nordin[1,9], Fong Suh Chen[1,10], Nur Izzatibinti Kamal Roslan[1,11], Nur Hidayahbinti Ismail[1,12] and Mazura binti Ishak[1,13]

*[1]Clinical Pharmacy Working Committee (Hepatology Pharmacy Subspecialty), Pharmaceutical Services Programme, Ministry of Health, Kuala Lumpur, Malaysia; [2]Department of Pharmacy, Hospital Sultanah Aminah, Johor Bahru, Malaysia; [3]Department of Pharmacy, Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia; [4]Faculty of Pharmacy, University of Malaya, Kuala Lumpur, Malaysia; [5]Pharmacy Practice and Development Division, Pharmaceutical Services Programme, Ministry of Health, Kuala Lumpur, Malaysia; [6]Department of Pharmacy, Hospital Tuanku Ja'afar, Seremban, Negeri Sembilan, Malaysia; [7]Department of Pharmacy, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia; [8]Department of Pharmacy, Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia; [9]Department of Pharmacy, Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia; [10]Department of Pharmacy, Hospital Melaka, Melaka City, Melaka, Malaysia; [11]Department of Pharmacy, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia; [12]Department of Pharmacy, Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia; [13]Department of Pharmacy, Hospital Pulau Pinang, George Town, Penang, Malaysia*

**Abstract:** ***Introduction:*** HCV infection has led to high mortality and morbidity rates, highlighting the need for immediate measures to contain and eradicate infection while providing optimal care to infected patients who may present with various comorbidities. Pharmacists play a crucial role in managing drug-drug interactions that exist with medications to treat comorbidities and DAAs.

***Method:*** A prospective cohort study was conducted among patients who received DAAs at 17 Ministry of Health (MOH) facilities. Following the screening, the obtainment of consent, and recruitment, details on demographic background, comorbidities, type of HCV infection, and treatment, along with medication reconciliation, were performed. A simple and multiple logistic regression was performed to determine factors associated with DDI occurrence.

***Results and Discussion:*** A total of 404 patients were recruited. Out of 291 patients (72%) who received at least one co-medication, drug-drug interactions (DDIs) were reported in 174 patients (59.8%). DDI with Amlodipine was the most common (n=77, 36.2%). Out of 213 DDI detected, 208 (97.7%) were categorized as moderate interaction. The number of comorbidities and the number of co-medications were significantly associated with the occurrence of DDIs

***Conclusion:*** Pharmacists play a key role in managing drug-drug interactions in HCV patients. With the high incidence of interaction observed in this study, it is crucial to manage individually since comorbidities vary with patients. As such, eradication of HCV infection can be undertaken with less opportunity of treatment failure.

ARTICLE HISTORY

Received: November 26, 2024
Revised: March 03, 2025
Accepted: March 27, 2025
DOI:
10.2174/0126662906401497625012503

**Keywords:** Pharmacists, drug-drug interaction, hepatitis C infection, comorbidities, co-medications, HCV patients.

**1. INTRODUCTION**

Hepatitis C is a life-threatening viral infection with significant liver involvement. Shockingly, 399,000 hepatitis C-related deaths are reported annually. Fifty-eight million people were living with chronic hepatitis C virus (HCV) infection in 2019, especially those from low- and middle-income countries [1]. Efforts have been undertaken to eliminate hepatitis C infection with the development of the WHO's Global Health Sector Strategies on Viral Hepatitis 2016-2021. Subsequently, a tenfold increase was seen in the number of people receiving treatment for chronic hepatitis C

*Address correspondence to this author at the Pharmacy Department, Hos-

Penerbitan artikel “Biosimilar medicines in Malaysia: Unveiling new guidance for practice”

*Publication of the article “Biosimilar medicines in Malaysia: Unveiling new guidance for practice”*



Contents lists available at ScienceDirect

Health Policy and Technology

journal homepage: www.elsevier.com/locate/hlpt

Original Article/Research

Biosimilar medicines in Malaysia: Unveiling new guidance for practice

N Saad *, Coleen SB Chow, H Chandriah, N Ahmad

*Pharmacy Practice & Development Division, Ministry of Health, Malaysia*

ARTICLE INFO

ABSTRACT

# BAHAGIAN PENGUATKUASAAN FARMASI

## *PHARMACY ENFORCEMENT DIVISION*

**4,208**
**PREMIS** I PREMISES
Bilangan Premis Farmasi Komuniti Swasta
*Number of Private Community Pharmacy Premises*

**2,274**
**AKTIVITI KESEDARAN**
*AWARENESS ACTIVITIES*
Jumlah Aktiviti Kesedaran Pihak-pihak berkepentingan
*Total Number of Awareness Activities for Sellers and Stakeholders*

**230**
**PERANTI DIGITAL**
*DIGITAL DEVICES*
Bilangan Peranti Digital Diterima Untuk Penganalisisan
*Total Number of Digital Devices Received for Analysis*

**30,574**
**IKLAN DISARING**
*ADVERTISEMENTS SCREENED*
Jumlah Iklan Disaring Yang Berkaitan Dengan Farmasi/ Kesihatan/ Perubatan (Media cetak, Media Elektronik, Media Baharu)
*Number of Advertisements Screened Related to Pharmacy/ Health/ Medicine (Print Media, Electronic Media, New Media)*

Bilangan Sekatan Akses/ Penurunan Kandungan URL
*Number of Access Restrictions/ Content Removal URLs*


**2,626**
**SEKATAN AKSES**
*ACCESS RESTRICTIONS*

**1,289**
**SERBUAN** I *RAIDS*

**RM70,176,607**
**NILAI RAMPASAN** I *VALUE OF SEIZURES*

Jumlah Serbuan yang dijalankan & Nilai Rampasan
*Total Raids Conducted & Value of Seizures*

**15,992**
**IKLAN DITURUNKAN**
*ADVERTISEMENT REMOVAL*
Bilangan Iklan yang dinotifikasi untuk diturunkan dari Platform e-dagang
*Number of Advertisements Notified for Removal from E-Commerce Platforms*




**Jumlah keseluruhan: 4,208**

Bilangan Premis Farmasi Komuniti Swasta
*Number of Private Community Pharmacy Premises*



# BAHAGIAN PENGUATKUASAAN FARMASI
# *PHARMACY ENFORCEMENT DIVISION*

## 1.0 PENGENALAN | *INTRODUCTION*

Bahagian Penguatkuasaan Farmasi (BPF) berperanan untuk memastikan semua produk farmaseutikal, tradisional dan kosmetik dalam pasaran adalah sah daripada segi pendaftaran dan notifikasi. Ia juga berfungsi untuk memastikan bahawa pengendalian rangkaian bekalan dan pemasaran, pengiklanan produk-produk kesihatan dan perkhidmatan perubatan dikendalikan dengan mematuhi peruntukan undang-undang yang dikuatkuasakan iaitu di bawah Akta Racun 1952, Akta Jualan Dadah 1952 dan Akta Ubat (Iklan dan Penjualan) 1956. Usaha ini dilakukan melalui aktiviti risikan dan operasi terancang, kawalan melalui sistem pelesenan pemantauan berterusan dan bersepadu dan juga aktiviti seranta bersama agensi-agensi berkepentingan bagi menurunkan permintaan terhadap produk yang tidak selamat atau membahayakan. Berikut merupakan fungsi utama bagi cawangan dan seksyen di bawah BPF:

*The Pharmacy Enforcement Division (PED) plays a pivotal role to ensure that all pharmaceutical products, traditional medicines and cosmetics available in the market are genuine in terms of registration and notification. It also acts to ensure that the link between supply and marketing, advertising of healthcare products and medical services is conducted in compliance with the provisions of the existing legislations in Poisons Act 1952, Sale of Drugs Act 1952 and Medicines (Advertisement and Sale) Act 1956. These activities are carried out through intelligence and operations, control of licensing and integrated monitoring and collaborative activities with stakeholders to reduce the demands for unsafe or hazardous products. Below are the main functions of branches and section under the PED:*

## CAWANGAN PERISIKAN DAN OPERASI | *INTELLIGENCE AND OPERATION BRANCH*

- Menyelaras aktiviti pengendalian aduan di peringkat ibu pejabat dan Cawangan Penguatkuasaan Farmasi (CPF) berkaitan aduan produk.
- Merancang dan memantau aktiviti pembasmian produk tidak berdaftar, produk tiruan dan produk campur racun di pasaran.

- *To coordinate complaints handling activities at the headquarters and Pharmacy Enforcement Branch (PEB) related to product complaints.*
- *To plan and monitor the eradication activities of unregistered products, counterfeit products and adulterated products in the market.*

## CAWANGAN PELESENAN | *LICENSING BRANCH*

- Mengeluarkan Lesen/Kebenaran Import/Kebenaran Eksport/Permit Import/Permit Eksport/Syarat Lesen Khas/Kebenaran Khas untuk aktiviti pengimportan, pengeksportan, pengedaran substans berjadual bagi dadah berbahaya, bahan psikotropik, serta prekursor (*pseudoephedrine* dan *ephedrine*) dan penetapan kuota bagi bahan-bahan tersebut serta kelulusan pengedaran bahan terkawal.
- Merancang, menyelaras, mengkoordinasi dan memantau aktiviti pelesenan dan pemeriksaan yang dijalankan oleh CPF Negeri serta aktiviti saringan dan pemeriksaan pengimportan di pintu-pintu masuk Kastam bagi produk dan bahan yang dikawal bagi memastikan kepatuhan terhadap peruntukan undang-undang yang dikuatkuasakan.
- Menguruskan perkara-perkara berkaitan konvensyen-konvensyen dadah antarabangsa di mana BPF merupakan Pihak Berkuasa Berwibawa (*Competent Authority*) yang melibatkan substan terkawal seperti dadah berbahaya(narkotik), bahan psikotropik dan prekursor serta menyelaras tindakan dengan agensi/ jabatan/ pihak berkuasa lain yang berkaitan dengan aktiviti pelesenan, pemeriksaan, kawalan pintu masuk dan kawalan substans terkawal selaras dengan konvensyen antarabangsa.

- *Issuing of Licence/Import Authorization/Export Authorization/ Import Permit/Export Permit/ Special Licence Conditions/Special Authorization for importation, exportation, distribution activities of scheduled substances for dangerous drugs, psychotropic substances and precursors (pseudoephedrine and ephedrine), and quotas setting for such substances as well as approval for controlled substances distribution.*
- *Plan, coordinate and monitor the activities of licensing and inspection carried out by the State PEB and inspection activities at Customs entry points on the importation of products and substances which are regulated under the Acts enforced to ensure compliance with the provisions of the law enforced.*
- *Manage related matters pertaining International Drug Conventions involving dangerous drugs (narcotics), psychotropic substances and precursors where PED as the Competent Authority for the Conventions and coordinate actions with other agencies/ departments/ authorities related to the activities such as licensing, inspection, entry points control and substance control as in accordance with international conventions.*

## CAWANGAN PERUNDANGAN | *LEGISLATIVE BRANCH*

- Menganalisis dan mengkaji undang-undang sedia ada untuk memastikan relevan dengan keperluan dan cabaran semasa serta meminda dan jika perlu, menggubal undang-undang untuk memantapkan dan memperkukuh kawalan dan penguatkuasaan.
- Mengkoordinasikan proses siasatan dan pendakwaan di semua CPF.

- *To conduct research and review on the existing laws to ensure their relevance to the current needs and challenges as well as to amend current laws or to enact new laws to strengthen the governance and regulatory control*
- *To coordinate investigation and prosecution activities in all PEB.*

## CAWANGAN KAWALAN IKLAN | *ADVERTISEMENT CONTROL BRANCH*

- Memproses kelulusan iklan produk ubat dan perkhidmatan kesihatan serta memproses pindaan/ pembatalan/tarik balik kelulusan iklan produk ubat dan perkhidmatan kesihatan; sebagai Sekretariat kepada Lembaga Iklan Ubat; serta menyediakan dan mengemas kini polisi Lembaga Iklan Ubat, garis panduan pengiklanan dan panduan berkaitan permohonan kelulusan iklan.
- Menjalankan saringan dan pemantauan ke atas iklan produk dan perkhidmatan perubatan dalam media cetak, media elektronik dan media baharu bagi memastikan peruntukan undang-undang sedia ada dipatuhi
- Merancang dan melaksanakan aktiviti kesedaran dan libat urus kepada pemegang taruh dan pihak yang berkepentingan bagi meningkatkan kefahaman dan kepatuhan kepada peruntukan undang-undang yang dikuatkuasakan.

- *Process approval/ amendments/ cancellations of advertisements for medicinal products and healthcare services and revocation of medicinal products and healthcare services advertisement; Secretariat for the Medicine Advertisement Board; prepare and update the Medicine Advertisement Board policy, advertising guidelines and guides relating to advertisement approval applications.*
- *Conduct screening and monitoring of medicinal products and healthcare services advertisements in print media, electronic media and new media to ensure compliance with existing legal provisions.*
- *Plan and implement awareness activities and engagement with various stakeholders and relevant parties to increase understanding and compliance with the currently enforced legal provisions.*

## CAWANGAN FORENSIK FARMASI | *FORENSIC PHARMACY BRANCH*

- Menjalankan forensik digital dan pemulihan data berhubung dengan jenayah farmaseutikal dalam talian bagi membolehkan bukti dibawa ke mahkamah
- Mengurus dan mengendalikan makmal forensik siber dan makmal forensik kimia untuk membantu tugas pemantauan dan risikan pasaran serta mewujudkan pangkalan data bagi sampel yang diuji

- *Conducting digital forensics and data recovery in relation to online pharmaceutical crimes to enable evidence to be presented in court*
- *Manage and operate cyber forensic laboratory and chemical forensic laboratory to assist in market monitoring and intelligence activities as well as creating database of tested samples*

## SEKSYEN PERKEMBANGAN PENGUATKUASAAN FARMASI | *PHARMACY ENFORCEMENT DEVELOPMENT SECTION*

- Memantau dan menyelaras peruntukan kewangan Aktiviti Penguatkuasaan Farmasi Ibu Pejabat dan Negeri, urusan sumber manusia, urusan latihan dan kompetensi pegawai di bawah Aktiviti Penguatkuasaan Farmasi
- Memantau dan menyelaras pelaksanaan Aktiviti Penguatkuasaan Farmasi supaya mencapai indikator dan objektif kualiti serta Dasar dan Pelan Tindakan yang ditetapkan
- Memantau dan menyelaras maklum balas dari Ibu Pejabat dan CPF Negeri kepada pihak yang berkepentingan dan pembangunan sistem sedia ada/ baru di BPF.

- *Monitor and coordinate budget allocation for pharmacy enforcement activities at the headquarters and state level; monitor and coordinate human resource matters, training matters and competencies for officers under Pharmacy Enforcement Activities*
- *Monitor and coordinate the implementation of Pharmacy Enforcement Activities to achieve quality indicators and objectives as well as set Policies and Action Plans.*
- *Monitor and coordinate feedback from the headquarters and the states to stakeholders as well as the development of existing/new systems in the PED.*

## 2.0 AKTIVITI DAN SOROTAN | *ACTIVITIES AND HIGHLIGHTS*

### LEMBAGA RACUN

Lembaga Racun dalam mesyuaratnya yang ke-101 pada 20 Mac 2025, telah memutuskan perkara-perkara berikut:

i. Pengelasan 17 bahan kimia sebagai racun baru di bawah Akta Racun 1952 [*Akta 366*].
ii. Pengelasan semula Tretinoin daripada Racun Kumpulan C dalam semua sediaan kepada kawalan seperti berikut:
    a) Racun Kumpulan C bagi sediaan untuk kegunaan luar;
    b) Racun Kumpulan B bagi semua sediaan selain daripada Kumpulan C; dan
    c) mencadangkan kepada Pihak Berkuasa Kawalan Dadah agar kawalan khas melalui arahan dan syarat pendaftaran yang dikenakan ke atas tretinoin dalam keluaran sedia ada dikekalkan.
iii. Menolak permohonan mengecualikan kawalan di bawah Akta 366 ke atas nikotin dalam sediaan lozeng dan sebaliknya mengekalkan kawalannya sebagai Racun Kumpulan C.

Seterusnya pada 31 Oktober 2025, YBhg. Datuk Dr. Mahathar bin Abd Wahab, Ketua Pengarah Kesihatan, Kementerian Kesihatan Malaysia yang baharu telah mempengerusikan buat kali pertama Mesyuarat Lembaga Racun ke-102 bertempat di Kementerian Kesihatan Malaysia, Putrajaya.

Mesyuarat kali ke-102 ini telah memutuskan perkara-perkara berikut:

i. Pengelasan 19 bahan kimia sebagai racun baru.
ii. Penyenaraian 6 bahan kimia/psikoaktif daripada keputusan Mesyuarat Commission on Narcotics Drugs ke-68 sebagai racun, bahan psikotropik atau dadah berbahaya.
iii. Mengelaskan semula Clotrimazole dalam sediaan untuk kegunaan luar bagi formulasi kombinasi daripada Racun Kumpulan B kepada Kumpulan C.
iv. Mengelaskan semula Adapalene 0.1% daripada Racun Kumpulan B kepada Racun Kumpulan C bagi sediaan untuk kegunaan sediaan luar.
v. Meminda Jadual Kedua Akta 366 dengan memotong butiran *"(other than Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both such substitution or such closure) or and by substitution in the aromatic ring, with or without substitution in the nitrogen atom; any salt of any substance falling within this item)"*.
vi. Menolak permohonan pengelasan semula Sildenafil 50 mg daripada Racun Kumpulan B kepada Racun Kumpulan C dan mengekalkan kawalannya sebagai Racun Kumpulan B di bawah Akta 366.

### *POISONS BOARD*

*The Poisons Board in its 101th meeting that was conducted on 20 March 2025 has decided on the following matter:*

*i. Classification of 17 chemicals as new poisons under the Poisons Act 1952 [Act 366].*
*ii. Reclassification of Tretinoin from Group C Poison for all preparations to the following controls:*
    *a) Group C Poison for preparations for external use;*
    *b) Group B Poison for all preparations unless in Group C; and*
    *c) to propose to the Drug Control Authority to maintain the existing special controls through directives and registration conditions imposed on Tretinoin in registered products.*
*iv. Disagreement on application to exempt Nicotine lozenge from controlled under Act 366; and instead maintain its control as a Group C poison.*

*On 31 October 2025, YBhg. Datuk Dr. Mahathar bin Abd Wahab, the new Director-General of Health, Ministry of Health Malaysia, chaired for the first time the 102nd Poisons Board Meeting held at the Ministry of Health Malaysia, Putrajaya.*

*The 102nd meeting agreed on the following decisions:*

*i. Classification of 19 chemicals as new poisons.*
*ii. Listing of 6 chemicals/psychoactive substances following the decisions of the 68th Commission on Narcotic Drugs Meeting as poisons, psychotropic substances, or dangerous drugs.*
*iii. Reclassification of Clotrimazole in combination formulations for external use from Group B Poison to Group C Poison.*
*iv. Reclassification of Adapalene 0.1% from Group B Poison to Group C Poison for external use preparations.*
*v. Amendment to the Second Schedule of Act 366 by deleting the particulars "(other than Adrenaline and other substances structurally derived from Phenethylamine by substitution in the aliphatic part or by ring closure therein (or by both such substitution or such closure) or and by substitution in the aromatic ring, with or without substitution in the nitrogen atom; any salt of any substance falling within this item)".*
*vi. Disagreement on the application for the reclassification of Sildenafil 50 mg from Group B Poison to Group C Poison and to maintain its control of as Group B Poison under Act 366.*




Mesyuarat Lembaga Racun ke-101 di Program Perkhidmatan Farmasi, Petaling Jaya
*The 101st Poisons Board Meeting at the Pharmaceutical Services Programme, Petaling Jaya*



Mesyuarat Lembaga Racun ke-102 di Kementerian Kesihatan Malaysia, Putrajaya
*The 102nd Poisons Board Meeting at the Ministry of Health Malaysia, Putrajaya*

## LEMBAGA IKLAN UBAT

Pada tahun 2025, Lembaga Iklan Ubat (LIU) telah mengadakan mesyuarat bersama ahli-ahlinya sebanyak dua kali. Mesyuarat Bil.1/2025 telah bersidang pada 6 Mac 2025 dan dipengerusikan oleh Ketua Pengarah Kesihatan, YBhg. Datuk Dr. Muhammad Radzi bin Abu Hassan. Beberapa polisi dan keputusan penting telah dibuat seperti berikut:

i. Produk ubat semula jadi dengan tuntutan terapeutik (nombor pendaftaran MAL dengan kod produk B) disenaraikan sebagai salah satu kategori produk yang tidak dibenarkan untuk pengiklanan, seiring dengan Racun Kumpulan B dan Racun Kumpulan C di bawah Akta Racun 1952.
ii. Produk ubat semulajadi dengan tuntutan moden (nombor pendaftaran MAL dengan kod produk M) disenaraikan sebagai salah satu kategori produk yang boleh diiklankan.
iii. Saiz tulisan bagi maklumat indikasi produk hendaklah lebih besar atau menonjol berbanding saiz tulisan bagi maklumat-maklumat lain dalam format iklan serta tidak boleh mengelirukan indikasi produk sebenar.
iv. Bagi iklan perkhidmatan kesihatan, maklumat *Corporate Social Responsibilities* (CSR) atau bantuan khas daripada kerajaan kini dibenarkan tertakluk kepada terma dan syarat yang ditetapkan.
v. Pemaparan wajah pesakit atau profesional kesihatan menggunakan model atau artis dibenarkan, tertakluk kepada syarat-syarat yang telah ditetapkan.
vi. Penerbitan dua panduan baharu berkaitan pengiklanan produk ubat berdaftar dan perkhidmatan kesihatan yang tidak memerlukan kelulusan LIU untuk rujukan pihak industri.

Pada 26 Ogos 2025 mesyuarat Bil.2/2025 yang dipengerusikan oleh Timbalan Ketua Pengarah Kesihatan (Perkhidmatan Farmasi), YBrs. Dr Azuana Binti Ramli telah membuat keputusan dan polisi seperti berikut:

i. Permulaan liberalisasi pengiklanan racun kumpulan C iaitu produk topikal mengandungi Diclofenac sahaja dibenarkan tertakluk kepada syarat-syarat dan format iklan yang telah ditetapkan.

## *MEDICINE ADVERTISEMENT BOARD*

*In 2025, the Medicine Advertisement Board (MAB) held two meetings with its members. Meeting No. 1/2025 convened on 6 March 2025, chaired by the Director General of Health, YBhg. Datuk Dr. Muhammad Radzi bin Abu Hassan. Key policies and decisions made are as follows:*

*i. Natural products with therapeutic claims (products registered with a MAL number with code B) are prohibited for general public advertising, aligned with Group B and Group C Poisons under the Poisons Act 1952.*
*ii. Natural products with modern claims (products registered with a MAL number with code M) are permitted for general public advertising.*
*iii. The font size for product indication information must be larger or more prominent than other information in the advertisement format and must not misrepresent the actual product indication.*
*iv. Information regarding Corporate Social Responsibility (CSR) or special aid programmes initiated by the government are allowed, subject to terms and conditions.*
*v. The depiction of patients and healthcare providers using models or actors/actresses are allowed, subject to terms and conditions.*
*vi. Publication of two new guidelines on permissible claims in registered product and skill/healthcare services advertisements exempted from MAB Approval, serving as a reference for the industry.*

*On 26 August 2025, Meeting No. 2/2025, chaired by the Deputy Director-General of Health (Pharmaceutical Services), YBrs. Dr. Azuana Binti Ramli, made the following decisions and policies:*

*i. The commencement of advertising liberalisation for Group C poisons, specifically topical products containing Diclofenac only, is allowed, subject to the specified conditions and advertisement format.*

ii. Senarai tuntutan tanda dan gejala penyakit yang dibenarkan dalam pengiklanan produk kategori *over the counter* (OTC) telah disediakan sebagai rujukan oleh pihak industri.

iii. Pengiklanan menggunakan kreativiti konsep jenaka dibenarkan tertakluk dengan syarat-syarat tertentu.

Maklumat berkaitan telekesihatan/ teleperubatan/ telekonsultasi boleh dibenarkan dalam iklan perkhidmatan kesihatan susulan KKM telah menerbitkan Garis Panduan Perkhidmatan Jagaan Kesihatan Dalam Talian pada 5 Mei 2025.

*ii. A list of approved disease signs and symptoms claims for the advertising of over the counter (OTC) category products has been prepared as a reference for the industry.*

*iii. Advertising using creative humorous concepts is allowed, subject to certain conditions. Advertising that incorporates creative and humorous concepts is permissible, provided that certain specified conditions are satisfied.*

*Information related to telehealth/ telemedicine/ teleconsultation can be allowed in healthcare service advertisements, following the publication of the Online Healthcare Services Guidelines by the Ministry of Health (MOH) on 5 May 2025.*



Mesyuarat Lembaga Iklan Ubat Bil.1/2025
*Medicine Advertisement Board Meeting No. 1/2025*



Mesyuarat Lembaga Iklan Ubat Bil.2/2025
*Medicine Advertisement Board Meeting No. 2/2025*

## KURSUS PEMANTAPAN AKTIVITI PELESENAN DAN PEMERIKSAAN PREMIS SELARAS DENGAN UNDANG-UNDANG DAN POLISI SEMASA, BPF KKM BAGI TAHUN 2025


Satu kursus telah diadakan di Lexis Hotel, Negeri Sembilan pada 19 hingga 21 Mei 2025 yang melibatkan wakil dari CPF Negeri dan Program Perkhidmatan Farmasi seramai 45 orang.

Kursus ini dianjurkan bagi memperkukuh pengetahuan dan kemahiran Pegawai Penguat Kuasa Farmasi dalam pelaksanaan aktiviti pelesenan dan pemeriksaan premis. Kursus ini menampilkan penceramah daripada Bahagian Regulatori Farmasi Negara (NPRA), BPF serta agensi berkaitan termasuk Jabatan Imigresen Malaysia dan Seksyen Psikologi dan Kaunseling, Jabatan Kesihatan Negeri Sembilan.

## *COURSE TO STRENGTHEN LICENSING AND PREMISES INSPECTION ACTIVITIES IN LINE WITH CURRENT LAWS AND POLICIES, PED MOH, FOR THE YEAR 2025*

*A course was held at Lexis Hotel, Negeri Sembilan, from 19 to 21 May 2025, involving 45 representatives from the State PED and the Pharmaceutical Services Programme.*

*The course aimed to strengthen the knowledge and skills of Pharmacy Enforcement Officers in licensing and inspection activities, featuring speakers from the National Pharmaceutical Regulatory Agency (NPRA), PED as well as the relevant agencies such as the Immigration Department of Malaysia and the Psychology and Counselling Section of the Negeri Sembilan State Health Department.*



Kursus Pemantapan Aktiviti Pelesenan Dan Pemeriksaan Premis Selaras Dengan Undang-Undang Dan Polisi Semasa
*Course to Strengthen Licensing and Premises Inspection Activities in Line with Current Laws and Policies*

## SESI LIBAT URUS CADANGAN ARAHAN KETUA PENGARAH KESIHATAN (KPK) DI BAWAH AKTA RACUN 1952 BAGI TAHUN 2025

Sesi libat urus cadangan Arahan Ketua Pengarah Kesihatan (KPK) di bawah Akta Racun 1952 bagi tahun 2025 telah diadakan pada 8 Januari 2025 di Program Perkhidmatan Farmasi dan dihadiri oleh 40 orang yang mewakili persatuan yang melibatkan farmasi di Malaysia serta wakil CPF Negeri dan wakil Bahagian/ Cawangan/ Seksyen di bawah Program Perkhidmatan Farmasi, KKM.

Sesi libat urus ini diadakan bagi menerangkan kepada ahli farmasi berdaftar mengenai cadangan Arahan KPK di bawah Akta Racun 1952 berkaitan aktiviti pelesenan bagi tahun 2025 melibatkan pengemaskinian Arahan KPK sedia ada berkaitan kawalan penjualan secara borong racun untuk tujuan penggalak tumbesaran atau pencegahan penyakit haiwan dan juga berkaitan kawalan pengimportan/ penjualan nikotin.

## *ENGAGEMENT SESSION ON THE DIRECTOR GENERAL OF HEALTH'S PROPOSED DIRECTIVE UNDER THE POISONS ACT 1952 FOR 2025*

*The engagement session on the proposed Director General (DG) of Health Directive under the Poisons Act 1952 for 2025 was held on 8 January 2025 at the Pharmaceutical Services Programme, attended by 40 participants representing pharmacy associations in Malaysia, CPF state representatives, and officers from divisions, branches, and sections under the Pharmaceutical Services Programme Ministry of Health.*

*The engagement session was conducted to inform registered pharmacists about the proposed DG of Health Directive under the Poisons Act 1952 for 2025, including updates to controls on wholesale sales of poisons for animal growth promotion or disease prevention, and on the importation and sale of nicotine.*

## SESI KUNJUNGAN DAN DIALOG BERSAMA PENGARAH BPF DENGAN CPF NEGERI PERLIS DAN SABAH SERTA KUNJUNGAN HORMAT KE AGENSI PENGUATKUASAAN MARITIM MALAYSIA (APMM) TAWAU

Pengarah BPF, Tuan Mohd. Zawawi Bin Abdullah bersama empat orang delegasi dari BPF telah mengadakan sesi kunjungan dan dialog bersama Pegawai Penguat Kuasa Farmasi CPF Perlis pada 21 hingga 23 Oktober 2025.

Tujuan utama kunjungan ini diadakan adalah untuk memberikan taklimat berkenaan Agensi Kawalan dan Perlindungan Sempadan (AKPS). Selain itu, sesi ini juga turut menjadi platform bagi mengumpul isu-isu yang dihadapi oleh CPF Negeri.

Di samping itu, dalam lawatan kerja ini deligasi dari BPF telah dibawa melawat ke Pejabat CPF Perlis di Kompleks ICQS Padang Besar, Stor Ekshibit CPF Perlis dan Pejabat CPF Perlis di pos ICQS Wang Kelian.

## *VISIT AND DIALOGUE SESSION WITH THE DIRECTOR OF THE PED TO THE PERLIS AND SABAH PEB, AS WELL AS A COURTESY VISIT TO THE MALAYSIAN MARITIME ENFORCEMENT AGENCY (APMM) TAWAU*

*The Director of the PED, Tuan Mohd. Zawawi Bin Abdullah, together with four delegates from PED, held a courtesy visit and dialogue session with the Pharmacy Enforcement Officer of CPF Perlis from 21 to 23 October 2025.*

*The main purpose of this visit was to provide a briefing regarding the Malaysia Control and Border Protection Agency (MCBA). In addition, this session also served as a platform to gather issues faced by the State Pharmaceutical Enforcement Branch.*

*Furthermore, during this working visit, the delegation from PED was taken to visit the CPF Perlis Office at the ICQS Padang Besar Complex, the CPF Perlis Exhibit Store and the CPF Perlis Office at the ICQS Wang Kelian post.*

Seterusnya pada 27-29 Oktober 2025, telah diadakan sesi dialog dan perbincangan serta kunjungan hormat ke APMM Kawasan Tawau yang diketuai oleh KDR (M) Norihan Bin Ngah selaku Timbalan Pengarah Zon (Operasi). BPF bersama-sama pegawai penguat kuasa farmasi CPF Sabah dan APMM telah membuat rondaan di perairan Tawau dan Pulau Sebatik. Lawatan ini bertujuan untuk meneliti dan memahami isu-isu yang dibangkitkan serta untuk memastikan bahawa aktiviti penguatkuasaan farmasi di kawasan-kawasan ini berjalan dengan lancar dan efektif.

*Subsequently, from 27–29 October 2025, a dialogue and discussion session as well as a courtesy visit were held at the APMM Tawau Zone, led by KDR (M) Norihan Bin Ngah in his capacity as Deputy Zone Director (Operations). PED, together with Pharmacy Enforcement Officers from PEB Sabah and APMM, conducted patrols in the waters of Tawau and Pulau Sebatik. The visit aimed to examine and better understand the issues raised, as well as to ensure that pharmacy enforcement activities in these areas are carried out smoothly and effectively*



Sesi Kunjungan Dan Dialog Bersama Pengarah BPF dengan CPF Negeri Perlis
*Visit and Dialogue Session with the Director of the PED to the Perlis Pharmaceutical Enforcement Branch*



Sesi Kunjungan Dan Dialog Bersama Pengarah BPF dengan APMM dan CPF Sabah
*Visit and Dialogue Session with the Director of BPF together with APMM and PEB Sabah*

## KURSUS PEMANTAPAN SIASATAN DAN PENDAKWAAN KESALAHAN DI MEDIA BAHARU

Kursus Pemantapan Siasatan dan Pendakwaan Kesalahan di Media Baharu telah dijalankan pada 23 hingga 25 September 2025 di Imperial Heritage Melaka yang disertai oleh Pegawai Penguat Kuasa Farmasi dari BPF dan CPF Negeri seluruh negara.

Tujuan kursus ini diadakan adalah untuk memantapkan pengetahuan pegawai penguat kuasa farmasi dalam undang-undang berkaitan keterangan elektronik dan meningkatkan kemahiran pegawai mengenai teknik siasatan dan pendakwaan kes melibatkan kesalahan di media baharu.

## *COURSE ON STRENGTHENING INVESTIGATION AND PROSECUTION OF NEW MEDIA OFFENCES*

*The Course on Strengthening Investigation and Prosecution of New Media Offences was successfully conducted from 23 to 25 September 2025 at Imperial Heritage, Melaka. This training session was attended by Pharmacy Enforcement Officers from both the PED and State PEB nationwide.*

*The primary purpose of this course was to bolster the legal competencies of enforcement officers regarding the complex laws and regulations surrounding electronic evidence, while simultaneously advancing their technical expertise and proficiency in modern investigation and prosecution techniques specifically designed for offences occurring on new media platforms.*



Kursus Pemantapan Siasatan dan Pendakwaan Kesalahan di Media Baharu
*Course on Strengthening Investigation and Prosecution of New Media Offences*

## LAWATAN KERJA RASMI KE MAKMAL FORENSIK KASTAM DIRAJA MALAYSIA

Lawatan kerja BPF ke Unit Siasatan Forensik, Jabatan Kastam Diraja Malaysia (JKDM) telah diadakan pada 5hb Ogos 2025. Objektif lawatan adalah untuk mendapatkan pendedahan berkaitan pengurusan makmal digital forensik serta mewujudkan perkongsian idea dan pengalaman antara JKDM dan BPF. Di samping itu, hasil dari sesi lawatan ini juga diharap dapat memperkukuh jaringan kerjasama antara agensi dalam bidang penguatkuasaan berasaskan forensik.

Seramai 12 pegawai menyertai lawatan kerja ini. Pegawai-pegawai adalah daripada Cawangan Forensik Farmasi dan Seksyen Perkembangan Penguatkuasaan Farmasi.

Lawatan kerja separuh hari ini dimulakan dengan sesi taklimat oleh Tuan Nik Mazdie Izham bin Nik Mohamed, Ketua Unit Siasatan Forensik, Cawangan Siasatan JKDM. Kemudian, delegasi dibawa melawat ke Makmal Forensik JKDM yang terdiri daripada bilik penerimaan eksibit, bilik acquisition, makmal forensik dokumen, makmal forensik audio visual, bilik server, recharge room dan mobile/ computer forensic workstation untuk pegawai Analisa.

Lawatan diakhiri dengan sesi bergambar dan acara penyampaian cenderahati oleh delegasi BPF kepada JKDM.

## *OFFICIAL WORKING VISIT TO ROYAL MALAYSIAN CUSTOM FORENSIC LABORATORY*

*The PED conducted an official working visit to the Forensic Investigation Unit, Royal Malaysian Customs Department (JKDM), on 5th August 2025. The objective of the visit is to gain insight into the management of digital forensic laboratories and to facilitate the exchange of ideas and experiences between JKDM and the PED. Additionally, this visit aims to strengthen inter-agency cooperation in forensic-based enforcement.*

*A total of 12 officers participated in this working visit, representing the Pharmacy Forensics Branch and Pharmacy Enforcement Development Section.*

*The half-day working visit started with a briefing by Mr. Nik Mazdie Izham bin Nik Mohamed, Head of the Forensic Investigation Unit, JKDM Investigation Branch. After that, the delegation toured the JKDM Forensic Laboratory, visiting key areas such as the exhibit reception room, acquisition room, document forensic laboratory, audio-visual forensic laboratory, server room, recharge room, and mobile/computer forensic workstations.*

*The visit concluded with a photo session and a souvenir presentation by the PED delegation to JKDM.*




Lawatan Kerja Rasmi Ke Makmal Forensik Kastam Diraja Malaysia
*Official Working Visit to Royal Malaysian Custom Forensic Laboratory*

## LAWATAN KERJA RASMI KE MAKMAL FORENSIK POLIS DIRAJA MALAYSIA

Program Perkhidmatan Farmasi telah mengadakan lawatan kerja rasmi ke Makmal Forensik PDRM pada 17 Julai 2025. Objektif lawatan ini adalah untuk memberi pendedahan tentang keperluan akreditasi di bawah pensijilan MS ISO/ IEC 17025:2017 serta meningkatkan kefahaman berkaitan fungsi dan operasi makmal.

Seramai 12 pegawai menyertai lawatan kerja ini. Pegawai-pegawai adalah daripada Cawangan Forensik Farmasi, Seksyen Perkembangan Penguatkuasaan Farmasi dan pegawai-pegawai daripada Bahagian Dasar dan Perancangan Strategik Farmasi.

Lawatan kerja separuh hari ini dimulakan dengan sesi bergambar dan sesi tandatangan buku pelawat di lobi makmal. Aktiviti diteruskan dengan ucapan perasmian oleh YDH SAC Mohamed Rafiq bin Mohamed Mustafa dan pembentangan oleh ACP Muhammad Zulkifly bin Mohd Isa selaku ketua seksyen Fizikal Makmal Forensik.

Lawatan diakhiri dengan delegasi dibawa melawat ke Makmal Forensik Fizikal yang terdiri daripada makmal forensik komputer, mobile, audio video, analisis dokumen dan *data recovery*. Selain itu, delegasi turut berpeluang melawat Pusat Data dengan kapasiti 1 petabyte yang dibangunkan untuk menyimpan pengekstrakan imej dari peranti yang dianalisis.

## *OFFICIAL WORKING VISIT TO ROYAL MALAYSIAN POLICE FORENSIC LABORATORY*

*The Pharmaceutical Services Program conducted a working visit to the PDRM Forensic Laboratory on 17 July 2025. The objective of this visit is to provide exposure to accreditation requirements under MS ISO/IEC 17025:2017 certification and to enhance understanding of laboratory functions and operations.*

*A total of 12 officers participated in this working visit, representing the Pharmacy Forensics Branch, Pharmacy Enforcement Development Section, and the Pharmacy Policy and Strategic Planning Division.*

*The half-day working visit commenced with a photo session and the signing of the visitor's book in the laboratory lobby. The program continued with an opening speech by YDH SAC Mohamed Rafiq bin Mohamed Mustafa, followed by a presentation from ACP Muhammad Zulkifly bin Mohd Isa, Head of the Physical Forensic Laboratory Section.*

*The official visit concluded with a tour of the Physical Forensic Laboratory, which includes computer forensics, mobile, audio-video, document analysis, and data recovery laboratories. The delegation also had the opportunity to visit a data centre with a 1-petabyte capacity, developed to store image extractions from the analyzed data.*




Lawatan Kerja Rasmi Ke Makmal Forensik Polis Diraja Malaysia
*Official Working Visit to Royal Malaysian Police Forensic Laboratory*

## KEMBARA TOLAK UBAT TIDAK SAH (TOBATS) 2025

Kembara Tolak Ubat Tidak Sah (TOBaTS) tahun 2025 merupakan kesinambungan kepada aktiviti kempen TOBaTS yang telah dilancarkan pada 20 November 2024. Objektif utama kembara ini adalah untuk menyampaikan mesej kesedaran khususnya kepada pengguna dan pemegang taruh di kawasan luar bandar bagi memastikan mereka mendapatkan bekalan ubat mereka daripada sumber yang sah sahaja.

Pelaksanaan kembara ini melibatkan kerjasama antara CPF Negeri dalam 5 zon yang telah ditetapkan. Pelancaran kembara ini telah disempurnakan oleh YB Datuk Seri Dr Dzulkefly Ahmad, Menteri Kesihatan semasa penganjuran Kembara TOBaTS Zon Tengah di Dewan Dato' Penggawa Permatang, Kuala Selangor pada 3 Mei 2025. Kembara ini merupakan anjuran bersama BPF, CPF Selangor dan CPF Kuala Lumpur dan Putrajaya.

Pelbagai aktiviti menarik telah dijalankan seperti ceramah, pameran, pemeriksaan kesihatan, sesi lawatan YBMK ke premis-premis farmasi dan banyak lagi. Sambutan hangat telah diterima daripada warga Kuala Selangor yang telah turut sama hadir memeriahkan kembara ini.

Penganjuran Kembara TOBaTS ini kemudiannya diteruskan bagi Zon Timur iaitu di Jeli, Kelantan pada 15-17 Mei 2025. Sesi ini dijalankan dengan kerjasama CPF Kelantan, CPF Terengganu dan CPF Pahang.

## *SAY NO TO ILLEGAL MEDICINES (TOBATS) EXPEDITION 2025*

*The 2025 Say No to Illegal Medicines (TOBaTS) Expedition is a continuation of the TOBaTS campaign activities launched on 20 November 2024. The primary objective of this expedition is to convey awareness messages, specifically to consumers and stakeholders in rural areas, to ensure they obtain their medicine supplies only from legitimate sources.*

*The implementation of this expedition involves cooperation between the States PED across five designated zones. The launch of this expedition was officiated by YB Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health during the Central Zone TOBaTS Expedition held at Dewan Dato' Penggawa Permatang, Kuala Selangor, on 3rd May 2025. This expedition is a joint initiative by the PED, CPF Selangor, and CPF Kuala Lumpur & Putrajaya.*

*Various engaging activities were conducted, including talks, exhibitions, health screenings, a walkabout visit by the YBMK to pharmacy premises, and many more. A warm reception was received from the residents of Kuala Selangor, who attended and participated in the event.*

*Following the initial launch, the TOBaTS Expedition moved to the East Zone, held in Jeli, Kelantan, from May 15 to 17, 2025. This session was conducted in collaboration with PEB Kelantan, PEB Terengganu, and PEB Pahang.*






Kembara Tolak Ubat Tidak Sah (TOBaTS) di Kuala Selangor, Selangor
*Say No to Illegal Medicines (TOBaTS) Expedition 2025 At Kuala Selangor, Selangor*



Kembara Tolak Ubat Tidak Sah (TOBaTS) di Jeli, Kelantan
*Say No to Illegal Medicines (TOBaTS) Expedition 2025 at Jeli, Kelantan*

## MESYUARAT SEMAKAN & PINDAAN PROSEDUR PEMPROFILAN MEDIA BAHARU

Mesyuarat Semakan dan Pindaan Prosedur Pemprofilan Media Baharu telah diadakan pada 19 hingga 20 Ogos 2025 bertempat di Dewan Serai Wangi, Bahagian Regulatori Farmasi Negara. Mesyuarat ini telah disertai oleh Pegawai Penguat Kuasa Farmasi daripada BPF serta CPF Negeri dari seluruh negara.

Mesyuarat ini bertujuan untuk menyemak, menilai dan mengemas kini Prosedur Pemprofilan Media Baharu sedia ada bagi memastikan prosedur tersebut kekal relevan, berkesan dan selari dengan keperluan semasa penguatkuasaan farmasi. Prosedur yang dipinda ini akan dijadikan rujukan rasmi kepada pegawai penguat kuasa farmasi dalam melaksanakan aktiviti pemprofilan media baharu secara seragam dan berstruktur di seluruh negara.

## *MEETING ON THE REVIEW AND AMENDMENT OF NEW MEDIA PROFILING PROCEDURES*

*The Meeting on the Review and Amendment of New Media Profiling Procedures was held from 19 to 20 August 2025 at Dewan Serai Wangi, National Pharmaceutical Regulatory Agency. The meeting was attended by Pharmacy Enforcement Officers from the PED as well as State PEB nationwide.*

*The meeting aimed to review, evaluate, and update the existing New Media Profiling Procedures to ensure that the procedures remain relevant, effective, and aligned with current pharmacy enforcement requirements. The revised procedures will serve as an official reference for pharmacy enforcement officers in conducting new media profiling activities in a consistent and structured manner nationwide.*



Mesyuarat Semakan & Pindaan Prosedur Pemprofilan Media Baharu
*Meeting on The Review and Amendment of New Media Profiling Procedures*

## LAIN-LAIN AKTIVITI
## *OTHER ACTIVITIES*

| | |
|---|---|
| Tajuk<br>*Title* | Taklimat Dan Libat Urus Kawalan Iklan Perubatan Di Bawah Akta Ubat (Iklan & Penjualan) 1956 Bersama Pemegang Taruh<br>*Briefing and Stakeholder Engagement on the Control of Medical Advertising Under the Medicines (Advertisement and Sale) Act 1956* |
| Tarikh<br>*Date* | 23 Januari 2025; 18 Jun 2025; 3 Julai 2025<br>*23 January 2025; 18 June 2025; 3 July 2025* |
| Tempat<br>*Venue* | Program Perkhidmatan Farmasi, Petaling Jaya<br>*Pharmaceutical Services Programme, Petaling Jaya* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 40 orang peserta daripada pelbagai syarikat media dan e-Dagang dan kurier serta agensi-agensi penguatkuasaan di pintu masuk kastam.<br>*40 participants from various media companies, e-commerce platforms, courier services, as well as enforcement agencies at customs entry points.* |
| Objektif<br>*Objectives* | Meningkatkan pematuhan terhadap peruntukan undang-undang berkaitan iklan produk dan perkhidmatan kesihatan dan inisiatif perkongsian awam-swasta secara sukarela.<br>*Strengthening adherence to regulatory frameworks regarding health-related advertisements and fostering collaborative, voluntary public-private engagement.* |
| *Hasil<br>**Outcome* | Peserta dapat meningkatkan kawal selia ke atas pengiklanan dan penjualan produk ubat-ubatan di media/platform dalam talian dalam Malaysia.<br>*Participants are able to enhance regulatory oversight over the advertising and sale of pharmaceutical products on media/online platforms in Malaysia.* |
| *Gambar<br>**Photo* |  <br>  |

| | |
|---|---|
| Tajuk<br>*Title* | Hari Kesedaran Farmasi – Tolak Ubat Tidak Sah 3.0<br>*Pharmacy Awareness Day – Say No to Illegal Medicine 3.0* |
| Tarikh<br>*Date* | 13 Februari 2025<br>*13 February 2025* |
| Tempat<br>*Venue* | KSL Esplanade Hotel, Klang<br>*KSL Esplanade Hotel, Klang* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 150 orang peserta daripada syarikat penghantar dan kurier serta agensi-agensi penguatkuasaan di pintu masuk kastam.<br>*150 participants from the various enforcement agencies at the custom entry point as well as those from forwarding and courier companies.* |
| Objektif<br>*Objectives* | Untuk meningkatkan kesedaran berhubung Kempen Tolak Ubat Tidak Sah, pengimportan dan penghantaran serta pembelian ubat yang selamat.<br>*To increase awareness toward the Say No to Illegal Medicines Campaign, importation and distribution as well as the safe purchasing of medicine.* |
| *Hasil<br>**Outcome* | Peserta dapat memahami kewalan pengimportan ubat-ubatan serta cara menyemak status sesuatu produk ubat sebelum membuat pembelian.<br>*Participants understand the control on importation of medicine and are able to check and verify status of the medicinal product before purchasing it.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Taklimat Dan Sesi Dialog BPF KKM Bersama Chemical Industries Council of Malaysia (CICM)<br>*Briefing & Dialogue Session Between PED, MOH Malaysia and The Chemical Industries Council of Malaysia (CICM)* |
| Tarikh<br>*Date* | 26 Februari 2025<br>*26 February 2025* |
| Tempat<br>*Venue* | Wisma FMM, Kuala Lumpur<br>*Wisma FMM, Kuala Lumpur* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 30 peserta daripada BPF dan Chemical Industries Council of Malaysia (CICM)<br>*30 participants from PED and Chemical Industries Council of Malaysia (CICM)* |
| Objektif<br>*Objectives* | Memperkukuhkan kawalan ke atas bahan kimia prekursor dan memberikan pendedahan terhadap kawalan prekursor dan Akta Racun 1952 dan pindaan terkini.<br>*Strengthening oversight of precursor chemicals and raising awareness of precursor controls, including the Poisons Act 1952 and its recent amendments.* |

| | |
|---|---|
| Tajuk<br>*Title* | Perbincangan Bagi Penganjuran Kursus Diploma Eksekutif Penguatkuasaan Undang-Undang Khusus Untuk Pegawai-Pegawai Penguat Kuasa Farmasi<br>*Discussion on the Organization of the Executive Diploma in Law Enforcement Specifically for Pharmacy Enforcement Officers* |
| Tarikh<br>*Date* | 5 Mei 2025<br>*5 May 2025* |
| Tempat<br>*Venue* | Fakulti Undang-Undang, Universiti Teknologi Mara (FUU UiTM)<br>*Faculty of Law, Universiti Teknologi MARA* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 5 pegawai daripada BPF<br>4 pegawai daripada FUU UiTM<br>*5 officers from PED*<br>*4 officers from FUU UiTM* |
| Objektif<br>*Objectives* | Objektif utama perbincangan ini adalah untuk mendapatkan input awal berhubung kolaborasi antara BPF dan FUU UiTM bagi pelaksanaan Kursus Diploma Eksekutif Penguatkuasaan Undang-Undang untuk Pegawai-pegawai Penguat Kuasa Farmasi.<br>*The primary objective of this discussion is to obtain preliminary input regarding the collaboration between PED and the FUU UiTM for the implementation of the Executive Diploma in Law Enforcement for Pharmacy Enforcement Officers.* |
| *Hasil<br>**Outcome* | Perbincangan ini telah mencapai persetujuan bahawa BPF akan mengemukakan cadangan skop modul kepada FUU UiTM bagi tujuan semakan kandungan dan penetapan tempoh pembelajaran. Kedua-dua pihak bersetuju untuk meneruskan siri perbincangan secara berkala sehingga struktur modul dapat dimuktamadkan sepenuhnya. Seterusnya, proses ini akan disusuli dengan pengemukaan sebut harga rasmi oleh pihak universiti bagi membolehkan permohonan bajet di bawah Peruntukan Operasi Latihan (POL) dilaksanakan oleh BPF.<br>*This discussion reached an agreement that BPF will submit a proposed scope of modules to the FUU UiTM for content review and the determination of the study duration. Both parties agreed to continue holding regular discussions until the module structure is fully finalized. Subsequently, this process will be followed by the submission of an official quotation from the university to enable PED to apply for budget allocation under the POL.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Kursus Pengenalan kepada Aktiviti Khas Cawangan Perundangan BPF, KKM Bagi Tahun 2025<br>*Introductory Course on Special Activities of the Legislation Branch, PED, MOH for the Year 2025* |
| Tarikh<br>*Date* | 14-15 Mei 2025<br>*14-15 May 2025* |
| Tempat<br>*Venue* | Dewan Serai Wangi, Bahagian Regulatori Farmasi Negara<br>*Dewan Serai Wangi, National Pharmaceutical Regulatory Agency* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 23 pegawai dari setiap Bahagian di bawah Program Perkhidmatan Farmasi dan 29 pegawai dari setiap CPF Negeri<br>*23 officers from each Division of the Pharmaceutical Services Programme and 29 officers from State PEB* |
| Objektif<br>*Objectives* | Kurus ini diadakan bertujuan untuk memberikan pengetahuan asas dan pemahaman berkenaan aktiviti-aktiviti khas yang dilaksanakan oleh Cawangan Perundangan, BPF serta untuk mengetahui dan memahami isu-isu atau kesukaran yang dialami oleh Pegawai Penguat Kuasa Farmasi di lapangan supaya urusan pengelasan bahan kimia dan pengeluaran kelulusan khas oleh Program Perkhidmatan Farmasi KKM boleh ditambah baik.<br>*This course is organized with the aim of providing basic knowledge and understanding regarding the special activities carried out by the Legislation Branch of the Pharmacy Enforcement Division. Additionally, it serves to identify and understand the issues or difficulties faced by pharmacy enforcement officers in the field, so that the classification of chemicals and the issuance of special approvals by the Pharmaceutical Services Programme can be improved.* |
| *Hasil<br>**Outcome* | Secara keseluruhan, kursus ini dinilai sangat berjaya, berinformasi dan bernilai tinggi dalam meningkatkan pengetahuan dan tahap kefahaman peserta terhadap aspek perundangan dan penguatkuasaan farmasi. Majoriti peserta kursus berpuas hati dengan pelaksanaan kursus ini dan berpendapat kursus ini sangat baik dalam menjawab kuiri awam dengan lebih berkesan, terutama di pintu masuk negara.<br>*Overall, this course was assessed as highly successful, informative, and of high value in enhancing the participants' knowledge and level of understanding regarding legal aspects and pharmacy enforcement. The majority of the participants were satisfied with the execution of the course and felt that the course was excellent in helping them address public queries more effectively, particularly at the customs port or entry point.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Mesyuarat Cadangan Pindaan Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984 Susulan Pindaan Akta Jualan Dadah 1952<br>*Meeting on Proposed Amendments to the Control of Drugs and Cosmetics Regulations 1984 Following Amendments to the Sale of Drugs Act 1952* |
| Tarikh<br>*Date* | 27-29 Mei 2025<br>*27-29 May 2025* |
| Tempat<br>*Venue* | Lexis Port Dickson<br>*Lexis Port Dickson* |

| | |
|---|---|
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 17 pegawai daripada BPF<br>22 pegawai daripada Bahagian lain di bawah Program Perkhidmatan Farmasi dan semua CPF Negeri<br>*17 officers from PED*<br>*22 officers from other Divisions under the Pharmaceutical Services Programme and all State PEB* |
| Objektif<br>*Objectives* | Mesyuarat ini dilaksanakan bagi memurnikan dan memuktamadkan cadangan peruntukan di bawah draf pindaan Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984 serta penyelesaian isu pentadbiran dan penguatkuasaan yang berkaitan sebelum dikemukakan kepada Pejabat Penasihat Undang-Undang.<br>*This meeting was conducted to refine and finalise all proposed provisions of amendments to the Control of Drugs and Cosmetics Regulations 1984, as well as to resolve related administrative and enforcement issues prior to submission to the Legal Advisor's Office.* |
| *Hasil<br>**Outcome* | Draf pindaan Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984 telah diperkemas dan dimuktamadkan untuk dikemukakan kepada Pejabat Penasihat Undang-Undang, serta telah membincangkan penyelesaian isu-isu tertentu melalui pendekatan pentadbiran.<br>*The draft amendments to the Control of Drugs and Cosmetics Regulations 1984 were refined and finalised for submission to the Legal Advisor's Office, and discussions were held on resolving certain issues through administrative approaches.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Latihan Kebangsaan Mengenai Pengukuhan Penyelarasan Antara Agensi Di Peringkat Negara Dalam Menangani Perdagangan Haram Merkuri: Mesyuarat Pelbagai Negara Berkaitan Penghapusan Produk Pencerah Kulit Berasaskan Merkuri (Slp)<br>*National Training on Strengthening Country-Level Inter-Agency Coordination on Illegal Trade of Mercury:*<br>*Multi-Country Meeting on Elimination of Mercury Added Skin Lightening Products (Slps)* |
| Tarikh<br>*Date* | 5–6 Jun 2025<br>*5–6 June 2025* |
| Tempat<br>*Venue* | Cinnamon Life Hotel, Colombo, Sri Lanka<br>*Cinnamon Life Hotel, Colombo, Sri Lanka* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 38 peserta<br>Melibatkan pegawai kerajaan daripada jabatan/agensi alam sekitar, kesihatan, dan kastam, NGO, pakar antarabangsa, serta pihak berkepentingan lain yang berkaitan daripada Sri Lanka, Thailand, Filipina, Malaysia, Indonesia, Vietnam, Nepal, Maldive, Pakistan<br>*38 participants*<br>*Government officials from environment, health, and customs agencies, NGOs, international experts, and other relevant stakeholders from Sri Lanka, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Nepal, Maldives, Pakistan* |

| | |
|---|---|
| Objektif<br>*Objectives* | Sesi yang dianjurkan oleh The United Nations Environment Programme (UNEP) ini adalah untuk meningkatkan kerjasama strategik agensi yang terlibat dalam kawalan pengimportan dan penjualan mercury sebagai menyokong keperluan kawalan di bawah Minamata Convention on Mercury ke arah mengurangkan atau menghapuskan *mercury added skin lightening products* dan bahan-bahan berbahaya lain.<br>*This session, organized by the United Nations Environment Programme (UNEP), aims to strengthen strategic collaboration among agencies involved in the control of mercury importation and sales, supporting regulatory requirements under the Minamata Convention on Mercury to reduce or eliminate mercury-added skin lightening products and other hazardous substances.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Sesi Perbincangan Berkaitan Cadangan Pengukuhan Kawalan Penggunaan Bahan Mentah Antibiotik (Racun Kumpulan A) Bagi Tujuan Dicampurkan Ke Dalam Makanan Haiwan<br>*Discussion Session on the Proposal to Strengthen Control over the Use of Antibiotic Raw Materials (Group A Poisons) for the Purpose of Incorporation into Animal Feed* |
| Tarikh<br>*Date* | 19 Jun 2025<br>*19 June 2025* |
| Tempat<br>*Venue* | Program Perkhidmatan Farmasi<br>*Pharmaceutical Services Programme* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 15 peserta daripada Jabatan Perkhidmatan Veterinar (DVS), NPRA dan BPF<br>*15 participants from Department of Veterinary Services (DVS), NPRA and PED* |
| Objektif<br>*Objectives* | Sesi perbincangan BPF bersama DVS dan NPRA berkaitan kesediaan industri veterinar untuk menggantikan penggunaan 26 racun daripada bahan mentah (racun Kumpulan A) kepada produk premix berdaftar (racun Kumpulan B) untuk dicampurkan ke dalam makanan haiwan sebagai penggalak tumbesaran (AGP) atau untuk tujuan pencegahan penyakit (prophylaxis).<br>*A discussion session PED with the DVS and the NPRA focused on the veterinary industry's readiness to replace 26 Group A poisons (raw materials) with Group B poisons (registered premix products) for use in animal feed as growth promoters (AGPs) or for disease prevention (prophylaxis).* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Perbincangan Bagi Pelaksanaan Pengkompaunan Kesalahan di Bawah Akta Kawalan Harga dan Antipencatutan 2011 [*Akta 723*]<br>*Discussion on the Implementation of Compounding of Offences Under the Price Control and Anti-Profiteering Act 2011 [Act 723]* |
| Tarikh<br>*Date* | 31 Julai 2025<br>*31 July 2025* |
| Tempat<br>*Venue* | Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup (KPDN)<br>*Ministry of Domestic Trade and Cost Of Living Affairs* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 4 pegawai daripada BPF<br>8 pegawai daripada KPDN<br>*4 officers from PED*<br>*8 officers from KPDN* |
| Objektif<br>*Objectives* | Objektif utama perbincangan ini adalah untuk mengesahkan borang tawaran kompaun bagi maksud mengkompaun kesalahan di bawah Perintah Kawalan Harga dan Antipencatutan (Penandaan Harga bagi Ubat) 2025.<br>*The primary objective of this discussion is to finalize the compound offer forms for the purpose of compounding offences under the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025.* |
| *Hasil<br>**Outcome* | Perbincangan ini berjaya menyelaraskan tatacara pengeluaran borang tawaran kompaun bagi tujuan pengkompaunan kesalahan di bawah Perintah Kawalan Harga dan Antipencatutan (Penandaan Harga bagi Ubat) 2025.<br>*This discussion has successfully streamlined the procedures for issuing compound offer forms for the purpose of compounding offences under Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Bengkel Pemantapan Intelligent Tracking & Recording Exhibit System (ITRES)<br>*Workshop on Strengthening Intelligent Tracking & Recording Exhibit System (iTRES)* |
| Tarikh<br>*Date* | 12-13 Ogos 2025<br>*12-13 August 2025* |
| Tempat<br>*Venue* | Dewan Serai Wangi<br>*Serai Wangi Hall* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 3 peserta daripada BPF<br>36 peserta daripada CPF Negeri<br>*3 participants from PED*<br>*36 participants from State PEB* |
| Objektif<br>*Objectives* | Objektif utama bengkel ini adalah untuk memantapkan kemahiran pegawai stor ekshibit dalam penggunaan iTRES dan mengubah iTRES berdasarkan pindaan proses pelupusan terkini.<br>*The primary objective of this workshop is to strengthen the skills of exhibit store officers in the use of iTRES and to modify the system based on the latest amendments to the disposal process.* |

| | |
|---|---|
| *Hasil<br>**Outcome* | Bengkel ini berjaya meningkatkan kemahiran dan kecekapan pegawai menggunakan iTRES dalam tugasan harian.<br>*This workshop has successfully enhanced the skills and efficiency of officers in utilizing the iTRES for their daily tasks.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Mesyuarat Pasukan Petugas Prekursor, Narkotik Dan Psikotropik Bil.1/2025<br>*Precursor, Narcotics, And Psychotropic Task Force Meeting No. 1/2025* |
| Tarikh<br>*Date* | 20 Ogos 2025<br>*20 August 2025* |
| Tempat<br>*Venue* | Bilik Mesyuarat Delima, Program Perkhidmatan Farmasi<br>*Delima Meeting Room, Pharmaceutical Services Programme* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 26 peserta daripada BPF, Kementerian Dalam Negeri, Agensi Antidadah Kebangsaan, Jabatan Siasatan Jenayah Narkotik, Polis Diraja Malaysia, Bahagian Penguatkuasaan, Kastam Diraja Malaysia, Bahagian Siasatan Jenayah Maritim, Agensi Penguatkuasaan Maritim Malaysia dan Jabatan Kimia, Malaysia<br>*26 participants from PED, Ministry of Home Affairs, National Anti-Drugs Agency, Royal Malaysia Police, Royal Malaysian Customs Department, Malaysian Maritime Enforcement Agency and Department of Chemistry, Malaysia.* |
| Objektif<br>*Objectives* | Memperkukuh kerjasama antara pelbagai agensi penguatkuasaan dalam kawalan prekursor, psikotropik dan narkotik dan berfungsi sebagai platform untuk berkongsi maklumat, membincangkan isu dan cabaran semasa, merangka pelan tindakan, serta menetapkan hala tuju bagi memperkukuh mekanisme kawalan ketiga-tiga kategori bahan tersebut.<br>*To strengthen cooperation among various enforcement agencies in the control of precursors, psychotropics, and narcotics, and to serve as a platform for information sharing, discussing current issues and challenges, formulating action plans, and setting the direction to enhance the control mechanisms for these three categories of substances.* |

| | |
|---|---|
| Tajuk<br>*Title* | Kursus Pemakaian Akta Kawalan Harga dan Antipencatutan 2011 [*Akta 723*] Dalam Penguatkuasaan Penandaan Harga Bagi Ubat di Kemudahan Jagaan Kesihatan Swasta dan Farmasi Komuniti<br>*Course on the Application of the Price Control and Anti-Profiteering Act 2011 [Act 723] in the Enforcement of Price Marking for Drug at Private Healthcare Facilities and Community Pharmacies* |
| Tarikh<br>*Date* | 3 September 2025<br>*3 September 2025* |
| Tempat<br>*Venue* | Pusat Konvensyen Antarabangsa Putrajaya dan dalam talian<br>*Putrajaya International Convention Centre (PICC) and online* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 50 peserta daripada BPF (20 secara bersemuka dan 30 secara dalam talian)<br>276 peserta daripada CPF Negeri (6 secara bersemuka dan 270 secara dalam talian)<br>2 peserta daripada BAPF (secara bersemuka)<br>*50 participants from PED (20 physical and 30 online)*<br>*276 participants from State PEB (6 physical and 270 online)*<br>*2 participants from BAPF (physical)* |

| | |
|---|---|
| Objektif<br>*Objectives* | Objektif utama kursus ini adalah untuk meningkatkan pemahaman Pegawai Penguat Kuasa Farmasi dalam pemakaian peruntukan Akta 723 untuk menguatkuasakan Perintah Kawalan Harga dan Antipencatutan (Penandaan Harga bagi Ubat) 2025.<br>*The primary objective of this course is to enhance the understanding of Pharmacy Enforcement Officers in applying the provisions of Act 723 to enforce the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025.* |
| *Hasil<br>**Outcome* | Pencerahan dan penerangan yang jelas daripada penceramah meningkatkan pemahaman dan keyakinan pegawai penguat kuasa farmasi dalam melaksanakan tugas penguatkuasaan di bawah Perintah Kawalan Harga dan Antipencatutan (Penandaan Harga bagi Ubat) 2025.<br>*The clear insights and explanations provided by the speakers have enhanced the understanding and confidence of pharmacy enforcement officers in executing enforcement duties under the Price Control and Anti-Profiteering (Price Marking for Drug) Order 2025.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Bengkel Memperkasakan Farmakovigilans Veterinar Dan Keupayaan Mengesan Produk Veterinar Substandard Dan Palsu Anjuran World Organisation for Animal Health<br>*Workshop for Strengthening Veterinary Pharmacovigilance and Detection Capabilities for Substandard and Falsified Veterinary Products Organized by The World Organisation for Animal Health* |
| Tarikh<br>*Date* | 1–3 Oktober 2025<br>*1–3 October 2025* |
| Tempat<br>*Venue* | Wyndham Ion Majestic Hotel, Genting Highlands<br>*Wyndham Ion Majestic Hotel, Genting Highlands* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 30 peserta daripada World Organisation for Animal Health (WOAH), Jabatan Perkhidmatan Veterinar (DVS), Bahagian Regulatori Farmasi Negara (NPRA), BPF, Jabatan Perikanan Malaysia (DOF), Lembaga Kemajuan Ikan Malaysia (LKIM), Kementerian Pertanian dan Keterjaminan Makanan (KPKM), Jabatan Perlindungan Hidupan Liar Dan Taman Negara (PERHILITAN) dan agensi mewakili Sabah dan Sarawak.<br>*30 participants from Department of Veterinary Services (DVS), National Pharmaceutical Regulatory Agency (NPRA), PED, Department of Fisheries Malaysia (DOF), Fisheries Development Authority of Malaysia (LKIM), Ministry of Agriculture and Food Security (KPKM), representatives from Sabah and Sarawak, Department of Wildlife and National Parks (PERHILITAN) and the agency from Sabah and Sarawak.* |
| Objektif<br>*Objectives* | WOAH menganjurkan bengkel ini bagi membincangkan lanjut pemilihan Malaysia sebagai salah satu negara di ASEAN untuk menerima khidmat sokongan dan penambahbaikan dalam aspek pelaksanaan farmakovigilans serta keupayaan untuk mengesan produk veterinar substandard dan palsu di lapangan.<br>*WOAH organizes this workshop to further discuss the selection of Malaysia as one of the ASEAN countries to receive support and enhancement services regarding the implementation of pharmacovigilance and the capability to detect substandard and falsified veterinary products in the field.* |
| *Hasil<br>**Outcome* | Cadangan kawalan dan sistem yang bersesuaian untuk dibangunkan<br>*Proposed control measures and appropriate systems to be developed* |

| | |
|---|---|
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Bengkel Pemurnian Panduan Pembuktian dan Pertuduhan Kesalahan di Bawah Akta-Akta yang Dikuatkuasakan<br>*Workshop for the Refinement of Guidelines on Establishing Proof and Formulating Charges for Offences Under Enforced Acts* |
| Tarikh<br>*Date* | 14-16 Oktober 2025<br>*14-16 October 2025* |
| Tempat<br>*Venue* | Hotel Crystal Crown, Pelabuhan Klang<br>*Crystal Crown Hotel, Port Klang* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 11 peserta daripada BPF<br>28 peserta daripada CPF Negeri<br>*11 participants from PED*<br>*28 participants from State PEB* |
| Objektif<br>*Objectives* | Objektif utama bengkel ini adalah untuk menyeragamkan panduan pertuduhan di bawah perundangan farmasi dan memperkasakan kompetensi pegawai dalam aspek pemakaian undang-undang, elemen pembuktian serta pengendalian kes yang melibatkan teknologi baharu.<br>*The primary objective of this workshop is to harmonize guidelines pertaining to charges under pharmacy legislation and to enhance officer competency in legal application, evidentiary elements, and the management of cases involving emerging technologies.* |
| *Hasil<br>**Outcome* | Bengkel ini berjaya menghasilkan Panduan Pembuktian dan Pertuduhan Kesalahan yang komprehensif. Dokumen ini akan menjadi rujukan piawai bagi menyeragamkan tatacara pertuduhan dan meningkatkan kecekapan pegawai dalam mengendalikan pembuktian kes terutamanya bagi kesalahan yang melibatkan modus operandi teknologi baharu.<br>*This workshop successfully produced a comprehensive set of Guidelines for Establishing Proof and Formulating Charges. This document will serve as a standard reference to unify charging procedures and enhance officer efficiency in managing case evidence, particularly for offences involving new technological modus operandi.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Sesi Kunjungan Hormat Pejabat Ketua Pendaftar Mahkamah Persekutuan Malaysia (PKPMP)<br>*Courtesy Call on The Office of The Chief Registrar of The Federal Court of Malaysia* |
| Tarikh<br>*Date* | 17 Oktober 2025<br>*17 October 2025* |
| Tempat<br>*Venue* | Istana Kehakiman, Putrajaya<br>*Palace of Justice, Putrajaya* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 8 pegawai daripada BPF<br>8 pegawai daripada PKPMP<br>*8 officers from PED*<br>*8 officers from PKPMP* |
| Objektif<br>*Objectives* | Objektif utama sesi kunjungan ini adalah untuk memperkukuh kerjasama strategik dan memantapkan jalinan profesional antara BPF dan institusi kehakiman. Selain itu, sesi ini turut bertujuan untuk bertukar pandangan dan maklumat berhubung peranan, fungsi dan isu-isu semasa berkaitan pentadbiran kehakiman.<br>*The primary objective of this courtesy call is to strengthen strategic cooperation and solidify professional ties between the PED and the judiciary. Additionally, this session aims to exchange views and information regarding roles, functions, and current issues related to judicial administration.* |
| *Hasil<br>**Outcome* | Sesi kunjungan hormat ini telah berjaya memantapkan jalinan antara kedua-dua pihak. Hasil perbincangan dua hala telah mewujudkan kesefahaman yang lebih jitu berhubung peranan masing-masing, sekaligus membuka ruang kepada penyelesaian isu-isu pentadbiran kehakiman secara kolaboratif demi kelancaran kes pendakwaan farmasi pada masa hadapan.<br>*This courtesy call has successfully strengthened the relationship between both parties. The bilateral discussions established a clearer mutual understanding of respective roles, while creating opportunities for the collaborative resolution of judicial administration issues to ensure the smooth conduct of future pharmacy prosecution cases.* |
| *Gambar<br>**Photo* |  |

| | |
|---|---|
| Tajuk<br>*Title* | Sesi Libat Urus Bersama Perbadanan Produktiviti Malaysia (MPC)<br>*Engagement Session with the Malaysia Productivity Corporation (MPC)* |
| Tarikh<br>*Date* | 5 November 2025<br>*5 November 2025* |
| Tempat<br>*Venue* | Bilik Perdana 3, Menara MATRADE, MPC Kuala Lumpur<br>*Perdana 3 Room, MATRADE Tower, MPC Kuala Lumpur* |
| Bil. Peserta & Organisasi<br>*No. of Participant & Their Organization* | 6 pegawai dari Cawangan Perundangan, BPF dan 2 pegawai dari Bahagian Regulatori Farmasi Negara<br>*6 officers from Legislation Branch of the PED and 2 officers from National Pharmaceutical Regulatory Agency* |
| Objektif<br>*Objectives* | Sesi libat urus dijalankan bagi membincangkan serta memperoleh pengesahan terhadap keputusan Digital Regulatory Notification (DRN). Inisiatif proaktif ini bertujuan memastikan proses gubalan dan pindaan perundangan dilaksanakan secara sistematik, telus dan selaras dengan Dasar Negara bagi Amalan Baik Peraturan (NPGRP).<br>*This session is conducted to discuss and obtain validation on the Digital Regulatory Notification (DRN) decisions. This proactive initiative aims to ensure that the drafting and amendment of legislation are implemented systematically, transparently, and in alignment with the National Policy on Good Regulatory Practice (NPGRP).* |

| | |
|---|---|
| *Hasil<br>**Outcome* | Hasil daripada sesi libat urus inklusif ini, pihak MPC telah mengesahkan keputusan DRN berhubung pindaan Akta Jualan Dadah 1952 dan Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984.<br>*As a result of this inclusive engagement session, MPC has validated the DRN decisions regarding the amendments to the Sale of Drugs Act 1952 and the Control of Drugs and Cosmetics Regulations 1984.* |
| *Gambar<br>**Photo* |  |

## 3.0 PENCAPAIAN DAN PENGIKTIRAFAN | *ACHIEVEMENT AND RECOGNITION*

### RANG UNDANG-UNDANG RACUN (PINDAAN) 2025

Rang Undang-undang Racun (Pindaan) 2025 telah dibentangkan dan berjaya diluluskan di Parlimen, setelah dibahaskan dan diluluskan di Dewan Rakyat pada 28 Julai 2025 dan seterusnya di Dewan Negara pada 10 September 2025. Rang undang-undang ini telah dibahaskan oleh 12 Ahli Dewan Rakyat dan 4 Ahli Dewan Negara semasa sesi perbahasan masing-masing.

RUU ini digubal untuk meminda Akta Racun 1952 [*Akta 366*] yang bertujuan untuk memperkukuh keberkesanan tindakan penguatkuasaan dalam mengekang penyalahgunaan racun dan bahan psikotropik. RUU ini juga memberikan kuasa penguatkuasaan kepada agensi kerajaan yang berkaitan agar sebarang pelanggaran undang-undang dapat ditangani sebaiknya, sekaligus menjamin keselamatan dan kesihatan rakyat dari risiko penyalahgunaan bahan yang boleh menggugat kestabilan sistem kesihatan awam.

Antara pindaan utama dalam RUU ini adalah meminda pangkat pegawai polis yang diberikan kuasa di bawah Akta 366 dan memperuntukkan kuasa kepada Menteri Kesihatan untuk melantik mana-mana orang sebagai "pegawai diberi kuasa" selain daripada pegawai sedia ada yang diberi kuasa di bawah Akta ini.

RUU ini telah mendapat perkenan Diraja pada 28 Oktober 2025 dan seterusnya telah diwartakan sebagai Akta Racun (Pindaan) 2025 [*Akta A1774*] pada 12 November 2025. Akta A1774 mula berkuat kuasa pada 1 Januari 2026.

### *POISONS (AMENDMENT) BILL 2025*

*The Poisons (Amendment) Bill 2025 was tabled and successfully passed by Parliament, having been debated and approved in the Dewan Rakyat on 28 July 2025 and subsequently in the Dewan Negara on 10 September 2025. This bill was debated by 12 members of theDewan Rakyat and 4 members of the Dewan Negara during their respective debate sessions.*

*This Bill was drafted to amend the Poisons Act 1952 [Act 366] with the objective to strengthen the enforcement effectiveness in curbing the misuse of poisons and psychotropic substances. This Bill also confers enforcement powers on the relevant government agencies to enable effective and swift action against any violations of the law, thereby ensuring the protection of public health and safety from the risks of substance abuse that may compromise the stability of the public healthcare system.*

*Key amendments to the Act include revising the ranks of police officers as the authorized officer under Act 366 and empowering the Minister of Health to appoint any person as an "authorized officer," in addition to the existing officers currently authorized under the Act.*

*The Bill received Royal Assent on 28 October 2025 and was subsequently gazetted as the Poisons (Amendment) Act 2025 [Act A1774] on 12 November 2025. Act A1774 came into force on 1 January 2026.*





Pembentangan Rang Undang-Undang Racun (Pindaan) 2025 di Dewan Rakyat
*Tabling of the Poisons (Amendment) Bill 2025 in the Dewan Rakyat*

## 4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*

### ANGGARAN PREVALENS PRODUK UBAT-UBATAN TIDAK BERDAFTAR DAN TIRUAN DI MALAYSIA: SATU KAJIAN KERATAN RENTAS KEBANGSAAN DARI MAC HINGGA NOVEMBER 2023

Kajian ini telah diterbitkan dalam Journal of Pharmaceutical Policy and Practice pada 24 September 2025. Artikel tersebut boleh diakses melalui pautan berikut: https://www.tandfonline.com/doi/full/10.1080/20523211.2025.2557879?scroll=top&needAccess=true#abstract

Kajian ini telah dijalankan dari Mac hingga November 2023 bertujuan untuk menentukan kadar prevalens produk ubat tidak berdaftar dan tiruan di premis farmasi komuniti, klinik perubatan (GP), dan premis komersial di Malaysia, di samping mengenal pasti faktor-faktor berkaitan yang menyumbang kepada isu tersebut


Sebanyak 27,137 sampel produk ubat daripada 1,688 premis di seluruh Malaysia telah diperiksa, di mana 270 produk tidak berdaftar dan 30 produk tiruan telah dikenal pasti. Kadar prevalens bagi produk tidak berdaftar adalah sebanyak 0.11% di farmasi komuniti, 0.18% di klinik perubatan (GP), dan 2.95% di premis komersial. Produk tiruan pula tidak ditemukan di farmasi komuniti mahupun klinik GP, namun mencatatkan kadar sebanyak 0.36% di premis komersial.

### *ESTIMATED PREVALENCE OF UNREGISTERED AND FALSIFIED MEDICINAL PRODUCTS IN MALAYSIA: A NATIONWIDE CROSS-SECTIONAL STUDY CONDUCTED FROM MARCH TO NOVEMBER 2023*

*This paper was published in the Journal of Pharmaceutical Policy and Practice on: 24 Sep 2025. It can be viewed at: https://www.tandfonline.com/doi/full/10.1080/20523211.2025.2557879?scroll=top&needAccess=true#abstract.*

*This study was conducted from March to November 2023 aimed to determine the prevalence of unregistered and falsified medicinal products in Malaysian community pharmacies, General Practitioner (GP) clinics, and commercial premises, and to identify associated factors.*

*27,137 medicinal products from 1,688 premises across Malaysia were examined whereas 270 unregistered and 30 falsified products were identified. The prevalence of unregistered products was 0.11% in community pharmacies, 0.18% in GP clinics, and 2.95% in commercial premises. Falsified products were absent in community pharmacies and GP clinics but constituted 0.36% in commercial premises.*



JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE
2025, VOL. 18, NO. 1
https://doi.org/10.1080/20523211.2025.2557879

Taylor & Francis
Taylor & Francis Group

Open access

**Estimated prevalence of unregistered and falsified medicinal products in Malaysia: a nationwide cross-sectional study conducted from March to November 2023**

Khairul Anuar Abdul Karim[a], Asyraf Elmiza Ahmad[a], Mohd Zawawi Abdullah[a], Asniza Alias[a], Salina Setan[b], Manzatul Azrul Azrie Sulaiman[a], and Nor Ilham 'Ainaa Muhsin[c]

[a] Pharmacy Enforcement Division, Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia [b] Pahang Pharmaceutical Services Division, State Health Department of Pahang, Ministry of Health Malaysia, Kuantan, Malaysia [c] Pharmacy Policy and Strategic Planning Division, Pharmaceutical Services Programme, Ministry of Health Malaysia, Petaling Jaya, Malaysia

**BACKGROUND** The global proliferation of unregistered and falsified medicinal products poses significant public health risks. In Malaysia, previous studies have shown concerning prevalence rates but are often limited to specific populations and targeted product brands, restricting the generalisability of the findings. This study aimed to determine the prevalence of unregistered and falsified medicinal products in Malaysian community pharmacies, General Practitioner (GP) clinics, and commercial premises, and to identify associated factors.

**METHODS** A cross-sectional study was conducted in Malaysia from March to November 2023. Medicinal products were sampled from community pharmacies, GP clinics, and commercial premises. Premises were selected using proportionate stratified random sampling and products within premises using convenience sampling. The MAL registration number and hologram on these products were analysed for registration status and authenticity. Data were analysed using descriptive and non-parametric tests (SPSS v.29), with $p < 0.05$ considered statistically significant.

**RESULTS** An examination of 27,137 samples from 1668 premises across Malaysia identified 270 unregistered and 30 falsified products. The prevalence of unregistered products was 0.11% in community pharmacies, 0.18% in GP clinics, and 2.95% in commercial premises. Falsified products were absent in community pharmacies and GP clinics but constituted 0.36% in commercial premises. Logistic regression revealed that region and premise category were significantly associated with the presence of unregistered and falsified products.

Penerbitan Kajian: *Estimated Prevalence of Unregistered and Falsified Medicinal Products in Malaysia: A Nationwide Cross-Sectional Study Conducted from March to November 2023*
*Publish of Paper: Estimated Prevalence of Unregistered and Falsified Medicinal Products in Malaysia: A Nationwide Cross-Sectional Study Conducted from March to November 2023*

## PENERBITAN E-BULETIN KKLIU EDISI 01/2025, 02/2025 DAN PANDUAN TUNTUTAN PENGIKLANAN YANG DIBENARKAN TANPA KELULUSAN LIU

Penerbitan E-Buletin KKLIU ini merupakan medium untuk Sekretariat Lembaga Iklan Ubat menyampaikan maklumat terkini dan juga berkongsi sebarang pindaan yang dibuat kepada polisi atau garis panduan sedia ada yang telah diputuskan dalam Mesyuarat Lembaga Iklan Ubat. Maklumat yang dikongsikan dalam E-Buletin ini adalah dalam bentuk penjelasan grafik dan ringkas untuk memudahkan rujukan dan pemahaman semua pihak yang berkepentingan.

Sekretariat Lembaga Iklan Ubat telah berjaya menerbitkan E-buletin KKLIU Edisi 01/2025 pada 30 Jun 2025 dan E-Buletin KKLIU Edisi 02/2025 pada awal tahun 2026.

Selain itu, LIU juga telah menerbitkan Panduan Tuntutan Pengiklanan yang Dibenarkan Tanpa Kelulusan LIU bertujuan untuk memaklumkan kriteria-kriteria yang perlu dipatuhi sekiranya syarikat ingin menyiarkan sesuatu iklan produk berdaftar atau perkhidmatan kesihatan tanpa mengemukakan permohonan kelulusan kepada LIU. Panduan tersebut telah diterbitkan pada 30 Oktober 2025.

Semua penerbitan ini boleh dimuat turun di Portal Program Perkhidmatan Farmasi www.pharmacy.moh.gov.my

## *PUBLICATION OF KKLIU E-BULLETIN EDITION 01/2025, EDITION 02/2025 AND GUIDELINES FOR PERMISSIBLE CLAIMS EXEMPTED FROM MAB APPROVAL*

*The KKLIU E-Bulletin is a platform used by the Secretariat of the Medicine Advertisements Board to disseminate the latest information and communicate amendments to policies or guidelines approved during the Medicine Advertisements Board Meetings. To ensure easy reference and understanding for all relevant stakeholders, the information in this E-Bulletin is presented in a concise and graphical format.*

*The Secretariat of the Medicine Advertisements Board successfully published two editions: KKLIU E-Bulletin Edition 01/2025 on 30 June 2025, and KKLIU E-Bulletin Edition 02/2025 in early 2026.*

*Apart from that, The Guidelines on Advertising Claims Permitted Without MAB Approval were published on 30 October 2025. The guidelines outlined the criteria that must be complied with should a company wish to publish an advertisement related to registered products or healthcare services without applying for approval to the MAB.*

*All those publications can be downloaded from the Pharmaceutical Services Programme Portal www.pharmacy.moh.gov.my.*







Penerbitan E-Buletin KKLIU Edisi 01/2025 dan Edisi 02/2025
*Publication of E-Bulletin KKLIU Edition 01/2025 and Edition 02/2025*







Garis Panduan Tuntutan Pengiklanan yang Dibenarkan Tanpa Kelulusan LIU (Produk Berdaftar dan Perkhidmatan Kesihatan)
*The Guidelines on Advertising Claims Permitted Without MAB Approval (Registered Products and Healthcare Services)*

## 5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA
## *INTERNATIONAL COLLABORATION AND PARTICIPATION*

### ASIAN FORENSIC SCIENCES NETWORK (AFSN) & ASIA PACIFIC MEDICO-LEGAL AGENCIES (APMLA) KOREA 2025

BPF telah secara rasmi diterima sebagai ahli Asian Forensic Science Network (AFSN) bagi disiplin forensik digital dan kimia semasa Mesyuarat Lembaga AFSN yang berlangsung pada 13 Februari 2025.

Keanggotaan ini disusuli dengan penyertaan dua wakil BPF ke persidangan AFSN & Asia Pacific Medico-Legal Agencies (APMLA) 2025 di Incheon, Korea Selatan pada 15 hingga 19 September 2025. Delegasi telah memanfaatkan platform ini untuk mendalami trend global dalam bidang forensik, termasuk aplikasi automasi, Kecerdasan Buatan (AI), serta pengurusan makmal berpusat. Program tersebut turut merangkumi lawatan teknikal ke Ibu Pejabat *National Forensic Service* (NFS) di Wonju, Korea Selatan, yang bertujuan memperkukuh kompetensi operasi dan teknikal jabatan setaraf piawaian antarabangsa.

### *ASIAN FORENSIC SCIENCES NETWORK (AFSN) & ASIA PACIFIC MEDICO-LEGAL AGENCIES (APMLA) KOREA 2025*

*The PED was officially inducted as a member of the Asian Forensic Science Network (AFSN) for the digital forensics and forensic chemistry disciplines during the AFSN Board Meeting on 13 February 2025.*

*Following this membership, two representatives from PED attended the AFSN & Asia Pacific Medico-Legal Agencies (APMLA) 2025 conference held from 15 to 19 September 2025 in Incheon, South Korea. This participation provided comprehensive exposure to global forensic advancements, specifically in digital forensics, automation, Artificial Intelligence (AI), and centralized laboratory management. The program also featured an exclusive technical visit to the National Forensic Service (NFS) Headquarters in Wonju, South Korea, further strengthening the Division's technical expertise and operational standards.*




Asian Forensic Sciences Network (AFSN) & Asia Pacific Medico-Legal Agencies (APMLA) Korea 2025
*Asian Forensic Sciences Network (AFSN) & Asia Pacific Medico-Legal Agencies (APMLA) Korea 2025*

### LATIHAN SANGKUTAN SINGKAT DI IBU PEJABAT PERTUBUHAN KESIHATAN SEDUNIA (WHO) DAN PERHIMPUNAN KESIHATAN SEDUNIA (WHA) KE-78

Wakil daripada BPF telah berpeluang menghadiri Latihan Sangkutan Singkat di Ibu Pejabat Pertubuhan Kesihatan Sedunia (WHO) dan Perhimpunan Kesihatan Sedunia (WHA) ke-78 yang diadakan di Geneva, Switzerland, dari 19 hingga 27 Mei 2025. Program latihan sangkutan tersebut telah dilaksanakan secara kolaboratif bersama pasukan *Incident and Substandard/Falsified (ISF)* daripada *WHO's Department of Regulation and Prequalification*.

### *SHORT STUDY ATTACHMENT TO WHO HEADQUARTERS AND 78TH WORLD HEALTH ASSEMBLY*

*Representatives from the PED undertook a Short Study Attachment at the World Health Organization (WHO) Headquarters and attended the 78th World Health Assembly (WHA78) in Geneva, Switzerland, from 19 to 27 May 2025. This program was conducted in strategic collaboration with the Incident and Substandard/Falsified (ISF) team under the WHO's Department of Regulation and Prequalification.*

Menerusi inisiatif ini, delegasi dapat mendalami pendekatan komprehensif WHO dalam mengawal selia produk ubat substandard dan palsu (*Substandard and Falsified* - SF), dengan tumpuan khusus terhadap pengurusan sistem pengawasan global serta mekanisme pelaporan kejadian yang berkesan. Selain itu, penglibatan ini turut memberikan pendedahan kritikal terhadap proses pembuatan keputusan kesihatan awam di peringkat antarabangsa melalui penyertaan dalam Perhimpunan Kesihatan Sedunia ke-78 (WHA78).

*Through this initiative, the delegation gained in-depth insights into the WHO's comprehensive approach to regulating Substandard and Falsified (SF) medical products, with a specific focus on global surveillance management systems and effective incident reporting mechanisms. Furthermore, participation in WHA78 provided critical exposure to the global public health policy-making and decision-making processes at the highest international level.*



Latihan Sangkutan Singkat di Ibu Pejabat Pertubuhan Kesihatan Sedunia (WHO)
dan Perhimpunan Kesihatan Sedunia (WHA) ke-78
*Short Study Attachment at the World Health Organization (WHO) Headquarters and the 78th World Health Assembly*

## 68TH COMMISSION ON NARCOTIC DRUGS

Mesyuarat telah diadakan pada 10 hingga 14 Mac 2025 di Vienna, Austria yang bertujuan untuk membincangkan hala tuju serta dasar-dasar berkaitan permasalahan dadah, mempertingkatkan peranan CND dan memperkasakan program-program antidadah di peringkat antarabangsa yang menumpukan kepada pengurangan bekalan dadah, pengurangan permintaan dadah dan kerjasama antarabangsa.

CND bertanggungjawab untuk mengawal selia pelaksanaan Konvensyen Dadah Antarabangsa iaitu:

i. Single Convention on Narcotic Drugs, 1961
ii. Convention on Psychotropic Substances, 1971
iii. Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988

Mesyuarat selama 5 hari ini tertumpu kepada sesi plenari yang terbahagi kepada *operational segment* yang membincangkan perkara-perkara mengenai pengurusan dan bajet manakala *normative segment* membincangkan mengenai pelaksanaan komitmen negara serta perbincangan resolusi. Di samping itu, terdapat juga acara sampingan yang diadakan sepanjang mesyuarat berlangsung.

## *68TH COMMISSION ON NARCOTIC DRUGS*

*The meeting was held from March 10 to 14 2025, in Vienna, Austria, with the aim of discussing the direction and policies related to drug issues, enhancing the role of the CND, and strengthening international anti-drug programs that focus on reducing the supply of drugs, reducing drug demand, and fostering international cooperation.*

*The CND is responsible for overseeing the implementation of the International Drug Conventions, namely:*

*i. Single Convention on Narcotic Drugs, 1961*
*ii. Convention on Psychotropic Substances, 1971*
*iii. Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, 1988*

*This 5-day meeting focuses on a plenary session divided into an operational segment, discussing matters related to management and budget, and a normative segment discussing the implementation of countries' commitments and resolution discussions. Additionally, there are side events held throughout the meeting.*





68th Commission on Narcotic Drugs
*68th Commission on Narcotic Drugs*

## MESYUARAT KE 14 MEKANISMA NEGARA ANGGOTA WORLD HEALTH ORGANIZATION (WHO) BAGI PRODUK PERUBATAN SUBSTANDARD DAN PALSU

Mesyuarat ke-14 Mekanisme Negara Anggota (MSM) yang berlangsung pada 12 hingga 14 November 2025 di Geneva, Switzerland, merupakan forum global utama bagi Negara-negara Anggota WHO untuk memperkukuh kerjasama strategik dalam aspek pencegahan, pengesanan, dan tindak balas terhadap produk perubatan substandard dan palsu. Matlamat utama mekanisme ini adalah untuk melindungi kesihatan awam sejagat melalui penyelarasan kawalan yang efektif serta pemantauan rantaian bekalan perubatan yang lebih utuh di peringkat antarabangsa.

## *14TH MEETING OF THE MEMBER STATE MECHANISM (MSM) ON SUBSTANDARD AND FALSIFIED MEDICAL PRODUCT*

*The 14th Meeting of the Member State Mechanism (MSM), held from 12 to 14 November 2025 in Geneva, Switzerland, serves as the premier global forum for WHO Member States to strengthen strategic collaboration in the prevention, detection, and response to substandard and falsified (SF) medical products. Its primary mission is to safeguard global public health by fostering effective cooperation to prevent and control the proliferation of SF medical products through robust regulatory oversight.*




Mesyuarat Ke 14 Mekanisma Negara Anggota World Health Organization (WHO) Bagi Produk Perubatan Substandard Dan Palsu
*14th Meeting of The Member State Mechanism (MSM) On Substandard and Falsified Medical Product*

# BAHAGIAN REGULATORI FARMASI NEGARA

## *NATIONAL PHARMACEUTICAL REGULATORY AGENCY*

## BILANGAN PERMOHONAN PENDAFTARAN PRODUK
*NUMBER OF PRODUCT REGISTRATION APPLICATION RECEIVED*

| 555 | 93 | 702 | 648 | 60 |
|---|---|---|---|---|
| **PRESKRIPSI** *PRESCRIPTION* | **BUKAN PRESKRIPSI** *NON-PRESCRIPTION* | **SEMULAJADI** *NATURAL* | **SUPPLEMEN KESIHATAN** *HEALTH SUPPLEMENT* | **VETERINAR** *VETERINARY* |

## BILANGAN PRODUK YANG DIDAFTARKAN
*NUMBER OF PRODUCT REGISTERED*

| 390 | 105 | 568 | 593 | 34 |
|---|---|---|---|---|
| **PRESKRIPSI** *PRESCRIPTION* | **BUKAN PRESKRIPSI** *NON-PRESCRIPTION* | **SEMULAJADI** *NATURAL* | **SUPPLEMEN KESIHATAN** *HEALTH SUPPLEMENT* | **VETERINAR** *VETERINARY* |

**132,105**

**BILANGAN PERMOHONAN NOTIFIKASI KOSMETIK**

*NUMBER OF NEW COSMETIC PRODUCT NOTIFICATION APPLICATION*



**35,708**

**BILANGAN LAPORAN ADR DAN AEFI YANG DITERIMA**

*NUMBER OF ADR AND AEFI REPORT RECEIVED*



## BILANGAN LESEN / SIJIL YANG DIKELUARKAN
*NUMBER OF LICENSE / CERTIFICATE ISSUED*

**300**
**LESEN PENGILANG**
*MANUFACTURER LICENSE*



**492**
**LESEN PENGIMPORT**
*IMPORTER LICENSE*



**1,203**
**LESEN PEMBORONG**
*WHOLESALER LICENSE*



**2,394**
**SIJIL PRODUK FARMASEUTIKAL**
*CERTIFICATE OF PHARMACEUTICAL PRODUCTS*

**47**
**SIJIL PENJUALAN BEBAS PRODUK VETERINAR**
*CFS Veterinary Products*

**2,226**
**SIJIL PENJUALAN BEBAS PRODUK KOSMETIK**
*CFS Cosmetic Products*

**236** **SIJIL LOT RELEASE VAKSIN**
*LOT RELEASE VACCINE CERTIFICATE*

**164** **SIJIL LOT RELEASE PRODUK PLASMA**
*PLASMA-DERIVED MEDICINAL PRODUCT (PDMP) LOT RELEASE CERTIFICATE*

**634** **SIJIL AMALAN PERKILANGAN BAIK**
*GOOD MANUFACTURING PRACTICE (GMP) CERTIFICATE*

**2,384**

**BILANGAN SAMPEL YANG DIAMBIL UNTUK AKTIVITI PEMANTAUAN KUALITI PRODUK BERDAFTAR DAN KOSMETIK BERNOTIFIKASI**
*NUMBER OF SAMPLES TAKEN FOR QUALITY MONITORING ACTIVITY FOR REGISTERED PRODUCTS AND NOTIFIED COSMETICS*

**534** **LESEN IMPORT PERCUBAAN KLINIKAL**
*CLINICAL TRIAL IMPORT LICENSE (CTIL)*

**38** **KEBENARAN MENGILANG UNTUK PERCUBAAN KLINIKAL**
*CLINICAL TRIAL EXEMPTION (CTX)*

**42,791** | **PENGUJIAN MAKMAL YANG DIJALANKAN**
*LABORATORY TESTS PERFORMED*

**7** | **PEMERIKSAAN AMALAN KLINIKAL BAIK (GCP)**
*GOOD CLINICAL PRACTICE (GCP) INSPECTIONS*

**382**
**BILANGAN PEMERIKSAAN AMALAN PERKILANGAN BAIK (APB)**
*NUMBER OF GOOD MANUFACTURING PRACTICE (GMP) INSPECTIONS*

**365** | **BILANGAN PEMERIKSAAN AMALAN EDARAN BAIK (AEB) YANG DIJALANKAN**
*NUMBER OF GOOD DISTRIBUTION PRACTICE (GDP) INSPECTIONS CONDUCTED*

**3** | **BILANGAN PEMERIKSAAN AMALAN MAKMAL BAIK YANG DIJALANKAN**
*NUMBER OF GOOD LABORATORY PRACTICE (GLP) INSPECTIONS CONDUCTED*

**3** | **BILANGAN PEMERIKSAAN JAWATANKUASA ETIKA YANG DIJALANKAN**
*NUMBER OF ETHIC COMMITTEE (EC) INSPECTIONS CONDUCTED*

**24** | **BILANGAN PEMERIKSAAN PUSAT KAJIAN BIOEKUIVALENS (BE)**
*NUMBER OF INSPECTIONS ON BIOEQUIVALENCE CENTRES (BE)*






# BAHAGIAN REGULATORI FARMASI NEGARA
# *NATIONAL PHARMACEUTICAL REGULATORY AGENCY*

## 1.0 PENGENALAN | *INTRODUCTION*

Bahagian Regulatori Farmasi Negara (NPRA) merupakan sebuah agensi kerajaan di bawah Program Perkhidmatan Farmasi, Kementerian Kesihatan Malaysia yang bertanggungjawab memastikan kualiti, keselamatan dan keberkesanan produk farmaseutikal, serta kualiti dan keselamatan produk semula jadi dan kosmetik yang dipasarkan di Malaysia.

NPRA bermula pada Oktober 1978 sebagai Makmal Kawalan Kimia Ubat Kebangsaan (MKKUK) dengan fungsi utama menjalankan kawalan kualiti produk farmaseutikal. Selaras dengan perluasan skop kawal selia, MKKUK telah dinamakan semula sebagai Biro Pengawalan Farmaseutikal Kebangsaan (BPFK) pada tahun 1993 dan berperanan sebagai pihak berkuasa regulatori farmaseutikal negara serta sekretariat kepada Pihak Berkuasa Kawalan Dadah (PBKD). Dalam tempoh ini, BPFK melaksanakan fungsi regulatori teras termasuk pendaftaran produk, analisis sampel, pemeriksaan dan pelesenan, aktiviti pasca pendaftaran serta pemantauan kesan advers ubat.

Pada 18 Julai 2016, BPFK secara rasminya telah dinamakan semula kepada Bahagian Regulatori Farmasi Negara (NPRA), mencerminkan pengukuhan peranannya sebagai sebuah badan regulatori yang komprehensif. NPRA kini mengawal selia pelbagai kategori produk termasuk produk generik, produk semula jadi, kosmetik, produk veterinar, Bahan Aktif Farmaseutikal (API), serta pelaksanaan aktiviti *Lot Release* bagi produk vaksin dan plasma.

Bagi menyokong keperluan regulatori yang semakin kompleks dan dinamik, NPRA telah melaksanakan penstrukturan semula organisasi berkuat kuasa pada 2 Disember 2019 bagi meningkatkan kecekapan kawal selia, tadbir urus dan penentuan keputusan berasaskan risiko. Melangkah ke hadapan, NPRA terus memperkukuh sistem regulatori selaras dengan amalan terbaik antarabangsa dan penanda aras global demi melindungi kesihatan awam serta memastikan akses tepat pada masanya kepada produk perubatan dan kosmetik yang selamat, berkesan dan berkualiti di Malaysia.

*The National Pharmaceutical Regulatory Agency (NPRA) is a government agency under the Pharmaceutical Services Programme, Ministry of Health Malaysia, mandated to ensure the quality, safety and efficacy of pharmaceutical products, as well as the quality and safety of natural products and cosmetics marketed in Malaysia.*

*NPRA traces its origins to October 1978 with the establishment of the National Drug Control Laboratory (NDCL), which was tasked with conducting quality control of pharmaceutical products. In line with the expansion of its regulatory scope, the NDCL was renamed the National Pharmaceutical Control Bureau (NPCB) in 1993 and assumed the role of Malaysia's national pharmaceutical regulatory authority, as well as the secretariat to the Drug Control Authority (DCA). During this period, the NPCB carried out core regulatory functions including product registration, sample analysis, inspection and licensing, post-registration activities and adverse drug reaction monitoring.*

*On 18 July 2016, the NPCB was officially renamed the National Pharmaceutical Regulatory Agency (NPRA), reflecting the strengthening of its role as a comprehensive regulatory authority. In response to evolving regulatory needs, NPRA expanded its oversight to include generic products (scheduled and non-scheduled poisons), natural products, cosmetics, veterinary products, Active Pharmaceutical Ingredients (APIs), as well as vaccine and plasma quality control through the implementation of Lot Release activities.*

*To further enhance regulatory effectiveness and governance, NPRA implemented an organisational restructuring effective 2 December 2019. This restructuring streamlined core functions, strengthened scientific assessment and risk-based decision-making, and improved overall regulatory efficiency. Moving forward, NPRA remains committed to strengthening its regulatory systems in alignment with international best practices and global benchmarks, with the aim of protecting public health and ensuring timely access to safe, effective and quality medical and cosmetic products in Malaysia.*

## PUSAT UTAMA NPRA & FUNGSI
## *NPRA MAIN CENTRES & FUNCTIONS*

**PENGARAH**
***DIRECTOR***

### Pusat Komplians dan Kawalan Kualiti
***Centre of Compliance and Quality Control***

- Pengujian makmal bagi semua kategori produk
  *Laboratory testing for all product categories*
- Pemantauan vaksin dan produk plasma melalui Lot Release
  *Monitoring of vaccines and plasma products via Lot Release activities*
- Membangunkan metodologi dan validasi tatacara pengujian
  *Development and validation of testing methodologies*
- Pengurusan perolehan bahan keperluan makmal
  *Procurement management of laboratory supplies*
- Pemantauan kualiti dan aduan produk berdaftar
  *Quality monitoring and handling of registered product complaints*
- Farmakovigilans / Pemantauan ADR dan AEFI
  *Pharmacovigilance / Monitoring of ADR and AEFI*
- Pemantauan iklan produk kosmetik
  *Monitoring of cosmetic advertisements*
- Pemeriksaan GMP, GDP, GPP, GCP, GLP, GVP
  *Inspection of GMP, GDP, GPP, GCP, GLP, GVP*
- Pengurusan mesyuarat JKPPPK
  *Management of JKPPPK meetings*
- Program Komplians NPRA
  *NPRA Compliance Programmes*
- Penilaian pelan aliran kerja & Distant Assessment (DiA)
  *Assessment of manufacturing workflow plans and Distant Assessment (DiA)*
- Penjanaan Sijil Amalan Perkilangan Baik (APB)
  *Issuance of Good Manufacturing Practice (GMP) Certificates*

### Pusat Penilaian Produk dan Kosmetik
***Centre of Product and Cosmetic Evaluation***

- Penilaian pendaftaran produk (farmaseutikal, biologik, semulajadi, suplemen kesihatan, veterinar)
  *Evaluation of product registration (pharmaceutical, biologic, natural products, health supplements, veterinary products)*
- Penilaian kualiti produk melibatkan kaedah & validasi pengujian
  *Evaluation of product quality including test methods and validation*
- Penilaian permohonan variasi dan pendaftaran semula
  *Evaluation of variation applications and re-registration*
- Pengurusan mesyuarat JKP Produk bersama PKPSR
  *Management of Product Evaluation Committee meetings with PKPSR*
- Penilaian permohonan CTIL dan CTX
  *Evaluation of CTIL and CTX applications*
- Penerimaan laporan keselamatan termasuk SUSAR
  *Receipt of safety reports including SUSAR*
- Notifikasi kosmetik dan penilaian keselamatan serta tuntutan
  *Cosmetic notification, safety evaluation and claims assessment*

### Pusat Koordinasi dan Perancangan Strategik Regulatori
***Centre of Regulatory Coordination and Strategic Planning***

- Perancangan pelan strategik dan penambahbaikan aktiviti serta prosedur kerja regulatori
  *Strategic planning and improvement of regulatory activities and work procedures*
- Pengendalian hubungan kolaborasi regulatori dalam & luar negara dan lawatan daripada pelawat tempatan dan delegasi luar negara
  *Management of domestic and international regulatory collaborations and visits from local and foreign delegations*
- Pengendalian isu perdagangan antarabangsa dan harta intelek
  *Management of international trade and intellectual property matters*
- Perancangan dan Pembangunan Infrastruktur, Aset dan Sistem ICT di NPRA
  *Planning and development of infrastructure, assets and ICT systems at NPRA*
- Pengendalian Sistem QUEST dan Laman sesawang NPRA
  *Management of QUEST System and NPRA Website*
- Pengurusan keselamatan siber dan rangkaian di NPRA
  *Management of cybersecurity and network systems at NPRA*
- Pengendalian latihan dalam dan luar negara, pengurusan sumber manusia (Pegawai Farmasi), kompetensi serta perkembangan kerjaya
  *Management of local and international training, human resource management (Pharmacists), competency and career development*
- Menyelaraskan Sistem Pengurusan Kualiti jabatan termasuk bagi pensijilan MS ISO 9001
  *Coordination of departmental Quality Management System including MS ISO 9001 certification*
- Pengurusan aduan berkaitan perkhidmatan yang diberikan oleh NPRA
  *Management of complaints related to services provided by NPRA*
- Pemantauan dan penyeliaan perlaksanaan kontrak Perkhidmatan Sokongan Hospital (PSH)
  *Monitoring and supervision of Hospital Support Services (PSH) contract implementation*
- Penjanaan lesen dan sijil termasuk Lesen Pengilang, Lesen Pemborong, Lesen Mengimport, CTIL, CTX, Sijil Penjualan Bebas dan Sijil Produk Farmaseutikal
  *Issuance of licences and certificates including Manufacturer's Licence, Wholesaler's Licence, Import Licence, CTIL, CTX, Free Sale Certificate and Certificate of Pharmaceutical Product*
- Pengendalian koordinasi regulatori produk dan kosmetik
  *Coordination of regulatory matters for products and cosmetics*
- Urusetia Mesyuarat Pihak Berkuasa Kawalan Dadah (PBKD)
  *Secretariat for Drug Control Authority (DCA) meetings*
- Pengemaskinian Drug Registration Guidance Document (DRGD)
  *Updating the Drug Registration Guidance Document (DRGD)*
- Penyediaan dan penyebaran maklumat serta perkhidmatan Helpdesk
  *Preparation and dissemination of information and Helpdesk services*
- Menyediakan perkhidmatan One Stop Centre untuk pembangunan dan komunikasi industri
  *Provision of One Stop Centre services for industry development and communication*

### Pusat Pentadbiran
***Centre of Administration***

- Mengurus urusan pentadbiran am jabatan
  *Management of general departmental administration*
- Mengurus perjawatan dan pelantikan
  *Management of establishment and appointments*
- Menyelaras keselamatan harian jabatan
  *Coordination of daily departmental security*
- Mengurus pemangkuan dan kenaikan pangkat
  *Management of acting appointments and promotions*
- Mengendalikan kutipan hasil kerajaan
  *Management of government revenue collection*
- Mengurus dan mengawal bajet NPRA
  *Management and control of NPRA budget*
- Melaksanakan perolehan jabatan
  *Implementation of departmental procurement*
- Mengurus kontrak jabatan
  *Management of departmental contracts*

## 2.0 AKTIVITI DAN SOROTAN | *ACTIVITIES AND HIGHLIGHTS*

### MEMORANDUM PERSEFAHAMAN (MOU) ANTARA NPRA DAN *NATIONAL INSTITUTES OF BIOTECHNOLOGY MALAYSIA* (NIBM)

NPRA telah memeterai Memorandum Persefahaman (MoU) bersama *National Institutes of Biotechnology Malaysia* (NIBM) pada 15 Oktober 2025 di Institut Farmaseutikal dan Nutraseutikal Malaysia (iPHARM), Pulau Pinang. Kerjasama ini adalah kesinambungan kepada siri perbincangan teknikal dan dasar antara NPRA dan NIBM sejak April 2024 yang memfokuskan kepada pelaksanaan pengujian *Lot Release* vaksin. Pelaksanaan *Lot Release* merupakan fungsi kritikal Pihak Berkuasa Regulatori Kebangsaan *(National Regulatory Authority)* dan juga antara keperluan utama di bawah penilaian *WHO Global Benchmarking Tool* (GBT) bagi menyokong pencapaian kematangan sistem kawal selia pada tahap 3 [*Maturity Level 3* (ML3)]. Sejajar dengan peranan tersebut, NPRA mengekalkan tanggungjawab sepenuhnya terhadap penilaian keputusan ujian, penentu keputusan regulatori serta pengeluaran sijil *Lot Release*. Secara keseluruhan, MoU ini menyokong pengukuhan fungsi teras Pihak Berkuasa Regulatori Kebangsaan serta peningkatan kematangan sistem regulatori vaksin selaras dengan penanda aras *(benchmarking)* WHO.

### *MEMORANDUM OF UNDERSTANDING BETWEEN NPRA AND NATIONAL INSTITUTES OF BIOTECHNOLOGY MALAYSIA (NIBM)*

*NPRA signed a Memorandum of Understanding (MoU) with the National Institutes of Biotechnology Malaysia (NIBM) on 15 October 2025 at the Institute of Pharmaceutical and Nutraceutical Malaysia (iPHARM), Penang. This collaboration is a continuation of a series of technical and policy discussions between NPRA and NIBM since April 2024, focusing on the implementation of vaccine Lot Release testing. The Lot Release function is a critical responsibility of the National Regulatory Authority and one of the key requirements under the World Health Organization (WHO) Global Benchmarking Tool (GBT) assessment to support the achievement of regulatory system maturity at Maturity Level 3 (ML3). In line with this role, NPRA retains full responsibility for the evaluation of test results, regulatory decision-making, and the issuance of Lot Release certificates. Overall, the MoU contributes to strengthening the core functions of the National Regulatory Authority and advancing the maturity of the vaccine regulatory system in line with WHO benchmarking standards.*



Pemeteraian MoU
*Signing Ceremony of the MoU*

### #MEDSAFETYWEEK 2025

Minggu Keselamatan Ubat (*#MedSafetyWeek*, #MSW) merupakan kempen global yang diterajui oleh *Uppsala Monitoring Centre*, Sweden bagi meningkatkan kesedaran mengenai penggunaan ubat secara selamat serta kepentingan pelaporan kesan sampingan ubat. Pada tahun 2025, kempen ini telah berlangsung dari 3-9 November 2025, bersempena ulang tahun ke-10 inisiatif antarabangsa ini dengan penyertaan hampir 120 buah negara di seluruh dunia.

Tahun 2025 menandakan penyertaan Malaysia bagi tahun kelima berturut-turut dalam kempen #MSW. Susulan kejayaan penganjuran terdahulu, pasukan petugas kebangsaan telah diperkukuh dengan penglibatan ahli farmasi dari setiap negeri di Malaysia. Kerjasama dengan sektor kesihatan swasta turut dipertingkatkan melalui penglibatan aktif *Pharmaceutical Association of Malaysia* (PhAMA) dan *Malaysian Pharmacists Society* (MPS). Hasil kerjasama yang diperluas ini jelas melalui pelaksanaan aktiviti #MSW2025 yang berjaya mencapai komuniti di seluruh negara. Pelbagai fasiliti kesihatan dan individu turut menyebarkan kandungan kempen melalui media sosial. Aktiviti advokasi seperti kempen kesedaran kesihatan, program bual bicara, temu bual radio, webinar dan kuiz secara langsung telah meningkatkan lagi capaian kempen.

Kemuncak utama tahun 2025 ialah pelancaran rasmi *#MedSafetyWeek* Malaysia pada 30 Oktober 2025 yang disiarkan secara langsung melalui saluran *YouTube* NPRA dan *Facebook* Program Perkhidmatan Farmasi. Majlis tersebut berjaya menarik lebih 2,000 peserta daripada pelbagai latar belakang. Program diteruskan dengan sesi *Continuing Medical Education* (CME) bertajuk *"Pharmacovigilance: What Happens After Approval."*

Penglibatan di peringkat nasional turut diperluas di luar platform dalam talian melalui hebahan bahan kempen menerusi perkhidmatan *"Info on Wheels"* Jabatan Penerangan Malaysia. Selain itu, pelbagai hospital dan jabatan kesihatan negeri telah menganjurkan pameran, karnival serta aktiviti interaktif kanak-kanak seperti pertandingan mewarna, permainan teka-teki dan aktiviti *"spot the candy vs medicine*". Inisiatif ini mencerminkan komitmen berterusan dalam meningkatkan kesedaran keselamatan keselamatan penggunaan ubat dalam kalangan profesional kesihatan dan masyarakat umum.

### *#MEDSAFETYWEEK 2025*

*#MedSafetyWeek (#MSW) is a global campaign spearheaded by the Uppsala Monitoring Centre in Sweden aimed at enhancing awareness on the safe use of medicines and the importance of reporting side effects. In 2025, the campaign ran from 3 to 9 November, marking the 10th anniversary of this international initiative and drawing participation from nearly 120 countries worldwide.*

*This year represented Malaysia's fifth consecutive year of involvement in the #MSW campaign. Building on the momentum from previous years, the national taskforce was further strengthened to include pharmacists from every state across Malaysia. Collaboration with the private*

*healthcare sector also grew, with active engagement from the Pharmaceutical Association of Malaysia (PhAMA) and the Malaysian Pharmacists Society (MPS).*

*The results of this expanded collaboration were quickly evident. #MSW2025 activities reached communities nationwide, with health facilities and individuals sharing campaign content through social media. A variety of outreach efforts, including health awareness campaigns, talk shows, radio interviews, webinars, and live quizzes, further amplified the campaign's visibility. A key highlight of 2025 was the official launch of #MedSafetyWeek Malaysia, held on 30 October 2025 via livestream on the NPRA YouTube channel and the Pharmaceutical Services Programme Facebook page. The event attracted more than 2,000 participants from diverse backgrounds. The launch concluded with a Continuing Medical Education session titled "Pharmacovigilance: What Happens After Approval."*

*Nationwide engagement extended beyond online platforms. Campaign materials were featured through the Malaysian Department of Information's "Info on Wheels" service, while numerous hospitals and state health departments held exhibitions, carnivals, and children's activities such as colouring competitions, puzzles, and "spot the candy vs medicine" games. These activities reflected a strong commitment to improving awareness on medicines safety among both healthcare professionals and the public.*




Para pemenang pertandingan mewarna di Hospital Selayang
*Winners of colouring contest at Hospital Selayang*

## SEMINAR *ENHANCING PATIENT SAFETY: PHARMACISTS AT THE FRONTLINE OF PRODUCT MONITORING*

Seminar ini telah diadakan secara dalam talian pada 10 September 2025 dengan penyertaan seramai 395 pegawai farmasi dari fasiliti kesihatan di seluruh Malaysia. Seminar ini bertujuan meningkatkan kefahaman peserta mengenai penyediaan laporan kesan advers ubat (*Adverse Drug Reaction*, ADR) dan kesan advers susulan imunisasi (*Adverse Event Following Immunisation*, AEFI) yang lengkap, tepat dan berkualiti. Selain itu, sesi turut memberi penekanan terhadap kepentingan pelaporan aduan kualiti produk sebagai sebahagian daripada sistem pemantauan keselamatan produk kesihatan yang komprehensif.

## *ENHANCING PATIENT SAFETY SEMINAR: PHARMACISTS AT THE FRONTLINE OF PRODUCT MONITORING*

*The seminar was conducted virtually on 10 September 2025, with the participation of 395 pharmacists from healthcare facilities nationwide. The seminar aimed to enhance participants' understanding of preparing well-documented, accurate, and high-quality reports on Adverse Drug Reactions (ADR) and Adverse Events Following Immunisation (AEFI). It also emphasised the importance of product quality complaint reporting as an integral component of a comprehensive health product safety monitoring system.*

## LAWATAN PENDIDIKAN KE NPRA

Pada tahun 2025, NPRA telah menganjurkan lawatan pendidikan melibatkan pelajar daripada 6 institusi pengajian tinggi tempatan dan antarabangsa. Lawatan ini bertujuan meningkatkan kefahaman terhadap sistem pengawalseliaan farmaseutikal negara yang merangkumi penilaian ubat, pemantauan keselamatan, pematuhan peraturan serta peranan strategik NPRA dalam memastikan kualiti ubat dan perlindungan kesihatan awam. Sepanjang tahun 2025, seramai 190 orang pelajar telah menyertai program ini. Pengisian lawatan termasuk sesi pembentangan oleh pegawai NPRA berkaitan fungsi teras agensi, proses pendaftaran produk dan notifikasi kosmetik, prinsip Amalan Perkilangan Baik (APB) serta aktiviti kawalan kualiti. Inisiatif ini menyokong pembangunan modal insan dan pemupukan kefahaman awal terhadap tadbir urus farmaseutikal negara.

## *EDUCATIONAL VISIT TO NPRA*

*In 2025, NPRA organised educational visits involving students from 6 local and international higher education institutions. These visits aimed to enhance understanding of Malaysia's pharmaceutical regulatory framework, including medicine evaluation, safety monitoring, regulatory compliance, and NPRA's strategic role in safeguarding medicine quality and public health. A total of 190 students participated during the reporting year. The programme comprised structured briefings by NPRA officers on the Agency's core functions, product registration and cosmetic notification processes, principles of Good Manufacturing Practice (GMP), and quality control activities. This initiative contributed to human capital development and fostered early awareness of pharmaceutical regulatory governance among future professionals.*



Lawatan daripada IUHW, Japan
*Visit from IUHW, Japan*

Senarai institusi yang telah membuat lawatan ke NPRA
*List of institutions involved in visits to NPRA*

| **Bil.** *No.* | **Institusi** *Institution* | **Program** *Programme* | **Bilangan peserta** *Number of participants* | **Tarikh** *Date* |
|---|---|---|---|---|
| 1. | Universiti MAHSA<br>*MAHSA University* | Ijazah Sarjana Muda Tahun 3 dan 4, Fakulti Farmasi dan Sains Biomedikal)<br>*Bachelor of Pharmacy and Biomedical Sciences (Year 3 and Year 4)* | 30 | 9 Januari 2025<br>*9 January 2025* |
| 2. | Universiti Sains Islam Malaysia<br>*Universiti Sains Islam Malaysia* | Fakulti Syariah dan Undang-Undang)<br>*Faculty of Shariah and Law* | 50 | 9 Mei 2025<br>*9 May 2025* |
| 3. | Universiti Malaysia Pahang Al-Sultan Abdullah (UMPSA)<br>*Universiti Malaysia Pahang Al-Sultan Abdullah (UMPSA)* | Sarjana Muda Teknologi Kejuruteraan Parmaseutikal dengan Kepujian, Fakulti Kejuruteraan Kimia & Proses)<br>*Bachelor of Pharmaceutical Engineering Technology (Honours), Faculty of Chemical and Process Engineering* | 26 | 16 Jun 2025<br>*16 June 2025* |
| 4. | *Institut Latihan Kesihatan Angkatan Tentera (INSAN AT)*<br>*Armed Forces Health Training Institute (INSAN AT)* | Diploma Farmasi<br>*Diploma in Pharmacy* | 15 | 7 Julai 2025<br>*7 July 2025*<br>*&*<br>31 Oktober 2025<br>*31 October 2025* |
| 5. | Management and Science University (MSU) dan International University of Health and Welfare (IUHW), Japan<br>*Management and Science University (MSU) dan International University of Health and Welfare (IUHW), Japan* | Pelajar tahun akhir<br>*Final-year students* | 27 | 12 Ogos 2025<br>*12 August 2025* |
| 6. | Kolej Professional MARA Bandar Melaka<br>*Kolej Professional MARA Bandar Melaka* | Diploma Industri Halal<br>*Diploma in Halal Industry* | 42 | 23 September 2025<br>*23 September 2025* |

## SENARAI PAMERAN YANG DISERTAI OLEH NPRA

Pameran merupakan sebahagian daripada inisiatif libat urus strategik NPRA**,** yang menyediakan platform dua hala bagi perkongsian maklumat berkaitan fungsi, peranan dan aktiviti pengawalseliaan farmaseutikal dengan pihak berkepentingan, termasuk orang awam dan industri.

## *LIST OF EXHIBITIONS PARTICIPATED BY NPRA*

*Exhibitions form part of NPRA's strategic outreach initiatives, providing a two-way platform for sharing information on pharmaceutical regulatory functions, roles and activities with stakeholders, including the general public and the industry.*

| **Bil.** *No.* | **Nama Pameran** *Name of Exhibition* | **Penganjur** *Organiser* | **Tarikh** *Date* |
|---|---|---|---|
| 1. | Hari Bertemu Pelanggan KKM Siri 1 Tahun 2025 | KKM<br>*MOH* | 27 Februari 2025<br>*27 February 2025* |
| 2. | Jaminan Kualiti Produk Farmaseutikal Sempena Program Kesedaran Farmasi 2025 | Fakulti Farmasi, Universiti Kebangsaan Malaysia (UKM)<br>*Faculty of Pharmacy, National University of Malaysia (UKM)* | 20 April 2025<br>*20 April 2025* |
| 3. | *UM Pharmacy Career Fair 2025* | Fakulti Farmasi, Universiti Malaya<br>*Faculty of Pharmacy, University of Malaya* | 23 April 2025<br>*23 April 2025* |

| Bil.<br>*No.* | Nama Pameran<br>*Name of Exhibition* | Penganjur<br>*Organiser* | Tarikh<br>*Date* |
|---|---|---|---|
| 4. | *Sea Healthcare & Pharma Show (SeaCare 2025)* | Qube Integrated (Malaysia) Sdn Bhd | 23-25 April 2025<br>*23-25 April 2025* |
| 5. | Kembara Tolak Ubat Tidak Sah (TOBaTs) Zon Tengah 2025 | Program Perkhidmatan Farmasi<br>*Pharmaceuticals Services Program* | 3 Mei 2025<br>*3 May 2025* |
| 6. | Pameran Sempena Simposium Kesedaran Berkaitan Kawalan Produk Kesihatan Dan Kosmetik di Malaysia | Jabatan Kesihatan Negeri WP Kuala Lumpur & Putrajaya<br>*WP Kuala Lumpur & Putrajaya State Department of Health* | 12 Jun 2025<br>*12 June 2025* |
| 7. | *MyPSA Pharmacy Graduate CareerForum (PGCF) 2025* | Persatuan Pelajar Farmasi Malaysia (MyPSA)<br>*Malaysian Pharmacy Students' Association (MyPSA)* | 29 Jun 2025<br>*29 June 2025* |
| 8. | *International Healthcare Week 2025* | MATRADE and Informa Markets | 16-18 Julai 2025<br>*16-18 July 2025* |
| 9. | *ISPE Malaysia Conference & Exhibition, Le Meridien Putrajaya* | International Society for Pharmaceutical Engineering (ISPE) Malaysia | 9-10 September 2025<br>*9-10 September 2025* |
| 10. | *2nd Malaysia Pharma and Healthcare Expo 2025* | ACE Group and Genesis Global Exhibitions | 7-9 Oktober 2025<br>*7-9 October 2025* |
| 11. | Majlis Sambutan Hari Farmasi Sedunia 2025 Peringkat Kebangsaan | Program Perkhidmatan Farmasi<br>*Pharmaceuticals Services Program* | 25 September 2025<br>*25 September 2025* |
| 12. | Program Jalinan Madani: Pemerkasaan Perubatan Tradisional Orang Asli Semenanjung, Anak Negeri Sabah Dan Anak Negeri Sarawak | Bahagian Perubatan Tradisional & Komplementari<br>*Traditional & Complementary Division* | 27-28 September 2025<br>*27-28 September 2025* |
| 13. | *MINDA 2025 (MySTI Innovation and Networking Day)* | Kementerian Sains, Teknologi dan Inovasi (MOSTI)<br>*Ministry of Science, Technology & Innovation (MOSTI)* | 20 November 2025<br>*20 November 2025* |

### *SESI DIALOG ANJURAN NPRA DENGAN INDUSTRI*
### *NPRA DIALOGUE SESSIONS WITH THE INDUSTRY*

| Bil<br>*No.* | Sesi Dialog<br>*Dialog Session* | Bilangan peserta<br>*No. of participants* | Tarikh<br>*Date* |
|---|---|---|---|
| *1.* | Dialog Industri NPRA-*Malaysian Association of Pharmaceutical Suppliers (MAPS)* Bil. 1/2025 | *43* | 20 Jun 2025<br>*20 June 2025* |
| *2.* | Dialog Industri NPRA-F*MM Malaysian Cosmetics & Toiletries Group (FMM MCTIG) & The Cosmetic, Toiletry and Fragrance Association of Malaysia (CTFA)* Bil. 1/2025 | *33* | 23 Jun 2025<br>*23 June 2025* |
| *3.* | Dialog Industri NPRA-*Malaysia Dietary Supplement Association (MADSA)* Bil. 1/2025 | *57* | 22 Julai 2025<br>*22 July 2025* |
| *4.* | Dialog Industri NPRA-*Pharmaceutical Association of Malaysia (PHAMA)* Bil. 1/2025 | *31* | 2 September 2025<br>*2 September 2025* |




Dialog Industri NPRA-FMM MCTIG & CTFA
*Industrial Dialogue NPRA-FMM MCTIG & CTFA*




Dialog Industri NPRA- PHAMA
*Industrial Dialogue NPRA-PHAMA*

## PENGLIBATAN MAKMAL DALAM *PROFICIENCY TESTING*

Makmal berperanan sebagai komponen kritikal dalam memastikan kesahihan dan kebolehpercayaan keputusan pengujian. Penyertaan dalam *Proficiency Testing* (PT) merupakan mekanisme penilaian objektif bagi menilai prestasi analisis melalui penandaarasan terhadap makmal setara serta bahan rujukan yang diiktiraf. Pelaksanaan program ini bertujuan mengesahkan kompetensi penganalisis dan memastikan pematuhan berterusan terhadap keperluan MS ISO/IEC 17025:2017**.**

## *LABORATORY INVOLVEMENT IN PROFICIENCY TESTING*

*The laboratory serves a critical function in maintaining the validity and dependability of test outcomes. Participation in Proficiency Testing (PT) provides an objective mechanism for evaluating analytical performance through benchmarking against peer laboratories and recognised reference standards. This programme is implemented to demonstrate analyst competence and to ensure continued compliance with the requirements of MS ISO/IEC 17025:2017.*

| **Bil.** *No.* | **Nama Pengujian** *Name of Test* | **Bilangan Peserta** *No. of participants* | **Penganjur** *Organiser* |
|---|---|---|---|
| 1. | *Cosmetics & Toiletries (Cosmetics) Proficiency Test CS059 Round 59 Testing for Heavy Metal Cadmium, Lead and Mercury* | 2 | LGC, United Kingdom |
| 2. | *Identification of hydroquinone, mercury compounds and retinoic acid in cosmetic products Proficiency Test CM04/2025* | 2 | *Bureau of Cosmetics and Hazardous Substances, Department of Medical Sciences, Ministry of Public Health, Thailand* |
| 3. | *Microbial Contamination Test in Cosmetics Products (Gel base)* | 1 | *Bureau of Cosmetics and Hazardous Substances, Department of Medical Sciences, Ministry of Public Health, Thailand* |
| 4. | *Microbial Contamination Test in Traditional Products* | 5 | *IFM Quality Services, Australia* |

## PENGLIBATAN MAKMAL DALAM *INTER LABORATORY COMPARISON 2025*

*Inter-Laboratory Comparison (ILC)* merupakan aktiviti jaminan kualiti yang melibatkan penilaian keputusan pengujian yang dihasilkan oleh makmal berbeza menggunakan sampel yang sama. Pelaksanaan ILC membolehkan pemantauan ketepatan, konsistensi dan prestasi keseluruhan makmal, serta mengenal pasti jurang berpotensi bagi tujuan penambahbaikan pembetulan. Inisiatif ini membantu untuk mengekalkan piawaian pengujian yang tinggi, pematuhan terhadap keperluan akreditasi seperti MS ISO/IEC 17025**,** serta meningkatkan tahap keyakinan terhadap output makmal.

## *LABORATORY INVOLVEMENT IN INTER LABORATORY COMPARISON 2025*

*Inter-Laboratory Comparison (ILC) is a quality assurance activity involving the evaluation of test results generated by different laboratories from identical samples. This exercise enables the monitoring of accuracy, consistency, and overall laboratory performance, as well as the identification of potential gaps for corrective improvement. ILC supports the maintenance of high testing standards, compliance with accreditation requirements such as MS ISO/IEC 17025, and strengthens confidence in laboratory outputs.*

| **Bil.** *No.* | **Nama Pengujian** *Name of Test* | **Bilangan Peserta** *No. of participants* | **Penganjur** *Organiser* |
|---|---|---|---|
| 1. | *Aluminium Content Test in Hepatitis B Vaccine* | 8 | Unit Perkhidmatan Analisis, Seksyen Perkhidmatan dan Bekalan, NPRA |
| 2. | *Determination of Lovastatin in Traditional Product using HPLC* | 8 | Unit Perkhidmatan Analisis, Seksyen Perkhidmatan dan Bekalan, NPRA |


## LAIN-LAIN AKTIVITI
## *OTHER ACTIVITIES*

| **Aktiviti** *Activity* | **Tarikh/ Tempat** *Date/ Venue* | **Peserta** *Participant* | **Objektif** *Objective* |
|---|---|---|---|
| Bengkel Data Mining, *Data Visualisation* dan *Article Writing*<br>*Data Mining, Data Visualisation dan Article Writing Workshop* | 17 April 2025; Google Meet<br>*17 April 2025; Google Meet* | 35 orang pegawai dan pembantu tadbir NPRA<br>*35 NPRA officers and administrative assistants* | Memberi latihan secara teori dan praktikal berkaitan analisis data, visualisasi data serta penulisan artikel kes, termasuk penggunaan AI dalam penulisan penyelidikan<br>*To provide theoretical and practical trainings on data analysis, data visualisation, and case article writing, including the use of AI in research writing* |
| Bengkel Pengujian Kawalan Kualiti Bahan Mentah Herba Bagi Produk Semulajadi 2025<br>*Herbal Raw Material Quality Control Testing Workshop for Natural Products 2025* | 4 September 2025; Institut Kesihatan Negara, Setia Alam<br>*4 September 2025; National Institutes of Health, Setia Alam* | 80 Peserta terdiri daripada pengilang produk semulajadi, pemegang pendaftaran produk, makmal swasta/ universiti, dan pegawai NPRA<br>*80 participants consisted of natural product manufacturers, product registration holders, private/ university laboratories, and NPRA officials* | • Mengukuhkan pemahaman mengenai keperluan pengendalian kawalan kualiti bahan mentah herba untuk pendaftaran dan pengilangan produk semula jadi<br>• Mengetahui jenis-jenis pengujian kawalan kualiti terhadap bahan mentah yang perlu dijalankan bagi tujuan pendaftaran produk, seperti ujian organoleptik, identifikasi, Purity, dan Safety Tests<br>• Menggalakkan penglibatan makmal-makmal tempatan dalam perkhidmatan analisis bahan mentah yang digunakan dalam produk semulajadi<br>• *Strengthen understanding of the requirements for quality control of herbal raw materials for registration and manufacturing of natural products*<br>• *Know the types of quality control testing of raw materials that need to be carried out for product registration purposes, such as organoleptic tests, identification, purity, and safety tests*<br>• *Encourage the involvement of local laboratories in the analysis of raw materials used in natural products* |
| Bengkel Pengemaskinian Dokumen PIC/S *Reassessment Programme*<br>*PIC/S Reassessment Programme Document Updating Workshop* | 9-10 Oktober 2025, Dewan Anggerik, NPRA<br>*9-10 October 2025; Dewan Anggerik, NPRA* | 25 pegawai NPRA<br>*25 NPRA officers* | Mengemas kini SOP dan dokumen kualiti selaras dengan keperluan PIC/S, memastikan prosedur reassessment jelas dan boleh dilaksanakan, meningkatkan kefahaman pegawai terhadap perubahan SOP, serta menggalakkan perkongsian idea dan maklum balas bagi penambahbaikan proses kerja<br>*To update SOPs and related quality documents in line with PIC/S requirements, ensure reassessment procedures are clear and implementable, enhance officers' understanding of SOP changes, and encourage idea-sharing and feedback to improve work processes* |

| **Aktiviti** *Activity* | **Tarikh/ Tempat** *Date/ Venue* | **Peserta** *Participant* | **Objektif** *Objective* |
|---|---|---|---|
| Bengkel Gemini AI@ Work *Gemini AI@Work Workshop* | 13-14 November 2025; Bilik Latihan, NPRA *13-14 November 2025; Training Room, NPRA* | 25 pegawai NPRA *25 NPRA officers* | • Meningkatkan pengetahuan dan kemahiran penggunaan AI (Gemini AI)<br>• Menyokong pendigitalan organisasi dan tugasan harian<br>• Menggalakkan penggunaan AI secara beretika dalam sektor awam<br>• Meningkatkan kecekapan, produktiviti dan kualiti penyampaian perkhidmatan<br>• *Enhance knowledge and skills in AI use (Gemini AI)*<br>• *Support organisational digitalisation and daily tasks*<br>• *Promote ethical AI adoption in the public sector*<br>• *Improve efficiency, productivity, and service delivery qualit* |
| Bengkel Perancangan Pelan Strategik Dan Pelan Tindakan NPRA 2026-2030 *Strategic Planning and Action Plan Workshop for NPRA 2026–2030* | 16-17 Oktober 2025; Dewan Anggerik, NPRA *16-17 October 2025; Dewan Anggerik NPRA* | 27 pegawai NPRA *27 NPRA officers* | • Perbincangan cadangan Pelan Strategik dan Pelan Tindakan NPRA 2026 - 2030 (mengikut pusat).<br>• *Discussion on the proposed NPRA Strategic Plan and Action Plan 2026–2030 (by centre)*<br>• Memuktamadkan Pelan Strategik NPRA dan Pelan Tindakan NPRA 2026-2030.<br>• *Finalisation of the NPRA Strategic Plan and Action Plan 2026–2030* |

## 3.0 PENCAPAIAN DAN PENGIKTIRAFAN | *ACHIEVEMENT AND RECOGNITION*

| | |
|---|---|
| QUALITY SYSTEM<br>**SIRIM**<br>Certified to MS ISO 9001:2015<br>Cert No.: QMS 00894 | NPRA telah memperolehi pensijilan MS ISO 9001 dari pihak SIRIM QAS Sdn. Bhd. pada tahun 2001. Bermula dengan pensijilan MS ISO 9002:1994, disusuli dengan MS ISO 9001:2000 dan MS ISO 9001:2008. Pensijilan terkini MS ISO 9001:2015 telah diperolehi pada tahun 2025 dengan nombor sijil QMS 01408 dan sah sehingga 23 Mac 2026.<br>*NPRA obtained MS ISO 9001 certification from SIRIM QAS Sdn. Bhd. in 2001. Starting with MS ISO 9002:1994 certification, followed by MS ISO 9001:2000 and MS ISO 9001:2008. The latest certification, MS ISO 9001:2015, was obtained in 2025 with certificate number QMS 01408 and is valid until 23 March 2026.* |
|  | Menerima pengiktirafan 3-bintang EMGS yang telah dilaksanakan oleh *Malaysian Green Technology & Climate Change Corporation (MGTC)* dan penerimaan sijil secara rasmi pada 21 Mei 2024. Audit dalaman pensijilan semula 3 bintang EMGS pada 22-23 Oktober 2025.<br>*Received a 3-star EMGS recognition implemented by the Malaysian Green Technology & Climate Change Corporation (MGTC), with the official certificate awarded on 21 May 2024. An internal audit for 3-star EMGS recertification was conducted on 22–23 October 2025.* |

| | |
|---|---|
|  | Menerima penarafan 2-Berlian bagi Penilaian Bangunan Tenaga Mampan Rendah Karbon pada 4 November 2025 sebagai pengiktirafan terhadap kejayaan pelaksanaan penggunaan elektrik cekap tenaga, penerapan tenaga boleh baharu serta pengurangan pelepasan karbon, yang telah menghasilkan pengurangan sebanyak 727.07 tan pelepasan karbon dioksida sepanjang tahun 2024. Inisiatif ini merupakan sebahagian daripada komitmen jangka panjang terhadap kelestarian alam sekitar.<br>*Received 2-diamond rating for the Sustainable Energy Low Carbon Building Assessment on 4 November 2025 in recognition of successful implementation of energy-efficient electricity usage, adoption of renewable energy, and reduction of carbon emissions, resulting in a reduction of 727.07 tons of carbon dioxide emissions throughout 2024. This initiative is part of a long-term commitment to environmental sustainability.* |
|  | Mendapat pengiktirafan 3-bintang bagi Pelabelan Prestasi Intensiti Tenaga Bangunan *(Building Intensity – BEI)* oleh Suruhanjaya Tenaga pada 4 Ogos 2025 untuk pencapaian penjimatan tenaga sepanjang tahun 2024. Ini merupakan inisiatif oleh Kementerian Sumber Asli, Alam Sekitar dan Perubahan Iklim (NRECC) dan dikelolakan oleh Suruhanjaya Tenaga.<br>*Received a 3-star recognition under the Building Energy Intensity (BEI) Performance Labelling programme from the Energy Commission on 4 August 2025, in recognition of energy-saving achievements throughout 2024. This initiative is led by the Ministry of Natural Resources, Environment and Climate Change (NRECC) and administered by the Energy Commission.* |
|  | Dianugerahkan Anugerah Kecemerlangan bagi kategori Operasi dan Penyelenggaraan di bawah Pensijilan *Malaysian Carbon Reduction & Environmental Sustainability Tool* (MyCREST) pada 30 Oktober 2025.<br>*NPRA was awarded the Excellence Award in the Operation and Maintenance category under the Malaysian Carbon Reduction & Environmental Sustainability Tool (MyCREST) Certification On 30 October 2025.* |
|  | Berada di kalangan Top 5 Agensi dengan penggunaan *Google Chat* tertinggi dalam e-Buletin MyGovUC Edisi ke-9<br>*NPRA was among the Top 5 Agencies with the highest usage of Google Chat in MyGovUC e-Buletin 9th Edition* |

## 4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*

### BULLETIN JAWATANKUASA PENASIHAT KESAN ADVERS MALAYSIA (MADRAC)

Pada tahun 2025, NPRA telah menerbitkan enam edisi Buletin MADRAC. Buletin MADRAC merupakan penerbitan dwibulanan yang menyediakan maklumat berkaitan:

i. Isyarat keselamatan tempatan
ii. Artikel yang membincangkan laporan keselamatan kes individu tempatan (*local Individual Case Safety Reports, ICSR*)
iii. Aktiviti berkaitan farmakovigilans yang dilaksanakan oleh NPRA
iv. Arahan serta amaran keselamatan berkaitan isu keselamatan ubat

### *MALAYSIAN ADVERSE DRUG REACTIONS ADVISORY COMMITTEE (MADRAC) BULLETIN*

*In 2025, NPRA published six issues of the MADRAC Bulletin. The MADRAC Bulletin is a bi-monthly publication that provides information on:*

*i. Local safety signals*
*ii. Articles discussing local individual case safety reports (ICSRs)*
*iii. Pharmacovigilance-related activities conducted by the NPRA*
*iv. Directives and safety alerts related to medicine safety issues*

### PENERBITAN SAINTIFIK

Penerbitan saintifik memainkan peranan penting dalam perkongsian penemuan penyelidikan, memastikan ketelusan data serta menyokong proses membuat keputusan pengawalseliaan. Melalui penerbitan yang dinilai oleh rakan setara (*peer-reviewed*), NPRA menyumbang kepada penggubalan dasar berasaskan bukti serta pembangunan sains farmaseutikal dan sains pengawalseliaan.

### *SCIENTIFIC PUBLICATIONS*

*Scientific publication is vital for disseminating research findings, ensuring data transparency, and supporting regulatory decisions. Through peer-reviewed publications, NPRA contributes to evidence-based policymaking and the advancement of pharmaceutical and regulatory science.*

| **Bil.** *No.* | **Tajuk & Penerbit** *Title & Publisher* | **Tarikh Penerbitan** *Date of publication* |
|---|---|---|
| 1. | *Efficacy of Fetal Wharton's Jelly Mesenchymal Stem Cells-Derived Small Extracellular Vesicles in Metabolic Syndrome*<br>Biomolecules, 15(1), 44.<br>https://doi.org/10.3390/biom15010044 | 1 Januari 2025<br>*1 January 2025* |
| 2. | *Quality Control of Fetal Wharton's Jelly Mesenchymal Stem Cells-Derived Small Extracellular Vesicles*<br>International Journal of Nanomedicine, 20, 1807–1820.<br>https://www.tandfonline.com/doi/full/10.2147/IJN.S497586 | 11 Februari 2025<br>*11 February 2025* |
| 3. | *Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials*<br>CPT: Pharmacometrics & Systems Pharmacology.<br>https://doi.org/10.1002/psp4.70018 | 27 Mac 2025<br>*27 March 2025* |
| 4. | *Assessing the Malaysian Regulatory Process for Medicinal Product Approval: An OpERA Methodology and Standardized Reporting Approach*<br>Therapeutic Innovation & Regulatory Science<br>https://doi.org/10.1007/s43441-025-00846-3 | 25 Julai 2025<br>*25 July 2025* |
| 5. | *GC–MS method for routine analysis of camphor, menthol, methyl salicylate, and thymol in traditional topical products: Addressing compliance and adulteration from Malaysia's National Pharmaceutical Regulatory Agency*<br>Results in Chemistry, 18, 102721.<br>https://doi.org/10.1016/j.rechem.2025.102721 | 15 September 2025<br>*15 September 2025* |
| 6. | *Safety Evaluation and Biodistribution of Fetal Umbilical Cord Mesenchymal Stem Cells-Derived Small Extracellular Vesicles in Sprague Dawley Rats*<br>International Journal of Molecular Sciences, 26, 6806.<br>https://doi.org/10.3390/ijms26146806 | 16 Julai 2025<br>*16 July 2025* |

| Bil. *No.* | Tajuk & Penerbit *Title & Publisher* | Tarikh Penerbitan *Date of publication* |
|---|---|---|
| 7. | *Clinical pharmacokinetics and pharmacometabolomics of Andrographis paniculata capsules: Bridging drug disposition and metabolic response to precision medicine* *Naunyn-Schmiedeberg's Archives of Pharmacology.* https://doi.org/10.1007/s00210-025-04656-0 | 2 Oktober 2025 *2 October 2025* |
| 8. | *Evaluation of the antiproliferative effect of Zingiber zerumbet essential oil against oral squamous cell carcinoma* South African Journal of Botany, 187, 337-350. https://doi.org/10.1016/j.sajb.2025.10.030 | 23 Oktober 2025 *23 October 2025* |
| 9. | *A Feasibility Study for Quality Control Testing on Raw Materials Used in Natural Products in Malaysia* Pharmacy Research Reports, 8 (2). https://research.pharmacy.gov.my/system/files/1.%20QC%20Test%20NPRA.pdf | November 2025 *November 2025* |

## 5.0 KOLABORASI DAN PENGLIBATAN ANTARABANGSA *INTERNATIONAL COLLABORATION AND PARTICIPATION*

### PENYERTAAN NPRA DALAM KUMPULAN KERJA ASEAN

NPRA terlibat secara aktif dalam tiga kumpulan kerja produk yang ditubuhkan di bawah *ASEAN Consultative Committee for Standards and Quality (ACCSQ)*, yang bertujuan membangunkan skim pengharmonian bagi peraturan farmaseutikal, produk semula jadi dan suplemen kesihatan serta kosmetik di negara-negara ASEAN. Selain itu, NPRA turut terlibat secara aktif dalam pembangunan *ASEAN Reference Standards (ARS)* dan telah menyumbang kepada penghasilan empat ARS, iaitu Niacinamide, Alpha Lipoic Acid, Hydroquinone dan Propylparaben.

### *NPRA'S PARTICIPATION IN ASEAN WORKING GROUPS*

*NPRA actively participates in three product-working groups established under the ASEAN Consultative Committee for Standards and Quality (ACCSQ) which aim to develop harmonization schemes of pharmaceuticals, natural products and health supplements as well as cosmetics regulations in ASEAN countries. Apart from that, NPRA is also actively involved in the development of ASEAN Reference Standard (ARS) and has contributed to the production of four ARS, namely Niacinamide, Alpha Lipoic Acid, Hydroquinone, and Propylparaben.*

Senarai mesyuarat di peringkat ASEAN yang telah dihadiri oleh pegawai NPRA, 2025
*List of ASEAN meetings attended by NPRA officers, 2025*

| Bil. *No.* | Mesyuarat *Meeting* | Tarikh *Date* |
|---|---|---|
| 1. | *41st Meeting of The ASEAN Cosmetic Committee* | 8-9 Mei 2025 *8-9 May 2025* |
| 2. | *37th Meeting of the ASEAN Traditional Medicines and Health Supplements Product Working Group (TMHS PWG) And Its Related Meetings* | 19-22 Mei 2025 *19-22 May 2025* |
| 3. | *39th Meeting of the Pharmaceutical Product Working Group (PPWG)* | 2-13 Jun 2025 *2-13 June 2025* |
| 4. | *17th Meeting on the Production of ASEAN Reference Substances (ARS)* | 16-18 Julai 2025 *16-18 July 2025* |
| 5. | *6th Meeting of the ASEAN Pharmaceutical Testing Laboratory Committee (APTLC)* | 11-12 November 2025 *11-12 November 2025* |
| 6. | *40th Meeting of the Pharmaceutical Product Working Group (PPWG)* | 13-14 November 2025 *13-14 November 2025* |
| 7. | *42nd Meeting of the ASEAN Cosmetic Scientific Body (ACSB)* | 17-18 November 2025 *17-18 November 2025* |
| 8. | *25th Meeting of the ASEAN Cosmetic Testing Laboratories Committee (ACTLC)* | 17-18 November 2025 *17-18 November 2025* |
| 9. | *Heads of Delegates of the 42nd ACC Meeting (HOD)* | 19 November 2025 *19 November 2025* |

| | | |
|---|---|---|
| 10. | *42nd Meeting of The ASEAN Cosmetic Committee* | 20-21 November 2025<br>*20-21 November 2025* |
| 11. | *38th Meeting of the Traditional Medicines and Health Supplements Product Working Group (TMHS PWG)* | 26-27 November 2025<br>*26-27 November 2025* |

### *14TH APAC (ASIA PARTNERSHIP CONFERENCE OF PHARMACEUTICAL ASSOCIATIONS)*

Persidangan ini telah diadakan pada 22 April 2025 di Tokyo, Jepun sebagai platform dialog strategik antara badan regulatori dan industri farmaseutikal di rantau Asia. Persidangan ini dianjurkan oleh *APAC Member Associations* dengan objektif memperkukuh kerjasama serantau, memacu inovasi dan menyokong harmonisasi regulatori. Seramai tiga orang pegawai kanan NPRA telah dijemput sebagai penceramah, dan persidangan ini turut dihadiri oleh Pengarah NPRA. Perbincangan merangkumi topik Peraturan dan Kelulusan, *minimum quality standards* (MQS), *e-labeling* serta pendekatan *regulatory reliance*, dengan fokus mempercepat akses kepada ubat-ubatan inovatif, meningkatkan kecekapan regulatori dan memajukan inisiatif digital berteraskan pesakit.

### *14TH APAC (ASIA PARTNERSHIP CONFERENCE OF PHARMACEUTICAL ASSOCIATIONS)*

*The conference was held on 22 April 2025 in Tokyo, Japan, serving as a strategic dialogue platform between regulatory authorities and the pharmaceutical industry in Asia. It was organised by APAC Member Associations to promote innovation and support regulatory harmonisation. Three senior NPRA officers were invited as speakers, and the conference was also attended by the Director of NPRA. Discussions covered key topics including Regulations and Approvals, minimum quality standards (MQS), MQS, e-labelling and regulatory reliance, with a focus on accelerating access to across the region.*




14th APAC (Asia Partnership Conference of Pharmaceutical Associations)
*14th APAC (Asia Partnership Conference of Pharmaceutical Associations)*

### PENGANJURAN *3RD MALAYSIA-JAPAN SYMPOSIUM ON PHARMACEUTICAL REGULATORY SYSTEM* (MJS 2025)

NPRA dengan kerjasama *Pharmaceuticals and Medical Devices Agency (PMDA),* Jepun serta *Malaysian Pharmacists Society (MPS)* telah menganjurkan *The 3rd Malaysia-Japan Symposium on Pharmaceutical Regulatory System* pada 31 Julai 2025 di *Kuala Lumpur Convention Centre* (KLCC). Simposium ini telah menghimpunkan 232 peserta daripada agensi regulatori, institusi akademik dan industri farmaseutikal dari Malaysia dan Jepun. Penganjuran ini bertujuan memperkukuh dialog dua hala serta kerjasama strategik dalam bidang regulatori farmaseutikal. Perbincangan memfokuskan kepada penggunaan *Real World Data*, pelaksanaan Pelan Pengurusan Risiko, *Facilitated Registration Pathway* dan penambahbaikan kerangka Ujian Klinikal. Simposium ini mencerminkan komitmen NPRA dalam memperkukuh Amalan Regulatori Baik demi memastikan akses kepada produk farmaseutikal yang berkualiti, selamat dan berkesan.

### *THE 3RD MALAYSIA-JAPAN SYMPOSIUM ON PHARMACEUTICAL REGULATORY SYSTEM (MJS 2025)*

*NPRA in collaboration with the Pharmaceuticals and Medical Devices Agency (PMDA), Japan, and the Malaysian Pharmacists Society (MPS) have organised the 3rd Malaysia-Japan Symposium on Pharmaceutical Regulatory System on 31 July 2025 at the Kuala Lumpur Convention Centre (KLCC). The symposium brought together 232 participants from regulatory authorities, academia and the pharmaceutical industry from Malaysia and Japan. It aimed to strengthen bilateral dialogue, enhance mutual understanding and reinforce strategic regulatory cooperation. Discussions focused on the use of Real World Data in regulatory decision-making, implementation of Risk Management Plans, application of Facilitated Registration Pathways and enhancements to the Clinical Trials framework. The symposium reflects NPRA's commitment to strengthening Good Regulatory Practice through international collaboration to ensure access to safe, effective and quality pharmaceutical products.*



*The 3rd Malaysia-Japan Symposium on Pharmaceutical Regulatory System*
*The 3rd Malaysia-Japan Symposium on Pharmaceutical Regulatory System*

## MESYUARAT BILATERAL ANTARA NPRA DAN *PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA), JEPUN*

Mesyuarat ini telah diadakan pada 1 Ogos 2025 sebagai platform kerjasama berterusan antara badan regulatori Malaysia dan Jepun. Mesyuarat berkala ini bertujuan memperkukuh hubungan dua hala serta meningkatkan kualiti, keselamatan dan keberkesanan produk farmaseutikal melalui proses regulatori yang cekap. Perbincangan memfokuskan potensi kolaborasi strategik bersama *National Cancer Center (NCC),* Jepun dan *PMDA Asia Office,* termasuk pelaksanaan Pelan Kerja NPRA–PMDA Tahun Kewangan 2026. Mesyuarat turut membincangkan inisiatif *regulatory reliance* bagi permohonan ujian klinikal serta kerjasama dalam bidang farmakovigilans di peringkat serantau bagi menyokong akses kepada produk farmaseutikal yang selamat, berkesan dan berkualiti di Asia.

## *BILATERAL MEETING BETWEEN NPRA AND THE PHARMACEUTICAL AND MEDICAL DEVICES AGENCY (PMDA), JAPAN*

*The meeting was held on 1 August 2025 as a platform for continued regulatory cooperation between Malaysia and Japan. This regular meeting aims to strengthen bilateral relations and enhance the quality, safety and efficacy of pharmaceutical products through efficient regulatory processes. Discussions focused on potential strategic collaboration with the National Cancer Center (NCC), Japan and the PMDA Asia Office, including the implementation of the NPRA–PMDA Workplan for Fiscal Year 2026. The meeting also covered proposed regulatory reliance initiatives for clinical trial applications and opportunities for cooperation in pharmacovigilance at the regional level to support access to safe, effective and quality pharmaceutical products across Asia.*




Mesyuarat *Bilateral Antara NPRA Dan Pharmaceutical and Medical Devices Agency (PMDA),* Jepun
*Bilateral Meeting Between NPRA and the Pharmaceutical and Medical Devices Agency (PMDA), Japan*

## *WHO INTERREGIONAL TRAINING WORKSHOP ON ENSURING THE QUALITY AND SAFETY OF TRADITIONAL COMPLEMENTARY & INTEGRATIVE MEDICINE (TCIM) PRODUCTS*

Bengkel ini telah diadakan pada 22-24 Oktober 2025 dengan penyertaan wakil badan regulatori, akademik dan agensi kerajaan dari 19 buah negara. Bengkel ini dianjurkan oleh Pertubuhan Kesihatan Sedunia (WHO) dengan kerjasama Macau SAR, China, yang bertujuan meningkatkan kefahaman terhadap pendekatan WHO dalam memastikan kualiti dan keselamatan produk TCIM selaras dengan *WHO Global Traditional Medicine Strategy 2025–2034*. Bengkel ini merangkumi sesi perkongsian amalan negara, perbincangan berkaitan sistem kualiti, keselamatan pesakit serta kajian TCIM. Bengkel ini turut disertai lawatan teknikal ke *WHO Collaborating Centre for Traditional Medicine* di Universiti Macau dan Universiti Sains dan Teknologi Macau.

## *WHO INTERREGIONAL TRAINING WORKSHOP ON ENSURING THE QUALITY AND SAFETY OF TRADITIONAL COMPLEMENTARY & INTEGRATIVE MEDICINE (TCIM) PRODUCTS*

*The workshop was held from 22-24 October 2025, with participation from regulatory authorities, academia and government agencies from 19 countries. It was organised by the World Health Organization (WHO) in collaboration with Macau SAR, China, the workshop aimed to enhance understanding of WHO's approach to ensuring the quality and safety of TCIM products in line with the WHO Global Traditional Medicine Strategy 2025–2034. The workshop included country sharing sessions, discussions on quality systems, patient safety and TCIM-related studies, as well as lectures by WHO Temporary Advisors. Participants also attended technical visits to the WHO Collaborating Centre for Traditional Medicine at the University of Macau and Macau University of Science and Technology.*




WHO Interregional Training Workshop on Ensuring the Quality and Safety of TCIM Products
*WHO Interregional Training Workshop on Ensuring the Quality and Safety of TCIM Products*

## SESI LATIHAN *CHINA–ASEAN SEMINAR ON TRADITIONAL MEDICINE CULTURAL EXCHANGE, CHINA*

Sesi latihan ini telah dilaksanakan pada 6-22 Mei 2025 di Beijing dan Nanning, China, dengan penyertaan 26 orang pakar daripada sektor kerajaan, akademia dan perubatan dari Laos, Indonesia, Thailand, Malaysia dan Myanmar. Program ini dianjurkan oleh *China Academy of Chinese Medical Sciences* (CACMS) sebagai platform pembelajaran dan komunikasi yang mengintegrasikan pendekatan teori dan praktikal. Kurikulum latihan merangkumi asas teori dan sejarah Perubatan Tradisional Cina (TCM), teknik diagnosis, rawatan akupuntur serta penerokaan sumber perubatan tradisional. Peserta turut mengikuti latihan klinikal, lawatan tapak dan aktiviti penyelidikan budaya. Inisiatif ini menyokong perkongsian pengetahuan, pertukaran budaya serta pengukuhan kerjasama serantau dalam bidang perubatan tradisional.

## *CHINA–ASEAN SEMINAR ON TRADITIONAL MEDICINE CULTURAL EXCHANGE TRAINING PROGRAMME, CHINA*

*This training programme was conducted from 6-22 May 2025 in Beijing and Nanning, China, with the participation of 26 experts from government, academic and medical sectors representing Laos, Indonesia, Thailand, Malaysia and Myanmar. Organised by the China Academy of Chinese Medical Sciences (CACMS), the programme served as an inclusive learning and communication platform integrating theoretical and practical approaches. The curriculum covered fundamental theories and history of Traditional Chinese Medicine (TCM), diagnostic techniques, acupuncture treatment and exploration of traditional medical resources. Participants also undertook clinical training, site visits and cultural research activities. This initiative supported knowledge sharing, cultural exchange and the strengthening of regional cooperation in the field of traditional medicine.*






Sesi Latihan China–ASEAN Seminar on Traditional Medicine Cultural Exchange, China
*China–ASEAN Seminar on Traditional Medicine Cultural Exchange Training Programme, China*

## KOLABORASI ANTARABANGSA BERSAMA *STANDARDS AND METROLOGY INSTITUTE FOR ISLAMIC COUNTRIES* (SMIIC)

Penglibatan strategik ini dilaksanakan melalui *Technical Committee 16 (TC16): Halal Medical Products and Services,* yang memberi tumpuan kepada pembangunan piawaian antarabangsa berkaitan produk perubatan halal. Kolaborasi ini mencerminkan pendekatan keseluruhan kerajaan (*whole-of-government approach*) dalam memajukan agenda piawaian halal di peringkat antarabangsa. TC16 bertanggungjawab membangunkan piawaian meliputi farmaseutikal halal, produk biologi, vaksin, peranti perubatan serta panduan penggunaan ubat dari perspektif Islam. Penglibatan bersama ini menyokong objektif strategik KKM dalam memperkukuh tadbir urus regulatori, memperluas kerjasama antarabangsa serta meningkatkan keupayaan sains regulatori negara. Inisiatif ini turut menyumbang kepada pengukuhan ekosistem halal negara melalui pembangunan piawaian yang selaras dengan amalan antarabangsa, sekaligus meningkatkan keyakinan pasaran dan menyokong akses eksport produk farmaseutikal Malaysia ke pasaran negara anggota OIC.

## *INTERNATIONAL COLLABORATION THROUGH THE STANDARDS AND METROLOGY INSTITUTE FOR ISLAMIC COUNTRIES (SMIIC)*

*This strategic engagement is carried out through Technical Committee 16 (TC16): Halal Medical Products and Services, which focuses on developing international standards for halal medical products. The collaboration reflects a whole-of-government approach in advancing international halal standardisation initiatives. TC16 is responsible for developing standards covering halal pharmaceuticals, biologics, vaccines, medical devices, and guidance on the use of medicines from an Islamic perspective. The joint involvement supports the MOH strategic objectives in strengthening regulatory governance, enhancing international collaboration, and advancing national regulatory science capacity. The initiative further contributes to strengthening Malaysia's halal ecosystem through internationally aligned standards, enhancing market confidence and facilitating export access for Malaysian pharmaceutical products within OIC markets.*




Delegasi lawatan teknikal sempena Minggu SMIIC TC 2025 ke-14
*Technical visit delegates in conjunction of 14th SMIIC TC Week 2025*

# BAHAGIAN LEMBAGA FARMASI MALAYSIA

## *PHARMACY BOARD MALAYSIA DIVISION*



# BAHAGIAN LEMBAGA FARMASI MALAYSIA
# *PHARMACY BOARD MALAYSIA DIVISION*

## 1.0 PENGENALAN | *INTRODUCTION*

Lembaga Farmasi Malaysia ditubuhkan mengikut peruntukan Seksyen 3(1) Akta Pendaftaran Ahli Farmasi 1951. Bahagian Lembaga Farmasi Malaysia (BLFM) berperanan dalam memastikan pendaftaran Ahli Farmasi dan Pertubuhan Perbadanan memenuhi keperluan Akta Pendaftaran Ahli Farmasi 1951 dan Peraturan-peraturan di bawahnya. Dalam memastikan standard bagi pendidikan, latihan dan etika ahli farmasi dipatuhi, isu-isu yang berkaitan akan dibincangkan dalam Mesyuarat LFM melalui BLFM yang juga bertindak sebagai sekretariat kepada LFM.

*Pharmacy Board Malaysia (PBM) was established according to Section 3(1), Registration of Pharmacists Act 1951. Pharmacy Board Malaysia Division (PBMD) has a role to ensure registration of pharmacists and bodies in accordance with the Registration of Pharmacists Act 1951 and its regulations. In ensuring that standards for pharmacist education, training and ethics are adhered to, relevant issues will be discussed at the PBM Meeting through PBMD which also acts as the secretariat to the PBM.*

Terdapat dua (2) Cawangan di bawah BLFM iaitu Cawangan Pendaftaran dan Cawangan Pengiktirafan & Etika. Fungsi dan peranan kedua-dua Cawangan adalah seperti berikut:

*There are two (2) branch under the PBMD, namely Registration Branch and Recognition & Ethics Branch. The functions and activities of both branches are as follows:*

**FUNGSI / AKTIVITI**
*FUNCTION / ACTIVITIES*

**CAWANGAN PENDAFTARAN**
*REGISTRATION BRANCH*

- Pendaftaran Ahli Farmasi Berdaftar Penuh (FRP) & Pertubuhan Perbadanan
  *Registration of Fully Registered Pharmacist & Body Corporate*
- Pendaftaran Ahli Farmasi Berdaftar Provisional (PRP)
  *Registration of Provisionally Registered Pharmacist*
- Pendaftaran Ahli Farmasi Berdaftar Sementara (TC)
  *Registration of Temporary Registered Pharmacist*
- Sijil Tahunan Ahli Farmasi & Pertubuhan Perbadanan
  *Annual Certificate & Registration of Body Corporate*
- Penyenaraian Premis Latihan PRP ke dalam Jadual Kedua, ROPA 1951
  *Listing of PRP Training Facilities*
- Urusan Latihan Provisional PRP (pelanjutan, buku log)
  *Issues regarding training of PRP (extension, log book)*
- Peperiksaan Kelayakan Mengamal Farmasi (PKUMF)
  *Qualifying Examination to Practise Pharmacy*
- Pengesahan Pendaftaran Ahli Farmasi & *Letter of Good Standing*
  *Verification of Pharmacist Registration*

**SEKSYEN SEKRETARIAT LFM & KOORDINASI BLFM**
*SECRETARIAT OF PBM & COORDINATION SECTION*

- Urusetia Mesyuarat LFM
  *Secretariat of PBM Meeting*
- Koordinasi Maklum Balas & Statistik BLFM
  *Coordination of BLFM feedback & statistics*
- Pentadbiran (Kewangan/ Latihan/Kualiti)
  *Administration (Budget/ Training/ Quality)*

**CAWANGAN PENGIKTIRAFAN DAN ETIKA**
*RECOGNITION & ETHICS BRANCH*

- Pengiktirafan Program Ijazah/ Diploma Farmasi
  *Recognition of Pharmacy Degree/ Diploma Programme*
- Pengemaskinian Standard Kelulusan Pengiktirafan Progam Ijazah/ Diploma Farmasi
  *Revision of Standard for Recognition of Pharmacy Degree/ Diploma Programme*
- Penyenaraian Awal Pemegang Diploma/Sijil Farmasi
  *Listing of Diploma Pharmacy Holder*
- MoA Latihamal Pelajar IPT di premis KKM untuk program Ijazah & Diploma Farmasi
  *MoA for Students Attachment*
- Penyiasatan Kes Salah Laku Ahli Farmasi & Pertubuhan Perbadanan
  *Investigation of pharmacist's & body corporate's misconduct*
- Isu-isu perundangan dan cadangan pindaan Akta Pendaftaran Ahli Farmasi 1951
  *Legal issues and proposed amendments to the Registration of Pharmacists Act 1951*
- Pengurusan aduan berkaitan Ahli Farmasi Berdaftar
  *Management of complaints related to registered pharmacists*
- Urusan pengiktirafan *credentialing* Ahli Farmasi Berdaftar
  *Credentialing of registered pharmacist*

## SENARAI IJAZAH FARMASI DIIKTIRAF OLEH LEMBAGA FARMASI MALAYSIA
## *LIST OF RECOGNIZED PHARMACY DEGREE BY PHARMACY BOARD OF MALAYSIA*

***REGISTRATION OF PHARMACISTS ACT 1951***
***FIRST SCHEDULE***
***[Paragraph 6(1)(a)]***

***LIST OF REGISTRABLE QUALIFICATIONS***

| **Negara** *Country* | **Nama Institusi** *Name of Institution* | **Deskripsi kelayakan** *Description of qualification* |
|---|---|---|
| Malaysia | Universiti Sains Malaysia (USM) | Sarjana Muda Farmasi (Kepujian) |
| | Universiti Malaya (UM) | Sarjana Muda Farmasi (Kepujian) |
| | Universiti Kebangsaan Malaysia (UKM) | Sarjana Muda Farmasi (Kepujian) |
| | | Sarjana Muda Farmasi dengan Kepujian/ *Bachelor of Pharmacy with Honours (Recognised on 8 September 2022)* |
| | Universiti Teknologi MARA (UiTM) | Sarjana Muda Farmasi (Kepujian) |
| | | Sarjana Muda Farmasi dengan Kepujian/ *Bachelor of Pharmacy with Honours (Recognised on 31 October 2023)* |
| | Universiti Islam Antarabangsa | Sarjana Muda Farmasi (Kepujian) |
| | AIMST *University* | *Bachelor of Pharmacy (Hons)* |
| | UCSI *University* | *Bachelor of Pharmacy (Hons)* |
| | *International Medical University* (IMU) | *Bachelor of Pharmacy (Hons)* |
| | *International Medical University* (IMU) (*twinning with University of Strathclyde*) | *Master of Pharmacy* |
| | *University of Nottingham Malaysia Campus* | *Master of Pharmacy* |
| | *University of Cyberjaya (Formerly known as Cyberjaya University College of Medical Sciences)* | *Bachelor of Pharmacy (Hons)* |
| | MAHSA *University* | *Bachelor of Pharmacy (Hons)* |
| | | Sarjana Muda Farmasi dengan Kepujian / *Bachelor of Pharmacy with Honours (Recognized on 14 August 2024)* |
| | *SEGI University* | *Bachelor of Pharmacy (Hons)* |
| | | Sarjana Muda Farmasi dengan Kepujian / *Bachelor of Pharmacy with Honours (Recognized on 14 August 2024)* |
| | *Lincoln University College* | *Bachelor of Pharmacy (Hons) (Recognized on 1 June 2017)* |
| | *Monash University Malaysia* | *Bachelor of Pharmacy (Recognised on 1 January 2013)* |
| | | *Bachelor of Pharmacy (Hons) (Recognized on 1 January 2013)* |
| | *Management & Science University* | *Bachelor of Pharmacy (Hons) (Recognized on 24 October 2012))* |
| | *Taylor's University* | *Bachelor of Pharmacy (Hons) (Recognized on 7 July 2015)* |
| | *Asia Metropolitan University* (AMU) | *Bachelor of Pharmacy (Hons) (Recognized on 10 July 2017)* |

| **Negara**<br>*Country* | **Nama Institusi**<br>*Name of Institution* | **Deskripsi kelayakan**<br>*Description of qualification* |
|---|---|---|
| Malaysia | *University Kuala Lumpur – Royal College of Medicine Perak* | *Bachelor of Pharmacy (Hons)*<br>*(Recognized on 8 September 2017)* |
| | *KPJ Healthcare University (Formerly known as KPJ Healthcare University College)* | *Bachelor of Pharmacy (Hons)*<br>*(Recognized on 19 July 2017)* |
| | *QUEST International University [Formerly known as QUEST International University Perak (QIUP)]* | *Bachelor of Pharmacy (Hons)*<br>*(Recognized on 8 February 2019)* |
| | | Sarjana Muda Farmasi dengan Kepujian / *Bachelor of Pharmacy with Honours*<br>*(Recognized on 14 August 2024)* |
| | *Universiti Sultan Zainal Abidin* | *Bachelor of Pharmacy (Hons)*<br>*(Recognised on 27 January 2023)* |
| Arab Saudi<br>*Saudi Arabia* | *University of Riyadh / King Saud University* | *Bachelor of Pharmacy* |
| Australia | *University of Adelaide* | *Bachelor of Pharmacy* |
| | *Monash University,*<br>*Victorian College of Pharmacy* | *Bachelor of Pharmacy* |
| | *University of Sydney* | *Bachelor of Pharmacy* |
| | *University of Queensland* | *Bachelor of Pharmacy* |
| | | *Bachelor of Pharmacy (Hons)*<br>*(Recognized on 2 April 2015)* |
| | *The University of South Australia* | *Bachelor of Pharmacy* |
| | *The University of Tasmania* | *Bachelor of Pharmacy* |
| | *Curtin University of Technology* | *Bachelor of Pharmacy*<br>*(Recognized on 10 July 2017)* |
| | *Griffith University Goaldcoast* | *Bachelor of Pharmacy*<br>*(Recognition takes effect from 1 December 2023)* |
| | | *Bachelor of Pharmacy (Hons)*<br>*(Recognition takes effect from 1 December 2023)* |
| Kanada<br>*Canada* | *University of British Columbia* | *Bachelor of Science (Pharmacy)* |
| | *University of Alberta* | *Bachelor of Science (Pharmacy)* |
| | *Dalhousie University* | *Bachelor of Science (Pharmacy)* |
| United Kingdom | *University of Bath* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Aston in Birmingham* | *Bachelor of Pharmacy /*<br>*Master of Pharmacy* |
| | *University of Bradford* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Brighton* | *Bachelor of Science (Pharmacy) / Master of Pharmacy* |
| | *University of Wales'*<br>*College of Cardiff*<br>*Cardiff University* | *Bachelor of Pharmacy /*<br>*Master of Pharmacy* |
| | *De Montfort University Leicester* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *Liverpool John Moores University* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |

| **Negara**<br>*Country* | **Nama Institusi**<br>*Name of Institution* | **Deskripsi kelayakan**<br>*Description of qualification* |
|---|---|---|
| United Kingdom | *University of London*<br>*King's College of London*<br>*The School of Pharmacy*<br>*Chelsea College* | *Bachelor of Pharmacy / Master of Pharmacy* |
| | *University of Manchester* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Nottingham* | *Bachelor of Pharmacy /*<br>*Master of Pharmacy* |
| | | *Master of Pharmacy with Honours in Pharmacy (with Integrated Foundation Training)*<br>*(Recognition takes effect on 1 January 2027)* |
| | *University of Portsmouth* | *Bachelor of Science (Pharmacy) / Master of Pharmacy* |
| | *University of Sunderland* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Strathclyde* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *Robert Gordon's Institute of Technology, Aberdeen* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *Heriot-Watt University of Edinburgh* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Reading* | *Master of Pharmacy*<br>*(Recognized on 12 December 2015)* |
| | *University College London* | *Master of Pharmacy*<br>*(Recognized on 17 October 2017)* |
| | *University of East Anglia (UEA)* | *Master of Pharmacy (MPharm)*<br>*(Recognized on 1 January 2022)* |
| | | *Master of Pharmacy with Placement (MPharm)*<br>*(Recognized on 1 January 2023)* |
| Ireland | *The Queen`s University of Belfast, Northern Ireland* | *Bachelor of Science (Pharmacy) /*<br>*Master of Pharmacy* |
| | *University of Dublin* | *Bachelor of Science (Pharmacy)* |
| | *Royal College of Surgeons of Ireland* (RCSI) | *Master of Pharmacy (Recognised on 12 December 2015)* |
| Indonesia | *Bandung Institute of Technology* | Sarjana Sains Farmasi |
| | | Sarjana Muda Farmasi (*Pharmaceutical Science and Technology Programme*) *(Recognised from 17 April 2014 until 31 December 2018)* |
| | | Sarjana Muda Farmasi (*Clinical and Community Pharmacy Programme*) *(Recognised on 1 January 2018)* |
| | | Sarjana Farmasi *(Recognised on 11 February 2019)* |
| | *Gadjah Mada University* | Sarjana Sains Farmasi /<br>Sarjana Farmasi |
| | *Airlangga Soerabaya University* | Sarjana Sains Farmasi |
| | | Sarjana Farmasi<br>(*Recognised on 16 April 2018)* |

| **Negara**<br>*Country* | **Nama Institusi**<br>*Name of Institution* | **Deskripsi kelayakan**<br>*Description of qualification* |
|---|---|---|
| Indonesia | *Padjadjaran University* | Sarjana Sains Farmasi |
| | | Sarjana Farmasi<br>(*Recognised on 16 April 2018)* |
| | Universiti Sumatera Utara (USU) | Sarjana Muda Farmasi (*Pharmaceutical Science and Technology Programme*) (Recognised on 30 May 2014) |
| | | Sarjana Muda Farmasi (*Clinical and Community Pharmacy Programme*) (Recognised on 30 May 2014) |
| | | Sarjana Farmasi *(Recognised on 11 February 2019)* |
| | *Hasanuddin University* (UNHAS) | Sarjana Sains *(Recognised on 8 November 2011)* |
| Iraq | *University of Baghdad* | *Bachelor of Pharmacy* |
| Jepun<br>*Japan* | *Kyoto University* | *Bachelor of Pharmaceutical Science* |
| | *Nagoya City University* | *Bachelor of Science (Pharmacy)* |
| | *Kumamoto University* | *Bachelor of Pharmaceutical Science* |
| | *Tohuku University* | *Bachelor of Pharmacy* |
| | *Hokkaido University* | *Bachelor of Pharmacy* |
| | *Tokyo University of Science* | *Bachelor of Pharmacy* |
| New Zealand | *University of Otago* | *Bachelor of Pharmacy* |
| Mesir<br>*Egypt* | *Cairo University* | *Bachelor of Pharmaceutical Science* |
| | *Alexandria University* | *Bachelor of Pharmaceutical Science* |
| | | *Bachelor of Pharmaceutical Science (Clinical Pharmacy) (Recognised on 19 May 2015)* |
| | *Mansoura University* | *Bachelor of Pharmaceutical Science* |
| | | *Bachelor of Pharmacy (Clinical Pharmacy) (Recognised on 19 May 2015)* |
| | *Zagazig University* | *Bachelor of Pharmaceutical Science* |
| | | *Bachelor of Pharmaceutical Science (Clinical Pharmacy) (Recognised on 19 May 2015)* |
| | | *Bachelor of Pharmacy (Clinical Pharmacy) (Recognised on 10 July 2017)* |
| Singapura<br>*Singapore* | *National University of Singapore* | *Bachelor of Science (Pharmacy)* |
| Turki<br>*Turkey* | *University of Ankara* | *Bachelor of Pharmacy* |
| | *Hacettepe University* | *Bachelor of Pharmacy* |
| | *University of Istanbul* | *Bachelor of Pharmacy* |
| USA | *University of Wisconsin* | *Bachelor of Science (Pharmacy) / Doctor of Pharmacy* |
| | *University of Iowa* | *Bachelor of Science (Pharmacy) / Doctor of Pharmacy* |
| | *University of Kansas* | *Bachelor of Science (Pharmacy) / Doctor of Pharmacy* |

| **Negara**<br>*Country* | **Nama Institusi**<br>*Name of Institution* | **Deskripsi kelayakan**<br>*Description of qualification* |
|---|---|---|
| USA | *South Western Oklahoma State University* | *Bachelor of Science (Pharmacy) /*<br>*Doctor of Pharmacy* |
| | *Ohio State University* | *Bachelor of Science (Pharmacy) /*<br>*Doctor of Pharmacy* |
| | *Massachusetts College of Pharmacy and Allied Health Sciences* | *Bachelor of Science (Pharmacy) /*<br>*Doctor of Pharmacy* |
| | *Northeast Lousiana University /*<br>*University of Lousiana* | *Bachelor of Science (Pharmacy) /*<br>*Doctor of Pharmacy* |
| | *Medical University of South Carolina* | *Bachelor of Science (Pharmacy) /*<br>*Doctor of Pharmacy* |
| | *Idaho State University* | *Doctor of Pharmacy* |
| | *University of Toledo* | *Bachelor of Pharmacy /*<br>*Doctor of Pharmacy* |
| | *Butler University, Indiana* | *Bachelor of Pharmacy /*<br>*Doctor of Pharmacy* |
| | *University of North Carolina* | *Doctor of Pharmacy* |
| India | *Banaras Hindu University* | *Bachelor of Pharmacy* |
| | *Nagpur University* | *Bachelor of Pharmacy* |
| Pakistan | *Punjab University, Lahore / University of the Punjab Allama Iqbal Campus* | *Bachelor of Pharmacy /*<br>*Doctor of Pharmacy* |
| Taiwan | *National Taiwan University* | *Bachelor of Science (Pharmacy)*<br>***(before 4th July 1997, excluded from recognition)*** |
| | *Kaohsiung Medical College /*<br>*Kaohsiung Medical University* | *Bachelor of Science (Pharmacy)*<br>***(before 30th November 1998, excluded from recognition)*** |
| | *Taipei Medical College /*<br>*Taipei Medical University* | *Bachelor of Science (Pharmacy)*<br>***(before 4th November 1999, excluded from recognition)*** |
| *United Arab Emirates* | *Gulf Medical University* | *Doctor of Pharmacy (Hons)*<br>*(Recognised on 17 April 2014)* |
| *Jordan* | *Zarqa University* | *Bachelor of Pharmacy*<br>*(Recognised on 14 May 2024)* |

## 2.0 AKTIVITI DAN SOROTAN | *ACTIVITIES AND HIGHLIGHTS*

### KURSUS PEMERKASAAN PROFESION AHLI FARMASI – INFORMASI TERKINI BERSAMA BAHAGIAN LEMBAGA FARMASI MALAYSIA (BLFM)

Pada tahun 2025, Bahagian Lembaga Farmasi Malaysia telah mengadakan Kursus Pemerkasaan Profesion Ahli Farmasi – Informasi Terkini Bersama Bahagian Lembaga Farmasi Malaysia (BLFM). Objektif kursus ini adalah untuk menyalurkan informasi terkini berkenaan profesion ahli farmasi yang merangkumi etika dan integriti dalam profesion ahli farmasi, *credentialing* ahli farmasi berdaftar Kementerian Kesihatan Malaysia (KKM) dan amalan farmasi dan perekodan di farmasi komuniti mengikut keperluan Akta dalam *Community Pharmacy Benchmarking Guideline (CPBG) Third Edition* 2025. Seramai 42 orang Pegawai Farmasi dari setiap negeri dan juga Hospital Kuala Lumpur telah dijemput sebagai peserta dalam kursus ini.

### *PHARMACIST PROFESSION EMPOWERMENT COURSE – LATEST UPDATES WITH THE PHARMACY BOARD MALAYSIA DIVISION (BLFM)*

*In 2025, the Pharmacy Board of Malaysia Division organized the Pharmacist Profession Empowerment Course – Latest Updates with the Pharmacy Board Malaysia Division (BLFM). The objective of this course was to disseminate the latest information related to the pharmacy profession, including ethics and integrity in the pharmacist profession, credentialing of registered pharmacists under the Ministry of Health Malaysia (MOH), as well as pharmacy practice and record-keeping in community pharmacies in accordance with the requirements of the Act as outlined in the Community Pharmacy Benchmarking Guideline (CPBG), Third Edition 2025. A total of 42 pharmacists from every states and Kuala Lumpur Hospital, were invited to participate in this course.*





Peserta Kursus Pemerkasaan Profesion Ahli Farmasi – Informasi Terkini Bersama Bahagian Lembaga Farmasi Malaysia (BLFM)
*Pharmacist Profession Empowerment Course – Latest Updates With The Pharmacy Board Malaysia Division (PBMD)*

### SESI LIBAT URUS DENGAN JABATAN KESIHATAN NEGERI SABAH DAN SABAH PHARMACEUTICAL SOCIETY BERHUBUNG AKTA PENDAFTARAN AHLI FARMASI 1951 [*AKTA 371*]

Seksyen Etika Farmasi telah mengadakan satu sesi libat urus dengan Jabatan Kesihatan Negeri Sabah dan Sabah Pharmaceutical Society pada 12 Disember 2025. Sesi libat urus ini telah dihadiri oleh seramai 20 orang, antaranya adalah Timbalan Ketua Pengarah Kanan (Perkhidmatan Farmasi), Pengarah Jabatan Kesihatan Negeri Sabah, Pengarah Bahagian Penguatkuasaan Farmasi, Pengarah Bahagian Lembaga Farmasi, Timbalan Setiausaha Bahagian Dasar dan Hubungan Antarabangsa, Timbalan Pengarah Kesihatan Negeri (Farmasi) Sabah, Timbalan-Timbalan Pengarah Bahagian Lembaga Farmasi Malaysia, wakil-wakil daripada Sabah Pharmaceutical Society dan wakil-wakil daripada Program Perkhidmatan Farmasi serta Jabatan Kesihatan Negeri Sabah.

### *ENGAGEMENT SESSION WITH THE SABAH STATE HEALTH DEPARTMENT AND SABAH PHARMACEUTICAL SOCIETY REGARDING THE REGISTRATION OF PHARMACISTS ACT 1951 [ACT 371]*

*The Pharmacy Ethics Section held an engagement session with the Sabah State Health Department and the Sabah Pharmaceutical Society on December 12, 2025. The session was attended by 20 individuals, including the Deputy Director-General of Health (Pharmaceutical Services), the Director of the Sabah State Health Department, the Director of the Pharmacy Enforcement Division, the Director of the Pharmacy Board Malaysia Division, the Deputy Under Secretary of the Policy and International Relations Division, the Deputy State Health Director (Pharmacy) of Sabah, Deputy Directors of the Pharmacy Board Malaysia Division, representatives from the Sabah Pharmaceutical Society, and representatives from the Pharmaceutical Services Program and the Sabah State Health Department.*

Sesi libat urus ini diadakan bertujuan untuk memberi penerangan kepada Jabatan Kesihatan Negeri Sabah dan Sabah Pharmaceutical Society berkaitan Akta Pendaftaran Ahli Farmasi 1951 [*Akta 371*] dan kepentingan pemerluasan akta ini ke negeri Sabah. Hasil sesi libat urus ini adalah Jabatan Kesihatan Negeri Sabah dan Sabah Pharmaceutical Society akan mempertimbangkan pemerluasan Akta 371 ke negeri Sabah secepat mungkin. Seterusnya, satu sesi libat urus akan diadakan bersama Peguam Besar Negeri Sabah untuk memberi taklimat berhubung kepentingan pemerluasan Akta 371 ke negeri Sabah dan mengesyorkan kepada Ketua Menteri Sabah untuk menerima cadangaan pemerluasan ini.

*The purpose of this engagement session was to provide a briefing to the Sabah State Health Department and the Sabah Pharmaceutical Society regarding the Registration of Pharmacists Act 1951 [Act 371] and the importance of extending this Act to the state of Sabah. As a result of this session, the Sabah State Health Department and the Sabah Pharmaceutical Society will consider the extension of Act 371 to Sabah as soon as possible. Subsequently, an engagement session will be held with the Sabah State Attorney General to give briefing on the importance of extending Act 371 to Sabah and to recommend that the Chief Minister of Sabah accept the proposal for this extension.*



Sesi Libat Urus Dengan Jabatan Kesihatan Negeri Sabah Dan Sabah Pharmaceutical Society Berhubung Akta Pendaftaran Ahli Farmasi 1951 [*Akta 371*]

*Engagement Session With The Sabah State Health Department And Sabah Pharmaceutical Society Regarding The Registration Of Pharmacists Act 1951 [Act 371]*

## KURSUS LANJUTAN PENYIASATAN KES SALAH LAKU PROFESIONAL AHLI FARMASI BERDAFTAR & PERTUBUHAN PERBADANAN BERDAFTAR

Seksyen Etika Farmasi telah menganjurkan Kursus Lanjutan Penyiasatan Kes Salah Laku Profesional Ahli Farmasi Berdaftar dan Pertubuhan Perbadanan Berdaftar pada 13 Februari 2025. Kursus tersebut telah dihadiri oleh seramai 40 orang peserta yang terdiri daripada ahli Jawatankuasa Siasatan yang dilantik oleh Lembaga Farmasi Malaysia di bawah Akta Pendaftaran Ahli Farmasi 1951 [*Akta 371*].

Kursus ini diadakan untuk meningkatkan kefahaman ahli Jawatankuasa Siasatan dalam mengendalikan siasatan kes disiplin ke atas ahli farmasi berdaftar dan pertubuhan perbadanan berdaftar berdasarkan peruntukan di bawah Akta 371 dan peraturannya serta *Code of Ethics for Pharmacists 2018*. Selain itu, terdapat juga perkongsian pengalaman dalam mengendalikan siasatan kes disiplin melibatkan profesion kesihatan lain bersama wakil dari *Malaysian Medical Council* dan *Malaysian Dental Council* bagi pengamal perubatan berdaftar dan pengamal pergigian berdaftar.

## *ADVANCED COURSE ON DISCIPLINARY CASE INVESTIGATION AGAINST REGISTERED PHARMACISTS AND REGISTERED BODIES CORPORATE*

*This course was held to enhance the COI members' understanding of handling disciplinary case investigations against registered pharmacists and registered bodies corporate, based on the provisions under Act 371 and its regulations, as well as the Code of Ethics for Pharmacists 2018. Apart from that, there was also a sharing of experience in handling disciplinary case investigations involving other healthcare professions, namely registered medical practitioners and registered dental practitioners from representatives of Malaysian Medical Council and Malaysian Dental Council.*

*The Pharmacy Ethics Section organized the Advanced Course on Disciplinary Case Investigation Against Registered Pharmacists and Registered Bodies Corporate on February 13, 2025. The course was attended by 40 participants, comprising members of the Committee of Inquiry (COI) appointed by the Pharmacy Board of Malaysia under the Registration of Pharmacists Act 1951 [Act 371].*



Peserta Kursus Lanjutan Penyiasatan Kes Salah Laku Profesional Ahli Farmasi Berdaftar dan Pertubuhan Perbadanan
*Participants of the Advanced Course On Disciplinary Case Investigation Against Registered Pharmacists And Registered Bodies Corporate*

**LATIHAN SANGKUTAN DI 'PHARMACY COUNCIL OF THAILAND" BERHUBUNG:**

**i) TATAKELAKUAN DAN ETIKA AHLI FARMASI, JENIS KESALAHAN DAN PROSES SIASATAN**

**ii) KERANGKA PERAKUAN DAN PENSIJILAN LATIHAN PENGKHUSUSAN / CREDENTIALING AHLI FARMASI**

BLFM telah menghantar dua (2) orang pegawai farmasi bagi menghadiri latihan jangka pendek luar negara di *Pharmacy Council of Thailand*, Nonthaburi, Thailand pada 10-13 Jun 2025 yang bertujuan untuk mempelajari:

- Undang-undang dan peraturan-peraturan berkaitan ahli farmasi.
- Peruntukan undang-undang dan etika berkaitan kesalahan dan hukuman ke atas salah laku profesional ahli farmasi.
- Proses inkuiri dan siasatan disiplin.
- Kod Etika Ahli Farmasi.
- Inisiatif yang dilaksanakan bagi meningkatkan kesedaran berhubung pematuhan Kod Etika Ahli Farmasi.
- Kerangka *credentialing* (termasuk modul latihan, premis latihan, preseptor, proses perakuan dan senarai daftar) ahli farmasi.
- Perakuan dan pensijilan latihan pengkhususan ahli farmasi.

***ATTACHMENT WITH THE PHARMACY COUNCIL OF THAILAND REGARDING:***

***i) PHARMACY ETHICAL CONDUCT, OFFENCES AND INVESTIGATION PROCESS***

***ii) FRAMEWORK OF RECOGNITION AND CERTIFICATION ON SPECIALIZED TRAINING BY BOARD OF PHARMACEUTICAL SPECIALTY***

*A short-term training at the Pharmacy Council of Thailand (PCT) Nonthaburi, Thailand on 10-13 June 2025 had been attended by two (2) PBMD officers, in view to learn:*

- *Overview of the laws and regulations concerning pharmacists.*
- *Ethical and legal provisions related to offences and punishments of pharmacists who have committed unethical conduct.*
- *Disciplinary inquiry processes.*
- *Code of Ethics for Pharmacists*
- *Initiatives to raise awareness of compliance with the Code of Ethics for Pharmacists.*
- *Credentialing framework (training modules, training facilities, preceptors, recognition process and registry) for pharmacists.*
- *Recognition and certification of specialized training for pharmacists.*






Latihan Sangkutan Di *Pharmacy Council Of Thailand* dan *Government Pharmaceutical Organization* (GPO), Rangsit pada 10-13 Jun 2025

*Attachment At The Pharmacy Council Of Thailand & GPO Rangsit Plant, 10-13 June 2025*

## BENGKEL *'TRAINING OF PRECEPTORS (TOP)'* BAGI PENGIKTIRAFAN *PRINCIPAL PRECEPTOR'* DAN *'MASTER PRECEPTOR'* UNTUK MENGENDALI LATIHAN PROVISIONAL SECARA LIBERALISASI KEPADA AHLI FARMASI PROVISIONAL (PRP) 2025

Pada tahun 2025, Bahagian Lembaga Farmasi Malaysia telah mengadakan 2 kali Bengkel *Training of Preceptors (TOP*) yang melibatkan seramai 96 peserta dari sektor Farmasi komuniti, Hospital Swasta, Industri Farmaseutikal Mengilang, Industri Farmaseutikal Tidak Mengilang dan R&D Akademia.

Objektif bengkel adalah untuk:

i. Memberi panduan dan latihan kepada *'Principal'* dan '*Master Preceptor'* untuk pengendalian latihan PRP secara liberalisasi di fasiliti latihan liberalisasi.
ii. Memberi penerangan dan latihan secara terperinci tentang penggunaan dan pengisian buku log latihan PRP di sektor terbabit.

## *TRAINING OF PERCEPTORS (TOP) WORKSHOPS TO ACCREDIT PRINCIPAL AND MASTER PRECEPTORS TO CONDUCT LIBERALISED INTERN TRAINING FOR PROVISIONALLY REGISTERED PHARMACIST (PRP) 2025*

*In 2025 Pharmacy Board Malaysia Division has held 2 sessions of Training of Preceptors (TOP) workshops for 96 candidates from Community Pharmacy, Private Hospital, Manufacturing Pharmaceutical Industry, Non Manufacturing Pharmaceutical Industry and R&D Academia.*

*The objectives of this workshop were:*

*i. To provide guidance and training to the Principal and Master preceptors to conduct intern training in liberalised training facilities.*
*ii. To provide detailed information and training for the usage and filling in of the training logbooks in the relevant sector.*

Bengkel *'Training Of Preceptors (TOP)'* bagi pengiktirafan *Principal Preceptor'* Dan '*Master Preceptor'* Bagi Latihan Provisional Secara Liberalisasi Kepada Ahli Farmasi Provisional (PRP) 2025

*Training of Perceptors (TOP) Workshop to Accredit Principal And Master Preceptors to Conduct Liberalised Intern Training for Provisionally Registered Pharmacist (PRP) 2025*

| **Sesi /** *Session* | **Jenis Premis /** *Type of Premises* | **Bil. Peserta /** *No. of participants* |
|---|---|---|
| Pertama *First* 11 Mac 2025 *11 March 2025* | R&D Akademia *R&D Academia* | 14 |
| | Hospital Swasta *Private Hospital* | 4 |
| | Industri Farmaseutikal Mengilang *Manufacturing Pharmaceutical Industry* | 1 |
| | Industri Farmaseutikal Tidak Mengilang *Non-Manufacturing Pharmaceutical Industry* | 2 |
| | Farmasi Komuniti *Community Pharmacy* | 10 |

| **Sesi /** *Session* | **Jenis Premis /** *Type of Premises* | **Bil. Peserta /** *No. of participants* |
|---|---|---|
| Kedua *Second* 22 Julai 2025 *22 July 2025* | R&D Akademia *R&D Academia* | 13 |
| | Hospital Swasta *Private Hospital* | 14 |
| | Industri Farmaseutikal Mengilang *Manufacturing Pharmaceutical Industry* | 9 |
| | Industri Farmaseutikal Tidak Mengilang *Non-Manufacturing Pharmaceutical Industry* | 3 |
| | Farmasi Komuniti *Community Pharmacy* | 26 |

## DIALOG BERSAMA PRESEPTOR DAN PRP DI FASILITI LATIHAN KEMENTERIAN KESIHATAN BERHUBUNG LATIHAN AHLI FARMASI PROVISIONAL (PRP)

Dialog bersama preseptor dan PRP di fasiliti latihan KKM berhubung latihan PRP telah diadakan sebanyak dua (2) sesi secara hibrid pada ketetapan seperti berikut:

Objektif dialog ini adalah seperti berikut:

i. Menyampaikan maklumat terkini berhubung latihan PRP kepada preseptor
ii. Membincangkan isu-isu berkaitan latihan PRP di fasiliti KKM

## *DIALOGUE WITH THE PRECEPTORS AND PROVISIONALLY REGISTERED PHARMACIST (PRP) FROM THE MINISTRY OF HEALTH TRAINING FACILITIES REGARDING TRAINING OF THE PRP*

*Dialogue with the preceptors and PRP from the Ministry of Health (MOH) training facilities has been conducted in hybrid two (2) times as below:*

*The objectives of the dialogue were as below:*

*i. This dialogue served as a platform to disseminate updates and related information to the preceptors regarding PRP training.*
*ii. As a sharing session for preceptors to discuss any issues related to PRP training.*

| **Sesi** *Session* | **Zon / Negeri** *Zone / State* | **Lokasi** *Venue* | **Jumlah Peserta** *Participants* | |
|---|---|---|---|---|
| | | | **Preseptor** | **PRP** |
| Pertama *First* 17 Jun 2025 *17 June 2025* | Zon Pantai Timur (Terengganu, Kelantan dan Pahang) Secara Hybrid | Bahagian Perkhidmatan Farmasi Negeri Terengganu | 104 | 69 |
| Kedua *Second* 23 September 2025 *23 September 2025* | Zon Malaysia Timur (WP Labuan, Sabah dan Sarawak) | Jabatan Kesihatan Negeri Wilayah Persekutuan Labuan | 105 | 35 |

*Dialog Bersama Preseptor dan PRP di Fasiliti Latihan Kementerian Kesihatan Berhubung Latihan Ahli Farmasi Provisional (PRP)*
*Dialogue With the Preceptors and PRPs From the Ministry of Health Training Facilities Regarding Training of The Provisionally Registered Pharmacist (PRP)*

## LAWATAN PEMANTAUAN PERJALANAN LATIHAN PROVISIONAL DI PREMIS LATIHAN BAGI AHLI FARMASI BERDAFTAR PROVISIONAL (PRP)

Bahagian Lembaga Farmasi Malaysia (BLFM) telah mengadakan lawatan pemantauan perjalanan latihan provisional di kedua-dua premis kerajaan dan liberalisasi.

Tujuan lawatan ini adalah untuk memastikan perjalanan latihan di premis latihan adalah berjalan mengikut keperluan buku log dan juga bagi mengenal pasti isu-isu yang dihadapi di premis latihan oleh preseptor dan juga PRP.

## *VISIT TO PROVISIONALLY REGISTERED PHARMACIST TRAINING PREMISES TO MONITOR TRAINING ACTIVITIES*

*Pharmacy Board Malaysia Division (PBMD) has visited both training premises under Ministry of Health (MOH) and also Liberalised premises. The objective of these visits is to ensure that the training being conducted in training facilities are in accordance to log books and also to identify issues faced by the preceptors and also PRPs in training facilities.*

| **Negeri**<br>*State* | **Nama Premis**<br>*Premise Name* | **Tarikh Lawatan**<br>*Visit Date* |
|---|---|---|
| Terengganu | Hospital Sultanah Nur Zahirah | 18 Jun 2025<br>*18 June 2025* |
| | Klinik Kesihatan Hiliran | |
| WP Labuan | Hospital Labuan | 24 September 2025<br>*24 September 2025* |
| | Klinik Kesihatan Labuan | |

## 3.0 PENCAPAIAN DAN PENGIKTIRAFAN | *ACHIEVEMENT AND RECOGNITION*

### LAWATAN PENGIKTIRAFAN PROGRAM IJAZAH FARMASI

Program Ijazah Farmasi adalah program yang dikawal selia oleh Badan Profesional iaitu Lembaga Farmasi Malaysia (LFM). LFM bertanggungjawab memastikan semua Pemberi Pendidikan Tinggi (PPT) yang menawarkan Program Ijazah Farmasi mematuhi keperluan yang ditetapkan di dalam *Standards for Undergraduate Pharmacy Programme 2024.* Pematuhan terhadap keperluan ini adalah penting bagi memastikan program ijazah farmasi yang ditawarkan oleh PPT berkenaan layak untuk diiktiraf.

Lawatan Pengiktirafan Semula program ijazah farmasi oleh Ahli Panel Penilai (APP) LFM akan dilaksanakan apabila sesebuah program tersebut menghampiri tempoh pembaharuan akreditasi. Lawatan ini bertujuan untuk menilai tahap pematuhan program terhadap *Standards for Undergraduate Pharmacy Programme 2024* sebelum syor untuk pemberian pengiktrafan semula dikemukakan kepada LFM.

Lawatan Pemantauan pula adalah proses pemantauan yang dijalankan oleh LFM bagi menilai pelaksanaan serta pematuhan berterusan Program Ijazah Farmasi terhadap standard dan keperluan yang ditetapkan. Lawatan ini bertujuan untuk menilai tindakan penambahbaikan yang telah diambil oleh PPT, mengenal pasti isu berbangkit, serta memastikan kualiti pelaksanaan program dikekalkan sepanjang tempoh pengiktirafan.

LFM juga terlibat dalam lawatan pengiktirafan penuh program farmasi yang ditawarkan oleh institusi pendidikan tinggi di luar negara. Lawatan pengiktirafan penuh ialah penilaian menyeluruh yang dijalankan oleh APP LFM bagi tujuan pemberian pengiktirafan serta memastikan Program Ijazah Farmasi yang ditawarkan di luar negara selaras dengan standard yang diguna pakai di Malaysia.

Sepanjang tahun 2025, sebanyak lima belas aktiviti berkaitan pengiktirafan program ijazah farmasi telah dilaksanakan seperti berikut:

### *PHARMACY DEGREE PROGRAMME RECOGNITION VISIT*

*The Pharmacy Degree Program is regulated by the Pharmacy Board Malaysia (PBM), the governing professional body for pharmacist in Malaysia. PBM is responsible for ensuring that all Higher Education Providers (HEP) offering the Pharmacy Degree Programme comply with the requirements stipulated in the Standards for Undergraduate Pharmacy Programme 2024. Compliance with these requirements is essential to ensure that the pharmacy degree programme offered by the respective HEP is eligible for recognition.*

*Re-accreditation visits for the pharmacy programme by the PBM panel of assessors are conducted when a programme approaches the accreditation renewal period. The purpose of these visits is to assess the programme's level of compliance with the Standards for Undergraduate Pharmacy Programme 2024 prior to submitting a recommendation for re-accreditation to PBM.*

*A monitoring visit refers to a monitoring process carried out by the PBM to evaluate the implementation and continued compliance of the pharmacy programme with the prescribed standards and requirements. The visit aims to assess improvement actions undertaken by the HEP, identify emerging issues, and ensure that programme quality is maintained throughout the recognition period.*

*PBM is also involved in the full accreditation visit for pharmacy degree programmes offered by higher education institutions overseas. A full accreditation visit is a comprehensive evaluation conducted by PBM's Panel of Assessors to grant recognition and to ensure that the overseas Pharmacy Degree Programme aligns with the standards adopted in Malaysia.*

*In 2025, a total of fifteen activities related to the recognition of the pharmacy program were carried out, as outlined below:*

| | | |
|---|---|---|
| **Lawatan Pengiktirafan Semula**<br>*Re-accreditation Visit* | | |
| 1. | Bachelor of Pharmacy (Hons)/ MAHSA University | 22 – 24 Januari 2025<br>*22 January – 24 January 2025* |
| 2. | *Bachelor of Pharmacy (Hons)/* Universiti Kuala Lumpur *Royal College of Medicine Perak* | 26 – 28 Februari 2025<br>*26 February – 28 February 2025* |
| 3. | *Bachelor of Pharmacy (Hons)/ Lincoln University College* | 22 – 24 April 2025<br>*22 April – 24 April 2025* |
| 4. | *Bachelor of Pharmacy (Hons)/ University of Cyberjaya* | 17 – 18 Jun 2025<br>*17 June – 18 June 2025* |
| 5. | *Bachelor of Pharmacy (Hons)/ AIMST University* | 12 – 14 Ogos 2025<br>*12 August – 14 August 2025* |
| 6. | *Bachelor of Pharmacy with Honours/* Universiti Kebangsaan Malaysia (UKM) | 23 – 25 September 2025<br>*23 September – 25 September 2025* |
| 7. | *Bachelor of Pharmacy (Hons)/ Taylor's University* | 1 – 3 Oktober 2025<br>*1 October – 3 October 2025* |
| 8. | *Bachelor of Pharmacy (Hons)/* Universiti Sultan Zainal Abidin (UniSZA) | 6 – 8 Oktober 2025<br>*6 October – 8 October 2025* |
| **Lawatan Pengiktirafan Penuh**<br>*Full Accreditation Visit* | | |
| 9. | *Bachelor Science of Pharmacy (Hons) & Doctor of Pharmacy (PharmD)/ Jordan University of Science and Technology* | 22 – 28 Februari 2025<br>*22 February – 28 February 2025* |
| 10. | *Master of Pharmacy/ Newcastle University, United Kingdom* | 13 – 17 Oktober 2025<br>*13 October – 17 October 2025* |
| **Lawatan Pemantauan**<br>*Monitoring Visit* | | |
| 11. | *Bachelor of Pharmacy (Hons)/ Management & Science University (MSU)* | 15 – 16 Oktober 2025<br>*15 October – 16 October 2025* |
| 12. | *Bachelor of Pharmacy with Honours/ Quest International University (QIU)* | 13 – 14 November 2025<br>*13 November – 14 November 2025* |
| 13. | *Bachelor of Pharmacy (Hons)/ KPJ Healthcare University (KPJU)* | 20 – 21 November 2025<br>*20 November – 21 November 2025* |
| **Lawatan Pemantauan Pengiktirafan Sementara**<br>*Monitoring Visit (Provisional Recognition)* | | |
| 14. | *Bachelor of Pharmacy (Hons)/ Nottingham University Malaysia* | 16 April – 17 April 2025<br>*16 April – 17 April 2025* |
| 15. | *Bachelor of Pharmacy (Hons)/ University College MAIWP International* | 16 – 17 Julai 2025<br>*16 July – 17 July 2025* |

## AKTIVITI LAWATAN PENGIKTIRAFAN PROGRAM FARMASI
## *ACTIVITIES RELATED TO PHARMACY PROGRAMME RECOGNITION VISITS*



MAHSA University
22 – 24 Januari 2025




UniKL – RCMP
26 – 28 Februari 2025



Jordan University of Science & Technology
22 – 24 Januari 2025




Nottingham University Malaysia
16 – 17 April 2025



Lincoln University College
22 – 24 April 2025




University of Cyberjaya
17 – 18 Jun 2025




Universiti Kebangsaan Malaysia
23 – 25 September 2025



Taylor's University
1 – 3 Oktober 2025




UCMI
16 – 17 Julai 2025



AIMST University
12 – 14 Ogos 2025




UniSZA
6 – 8 Oktober 2025



Newcastle University, UK
13 – 17 Oktober 2025



Management & Science University
15 – 16 Oktober 2025




Quest International University
13 – 14 November 2025



KPJU
20 – 21 November 2025

## 4.0 PENERBITAN DAN KAJIAN | *PUBLICATION AND RESEARCH*

### COMMUNITY PHARMACY BENCHMARKING GUIDELINE




Garis panduan ini berfungsi sebagai satu penanda aras keperluan yang perlu dipatuhi bagi penubuhan farmasi komuniti, aktiviti latihan (prasiswazah / pra-pendaftaran), audit dan keperluan pelesenan

*This benchmarking guideline serves as a set of standards that needs to be complied with for the purpose of community pharmacy practice set up, training activities (undergraduate / pre-registration), audits and complementing the licensing requirement.*

# GLOSARI TERMA, SINGKATAN DAN AKRONIM

## *GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS*

# GLOSARI TERMA, SINGKATAN DAN AKRONIM
## *GLOSSARY OF TERMS, ABBREVIATIONS AND ACRONYMS*

| | |
|---|---|
| AC | *Anticoagulation* |
| ACCSQ | *ASEAN Consultative Committee for Standards and Quality* |
| ACTLC | *ASEAN Cosmetic Testing Laboratories Committee* |
| APTLC | *ASEAN Pharmaceutical Testing Laboratory Committee* |
| ADAF | Audit Dalam Amalan Farmasi |
| ADR | Kesan Advers Ubat<br>*Adverse Drug Reaction* |
| ADC | *ASEAN Leaders Declaration of Commitment* |
| ADSSR | *ASEAN Drug Security and Self-Reliance* |
| ADxSSR | *ASEAN Diagnostic Security and Self-Reliance* |
| AEB \| GDP | Amalan Pengedaran Baik<br>*Good Distribution Practice* |
| AEC | *ASEAN Economic Community* |
| AEFI | *Adverse Events Following Immunisation* |
| AFSN | *Asian Forensic Science Network* |
| AHC | *ASEAN Health Cluster* |
| AKI | Anugerah Khas Inovasi |
| AKPS \| MCBA | Agensi Kawalan dan Perlindungan Sempadan<br>*Malaysia Control and Border Protection Agency* |
| AIKKM | Anugerah Inovasi Kementerian Kesihatan Malaysia |
| AMB \| GLP | Amalan Makmal Baik<br>*Good Laboratory Practice* |
| AMS | *ASEAN Member States* |
| AMS | *Antimicrobial stewardship* |
| APB \| GMP | Amalan Perkilangan Baik<br>*Good Manufacturing Practice* |
| APPL | *Approved Products Purchase List* |
| APRP | *ASEAN Pharmaceutical Regulatory Policy* |
| ASCC | *ASEAN Socio-Cultural Community* |
| ASEAN | *Association of Southeast Asian Nations* |
| ATPMs | *Advanced Therapy Medicinal Products* |
| AVSSR | *ASEAN Vaccine Security and Self-Reliance* |
| BDPSF | Bahagian Dasar dan Perancangan Strategik Farmasi |
| BE | Bioekuivalens |
| BIA | Analisis Impak Bajet<br>*Budget Impact Analysis* |
| BLFM \| PBMD | Bahagian Lembaga Farmasi Malaysia<br>*Pharmacy Board Malaysia Division* |
| BPF \| PED | Bahagian Penguatkuasaan Farmasi<br>*Pharmacy Enforcement Division* |
| BPF | Bahagian Perkhidmatan Farmasi |
| CAPD/HD | *Peritoneal Dialysis/ Haemodialysis* |
| CEA | *Cost-effectiveness analysis* |
| CEPI | *Coalition for Epidemic Preparedness Innovations* |
| CFS | *Certificate of Free Sale* |
| CND | *Commission on Narcotic Drugs* |
| COH | *Change of Product Registration Holder* |
| COI | *Committee of Inquiry* |
| COS | *Change of Manufacturing Site* |
| COSTI | *Committee on Science, Technology and Innovation* |
| CPD | Pembangunan Profesional Berterusan<br>*Continuous Professional Development* |
| CPE | *Continuous Pharmacy Education* |
| CPF | Cawangan Penguatkuasaan Farmasi |
| CPP | *Certificate of Pharmaceutical Products* |
| CTIL \| LIPK | Lesen Import Percubaan Klinikal<br>*Clinical Trial Import License* |
| CTX | Kebenaran Mengilang untuk Percubaan Klinikal<br>*Clinical Trial Exemption* |
| CUA | *Cost-utility analysis* |
| DDSA | Dimensi Daya Saing Agensi<br>*Agency Competitiveness Dimension* |
| DET | *Disablity Equality Training* |
| DRN | *Digital Regulatory Notification* |
| DUNas | Dasar Ubat Nasional |
| ERAT | *Empowering Patients Living with Diabetes* |
| ERIA | *Economic Research Institute for ASEAN and East Asia* |
| FRP | Ahli Farmasi Berdaftar Penuh<br>*Fully Registered Pharmacist* |
| FUKKM \| MOHMF | Formulari Ubat-ubatan Kementerian Kesihatan Malaysia<br>*Ministry of Health Medicines Formulary* |
| GBT | *Global Benchmarking Tool* |
| GCP | *Good Clinical Practice* |
| GLP | *Good Laboratory Practice* |
| HKL | Hospital Kuala Lumpur |
| HMR | *Home Medication Review* |
| HTA | *Health Technology Assessment* |
| ICAPS | *Initiative for Coordinated Antidotes in the South-East Asia Region* |
| ICQS | Kompleks Imigresen, Kastam, Kuarantin dan Keselamatan |

| | |
|---|---|
| ICSR | *Individual Case Safety Reports* |
| ICT | Teknologi Maklumat dan Komunikasi |
| ICU | *Intensive Care Unit* |
| IHPP | *International Health Policy Program* |
| IIM | Institut Integriti Malaysia |
| IJN | Institut Jantung Negara |
| IKN | Institut Kanser Negara |
| ILC | *Inter-Laboratory Comparison* |
| Ipharm | *Malaysian Institute of Pharmaceuticals and Nutraceuticals* |
| IPKKM | Ibu Pejabat Kementerian Kesihatan Malaysia |
| IPT | Institut Pengajian Tinggi |
| IPTS | Institut Pengajian Tinggi Swasta |
| ISF | *Incident and Substandard/Falsified* |
| iTRES | *Intelligent Tracking & Recording Exhibit System* |
| IVI | *International Vaccine Institute* |
| JKDM | Jabatan Kastam Diraja Malaysia<br>*Royal Malaysian Customs Department* |
| JKN | Jabatan Kesihatan Negeri |
| JKUT | Jawatankuasa Ubat dan Terapeutik<br>*Drug and Therapeutics Committee* |
| JPPIF | Jawatankuasa Panel Penilai Inovasi Farmasi |
| KIK | Kumpulan Inovatif dan Kreatif |
| KK | Klinik Kesihatan |
| KKM \| MOH | Kementerian Kesihatan Malaysia<br>*Ministry of Health* |
| KPDN | Kementerian Perdagangan Dalam Negeri dan Kos Sara Hidup<br>*Ministry of Domestic Trade and Cost of Living* |
| KPHU | Kajian Pemantauan Harga Ubat |
| KPI | Petunjuk Prestasi Utama<br>*Key Performance Indicator* |
| KPT \| MOHE | Kementerian Pengajian Tinggi<br>*Ministry of Higher Education* |
| LIU \| MAB | Lembaga Iklan Ubat<br>*Medicines Advertisement Board* |
| MADRAC | Jawatankuasa Penasihat Kesan Advers Malaysia<br>*Malaysian Adverse Drug Reactions Advisory Committee* |
| MCBA | Agensi Kawalan dan Perlindungan Sempadan<br>*Malaysia Control and Border Protection Agency* |
| MDA | *Medical Device Authority* |

| | |
|---|---|
| MERS | Sistem Pelaporan Kesilapan Pengubatan |
| MIDA | Lembaga Pembangunan Pelaburan Malaysia<br>*Malaysian Investment Development Authority* |
| ML3 | *Maturity Level 3* |
| MOSTI | Kementerian Sains, Teknologi dan Inovasi<br>*Ministry of Science, Technology and Innovation* |
| MoU | Memorandum Persefahaman<br>*Memorandum of Understanding* |
| MPC | Perbadanan Produktiviti Malaysia<br>*Malaysia Productivity Corporation* |
| MSOM | *Malaysian Statistics on Medicines* |
| MTAC | *Medication Therapy Adherence Clinic* |
| MVPO | *Malaysia Vaccine Project Office* |
| MyACCP | *Malaysia Advanced Clinical Pharmacy Programme* |
| MyMediSAFE | Pelupusan Ubat-Ubatan dalam Simpanan Pesakit Demi Kelestarian Alam Sekitar |
| MyMedSecure | *Malaysia Medicine Security* |
| MyPhIS | *Pharmacy Information System* |
| NGO | *Non-Governmental Organization* |
| NIBM | *National Institutes of Biotechnology Malaysia* |
| NIDF | Dana Pembangunan Perindustrian Baharu<br>*New Industrial Development Fund* |
| NIMP | Pelan Induk Perindustrian Baharu<br>*New Industrial Master Plan* |
| NPGRP | Dasar Negara bagi Amalan Baik Peraturan<br>*National Policy on Good Regulatory Practice* |
| NPRA | Bahagian Regulatori Farmasi Negara<br>*National Pharmaceutical Regulatory Agency* |
| OACP | *Organizational Anti-Corruption Plan* |
| OKU \| PWD | *Orang Kurang Upaya*<br>*Person with Disabilities* |
| OTC | *Over-the-counter* |
| PAHO | *Pan American Health Organization* |
| PBKD \| DCA | Pihak Berkuasa Kawalan Dadah<br>*Drug Control Authority* |
| Ph.D | Doktor Falsafah |
| PharmQIIs | *Pharmacy Quality Improvement Initiatives* |
| PhIS | *Pharmacy Information System* |

| | |
|---|---|
| PICC | *Pharmacy Integrated Community Care* |
| PICC | *Putrajaya International Convention Centre* |
| PIEMEDS | *Price Information Exchange for Medical Products* |
| PKD | Pejabat Kesihatan Daerah |
| PMDA | *Pharmaceuticals and Medical Devices Agency* |
| PN | *Parenteral Nutrition* |
| PPF \| PSP | Program Perkhidmatan Farmasi<br>*Pharmaceutical Services Programme* |
| PPWG | *Pharmaceutical Product Working Group* |
| PRP | Ahli Farmasi Berdaftar Provisional<br>*Provisionally Registered Pharmacist* |
| QA | *Quality Assurance* |
| QIIs | Quality Improvement Initiatives |
| R&D | *Research and Development* |
| RVMC | *Regional Vaccine Management Committee* |
| RWE | *Real-world evidence* |
| SCCS | *Self-Controlled Case Series* |
| SMBG | *Self-Monitoring of Blood Glucose* |
| SOMHD | *Senior Officials' Meeting on Health Development* |
| SOP | *Standard Operating Procedures* |
| SSPA | Sistem Saraan Perkhidmatan Awam<br>*Public Service Remuneration System* |
| TCM | *Traditional Chinese Medicine* |
| TMHS | *Traditional Medicines, Health Supplements* |
| TOBaTS | Tolak Ubat Tidak Sah<br>*Say No to Illegal Medicines* |
| TOT | *Training of Trainers* |
| TTR | *Time in Therapeutic Range* |
| UHC | *Universal Health Coverage* |
| UKK \| SAM | Ubat Kelulusan Khas<br>*Special Approval Medicine* |
| URL | *Uniform Resource Locator* |
| VAS | Perkhidmatan Nilai Tambah |
| WHA | *World Health Assembly* |
| WHO | *World Health Organization* |
| WPKL&P | Wilayah Persekutuan Kuala Lumpur dan Putrajaya |



**KEMENTERIAN KESIHATAN MALAYSIA**
PROGRAM PERKHIDMATAN FARMASI
*Lot 36, Jalan Profesor Diraja Ungku Aziz,*
*46200 Petaling Jaya, Selangor Darul Ehsan.*

03-7841 3200

www.pharmacy.gov.my

Program Perkhidmatan
Farmasi KKM